{"00885e00f71d2bc50bcfe1fe31a5609ee79d3d15": [["I. INTRODUCTIONThe world has been witnessing the increasing spread of COVID-19 since the beginning of 2020.", [["COVID", "TEST", 70, 75], ["increasing", "OBSERVATION_MODIFIER", 49, 59], ["spread", "OBSERVATION_MODIFIER", 60, 66]]], ["This novel virus has brought everyone's lives to a standstill and the economy to its knees.", [["knees", "ANATOMY", 85, 90], ["knees", "ORGANISM_SUBDIVISION", 85, 90], ["This novel virus", "PROBLEM", 0, 16], ["virus", "OBSERVATION", 11, 16], ["knees", "ANATOMY", 85, 90]]], ["Although most people are actively following social distancing norms, proper hygiene, and other preventive measures, it is likely that normal day-to-day life will continue to be affected until an effective vaccine is developed.", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20], ["an effective vaccine", "TREATMENT", 192, 212]]], ["To mitigate this situation and return to some semblance of normalcy, we believe there is a need for preventive methods that actively combat the virus instead of providing passive protection (e.g., physical barriers).", [["preventive methods", "TREATMENT", 100, 118], ["the virus", "PROBLEM", 140, 149], ["passive protection", "TREATMENT", 171, 189]]], ["Implementing such improved methods requires smart devices that can detect, quantify, and actively eradicate viruses and other pathogens.I. INTRODUCTIONTypical Personal Protective Equipment (PPE), such as face masks (cloth, surgical, or N95), face shields, eye protection, disposable gloves, and coveralls all provide passive protection: these devices only prevent pathogens from entering the body by filtering them out.", [["eye", "ANATOMY", 256, 259], ["body", "ANATOMY", 392, 396], ["eye", "ORGAN", 256, 259], ["body", "ORGANISM_SUBDIVISION", 392, 396], ["smart devices", "TREATMENT", 44, 57], ["actively eradicate viruses", "PROBLEM", 89, 115], ["other pathogens", "PROBLEM", 120, 135], ["Personal Protective Equipment (PPE)", "TREATMENT", 159, 194], ["face masks (cloth", "TREATMENT", 204, 221], ["surgical, or N95", "TREATMENT", 223, 239], ["face shields", "TREATMENT", 242, 254], ["eye protection", "TREATMENT", 256, 270], ["disposable gloves", "TREATMENT", 272, 289], ["coveralls", "TREATMENT", 295, 304], ["passive protection", "TREATMENT", 317, 335], ["these devices", "TREATMENT", 337, 350], ["pathogens", "PROBLEM", 364, 373], ["eye", "ANATOMY", 256, 259], ["pathogens", "OBSERVATION", 364, 373], ["body", "ANATOMY", 392, 396]]], ["By contrast, active protection devices can actively attack and destroy pathogens near vulnerable parts of the body (e.g., the nose and mouth).", [["body", "ANATOMY", 110, 114], ["nose", "ANATOMY", 126, 130], ["mouth", "ANATOMY", 135, 140], ["body", "ORGANISM_SUBDIVISION", 110, 114], ["nose", "ORGANISM_SUBDIVISION", 126, 130], ["mouth", "ORGANISM_SUBDIVISION", 135, 140], ["active protection devices", "TREATMENT", 13, 38], ["body", "ANATOMY", 110, 114], ["nose", "ANATOMY", 126, 130], ["mouth", "ANATOMY", 135, 140]]], ["Here we consider closed-loop active or \"smart\" masks for use in places where potentially virus-laden respiratory droplets (typically 0.1-10 \u00b5m in diameter) are most likely to be transmitted; examples include bathrooms, doctor's offices, daycare centers, and public transportation.", [["respiratory droplets", "ANATOMY", 101, 121], ["\"smart\" masks", "TREATMENT", 39, 52], ["laden respiratory droplets", "PROBLEM", 95, 121], ["laden", "OBSERVATION_MODIFIER", 95, 100], ["respiratory droplets", "OBSERVATION", 101, 121], ["most likely", "UNCERTAINTY", 160, 171]]], ["Fig. 1 gives an overview of the proposed smart mask architecture.", [["the proposed smart mask architecture", "TREATMENT", 28, 64]]], ["A detailed comparison of existing masks with the proposed smart mask is shown in Table I .", [["existing masks", "TREATMENT", 25, 39], ["the proposed smart mask", "TREATMENT", 45, 68], ["smart mask", "OBSERVATION", 58, 68]]], ["The table shows that the proposed system detects airborne droplets (potentially containing viruses for COVID-19, influenza, measles, or other diseases) and limits their spread via an appropriate situation-aware mitigation strategy.", [["COVID-19", "CHEMICAL", 103, 111], ["influenza", "DISEASE", 113, 122], ["measles", "DISEASE", 124, 131], ["airborne droplets", "PROBLEM", 49, 66], ["COVID", "TEST", 103, 108], ["influenza", "PROBLEM", 113, 122], ["measles", "PROBLEM", 124, 131], ["other diseases)", "PROBLEM", 136, 151], ["airborne droplets", "OBSERVATION", 49, 66]]], ["The chosen strategy should be \"smart\", i.e., adaptive based on sensor outputs that provide information on concentration, size distribution, and other properties of the droplets.", [["the droplets", "PROBLEM", 164, 176], ["size", "OBSERVATION_MODIFIER", 121, 125]]], ["In our initial implementation, mitigation is provided by a cold mist generator that loads the droplets (thus making them quickly fall to the ground), and adaptation is provided by algorithms running on an on-board controller that adjust the spray angle, intensity, and duration of the generator based on sensor data.", [["a cold mist generator", "TREATMENT", 57, 78], ["the spray angle", "TREATMENT", 237, 252], ["sensor data", "TEST", 304, 315]]], ["Such active closed-loop protection can remove viruses (and other pathogens) from the air before they infect others, thereby reducing the need for periodic disinfection of the area, while providing increased protection to the wearer.I. INTRODUCTIONThe paper is organized as follows.", [["closed-loop protection", "TREATMENT", 12, 34], ["viruses", "PROBLEM", 46, 53], ["other pathogens", "PROBLEM", 59, 74], ["periodic disinfection of the area", "TREATMENT", 146, 179], ["active", "OBSERVATION_MODIFIER", 5, 11], ["closed", "OBSERVATION", 12, 18]]], ["The airborne transmission of viruses is briefly reviewed in Section II.", [["viruses", "PROBLEM", 29, 36], ["viruses", "OBSERVATION", 29, 36]]], ["The system-level architecture and operating principles of smart masks are presented in Sections II-A and II-B, Closed Loop active sensing and protection system respectively.", [["smart masks", "TREATMENT", 58, 69], ["Closed Loop active sensing and protection system", "TREATMENT", 111, 159], ["smart masks", "OBSERVATION", 58, 69]]], ["The experimental setup, results, and key observations are explained in Sections III-A, III-B, and III-C, respectively.", [["III-C", "SIMPLE_CHEMICAL", 98, 103], ["The experimental setup", "TEST", 0, 22]]], ["The commercial feasibility of smart masks is discussed in Section III-D, and future work and conclusions are presented in Section IV.II. SYSTEM ARCHITECTURE AND IMPLEMENTATIONHumans naturally generate a variety of droplets (e.g., due to breathing, talking, sneezing, and coughing).", [["II", "CHEMICAL", 133, 135], ["sneezing", "DISEASE", 257, 265], ["coughing", "DISEASE", 271, 279], ["smart masks", "TREATMENT", 30, 41], ["a variety of droplets", "TREATMENT", 201, 222], ["breathing", "PROBLEM", 237, 246], ["sneezing", "PROBLEM", 257, 265], ["coughing", "PROBLEM", 271, 279], ["smart masks", "OBSERVATION", 30, 41]]], ["These include various cell types (e.g., epithelial and immune system cells), physiological electrolytes contained in mucus and saliva (e.g., Na + , K + , Cl \u2212 ), and, potentially, various infectious agents (e.g., bacteria, fungi, and viruses).", [["cell", "ANATOMY", 22, 26], ["epithelial", "ANATOMY", 40, 50], ["immune system cells", "ANATOMY", 55, 74], ["mucus", "ANATOMY", 117, 122], ["Na", "CHEMICAL", 141, 143], ["K", "CHEMICAL", 148, 149], ["Cl", "CHEMICAL", 154, 156], ["Na +", "CHEMICAL", 141, 145], ["K +", "CHEMICAL", 148, 151], ["Cl", "CHEMICAL", 154, 156], ["cell", "CELL", 22, 26], ["epithelial", "CELL", 40, 50], ["immune system cells", "CELL", 55, 74], ["mucus", "TISSUE", 117, 122], ["saliva", "ORGANISM_SUBSTANCE", 127, 133], ["Na +", "SIMPLE_CHEMICAL", 141, 145], ["K +", "SIMPLE_CHEMICAL", 148, 151], ["Cl \u2212", "SIMPLE_CHEMICAL", 154, 158], ["epithelial and immune system cells", "CELL_TYPE", 40, 74], ["various cell types", "TEST", 14, 32], ["epithelial and immune system cells", "PROBLEM", 40, 74], ["physiological electrolytes", "TEST", 77, 103], ["mucus and saliva", "TEST", 117, 133], ["Na", "TEST", 141, 143], ["K", "TEST", 148, 149], ["various infectious agents", "PROBLEM", 180, 205], ["bacteria", "PROBLEM", 213, 221], ["fungi", "PROBLEM", 223, 228], ["viruses", "PROBLEM", 234, 241], ["various cell types", "OBSERVATION", 14, 32], ["infectious", "OBSERVATION", 188, 198]]], ["Droplets > 5 \u00b5m in diameter tend to remain trapped in the upper respiratory tract (the oropharynx, i.e., nose and throat area).", [["upper respiratory tract", "ANATOMY", 58, 81], ["oropharynx", "ANATOMY", 87, 97], ["nose", "ANATOMY", 105, 109], ["throat area", "ANATOMY", 114, 125], ["upper", "ORGANISM_SUBDIVISION", 58, 63], ["respiratory tract", "ORGANISM_SUBDIVISION", 64, 81], ["oropharynx", "ORGAN", 87, 97], ["nose", "ORGANISM_SUBDIVISION", 105, 109], ["throat", "ORGANISM_SUBDIVISION", 114, 120], ["Droplets", "TEST", 0, 8], ["nose and throat area", "PROBLEM", 105, 125], ["trapped", "OBSERVATION", 43, 50], ["upper", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81], ["oropharynx", "ANATOMY", 87, 97], ["nose", "ANATOMY", 105, 109], ["throat", "ANATOMY", 114, 120]]], ["By contrast, smaller droplets can be inhaled into the lower respiratory tract (the bronchi and alveoli in the lungs) [2] .II. SYSTEM ARCHITECTURE AND IMPLEMENTATIONInfectious aerosols are generated when pathogens from patients' respiratory tracts come into contact with exhaled air and dissolve in any droplets produced by sneezing, coughing, or talking.", [["lower respiratory tract", "ANATOMY", 54, 77], ["bronchi", "ANATOMY", 83, 90], ["alveoli", "ANATOMY", 95, 102], ["lungs", "ANATOMY", 110, 115], ["respiratory tracts", "ANATOMY", 228, 246], ["II", "CHEMICAL", 122, 124], ["sneezing", "DISEASE", 323, 331], ["coughing", "DISEASE", 333, 341], ["lower", "ORGANISM_SUBDIVISION", 54, 59], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["bronchi", "MULTI-TISSUE_STRUCTURE", 83, 90], ["alveoli", "MULTI-TISSUE_STRUCTURE", 95, 102], ["lungs", "ORGAN", 110, 115], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["smaller droplets", "TREATMENT", 13, 29], ["IMPLEMENTATIONInfectious aerosols", "TREATMENT", 150, 183], ["pathogens", "PROBLEM", 203, 212], ["patients' respiratory tracts", "PROBLEM", 218, 246], ["sneezing", "PROBLEM", 323, 331], ["coughing", "PROBLEM", 333, 341], ["smaller", "OBSERVATION_MODIFIER", 13, 20], ["droplets", "OBSERVATION", 21, 29], ["lower", "ANATOMY_MODIFIER", 54, 59], ["respiratory tract", "ANATOMY", 60, 77], ["bronchi", "ANATOMY", 83, 90], ["alveoli", "ANATOMY_MODIFIER", 95, 102], ["lungs", "ANATOMY", 110, 115]]], ["According to some publications [1] , [3] , a single sneeze may produce as many as 40, 000 droplets with diameters between 0.5-12 \u00b5m ( Fig. 2(a) ).", [["[3]", "SIMPLE_CHEMICAL", 37, 40], ["diameters", "TEST", 104, 113]]], ["By contrast, a single cough may produce up to 3, 000 droplet nuclei, and similar numbers are typically recorded after talking for five minutes.", [["droplet nuclei", "ANATOMY", 53, 67], ["cough", "DISEASE", 22, 27], ["nuclei", "CELLULAR_COMPONENT", 61, 67], ["a single cough", "PROBLEM", 13, 27]]], ["Air flows can carry infectious droplets long distances; such flows occur even during the most innocuous daily activities, such as walking or opening doors.", [["Air flows", "PROBLEM", 0, 9], ["infectious droplets long distances", "PROBLEM", 20, 54], ["infectious", "OBSERVATION_MODIFIER", 20, 30]]], ["In addition, differences in temperature (and thus density) across open doorways result in convective currents that exchange air between nearby areas.II. SYSTEM ARCHITECTURE AND IMPLEMENTATIONVirus particles do not float freely in the air, but are always suspended in droplet nuclei that are significantly larger than the virus itself.", [["droplet nuclei", "ANATOMY", 267, 281], ["II", "CHEMICAL", 149, 151], ["differences in temperature (and thus density)", "PROBLEM", 13, 58], ["open doorways", "TREATMENT", 66, 79], ["convective currents", "TREATMENT", 90, 109], ["IMPLEMENTATIONVirus particles", "PROBLEM", 177, 206], ["convective currents", "OBSERVATION", 90, 109], ["air", "OBSERVATION", 124, 127], ["air", "OBSERVATION", 234, 237], ["droplet nuclei", "OBSERVATION", 267, 281], ["significantly", "OBSERVATION_MODIFIER", 291, 304], ["larger", "OBSERVATION_MODIFIER", 305, 311], ["virus", "OBSERVATION", 321, 326]]], ["The SARS-CoV-2 virus is 100 nm in diameter, and can remain suspended within droplets > 0.2 \u00b5m in size.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["CoV-2 virus", "SPECIES", 9, 20], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["droplets", "TEST", 76, 84], ["100 nm", "OBSERVATION_MODIFIER", 24, 30], ["size", "OBSERVATION_MODIFIER", 97, 101]]], ["Droplets > 5 \u00b5m fall to the ground quickly, while very small droplets evaporate [4] and aerosolize in a few seconds to droplet nuclei \u223c1 \u00b5m in size [5] .", [["Droplets", "TEST", 0, 8], ["aerosolize", "TREATMENT", 88, 98], ["size", "OBSERVATION_MODIFIER", 143, 147]]], ["Fortunately, most masks can filter out droplets of this size: many materials have \u2265 96% filtration efficacy for particles > 0.3 \u00b5m, including 600 TPI (threads per inch) cotton, cotton quilts, and cotton layered with chiffon, silk, or flannel [6] , [7] .", [["quilts", "ANATOMY", 184, 190], ["cotton", "SPECIES", 177, 183], ["many materials", "PROBLEM", 62, 76], ["particles", "TEST", 112, 121], ["cotton", "TREATMENT", 169, 175], ["cotton quilts", "TREATMENT", 177, 190], ["cotton layered with chiffon, silk", "TREATMENT", 196, 229], ["size", "OBSERVATION_MODIFIER", 56, 60]]], ["Thus, the most important requirement for the proposed smart mask is to eliminate the small (but potentially significant) fraction of virus-laden droplets that are < 0.3 \u00b5m in size.", [["the proposed smart mask", "TREATMENT", 41, 64], ["the small (but potentially significant) fraction of virus-laden droplets", "PROBLEM", 81, 153], ["small", "OBSERVATION_MODIFIER", 85, 90], ["virus", "OBSERVATION", 133, 138], ["laden", "OBSERVATION_MODIFIER", 139, 144], ["droplets", "OBSERVATION_MODIFIER", 145, 153], ["size", "OBSERVATION_MODIFIER", 175, 179]]], ["These small droplets are removed by creating an air-flow pattern close to the mask through spraying a mist.", [["These small droplets", "TREATMENT", 0, 20], ["an air-flow pattern", "TEST", 45, 64], ["the mask", "TREATMENT", 74, 82], ["small", "OBSERVATION_MODIFIER", 6, 11], ["droplets", "OBSERVATION", 12, 20], ["air", "OBSERVATION", 48, 51], ["flow pattern", "OBSERVATION", 52, 64]]], ["It blows the droplets away from the wearer and also \"loads\" them (i.e., increases their mass and size), thus causing them to quickly fall to the ground (Fig. 2(c) ).A. System ArchitectureThe smart mask has two main components: a particulate sensor and an active mitigation device.", [["The smart mask", "TREATMENT", 187, 201], ["a particulate sensor", "TREATMENT", 227, 247], ["an active mitigation device", "TREATMENT", 252, 279], ["mass", "OBSERVATION", 88, 92], ["size", "OBSERVATION_MODIFIER", 97, 101], ["smart mask", "OBSERVATION", 191, 201], ["two", "OBSERVATION_MODIFIER", 206, 209], ["main", "OBSERVATION_MODIFIER", 210, 214], ["components", "OBSERVATION_MODIFIER", 215, 225], ["active", "OBSERVATION_MODIFIER", 255, 261], ["mitigation device", "OBSERVATION", 262, 279]]], ["Methods for sensing airborne pathogens and allergens can be divided into sampling-based (local) and remote detection approaches.", [["Methods", "TREATMENT", 0, 7], ["sensing airborne pathogens", "PROBLEM", 12, 38], ["allergens", "TREATMENT", 43, 52], ["remote detection approaches", "TEST", 100, 127]]], ["A variety of pre-concentration and sampling methods based on solid impactors, liquid impactors, and filters are available [8] .", [["pre-concentration and sampling methods", "TREATMENT", 13, 51], ["solid impactors", "TREATMENT", 61, 76], ["liquid impactors", "TREATMENT", 78, 94], ["variety", "OBSERVATION_MODIFIER", 2, 9]]], ["These methods have the advantage that the sampled pathogens can be analyzed, identified, and quantified using sensitive lab-based techniques, such as real-time polymerase chain reaction (RT-PCR) [9] or surface-enhanced Raman spectroscopy (SERS) [10] , [11] .", [["the sampled pathogens", "PROBLEM", 38, 59]]], ["However, incorporating such sensitive detectors into a wearable form factor is extremely difficult.A. System ArchitectureDue to this limitation, we focus on a remote detection approach.", [["wearable form factor", "PROTEIN", 55, 75], ["a remote detection approach", "TREATMENT", 157, 184]]], ["Remote (also known as stand-off) detection of pathogens has been demonstrated using a variety of optical methods, using asymmetric microsphere resonant cavities [12] , laser-induced fluorescence [13] , and random Raman lasing [14] , as well as non-optical methods, such as THz imaging and spectroscopy [15] , [16] .", [["pathogens", "PROBLEM", 46, 55], ["optical methods", "TREATMENT", 97, 112], ["asymmetric microsphere resonant cavities", "TREATMENT", 120, 160], ["laser-induced fluorescence", "TREATMENT", 168, 194], ["random Raman lasing", "TEST", 206, 225], ["THz imaging", "TEST", 273, 284], ["spectroscopy", "TEST", 289, 301]]], ["Here, we propose a particulate matter (PM) sensor that makes use of laser scattering to precisely count airborne particles in multiple size \"bins\".", [["laser scattering", "TREATMENT", 68, 84], ["multiple", "OBSERVATION_MODIFIER", 126, 134], ["size", "OBSERVATION_MODIFIER", 135, 139]]], ["In addition, the control algorithm also uses data from auxiliary sensors (such as relative humidity and temperature) while determining the optimal parameters for the mitigation device (i.e,. mist generator), since aerosol travel distances depend on such environmental factors [8] .A. System ArchitectureThe mitigation device generates aerosolized mist on-demand using a piezoelectric transducer.", [["auxiliary sensors", "TEST", 55, 72], ["relative humidity and temperature", "TREATMENT", 82, 115], ["the mitigation device", "TREATMENT", 162, 183], ["mist generator", "TREATMENT", 191, 205], ["The mitigation device", "TREATMENT", 303, 324], ["a piezoelectric transducer", "TREATMENT", 368, 394], ["aerosolized mist", "OBSERVATION", 335, 351]]], ["A variety of liquids, including pure water or mixtures of water with various impurities (to increase droplet mass) or disinfectants, can be used to generate the mist.", [["water", "SIMPLE_CHEMICAL", 58, 63], ["A variety of liquids", "TREATMENT", 0, 20], ["various impurities", "TREATMENT", 69, 87], ["droplet mass", "PROBLEM", 101, 113], ["variety", "OBSERVATION_MODIFIER", 2, 9]]], ["The best disinfectant for a given pathogen can be found using guidelines provided by the U.S. Centers for Disease Control and Prevention (CDC) [17] and Environmental Protection Agency (EPA) [18] .", [["pathogen", "PROBLEM", 34, 42], ["Disease Control", "TREATMENT", 106, 121]]], ["Common disinfectants include diluted bleach, soap, and > 70% alcohol solution.B. Operational PrinciplesThe smart mask integrates a sensing module, as shown in Fig. 3(a) , that senses the presence of airborne aerosol droplets (typical diameter 0.1-10 \u00b5m) in the vicinity of the users respiratory tract.", [["respiratory tract", "ANATOMY", 283, 300], ["alcohol", "CHEMICAL", 61, 68], ["alcohol", "CHEMICAL", 61, 68], ["alcohol", "SIMPLE_CHEMICAL", 61, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 283, 300], ["Common disinfectants", "TREATMENT", 0, 20], ["diluted bleach", "TREATMENT", 29, 43], ["soap", "TREATMENT", 45, 49], ["The smart mask", "TREATMENT", 103, 117], ["a sensing module", "TREATMENT", 129, 145], ["airborne aerosol droplets", "TREATMENT", 199, 224], ["smart mask", "OBSERVATION", 107, 117], ["airborne aerosol", "OBSERVATION", 199, 215], ["respiratory tract", "ANATOMY", 283, 300]]], ["It incorporates an optical detector system and auxiliary humidity and temperature sensors (as described previously) to quantify the total number and size distribution of these droplets as they approach the protected region (i.e., the nose and mouth).", [["nose", "ANATOMY", 234, 238], ["mouth", "ANATOMY", 243, 248], ["nose", "ORGANISM_SUBDIVISION", 234, 238], ["mouth", "ORGANISM_SUBDIVISION", 243, 248], ["temperature sensors", "TEST", 70, 89], ["these droplets", "TREATMENT", 170, 184], ["size", "OBSERVATION_MODIFIER", 149, 153], ["nose", "ANATOMY", 234, 238], ["mouth", "ANATOMY", 243, 248]]], ["The outputs of both sensors are processed by an air quality analyzer module.", [["an air quality analyzer module", "PROBLEM", 45, 75], ["outputs", "OBSERVATION_MODIFIER", 4, 11], ["air", "OBSERVATION", 48, 51], ["quality analyzer", "OBSERVATION", 52, 68]]], ["The latter uses algorithms to analyze sensor data and thereby classify the quality of the incoming air stream based on health risk (e.g., \"very high\", \"high\", \"moderate\", and \"low\").", [["sensor data", "TEST", 38, 49]]], ["These risk categories are then encrypted for security and sent to the protection module either wirelessly (e.g., over Bluetooth) or by using a wired connection.", [["a wired connection", "TREATMENT", 141, 159]]], ["A \"high risk\" output triggers the active protection mechanism, as summarized in Fig. 3(b) .", [["A \"high risk\" output", "PROBLEM", 0, 20], ["active protection", "OBSERVATION", 34, 51]]], ["The protection mechanism sprays a mist that is safe for human exposure by using a micro nozzle.", [["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["The protection mechanism sprays", "TREATMENT", 0, 31], ["a micro nozzle", "TREATMENT", 80, 94]]], ["This module is triggered by an electromechanical relay driven by the system controller.B. Operational PrinciplesThe hardware and software required for both sensing and protection modules are implemented using low-cost commercial off-the-shelf components (a low-power microcontroller and a wireless system-on-module) built within a mask, thus enabling widespread deployment in the vulnerable population.", [["The hardware", "TREATMENT", 112, 124], ["both sensing and protection modules", "TREATMENT", 151, 186], ["a low-power microcontroller", "TREATMENT", 255, 282], ["a wireless system", "TREATMENT", 287, 304], ["a mask", "TREATMENT", 329, 335], ["hardware", "OBSERVATION", 116, 124], ["widespread", "OBSERVATION_MODIFIER", 351, 361], ["deployment", "OBSERVATION", 362, 372], ["vulnerable", "OBSERVATION_MODIFIER", 380, 390], ["population", "OBSERVATION", 391, 401]]], ["Further, the device can be equipped with machine learning (ML) algorithms that learn when respiratory droplets are likely to be present in a location and proactively employ the proposed active protection mechanism.", [["respiratory droplets", "ANATOMY", 90, 110], ["the device", "TREATMENT", 9, 19], ["machine learning (ML) algorithms", "TREATMENT", 41, 73], ["respiratory droplets", "PROBLEM", 90, 110], ["the proposed active protection mechanism", "TREATMENT", 173, 213]]], ["The smart mask can also connect to authorized mobile devices through its wireless module.", [["The smart mask", "TREATMENT", 0, 14], ["authorized mobile devices", "TREATMENT", 35, 60], ["smart mask", "OBSERVATION", 4, 14]]], ["Users can use a mobile application to monitor current air quality, check system status (e.g., battery and liquid levels), and also manually override the on-board mitigation algorithm if needed.A. Test Setup3D views of our smart mask prototype are shown in Fig. 4(a) -(c) respectively; a photograph of the fully-assembled version is shown in Fig. 4(d, e) .", [["a mobile application", "TREATMENT", 14, 34], ["battery and liquid levels", "TEST", 94, 119], ["our smart mask prototype", "TREATMENT", 218, 242]]], ["The experimental setup for testing the functional prototype uses a humidifier to replicate aerosol-sized droplets generated during daily activities like talking, coughing, and sneezing.", [["coughing", "DISEASE", 162, 170], ["sneezing", "DISEASE", 176, 184], ["The experimental setup", "TREATMENT", 0, 22], ["a humidifier", "TREATMENT", 65, 77], ["aerosol-sized droplets", "TREATMENT", 91, 113], ["coughing", "PROBLEM", 162, 170], ["sneezing", "PROBLEM", 176, 184], ["sneezing", "OBSERVATION", 176, 184]]], ["The humidifier (Fig. 4(h) ) produces mist droplets in the 0.3-2.5 \u00b5m range.", [["The humidifier (Fig.", "TREATMENT", 0, 20], ["mist droplets", "TEST", 37, 50]]], ["Since standard face masks filter out most large droplets (as mentioned earlier) [6] , [7] , we check the smart mask's performance against droplets of size < 0.3 \u00b5m.", [["standard face masks filter", "TREATMENT", 6, 32], ["most large droplets", "PROBLEM", 37, 56], ["the smart mask's performance", "TEST", 101, 129], ["large", "OBSERVATION_MODIFIER", 42, 47], ["droplets", "OBSERVATION", 48, 56], ["size", "OBSERVATION_MODIFIER", 150, 154]]], ["We use two PM sensors (Sensirion SPS30, see Fig. 4 (g)): one on the smart mask (which is placed at a height of \u223c1.6 m), and the other on the ground (Fig. 4(f) ).", [["two PM sensors (Sensirion SPS30", "TREATMENT", 7, 38], ["the smart mask", "TREATMENT", 64, 78]]], ["The use of two sensors allows us to quantify both predicted effects of PM loading by the mitigation spray: i) reduction in PM count near the mask, and ii) increase in PM count on the ground (due to the rapid falling of loaded particles).", [["PM", "SIMPLE_CHEMICAL", 71, 73], ["PM loading", "TREATMENT", 71, 81], ["the mask", "TREATMENT", 137, 145], ["PM count", "TEST", 167, 175], ["the rapid falling of loaded particles", "TREATMENT", 198, 235], ["increase", "OBSERVATION_MODIFIER", 155, 163]]], ["Note that the PM sensor on the ground is not part of the mask, and only used during testing.", [["the mask", "TREATMENT", 53, 61], ["testing", "TEST", 84, 91]]], ["The chosen PM sensor is based on laser scattering and has built-in \"contamination resistance\" feature in which artificial air flow (created using a small built-in fan) is used to drive deposited particles out of the sensor.", [["artificial air flow", "PROBLEM", 111, 130], ["a small built-in fan)", "TREATMENT", 146, 167], ["air flow", "OBSERVATION", 122, 130]]], ["Due to the placement of the exhaust vent, this air flow interferes with the incoming air.", [["the exhaust vent", "TREATMENT", 24, 40], ["this air flow", "PROBLEM", 42, 55], ["exhaust vent", "OBSERVATION", 28, 40], ["air flow", "OBSERVATION", 47, 55]]], ["To reduce this effect, we provided a guided path for the exhaust as shown in Fig. 4(g) .A. Test SetupThe smart mitigation module uses a piezoelectric transducer (Fig. 4(i) ) that vibrates at a frequency of 110 kHz.", [["The smart mitigation module", "TREATMENT", 101, 128], ["a piezoelectric transducer", "TREATMENT", 134, 160]]], ["The vibrating portion of the transducer is a mesh-like structure with one side facing the liquid and the other side facing the atmosphere.", [["a mesh-like structure", "TREATMENT", 43, 64], ["vibrating", "OBSERVATION_MODIFIER", 4, 13], ["portion", "OBSERVATION_MODIFIER", 14, 21], ["transducer", "OBSERVATION_MODIFIER", 29, 39], ["mesh", "OBSERVATION", 45, 49], ["one", "OBSERVATION_MODIFIER", 70, 73], ["liquid", "OBSERVATION", 90, 96], ["atmosphere", "OBSERVATION_MODIFIER", 127, 137]]], ["The pressure drop created by the vibration converts liquid water into vapor, which exits the transducer as shown in Fig. 4(d) .", [["The pressure drop", "TEST", 0, 17], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["drop", "OBSERVATION_MODIFIER", 13, 17]]], ["The transducer runs at 12 V while consuming up to 0.2 A of current.", [["The transducer runs", "TEST", 0, 19], ["transducer", "OBSERVATION_MODIFIER", 4, 14], ["runs", "OBSERVATION_MODIFIER", 15, 19], ["12 V", "OBSERVATION_MODIFIER", 23, 27]]], ["Power is provided by four 18650 Li-ion cells connected in series with a total capacity of 2000 mAh, which is sufficient for a typical day of heavy use.", [["18650 Li-ion cells", "ANATOMY", 26, 44], ["Li-ion cells", "CELL", 32, 44], ["18650 Li-ion cells", "CELL_LINE", 26, 44], ["four 18650 Li-ion cells", "TREATMENT", 21, 44]]], ["All experiments were conducted in a well-controlled indoor environment with no nearby air vents; this is because aerosols are very sensitive to weak air flows (e.g., due to air-conditioning).B. Experimental ResultsInitially, the outputs of the two sensors were checked to ensure a stable and uniform PM concentration in the area around the experimental setup.", [["PM", "SIMPLE_CHEMICAL", 300, 302], ["nearby air vents", "TREATMENT", 79, 95], ["weak air flows", "PROBLEM", 144, 158], ["the two sensors", "TEST", 240, 255], ["air vents", "OBSERVATION", 86, 95], ["stable", "OBSERVATION_MODIFIER", 281, 287], ["experimental setup", "OBSERVATION", 340, 358]]], ["First, the humidifier was turned ON, which imitates droplets produced by human actions, for 15 sec with the mitigation module turned OFF.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["the humidifier", "TREATMENT", 7, 21], ["the mitigation module", "TREATMENT", 104, 125]]], ["The aerosols were then allowed to settle for 160 sec, with both PM sensors recording their local number and mass concentrations.", [["The aerosols", "TREATMENT", 0, 12], ["mass concentrations", "PROBLEM", 108, 127], ["mass concentrations", "OBSERVATION", 108, 127]]], ["Second, the same experiment was repeated, but with the smart mask's mitigation module turned ON under normal conditions i.e., with the humidifier turned OFF.", [["the smart mask's mitigation module", "TREATMENT", 51, 85], ["the humidifier", "TREATMENT", 131, 145]]], ["Finally, the effectiveness of the smart mask was verified, as follows.", [["the smart mask", "TREATMENT", 30, 44]]], ["The humidifier was turned ON for 15 sec, and the smart mask activated for 15 sec once its sensor detects a significant local change in PM concentration.", [["PM", "SIMPLE_CHEMICAL", 135, 137], ["The humidifier", "TREATMENT", 0, 14], ["the smart mask", "TREATMENT", 45, 59], ["a significant local change in PM concentration", "PROBLEM", 105, 151], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["local", "OBSERVATION_MODIFIER", 119, 124], ["change", "OBSERVATION", 125, 131]]], ["The outputs of both PM sensors were then monitored until all aerosols settle out (\u223c160 sec).", [["PM sensors", "TEST", 20, 30], ["outputs", "OBSERVATION_MODIFIER", 4, 11]]], ["The results of these experiments are analyzed in the next section.", [["these experiments", "TEST", 15, 32]]], ["Clearly, the mitigation module (mist generator) significantly reduces the local PM number within this critical size range -simple analysis suggests a time-averaged reduction of \u223c20%.", [["the mitigation module (mist generator", "TREATMENT", 9, 46], ["simple analysis", "TEST", 123, 138], ["size", "OBSERVATION_MODIFIER", 111, 115]]], ["Moreover, the PM count with the mitigation module ON is artificially increased due to the aerosols generated by the module itself ( Fig. 5(b) ).", [["the PM count", "TEST", 10, 22], ["the mitigation module", "PROBLEM", 28, 49], ["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["Once this self-interference term is subtracted, the time-averaged reduction in PM count due to the mask becomes even more significant - Fig. 5 (c) suggests \u223c40%.B. Experimental ResultsThe aerosol concentrations produced by the humidifier in the 0.3-2.5 \u00b5m range resemble those produced during daily activities, and are shown in Fig. 5(d) .", [["PM count", "TEST", 79, 87], ["the mask", "TREATMENT", 95, 103], ["The aerosol concentrations", "TREATMENT", 184, 210], ["the humidifier", "TREATMENT", 223, 237], ["aerosol concentrations", "OBSERVATION", 188, 210]]], ["Next, we analyze the effect of the smart mask on the concentration of these aerosolized particles.", [["the smart mask", "TREATMENT", 31, 45], ["these aerosolized particles", "TREATMENT", 70, 97], ["aerosolized particles", "OBSERVATION", 76, 97]]], ["5(e) and (f) compare the time-averaged mass and number concentrations with the mask ON and OFF for both internal (on the mask) and external (on the ground) PM sensors.", [["averaged mass", "PROBLEM", 30, 43], ["number concentrations", "PROBLEM", 48, 69], ["the mask", "TREATMENT", 75, 83], ["the mask", "TREATMENT", 117, 125], ["mass", "OBSERVATION", 39, 43]]], ["The data shows that the mass concentrations measured by the external sensor in the 0.3-1.0 \u00b5m and 1.0-2.5 \u00b5m ranges increase by \u223c63% and \u223c60%, respectively, when the mask is turned ON.", [["The data", "TEST", 0, 8], ["the mass concentrations", "PROBLEM", 20, 43], ["the external sensor", "TEST", 56, 75], ["the mask", "TREATMENT", 162, 170], ["mass", "OBSERVATION", 24, 28], ["concentrations", "OBSERVATION_MODIFIER", 29, 43], ["external", "OBSERVATION_MODIFIER", 60, 68], ["increase", "OBSERVATION_MODIFIER", 116, 124]]], ["Similarly, the corresponding number concentrations increase by \u223c62% and \u223c50%, respectively.", [["number", "OBSERVATION_MODIFIER", 29, 35], ["concentrations", "OBSERVATION_MODIFIER", 36, 50], ["increase", "OBSERVATION_MODIFIER", 51, 59]]], ["These results suggest that the smart mask is loading the local aerosol particles, as expected, thus causing them to fall faster to the ground.D. Mechanical Design and Cost AnalysisThe mechanical structure of the mask is based on a open-source 3D design, but was modified to include a compartment for liquid storage.", [["the smart mask", "TREATMENT", 27, 41], ["the local aerosol particles", "TREATMENT", 53, 80], ["Cost Analysis", "TEST", 167, 180], ["the mask", "TREATMENT", 208, 216], ["liquid storage", "TREATMENT", 300, 314], ["smart mask", "OBSERVATION", 31, 41], ["aerosol particles", "OBSERVATION", 63, 80], ["mechanical structure", "OBSERVATION", 184, 204]]], ["This compartment has two holes: one for refilling and the other for the transducer.", [["the transducer", "TREATMENT", 68, 82], ["two", "OBSERVATION_MODIFIER", 21, 24], ["holes", "OBSERVATION", 25, 30]]], ["The transducer is placed flush with the mask's outer surface, with one of its sides facing the liquid.", [["outer surface", "ANATOMY", 47, 60], ["outer surface", "CELLULAR_COMPONENT", 47, 60], ["The transducer", "TREATMENT", 0, 14], ["the mask's outer surface", "TREATMENT", 36, 60], ["flush", "OBSERVATION", 25, 30], ["surface", "OBSERVATION_MODIFIER", 53, 60], ["liquid", "OBSERVATION", 95, 101]]], ["A plastic layer is used to ensure a watertight seal around the transducer.", [["A plastic layer", "TREATMENT", 0, 15], ["a watertight seal around the transducer", "TREATMENT", 34, 73], ["plastic", "OBSERVATION_MODIFIER", 2, 9], ["layer", "OBSERVATION_MODIFIER", 10, 15], ["watertight seal", "OBSERVATION", 36, 51]]], ["Small perforations backed by replaceable air filters are added on the sides of the mask to ensure adequate air intake.", [["perforations", "DISEASE", 6, 18], ["Small perforations", "PROBLEM", 0, 18], ["replaceable air filters", "TREATMENT", 29, 52], ["the mask", "TREATMENT", 79, 87], ["perforations", "OBSERVATION", 6, 18], ["replaceable", "OBSERVATION_MODIFIER", 29, 40], ["air filters", "OBSERVATION", 41, 52], ["adequate", "OBSERVATION_MODIFIER", 98, 106], ["air intake", "OBSERVATION", 107, 117]]], ["Additionally, the edges are lined with silicone, thus ensuring a good seal with the skin.", [["skin", "ANATOMY", 84, 88], ["skin", "ORGAN", 84, 88], ["silicone", "TREATMENT", 39, 47], ["edges", "OBSERVATION_MODIFIER", 18, 23], ["lined", "OBSERVATION", 28, 33], ["silicone", "OBSERVATION", 39, 47], ["good", "OBSERVATION_MODIFIER", 65, 69], ["seal", "OBSERVATION_MODIFIER", 70, 74], ["skin", "ANATOMY", 84, 88]]], ["A second compartment on the mask holds the sensor and wiring harness, while a small pocket-or belt-worn external unit houses the battery and system controller.", [["the mask", "TREATMENT", 24, 32], ["a small pocket", "PROBLEM", 76, 90]]], ["The mask was 3D-printed for testing purposes, but can instead be injection-molded to reduce cost for bulk production.", [["The mask", "TREATMENT", 0, 8], ["testing purposes", "TEST", 28, 44], ["bulk production", "PROBLEM", 101, 116]]], ["In this case, the overall manufacturing cost per mask (including the electronics) is expected to be near $25 based on the bill of materials.E. Integration with smartphoneThe integration of the mask with a smartphone is a vital part of the project.", [["the mask", "TREATMENT", 189, 197], ["a smartphone", "TREATMENT", 203, 215]]], ["It helps in the transfer and visualization of the data, changing modes, and controlling the smart mask.", [["visualization of the data", "TEST", 29, 54], ["the smart mask", "TREATMENT", 88, 102]]], ["We developed an android application that can connect to multiple smart masks at the same time.", [["an android application", "TREATMENT", 13, 35], ["multiple smart masks", "TREATMENT", 56, 76]]], ["It collects data from the smart mask using Bluetooth connection.", [["the smart mask", "TREATMENT", 22, 36], ["Bluetooth connection", "TREATMENT", 43, 63]]], ["The mask sends important particulate matter data to the application which is processed and shown to the user in the form of real-time plots.", [["The mask", "TREATMENT", 0, 8]]], ["Using the transferred data, the application can also suggest the user decontaminate the mask in the form of a notification when the number of particles the mask is exposed to exceeds a threshold.", [["the mask", "TREATMENT", 84, 92], ["the mask", "TREATMENT", 152, 160]]], ["The application can control the switching of the mask between turn-ON and turn-OFF.", [["The application", "TREATMENT", 0, 15], ["the mask", "TREATMENT", 45, 53]]], ["Also, the application helps in choosing different functioning modes of the mask: automatic, and manual.", [["the mask", "TREATMENT", 71, 79]]], ["In manual mode, the user has the power of when to turn-ON or turn-OFF the mask.", [["the mask", "TREATMENT", 70, 78]]], ["In the automatic mode, the smart mask automatically switches based on the particulate matter density in its surroundings.IV. CONCLUSION AND FUTURE WORKWe have presented a new paradigm of active closed-loop defense, in the form of a smart mask, against airborne pathogens including SARS-CoV-2.", [["SARS-CoV", "SPECIES", 281, 289], ["the smart mask", "TREATMENT", 23, 37], ["IV", "TREATMENT", 121, 123], ["a smart mask", "TREATMENT", 230, 242], ["airborne pathogens", "PROBLEM", 252, 270], ["SARS", "PROBLEM", 281, 285], ["particulate matter", "OBSERVATION_MODIFIER", 74, 92], ["density", "OBSERVATION", 93, 100], ["active", "OBSERVATION_MODIFIER", 187, 193], ["closed", "OBSERVATION", 194, 200], ["loop defense", "OBSERVATION_MODIFIER", 201, 213]]], ["We have presented the system design, and using a functional prototype of the mask, also demonstrated the major operational characteristics.", [["the mask", "TREATMENT", 73, 81]]], ["Various levels of smartness can be incorporated into the proposed system to control the time, duration, and intensity of mitigation based on awareness of the location (e.g., hospitals, quarantined zones, or care centers with infected patients), ambient conditions (e.g., humidity and air temperature, human occupancy), and overall health of the user (e.g., age, pre-existing conditions, etc.).", [["patients", "ORGANISM", 234, 242], ["human", "ORGANISM", 301, 306], ["patients", "SPECIES", 234, 242], ["human", "SPECIES", 301, 306], ["human", "SPECIES", 301, 306], ["smartness", "TREATMENT", 18, 27]]], ["The proposed mask can also be extended to protect against pollutants, dust particles, and pollen, e.g., for vulnerable populations with pollen and/or dust allergies.", [["pollen", "ANATOMY", 90, 96], ["pollen", "ANATOMY", 136, 142], ["allergies", "DISEASE", 155, 164], ["pollen", "ORGANISM_SUBDIVISION", 136, 142], ["The proposed mask", "TREATMENT", 0, 17], ["vulnerable populations", "PROBLEM", 108, 130], ["dust allergies", "PROBLEM", 150, 164]]], ["It can also be extended to other usage scenarios, e.g., military personnel exposed to harmful airborne particles; dentists performing dental procedures; and day-care or elementary schools where social distancing is hard to maintain.", [["dental procedures", "TREATMENT", 134, 151]]], ["While more testing and evaluation is needed to fully establish the merits of the smart mask and identify remaining design challenges and associated trade-offs, the initial results are highly promising.", [["evaluation", "TEST", 23, 33], ["the smart mask", "TREATMENT", 77, 91]]], ["The proposed defense can be applied to existing masks as an add-on reusable assembly, as well as to new mask designs as demonstrated here.", [["existing masks", "TREATMENT", 39, 53], ["new mask designs", "TREATMENT", 100, 116]]], ["It also has the potential to completely replace traditional masks for specific applications.", [["traditional masks", "TREATMENT", 48, 65], ["specific applications", "TREATMENT", 70, 91]]], ["Our future studies will focus on these topics.", [["Our future studies", "TEST", 0, 18]]]], "PMC7302823": [["Different from traditional plain networks where only the topological structure information is utilized, attributed networks also associated with rich features or attributes, which enrich the knowledge inside representations for network analysis.", [["network analysis", "TEST", 228, 244]]], ["For example, in social networks, in addition to friend relationships, rich profile information is also an important attribute for describing user characteristics; in online shopping networks, purchase records associated with reviews provide valuable information.", [["social networks", "MULTI-TISSUE_STRUCTURE", 16, 31]]], ["Studies from social science have revealed the influence of interaction between the attributes of nodes and their structures [21, 24].", [["nodes", "ANATOMY", 97, 102], ["Studies from social science", "TEST", 0, 27], ["nodes", "OBSERVATION", 97, 102]]], ["Going through these insights, we can discover deeper patterns from attributed networks.IntroductionAnomaly detection plays a vital role in many information systems to achieve secure cyberspace.", [["secure cyberspace", "TREATMENT", 175, 192], ["Anomaly", "OBSERVATION", 99, 106]]], ["Recently, there is emerging research of anomaly detection focusing on attributed networks due to the potential rich information contained in the attributed network.", [["anomaly detection", "PROBLEM", 40, 57], ["anomaly", "OBSERVATION", 40, 47]]], ["However, how to model network structure information and rich semantic nodal information into a unified representation is still a challenging problem.IntroductionConventional anomaly detection methods mainly focus on exploiting the structure of the network to find patterns and spot anomalies such as structural-based or community-based [3] methods.", [["nodal", "MULTI-TISSUE_STRUCTURE", 70, 75], ["Conventional anomaly detection methods", "TREATMENT", 161, 199], ["spot anomalies", "PROBLEM", 277, 291], ["anomaly", "OBSERVATION", 174, 181]]], ["Besides, feature-based methods assume that complex anomalies only exist in a subset according to node features.", [["node", "ANATOMY", 97, 101], ["node", "MULTI-TISSUE_STRUCTURE", 97, 101], ["complex anomalies", "PROBLEM", 43, 60], ["complex", "OBSERVATION_MODIFIER", 43, 50], ["anomalies", "OBSERVATION", 51, 60], ["node", "OBSERVATION", 97, 101]]], ["To address the problems as mentioned above, inspired by graph convolutional network (GCN) [16], we resort to embedding the input topological structure as well as nodal attributes seamlessly into a unified representation through stacking GCN layers.", [["GCN layers", "TISSUE", 237, 247], ["the problems", "PROBLEM", 11, 23], ["stacking GCN layers", "PROBLEM", 228, 247]]], ["Meanwhile, the proposed model enforces the learned node representation to preserve various proximities.", [["node", "ANATOMY", 51, 55], ["node", "MULTI-TISSUE_STRUCTURE", 51, 55], ["the learned node representation", "TREATMENT", 39, 70], ["node", "OBSERVATION", 51, 55]]], ["Then we aim to spot anomalies leveraging by the reconstruction errors both from the two kinds of modalities.", [["spot anomalies leveraging", "PROBLEM", 15, 40], ["the reconstruction errors", "TEST", 44, 69]]], ["The contributions of this paper are listed as follow:We propose a novel joint embedding approach DeepAD modeled by graph autoencoder DeepAD to capture the underlying high non-linearity in both topological structure and nodal attributes and detect anomalies according to the reconstruction errors.DeepAD jointly preserves the first-order, high-order, and cross-modal proximities in original networks towards a unified complementary representation.Experimental results show that DeepAD outperforms several state-of-art methods on benchmark datasets.", [["nodal", "MULTI-TISSUE_STRUCTURE", 219, 224], ["DeepAD", "PROTEIN", 477, 483], ["a novel joint embedding approach", "TREATMENT", 64, 96], ["the underlying high non-linearity", "PROBLEM", 151, 184], ["detect anomalies", "PROBLEM", 240, 256], ["joint", "ANATOMY", 72, 77], ["high non-linearity", "OBSERVATION", 166, 184], ["both", "ANATOMY_MODIFIER", 188, 192], ["topological structure", "OBSERVATION", 193, 214], ["nodal attributes", "OBSERVATION", 219, 235]]]], "PMC7149789": [["IntroductionBacteria are ubiquitous.", [["IntroductionBacteria", "PROBLEM", 0, 20]]], ["Only a small percentage of the world's bacteria cause infection and disease.", [["infection", "DISEASE", 54, 63], ["infection", "PROBLEM", 54, 63], ["disease", "PROBLEM", 68, 75], ["small", "OBSERVATION_MODIFIER", 7, 12], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["infection", "OBSERVATION", 54, 63]]], ["These bacterial infections have a large impact on public health.", [["bacterial infections", "DISEASE", 6, 26], ["These bacterial infections", "PROBLEM", 0, 26], ["bacterial", "OBSERVATION_MODIFIER", 6, 15], ["infections", "OBSERVATION", 16, 26], ["large", "OBSERVATION_MODIFIER", 34, 39], ["impact", "OBSERVATION_MODIFIER", 40, 46]]], ["As a general rule, bacterial infections are easier to treat than viral infections, since the armamentarium of antimicrobial agents with activity against bacteria is more extensive.", [["bacterial infections", "DISEASE", 19, 39], ["viral infections", "DISEASE", 65, 81], ["bacterial infections", "PROBLEM", 19, 39], ["viral infections", "PROBLEM", 65, 81], ["antimicrobial agents", "TREATMENT", 110, 130], ["bacteria", "PROBLEM", 153, 161], ["bacterial", "OBSERVATION_MODIFIER", 19, 28], ["infections", "OBSERVATION", 29, 39], ["infections", "OBSERVATION", 71, 81], ["more extensive", "OBSERVATION_MODIFIER", 165, 179]]], ["More so than with infectious diseases caused by viruses and parasites, however, bacterial resistance to antimicrobials is a rapidly growing problem with potentially devastating consequences.IntroductionBacteria are unique among the prokaryotes in that so many of them are normal flora that colonize the host without causing infection.", [["infectious diseases", "DISEASE", 18, 37], ["infection", "DISEASE", 324, 333], ["infectious diseases", "PROBLEM", 18, 37], ["viruses", "PROBLEM", 48, 55], ["parasites", "PROBLEM", 60, 69], ["bacterial resistance to antimicrobials", "PROBLEM", 80, 118], ["IntroductionBacteria", "PROBLEM", 190, 210], ["infection", "PROBLEM", 324, 333], ["viruses", "OBSERVATION", 48, 55], ["bacterial resistance", "OBSERVATION", 80, 100], ["devastating", "OBSERVATION_MODIFIER", 165, 176], ["without causing", "UNCERTAINTY", 308, 323], ["infection", "OBSERVATION", 324, 333]]], ["Once a person is infected, clinically apparent disease may or may not be seen, and only in a small subset of infections do we see clinically significant disease.", [["infections", "DISEASE", 109, 119], ["person", "SPECIES", 7, 13], ["infected", "PROBLEM", 17, 25], ["clinically apparent disease", "PROBLEM", 27, 54], ["a small subset of infections", "PROBLEM", 91, 119], ["significant disease", "PROBLEM", 141, 160], ["disease", "OBSERVATION", 47, 54], ["may not be", "UNCERTAINTY", 62, 72], ["small", "OBSERVATION_MODIFIER", 93, 98], ["infections", "OBSERVATION", 109, 119], ["disease", "OBSERVATION", 153, 160]]], ["Bacterial infections can be transmitted by a variety of mechanisms.", [["infections", "DISEASE", 10, 20], ["Bacterial infections", "PROBLEM", 0, 20], ["infections", "OBSERVATION", 10, 20]]], ["Many bacteria have adapted to survive in water, soil, food, and elsewhere.", [["Many bacteria", "PROBLEM", 0, 13], ["bacteria", "OBSERVATION", 5, 13]]], ["Some infect vectors such as animals or insects before being transmitted to another human.IntroductionNew species and new variants of familiar species continue to be discovered, particularly as we intrude into new ecosystems.", [["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["Some infect vectors", "PROBLEM", 0, 19], ["New species", "PROBLEM", 101, 112], ["familiar species", "PROBLEM", 133, 149]]], ["Both Lyme disease and Legionnaire's disease, now well-known to health-care professionals, were discovered as recently as the 1970s.", [["Lyme disease", "DISEASE", 5, 17], ["Legionnaire's disease", "DISEASE", 22, 43], ["Both Lyme disease", "PROBLEM", 0, 17], ["Legionnaire's disease", "PROBLEM", 22, 43], ["Lyme disease", "OBSERVATION", 5, 17]]], ["The recent increased prevalence of highly immunosuppressed individuals, both due to AIDS and the increasing use of immunosuppressive drugs as chemotherapy and for transplantation of organs, tissues, and cells, has led to a population of patients highly susceptible to types of bacterial infections that were comparatively rare before.IntroductionSeveral factors lead to the development of bacterial infection and disease.", [["organs", "ANATOMY", 182, 188], ["tissues", "ANATOMY", 190, 197], ["cells", "ANATOMY", 203, 208], ["AIDS", "DISEASE", 84, 88], ["bacterial infections", "DISEASE", 277, 297], ["bacterial infection", "DISEASE", 389, 408], ["organs", "ORGAN", 182, 188], ["tissues", "TISSUE", 190, 197], ["cells", "CELL", 203, 208], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["highly immunosuppressed individuals", "PROBLEM", 35, 70], ["AIDS", "PROBLEM", 84, 88], ["immunosuppressive drugs", "TREATMENT", 115, 138], ["chemotherapy", "TREATMENT", 142, 154], ["transplantation", "TREATMENT", 163, 178], ["organs, tissues, and cells", "PROBLEM", 182, 208], ["bacterial infections", "PROBLEM", 277, 297], ["bacterial infection", "PROBLEM", 389, 408], ["disease", "PROBLEM", 413, 420], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["highly", "OBSERVATION_MODIFIER", 35, 41], ["immunosuppressed", "OBSERVATION", 42, 58], ["organs", "ANATOMY", 182, 188], ["bacterial", "OBSERVATION_MODIFIER", 277, 286], ["infections", "OBSERVATION", 287, 297], ["bacterial", "OBSERVATION_MODIFIER", 389, 398], ["infection", "OBSERVATION", 399, 408]]], ["First, the infectivity of an organism determines the number of individuals that will be infected compared to the number who are susceptible and exposed.", [["an organism", "PROBLEM", 26, 37]]], ["Second, the pathogenicity is a measure of the potential for an infectious organism to cause disease.", [["the pathogenicity", "PROBLEM", 8, 25], ["an infectious organism", "PROBLEM", 60, 82], ["disease", "PROBLEM", 92, 99], ["pathogenicity", "OBSERVATION", 12, 25], ["infectious", "OBSERVATION", 63, 73]]], ["Pathogenic bacteria possess characteristics that allow them to evade the body's protective mechanisms and use its resources, causing disease.", [["body", "ANATOMY", 73, 77], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["Pathogenic bacteria", "PROBLEM", 0, 19], ["disease", "PROBLEM", 133, 140]]], ["Finally, virulence describes the organism's propensity to cause disease, through properties such as invasiveness and the production of toxins.", [["virulence", "PROBLEM", 9, 18], ["disease", "PROBLEM", 64, 71], ["toxins", "PROBLEM", 135, 141]]], ["Host factors are critical in determining whether disease will develop following transmission of a bacterial agent.", [["disease", "PROBLEM", 49, 56], ["a bacterial agent", "TREATMENT", 96, 113]]], ["These factors include genetic makeup, nutritional status, age, duration of exposure to the organism, and coexisting illnesses.", [["the organism", "PROBLEM", 87, 99], ["coexisting illnesses", "PROBLEM", 105, 125]]], ["Air pollution as well as chemicals and contaminants in the environment weaken the body's defenses against bacterial infection.Structure and Classification of BacteriaBacteria are prokaryotic organisms that carry their genetic information in a double-stranded circular molecule of DNA.", [["body", "ANATOMY", 82, 86], ["bacterial infection", "DISEASE", 106, 125], ["body", "ORGANISM_SUBDIVISION", 82, 86], ["BacteriaBacteria", "GENE_OR_GENE_PRODUCT", 158, 174], ["DNA", "CELLULAR_COMPONENT", 280, 283], ["double-stranded circular molecule", "PROTEIN", 243, 276], ["Air pollution", "PROBLEM", 0, 13], ["bacterial infection", "PROBLEM", 106, 125], ["BacteriaBacteria", "PROBLEM", 158, 174], ["prokaryotic organisms", "PROBLEM", 179, 200], ["pollution", "OBSERVATION", 4, 13], ["bacterial", "OBSERVATION_MODIFIER", 106, 115], ["infection", "OBSERVATION", 116, 125]]], ["Some species also contain small circular plasmids of additional DNA.", [["plasmids", "ANATOMY", 41, 49], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["small circular plasmids", "DNA", 26, 49], ["Some species", "PROBLEM", 0, 12], ["small circular plasmids of additional DNA", "PROBLEM", 26, 67], ["species", "OBSERVATION", 5, 12], ["small", "OBSERVATION_MODIFIER", 26, 31], ["circular plasmids", "OBSERVATION", 32, 49], ["additional DNA", "OBSERVATION", 53, 67]]], ["The cell cytoplasm contains ribosomes and there is both a cell membrane and, in all species except Mycoplasma, a complex cell wall.", [["cell cytoplasm", "ANATOMY", 4, 18], ["ribosomes", "ANATOMY", 28, 37], ["cell membrane", "ANATOMY", 58, 71], ["cell wall", "ANATOMY", 121, 130], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 4, 18], ["ribosomes", "CELLULAR_COMPONENT", 28, 37], ["cell membrane", "CELLULAR_COMPONENT", 58, 71], ["cell wall", "CELLULAR_COMPONENT", 121, 130], ["a cell membrane", "PROBLEM", 56, 71], ["Mycoplasma", "PROBLEM", 99, 109], ["a complex cell wall", "PROBLEM", 111, 130], ["cell cytoplasm", "OBSERVATION", 4, 18], ["ribosomes", "OBSERVATION_MODIFIER", 28, 37], ["both", "OBSERVATION_MODIFIER", 51, 55], ["cell membrane", "OBSERVATION", 58, 71], ["Mycoplasma", "OBSERVATION", 99, 109], ["complex", "OBSERVATION_MODIFIER", 113, 120], ["cell", "OBSERVATION", 121, 125], ["wall", "ANATOMY_MODIFIER", 126, 130]]], ["External to the cell wall, some bacteria have capsules, flagella, or pili (see Figure 1).", [["cell wall", "ANATOMY", 16, 25], ["capsules", "ANATOMY", 46, 54], ["flagella", "ANATOMY", 56, 64], ["cell wall", "CELLULAR_COMPONENT", 16, 25], ["flagella", "CELLULAR_COMPONENT", 56, 64], ["pili", "PROTEIN", 69, 73], ["some bacteria", "PROBLEM", 27, 40], ["capsules", "TREATMENT", 46, 54], ["flagella", "PROBLEM", 56, 64], ["cell wall", "ANATOMY", 16, 25], ["some", "OBSERVATION_MODIFIER", 27, 31], ["bacteria", "OBSERVATION", 32, 40]]], ["Bacteria normally reproduce by binary fission.", [["Bacteria", "PROBLEM", 0, 8], ["binary fission", "OBSERVATION", 31, 45]]], ["Under the proper conditions, some bacteria can divide and multiply rapidly.", [["some bacteria", "PROBLEM", 29, 42], ["bacteria", "OBSERVATION", 34, 42], ["multiply", "OBSERVATION_MODIFIER", 58, 66], ["rapidly", "OBSERVATION_MODIFIER", 67, 74]]], ["Consequently, some infections require only a small number of organisms to cause potentially overwhelming infection.Structure and Classification of BacteriaBacteria are classified as Gram-positive or Gram-negative based on the characteristics of their cell wall, as seen under a microscope after stains have been administered, a procedure called Gram staining, that was developed in 1882 by Hans Christian Gram (see Figure 2).", [["cell wall", "ANATOMY", 251, 260], ["infections", "DISEASE", 19, 29], ["infection", "DISEASE", 105, 114], ["Gram-", "GENE_OR_GENE_PRODUCT", 182, 187], ["Gram", "GENE_OR_GENE_PRODUCT", 199, 203], ["cell wall", "MULTI-TISSUE_STRUCTURE", 251, 260], ["some infections", "PROBLEM", 14, 29], ["overwhelming infection", "PROBLEM", 92, 114], ["BacteriaBacteria", "TEST", 147, 163], ["Gram-", "TEST", 182, 187], ["Gram", "TEST", 199, 203], ["a procedure", "TREATMENT", 326, 337], ["Gram staining", "TEST", 345, 358], ["some", "OBSERVATION_MODIFIER", 14, 18], ["infections", "OBSERVATION", 19, 29], ["small number", "OBSERVATION_MODIFIER", 45, 57], ["overwhelming", "OBSERVATION_MODIFIER", 92, 104], ["infection", "OBSERVATION", 105, 114], ["cell", "OBSERVATION", 251, 255], ["wall", "ANATOMY_MODIFIER", 256, 260]]], ["Most, but not all, bacteria fall into one of these two categories.", [["bacteria fall", "PROBLEM", 19, 32], ["bacteria", "OBSERVATION", 19, 27]]], ["Clinically, one of the main differences between gram-positive and gram-negative organisms is that gram-negative bacteria tend to produce an endotoxin that can cause tissue destruction, shock, and death.", [["tissue", "ANATOMY", 165, 171], ["shock", "DISEASE", 185, 190], ["death", "DISEASE", 196, 201], ["gram-positive", "GENE_OR_GENE_PRODUCT", 48, 61], ["tissue", "TISSUE", 165, 171], ["gram", "TEST", 48, 52], ["gram", "TEST", 66, 70], ["gram-negative bacteria", "PROBLEM", 98, 120], ["an endotoxin", "PROBLEM", 137, 149], ["tissue destruction", "PROBLEM", 165, 183], ["shock", "PROBLEM", 185, 190], ["death", "PROBLEM", 196, 201], ["main", "OBSERVATION_MODIFIER", 23, 27], ["negative organisms", "OBSERVATION", 71, 89], ["negative bacteria", "OBSERVATION_MODIFIER", 103, 120], ["destruction", "OBSERVATION", 172, 183], ["shock", "OBSERVATION", 185, 190]]], ["The two classes of bacteria differ in their antibiotic susceptibilities as well.Structure and Classification of BacteriaBacteria can also be classified based on their growth responses in the presence and absence of oxygen.", [["oxygen", "CHEMICAL", 215, 221], ["oxygen", "CHEMICAL", 215, 221], ["oxygen", "SIMPLE_CHEMICAL", 215, 221], ["bacteria", "PROBLEM", 19, 27], ["their antibiotic susceptibilities", "TEST", 38, 71], ["BacteriaBacteria", "TREATMENT", 112, 128], ["oxygen", "TREATMENT", 215, 221], ["bacteria", "OBSERVATION", 19, 27], ["oxygen", "OBSERVATION_MODIFIER", 215, 221]]], ["Aerobic bacteria, or aerobes, grow in the presence of oxygen.", [["oxygen", "CHEMICAL", 54, 60], ["oxygen", "CHEMICAL", 54, 60], ["oxygen", "SIMPLE_CHEMICAL", 54, 60], ["Aerobic bacteria", "PROBLEM", 0, 16], ["aerobes", "PROBLEM", 21, 28], ["bacteria", "OBSERVATION", 8, 16], ["aerobes", "OBSERVATION", 21, 28], ["oxygen", "OBSERVATION_MODIFIER", 54, 60]]], ["Obligate aerobes such as Bordetella pertussis require oxygen.", [["Bordetella pertussis", "DISEASE", 25, 45], ["oxygen", "CHEMICAL", 54, 60], ["oxygen", "CHEMICAL", 54, 60], ["Bordetella pertussis", "ORGANISM", 25, 45], ["oxygen", "SIMPLE_CHEMICAL", 54, 60], ["Bordetella pertussis", "SPECIES", 25, 45], ["Bordetella pertussis", "SPECIES", 25, 45], ["Obligate aerobes", "PROBLEM", 0, 16], ["Bordetella pertussis", "PROBLEM", 25, 45], ["oxygen", "TREATMENT", 54, 60], ["aerobes", "OBSERVATION", 9, 16]]], ["Facultative organisms can grow in the presence or absence of oxygen.", [["oxygen", "CHEMICAL", 61, 67], ["oxygen", "CHEMICAL", 61, 67], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["Facultative organisms", "PROBLEM", 0, 21], ["oxygen", "TREATMENT", 61, 67], ["oxygen", "OBSERVATION_MODIFIER", 61, 67]]], ["Anaerobic bacteria such as the Clostridia are able to grow in the absence of oxygen and obligate anaerobes require its absence.Structure and Classification of BacteriaSome bacteria are not classified as Gram-positive or Gram-negative.", [["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "SIMPLE_CHEMICAL", 77, 83], ["Gram-", "GENE_OR_GENE_PRODUCT", 203, 208], ["Gram-", "GENE_OR_GENE_PRODUCT", 220, 225], ["Anaerobic bacteria", "PROBLEM", 0, 18], ["the Clostridia", "PROBLEM", 27, 41], ["oxygen", "TREATMENT", 77, 83], ["obligate anaerobes", "PROBLEM", 88, 106], ["BacteriaSome bacteria", "PROBLEM", 159, 180], ["Gram-", "TEST", 220, 225], ["bacteria", "OBSERVATION", 10, 18], ["BacteriaSome bacteria", "OBSERVATION", 159, 180]]], ["These include the mycobacteria, of which Mycobacterium tuberculosis is the most well-known, which can be seen under the microscope using a special stain called the acid-fast stain; organisms that do not take up Gram stain such as the spirochetes (which cause diseases such as syphilis and Lyme disease); and the Rickettsia (which cause Rocky Mountain spotted fever and epidemic typhus).Clinical Manifestations of Bacterial InfectionAll of the human organs are susceptible to bacterial infection.", [["organs", "ANATOMY", 449, 455], ["Mycobacterium tuberculosis", "DISEASE", 41, 67], ["syphilis", "DISEASE", 276, 284], ["Lyme disease", "DISEASE", 289, 301], ["Rocky Mountain spotted fever", "DISEASE", 336, 364], ["typhus", "DISEASE", 378, 384], ["bacterial infection", "DISEASE", 475, 494], ["Mycobacterium tuberculosis", "ORGANISM", 41, 67], ["human", "ORGANISM", 443, 448], ["organs", "ORGAN", 449, 455], ["Mycobacterium tuberculosis", "SPECIES", 41, 67], ["human", "SPECIES", 443, 448], ["Mycobacterium tuberculosis", "SPECIES", 41, 67], ["Rocky Mountain spotted fever and epidemic typhus", "SPECIES", 336, 384], ["human", "SPECIES", 443, 448], ["the mycobacteria", "PROBLEM", 14, 30], ["Mycobacterium tuberculosis", "PROBLEM", 41, 67], ["a special stain", "TEST", 137, 152], ["the acid-fast stain", "TEST", 160, 179], ["organisms", "PROBLEM", 181, 190], ["Gram stain", "TEST", 211, 221], ["the spirochetes", "PROBLEM", 230, 245], ["diseases", "PROBLEM", 259, 267], ["syphilis", "PROBLEM", 276, 284], ["Lyme disease)", "PROBLEM", 289, 302], ["the Rickettsia", "PROBLEM", 308, 322], ["Rocky Mountain spotted fever", "PROBLEM", 336, 364], ["epidemic typhus", "PROBLEM", 369, 384], ["Bacterial InfectionAll of the human organs", "PROBLEM", 413, 455], ["bacterial infection", "PROBLEM", 475, 494], ["mycobacteria", "OBSERVATION", 18, 30], ["Mycobacterium", "OBSERVATION_MODIFIER", 41, 54], ["tuberculosis", "OBSERVATION", 55, 67], ["Bacterial InfectionAll", "OBSERVATION", 413, 435], ["human organs", "ANATOMY", 443, 455], ["bacterial", "OBSERVATION_MODIFIER", 475, 484], ["infection", "OBSERVATION", 485, 494]]], ["Each species of bacteria has a predilection to infect certain organs and not others.", [["organs", "ANATOMY", 62, 68], ["organs", "ORGAN", 62, 68], ["bacteria", "PROBLEM", 16, 24], ["bacteria", "OBSERVATION", 16, 24]]], ["For example, Neisseria meningitidis normally infects the meninges (covering) of the central nervous system, causing meningitis, and can also infect the lungs, causing pneumonia.", [["meninges", "ANATOMY", 57, 65], ["central nervous system", "ANATOMY", 84, 106], ["lungs", "ANATOMY", 152, 157], ["Neisseria meningitidis", "DISEASE", 13, 35], ["meningitis", "DISEASE", 116, 126], ["pneumonia", "DISEASE", 167, 176], ["Neisseria meningitidis", "ORGANISM", 13, 35], ["meninges", "ORGAN", 57, 65], ["central nervous system", "ANATOMICAL_SYSTEM", 84, 106], ["lungs", "ORGAN", 152, 157], ["Neisseria meningitidis", "SPECIES", 13, 35], ["Neisseria meningitidis", "SPECIES", 13, 35], ["Neisseria meningitidis", "PROBLEM", 13, 35], ["meningitis", "PROBLEM", 116, 126], ["pneumonia", "PROBLEM", 167, 176], ["Neisseria", "OBSERVATION_MODIFIER", 13, 22], ["meningitidis", "OBSERVATION", 23, 35], ["meninges", "OBSERVATION_MODIFIER", 57, 65], ["central", "ANATOMY_MODIFIER", 84, 91], ["nervous system", "ANATOMY", 92, 106], ["meningitis", "OBSERVATION", 116, 126], ["lungs", "ANATOMY", 152, 157], ["pneumonia", "OBSERVATION", 167, 176]]], ["It is not, however, a cause of skin infection.", [["skin", "ANATOMY", 31, 35], ["skin infection", "DISEASE", 31, 45], ["skin", "ORGAN", 31, 35], ["skin infection", "PROBLEM", 31, 45], ["skin", "ANATOMY", 31, 35], ["infection", "OBSERVATION", 36, 45]]], ["Staphylococcus aureus, which people typically carry on their skin or mucus membranes, often causes skin and soft tissue infections, but also spreads readily throughout the body via the bloodstream and can cause infection of the lungs, abdomen, heart valves, and almost any other site.Clinical Manifestations of Bacterial InfectionDisease can be caused by destruction of the body's cells by the organism or the body's immune response to the infection.", [["skin", "ANATOMY", 61, 65], ["mucus membranes", "ANATOMY", 69, 84], ["skin", "ANATOMY", 99, 103], ["soft tissue", "ANATOMY", 108, 119], ["body", "ANATOMY", 172, 176], ["bloodstream", "ANATOMY", 185, 196], ["lungs", "ANATOMY", 228, 233], ["abdomen", "ANATOMY", 235, 242], ["heart", "ANATOMY", 244, 249], ["body", "ANATOMY", 374, 378], ["cells", "ANATOMY", 381, 386], ["body", "ANATOMY", 410, 414], ["Staphylococcus aureus", "DISEASE", 0, 21], ["skin and soft tissue infections", "DISEASE", 99, 130], ["infection of the lungs", "DISEASE", 211, 233], ["Bacterial InfectionDisease", "DISEASE", 311, 337], ["infection", "DISEASE", 440, 449], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["people", "ORGANISM", 29, 35], ["skin", "ORGAN", 61, 65], ["mucus membranes", "CELLULAR_COMPONENT", 69, 84], ["skin", "ORGAN", 99, 103], ["soft tissue", "TISSUE", 108, 119], ["body", "ORGANISM_SUBDIVISION", 172, 176], ["lungs", "ORGAN", 228, 233], ["abdomen", "ORGAN", 235, 242], ["heart valves", "MULTI-TISSUE_STRUCTURE", 244, 256], ["body's cells", "CELL", 374, 386], ["body", "ORGANISM_SUBDIVISION", 410, 414], ["Staphylococcus aureus", "SPECIES", 0, 21], ["people", "SPECIES", 29, 35], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "PROBLEM", 0, 21], ["mucus membranes", "PROBLEM", 69, 84], ["skin and soft tissue infections", "PROBLEM", 99, 130], ["infection of the lungs, abdomen, heart valves", "PROBLEM", 211, 256], ["Bacterial InfectionDisease", "PROBLEM", 311, 337], ["destruction of the body's cells", "PROBLEM", 355, 386], ["the organism", "PROBLEM", 390, 402], ["the infection", "PROBLEM", 436, 449], ["aureus", "OBSERVATION", 15, 21], ["skin", "ANATOMY", 61, 65], ["mucus membranes", "OBSERVATION", 69, 84], ["skin", "ANATOMY", 99, 103], ["soft tissue", "OBSERVATION_MODIFIER", 108, 119], ["infections", "OBSERVATION", 120, 130], ["bloodstream", "ANATOMY", 185, 196], ["infection", "OBSERVATION", 211, 220], ["lungs", "ANATOMY", 228, 233], ["abdomen", "ANATOMY", 235, 242], ["heart valves", "ANATOMY", 244, 256], ["Bacterial InfectionDisease", "OBSERVATION", 311, 337], ["destruction", "OBSERVATION", 355, 366], ["body", "ANATOMY", 374, 378], ["infection", "OBSERVATION", 440, 449]]], ["Antibiotics may be of little or no use when the disease manifestations are a result of the body's attempts to rid itself of the bacteria.", [["body", "ANATOMY", 91, 95], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["Antibiotics", "TREATMENT", 0, 11], ["the disease manifestations", "PROBLEM", 44, 70], ["the bacteria", "PROBLEM", 124, 136], ["bacteria", "OBSERVATION", 128, 136]]], ["The systemic inflammatory response syndrome (SIRS), usually caused by a bacterial infection, is an overwhelming inflammatory response to infection, manifested by the release of large numbers of cytokines and presenting with signs of infection and early signs of hemodynamic instability.", [["systemic inflammatory response syndrome", "DISEASE", 4, 43], ["SIRS", "DISEASE", 45, 49], ["bacterial infection", "DISEASE", 72, 91], ["infection", "DISEASE", 137, 146], ["infection", "DISEASE", 233, 242], ["hemodynamic instability", "DISEASE", 262, 285], ["cytokines", "PROTEIN", 194, 203], ["The systemic inflammatory response syndrome", "PROBLEM", 0, 43], ["SIRS", "PROBLEM", 45, 49], ["a bacterial infection", "PROBLEM", 70, 91], ["an overwhelming inflammatory response", "PROBLEM", 96, 133], ["infection", "PROBLEM", 137, 146], ["large numbers of cytokines", "PROBLEM", 177, 203], ["infection", "PROBLEM", 233, 242], ["hemodynamic instability", "PROBLEM", 262, 285], ["systemic", "OBSERVATION_MODIFIER", 4, 12], ["inflammatory response syndrome", "OBSERVATION", 13, 43], ["bacterial", "OBSERVATION_MODIFIER", 72, 81], ["infection", "OBSERVATION", 82, 91], ["overwhelming", "OBSERVATION_MODIFIER", 99, 111], ["inflammatory", "OBSERVATION_MODIFIER", 112, 124], ["infection", "OBSERVATION", 137, 146], ["large", "OBSERVATION_MODIFIER", 177, 182], ["numbers", "OBSERVATION_MODIFIER", 183, 190], ["infection", "OBSERVATION", 233, 242], ["hemodynamic instability", "OBSERVATION", 262, 285]]], ["If allowed to progress, SIRS patients can go on to develop sepsis, with multiorgan failure and death.", [["multiorgan", "ANATOMY", 72, 82], ["SIRS", "DISEASE", 24, 28], ["sepsis", "DISEASE", 59, 65], ["multiorgan failure", "DISEASE", 72, 90], ["death", "DISEASE", 95, 100], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["SIRS", "PROBLEM", 24, 28], ["sepsis", "PROBLEM", 59, 65], ["multiorgan failure", "PROBLEM", 72, 90], ["death", "PROBLEM", 95, 100], ["sepsis", "OBSERVATION", 59, 65], ["multiorgan failure", "OBSERVATION", 72, 90]]], ["Once the cascade of events has begun, even the strongest antibiotics are often powerless to stop this progression.Human reservoirs ::: Reservoirs ::: EpidemiologyHumans are the reservoirs for many bacterial infections and in some instances they are the exclusive host in nature to harbor the bacteria.", [["bacterial infections", "DISEASE", 197, 217], ["Human", "ORGANISM", 114, 119], ["Human", "SPECIES", 114, 119], ["Human", "SPECIES", 114, 119], ["the strongest antibiotics", "TREATMENT", 43, 68], ["EpidemiologyHumans", "TREATMENT", 150, 168], ["the reservoirs", "TREATMENT", 173, 187], ["many bacterial infections", "PROBLEM", 192, 217], ["reservoirs", "OBSERVATION_MODIFIER", 177, 187], ["bacterial", "OBSERVATION_MODIFIER", 197, 206], ["infections", "OBSERVATION", 207, 217], ["bacteria", "OBSERVATION", 292, 300]]], ["When a human is colonized with a pathogen without manifesting disease, he or she is referred to as a carrier.", [["human", "ORGANISM", 7, 12], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["manifesting disease", "PROBLEM", 50, 69]]], ["Passive carriers carry pathogens without ever having the disease.", [["Passive carriers carry pathogens", "PROBLEM", 0, 32], ["the disease", "PROBLEM", 53, 64], ["disease", "OBSERVATION", 57, 64]]], ["The deadly meningitis caused by Neisseria meningitidis is often transmitted by passive carriers who harbor the bacteria in their respiratory tracts.", [["respiratory tracts", "ANATOMY", 129, 147], ["meningitis", "DISEASE", 11, 21], ["Neisseria meningitidis", "DISEASE", 32, 54], ["Neisseria meningitidis", "ORGANISM", 32, 54], ["Neisseria meningitidis", "SPECIES", 32, 54], ["Neisseria meningitidis", "SPECIES", 32, 54], ["The deadly meningitis", "PROBLEM", 0, 21], ["Neisseria meningitidis", "PROBLEM", 32, 54], ["the bacteria in their respiratory tracts", "PROBLEM", 107, 147], ["deadly", "OBSERVATION_MODIFIER", 4, 10], ["meningitis", "OBSERVATION", 11, 21], ["Neisseria meningitidis", "OBSERVATION", 32, 54], ["bacteria", "OBSERVATION", 111, 119], ["respiratory tracts", "ANATOMY", 129, 147]]], ["An incubatory carrier is a person who is harboring, and can transmit, an infection during the incubation period (the time between acquisition and manifestation of illness) for that infection.", [["infection", "DISEASE", 73, 82], ["illness", "DISEASE", 163, 170], ["infection", "DISEASE", 181, 190], ["person", "SPECIES", 27, 33], ["an infection", "PROBLEM", 70, 82], ["illness", "PROBLEM", 163, 170], ["that infection", "PROBLEM", 176, 190], ["infection", "OBSERVATION", 73, 82], ["infection", "OBSERVATION", 181, 190]]], ["Sexually transmitted infections are frequently transferred by individuals who have not yet shown symptoms.", [["Sexually transmitted infections", "DISEASE", 0, 31], ["Sexually transmitted infections", "PROBLEM", 0, 31], ["symptoms", "PROBLEM", 97, 105], ["infections", "OBSERVATION", 21, 31]]], ["Convalescent carriers manifested symptoms of an infectious disease in the recent past and continue to carry the organism during their recovery period.", [["Convalescent carriers", "PROBLEM", 0, 21], ["symptoms", "PROBLEM", 33, 41], ["an infectious disease", "PROBLEM", 45, 66], ["infectious", "OBSERVATION", 48, 58]]], ["Active carriers have completely recovered from a disease and harbor the organism indefinitely.", [["Active carriers", "PROBLEM", 0, 15], ["a disease and harbor the organism", "PROBLEM", 47, 80], ["disease", "OBSERVATION", 49, 56]]], ["Salmonella, especially Salmonella Typhi, the cause of typhoid fever, is an example of a bacterial infection that can produce a prolonged carrier state without the individual being aware of the condition.", [["Salmonella", "CHEMICAL", 0, 10], ["Salmonella Typhi", "DISEASE", 23, 39], ["typhoid fever", "DISEASE", 54, 67], ["bacterial infection", "DISEASE", 88, 107], ["Salmonella Typhi", "ORGANISM", 23, 39], ["Salmonella Typhi", "SPECIES", 23, 39], ["Salmonella", "SPECIES", 0, 10], ["Salmonella Typhi", "SPECIES", 23, 39], ["Salmonella", "PROBLEM", 0, 10], ["Salmonella Typhi", "PROBLEM", 23, 39], ["typhoid fever", "PROBLEM", 54, 67], ["a bacterial infection", "PROBLEM", 86, 107], ["typhoid", "OBSERVATION_MODIFIER", 54, 61], ["fever", "OBSERVATION", 62, 67], ["bacterial", "OBSERVATION_MODIFIER", 88, 97], ["infection", "OBSERVATION", 98, 107]]], ["Salmonella can lurk in a quiescent state in organs such as the gallbladder, sometimes even permanently.", [["organs", "ANATOMY", 44, 50], ["gallbladder", "ANATOMY", 63, 74], ["organs", "ORGAN", 44, 50], ["gallbladder", "ORGAN", 63, 74], ["Salmonella", "SPECIES", 0, 10], ["Salmonella", "PROBLEM", 0, 10], ["gallbladder", "ANATOMY", 63, 74]]], ["Mary Mallon, a New York City cook in the early 1900s, known as Typhoid Mary, was a carrier responsible for many cases of typhoid fever.Animal reservoirs ::: Reservoirs ::: EpidemiologyInfections acquired from animal reservoirs are referred to as zoonoses or zoonotic diseases.", [["Typhoid", "DISEASE", 63, 70], ["typhoid fever", "DISEASE", 121, 134], ["Infections", "DISEASE", 184, 194], ["zoonoses", "DISEASE", 246, 254], ["zoonotic diseases", "DISEASE", 258, 275], ["typhoid fever", "PROBLEM", 121, 134], ["Infections", "PROBLEM", 184, 194], ["animal reservoirs", "TREATMENT", 209, 226], ["zoonotic diseases", "PROBLEM", 258, 275], ["New", "OBSERVATION_MODIFIER", 15, 18], ["typhoid", "OBSERVATION", 121, 128]]], ["Humans acquire infection from animals either by direct contact, as in the case of pets or farm animals, by ingestion of the animal or inhalation of bacteria in or around its hide, or through an insect vector that transmits the pathogen from the animal to the human via a bite.", [["infection", "DISEASE", 15, 24], ["Humans", "ORGANISM", 0, 6], ["human", "ORGANISM", 259, 264], ["human", "SPECIES", 259, 264], ["human", "SPECIES", 259, 264], ["Humans acquire infection", "PROBLEM", 0, 24], ["bacteria", "PROBLEM", 148, 156], ["infection", "OBSERVATION", 15, 24]]], ["Diarrhea caused by Salmonella can occur after handling turtles and contaminating one's hands with their feces, or from ingesting undercooked chicken contaminated with the bacteria, or through other routes such as eating undercooked or raw chicken eggs.", [["feces", "ANATOMY", 104, 109], ["eggs", "ANATOMY", 247, 251], ["Diarrhea", "DISEASE", 0, 8], ["hands", "ORGANISM_SUBDIVISION", 87, 92], ["feces", "ORGANISM_SUBDIVISION", 104, 109], ["chicken", "ORGANISM", 141, 148], ["chicken", "ORGANISM", 239, 246], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 247, 251], ["chicken", "SPECIES", 141, 148], ["chicken", "SPECIES", 239, 246], ["Salmonella", "SPECIES", 19, 29], ["chicken", "SPECIES", 141, 148], ["chicken", "SPECIES", 239, 246], ["Diarrhea", "PROBLEM", 0, 8], ["Salmonella", "PROBLEM", 19, 29], ["their feces", "PROBLEM", 98, 109], ["the bacteria", "PROBLEM", 167, 179], ["Salmonella", "OBSERVATION", 19, 29]]], ["The disease tularemia, caused by the organism Francisella tularensis, is often seen in individuals who have recently skinned a rabbit.", [["tularemia", "DISEASE", 12, 21], ["Francisella tularensis", "ORGANISM", 46, 68], ["rabbit", "ORGANISM", 127, 133], ["Francisella tularensis", "SPECIES", 46, 68], ["rabbit", "SPECIES", 127, 133], ["Francisella tularensis", "SPECIES", 46, 68], ["rabbit", "SPECIES", 127, 133], ["The disease tularemia", "PROBLEM", 0, 21], ["the organism Francisella tularensis", "PROBLEM", 33, 68], ["disease", "OBSERVATION_MODIFIER", 4, 11], ["tularemia", "OBSERVATION", 12, 21], ["Francisella tularensis", "OBSERVATION", 46, 68]]], ["Similarly, anthrax caused by Bacillus anthracis follows either inhalation of spores from dead animals or hides, or entry of spores into a wound.", [["spores", "ANATOMY", 124, 130], ["wound", "ANATOMY", 138, 143], ["anthrax", "DISEASE", 11, 18], ["Bacillus anthracis", "ORGANISM", 29, 47], ["wound", "PATHOLOGICAL_FORMATION", 138, 143], ["Bacillus anthracis", "SPECIES", 29, 47], ["Bacillus anthracis", "SPECIES", 29, 47], ["anthrax", "PROBLEM", 11, 18], ["Bacillus anthracis", "PROBLEM", 29, 47], ["a wound", "PROBLEM", 136, 143], ["wound", "OBSERVATION", 138, 143]]], ["In Lyme disease, the deer tick transmits the spirochete Borrelia from the white-footed mouse to the human.Animal reservoirs ::: Reservoirs ::: EpidemiologyOverflow is a phenomenon particularly relevant to zoonotic diseases.", [["Lyme disease", "DISEASE", 3, 15], ["zoonotic diseases", "DISEASE", 205, 222], ["deer", "ORGANISM", 21, 25], ["spirochete Borrelia", "ORGANISM", 45, 64], ["mouse", "ORGANISM", 87, 92], ["human", "ORGANISM", 100, 105], ["deer", "SPECIES", 21, 25], ["mouse", "SPECIES", 87, 92], ["human", "SPECIES", 100, 105], ["deer tick", "SPECIES", 21, 30], ["white-footed mouse", "SPECIES", 74, 92], ["human", "SPECIES", 100, 105], ["Lyme disease", "PROBLEM", 3, 15], ["the spirochete Borrelia", "PROBLEM", 41, 64], ["a phenomenon", "PROBLEM", 167, 179], ["zoonotic diseases", "PROBLEM", 205, 222], ["Lyme disease", "OBSERVATION", 3, 15], ["spirochete", "OBSERVATION_MODIFIER", 45, 55], ["human", "ANATOMY", 100, 105]]], ["Using the example of Lyme disease, the cycle of transmission between tick hosts and animal hosts (such as deer and mice) leads to the presence of infected ticks that can also infect humans.", [["Lyme disease", "DISEASE", 21, 33], ["tick hosts", "ORGANISM", 69, 79], ["deer", "ORGANISM", 106, 110], ["mice", "ORGANISM", 115, 119], ["ticks", "ORGANISM", 155, 160], ["humans", "ORGANISM", 182, 188], ["deer", "SPECIES", 106, 110], ["mice", "SPECIES", 115, 119], ["humans", "SPECIES", 182, 188], ["deer", "SPECIES", 106, 110], ["mice", "SPECIES", 115, 119], ["humans", "SPECIES", 182, 188], ["Lyme disease", "PROBLEM", 21, 33], ["tick hosts", "TREATMENT", 69, 79], ["infected ticks", "PROBLEM", 146, 160], ["Lyme disease", "OBSERVATION", 21, 33], ["infected", "OBSERVATION_MODIFIER", 146, 154], ["ticks", "OBSERVATION", 155, 160]]], ["Thus the cycle allows the Lyme organisms to overflow from the natural cycle of infection into humans.", [["infection", "DISEASE", 79, 88], ["humans", "ORGANISM", 94, 100], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["the Lyme organisms", "PROBLEM", 22, 40], ["overflow", "PROBLEM", 44, 52], ["infection into humans", "PROBLEM", 79, 100], ["infection", "OBSERVATION", 79, 88]]], ["Reducing the number of infected deer on a New England island through culling, for example, has been shown to greatly decrease the number of infected ticks and almost eliminate infection in humans.Arthropod reservoirs ::: Reservoirs ::: EpidemiologyArthropods reservoirs include insects and arachnids.", [["infection", "DISEASE", 176, 185], ["deer", "ORGANISM", 32, 36], ["humans", "ORGANISM", 189, 195], ["humans", "SPECIES", 189, 195], ["deer", "SPECIES", 32, 36], ["humans", "SPECIES", 189, 195], ["infected ticks", "PROBLEM", 140, 154], ["infection in humans", "PROBLEM", 176, 195], ["Arthropods reservoirs", "TREATMENT", 248, 269], ["arachnids", "TREATMENT", 290, 299], ["number", "OBSERVATION_MODIFIER", 13, 19], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["New", "OBSERVATION_MODIFIER", 42, 45], ["decrease", "OBSERVATION_MODIFIER", 117, 125], ["number", "OBSERVATION_MODIFIER", 130, 136], ["infected", "OBSERVATION_MODIFIER", 140, 148], ["ticks", "OBSERVATION", 149, 154], ["infection", "OBSERVATION", 176, 185]]], ["A vector is commonly understood to be an arthropod that is involved in the transmission of disease.", [["A vector", "TREATMENT", 0, 8], ["disease", "PROBLEM", 91, 98], ["disease", "OBSERVATION", 91, 98]]], ["Common insect vectors for bacterial infection include fleas, lice, and flies.", [["bacterial infection", "DISEASE", 26, 45], ["lice", "ORGANISM_SUBDIVISION", 61, 65], ["Common insect vectors", "TREATMENT", 0, 21], ["bacterial infection", "PROBLEM", 26, 45], ["fleas", "PROBLEM", 54, 59], ["bacterial", "OBSERVATION_MODIFIER", 26, 35], ["infection", "OBSERVATION", 36, 45]]], ["Arachnid vectors include mites and ticks.", [["Arachnid vectors", "TREATMENT", 0, 16]]], ["The diseases caused by the bacteria Borrelia (which include relapsing fever and the disease referred to in the Unites States as Lyme disease after it was discovered in Lyme, Connecticut) infects ticks that take a blood meal from an infected deer or mouse.", [["blood", "ANATOMY", 213, 218], ["Borrelia", "DISEASE", 36, 44], ["relapsing fever", "DISEASE", 60, 75], ["Lyme disease", "DISEASE", 128, 140], ["Lyme", "DISEASE", 168, 172], ["ticks", "ORGANISM", 195, 200], ["blood", "ORGANISM_SUBSTANCE", 213, 218], ["deer", "ORGANISM", 241, 245], ["mouse", "ORGANISM", 249, 254], ["deer", "SPECIES", 241, 245], ["mouse", "SPECIES", 249, 254], ["deer", "SPECIES", 241, 245], ["mouse", "SPECIES", 249, 254], ["The diseases", "PROBLEM", 0, 12], ["the bacteria Borrelia", "PROBLEM", 23, 44], ["relapsing fever", "PROBLEM", 60, 75], ["the disease", "PROBLEM", 80, 91], ["Lyme disease", "PROBLEM", 128, 140], ["a blood meal", "TREATMENT", 211, 223], ["diseases", "OBSERVATION", 4, 12], ["infected", "OBSERVATION", 232, 240]]], ["These ticks (see Figure 3) then inject the bacteria into a human some time later during another blood meal.", [["blood", "ANATOMY", 96, 101], ["human", "ORGANISM", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["the bacteria", "PROBLEM", 39, 51], ["another blood meal", "TREATMENT", 88, 106]]], ["Other bacterial diseases caused by arthropods include epidemic, murine, and scrub typhus, caused by Rickettsia carried by lice, fleas, and mites, respectively, Rocky Mountain spotted fever also caused by Rickettsia and carried by ticks, and bubonic plague carried by fleas.Nonliving reservoirs ::: Reservoirs ::: EpidemiologyAir can become contaminated by dust or human respiratory secretions containing pathogenic bacteria.", [["respiratory secretions", "ANATOMY", 370, 392], ["bacterial diseases", "DISEASE", 6, 24], ["murine, and scrub typhus", "DISEASE", 64, 88], ["fever", "DISEASE", 183, 188], ["bubonic plague", "DISEASE", 241, 255], ["murine", "ORGANISM", 64, 70], ["scrub typhus", "ORGANISM", 76, 88], ["dust", "ORGANISM_SUBSTANCE", 356, 360], ["human", "ORGANISM", 364, 369], ["murine", "SPECIES", 64, 70], ["human", "SPECIES", 364, 369], ["scrub typhus", "SPECIES", 76, 88], ["human", "SPECIES", 364, 369], ["Other bacterial diseases", "PROBLEM", 0, 24], ["scrub typhus", "PROBLEM", 76, 88], ["Rickettsia", "PROBLEM", 100, 110], ["fever", "PROBLEM", 183, 188], ["Rickettsia", "PROBLEM", 204, 214], ["bubonic plague", "PROBLEM", 241, 255], ["human respiratory secretions", "PROBLEM", 364, 392], ["pathogenic bacteria", "PROBLEM", 404, 423], ["bacterial diseases", "OBSERVATION", 6, 24], ["respiratory secretions", "OBSERVATION", 370, 392], ["pathogenic", "OBSERVATION_MODIFIER", 404, 414], ["bacteria", "OBSERVATION_MODIFIER", 415, 423]]], ["Bacteria do not multiply in the air itself, but may be transported by air currents to areas more conducive to their growth.", [["Bacteria", "PROBLEM", 0, 8], ["air", "OBSERVATION", 32, 35], ["may be", "UNCERTAINTY", 48, 54]]], ["Infections acquired through the air are characterized as airborne.", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10], ["air", "OBSERVATION", 32, 35], ["airborne", "OBSERVATION_MODIFIER", 57, 65]]], ["The classic airborne bacterial infection is tuberculosis.Nonliving reservoirs ::: Reservoirs ::: EpidemiologySoil is typically a reservoir for bacteria that form spores when not in a host.", [["spores", "ANATOMY", 162, 168], ["bacterial infection", "DISEASE", 21, 40], ["tuberculosis", "DISEASE", 44, 56], ["The classic airborne bacterial infection", "PROBLEM", 0, 40], ["tuberculosis", "PROBLEM", 44, 56], ["EpidemiologySoil", "TREATMENT", 97, 113], ["bacteria", "PROBLEM", 143, 151], ["airborne", "OBSERVATION_MODIFIER", 12, 20], ["bacterial", "OBSERVATION_MODIFIER", 21, 30], ["infection", "OBSERVATION", 31, 40], ["tuberculosis", "OBSERVATION", 44, 56]]], ["The various species of Clostridium can be acquired from exposure of a wound to dirt or soil.", [["wound", "ANATOMY", 70, 75], ["Clostridium", "ORGANISM", 23, 34], ["wound", "PATHOLOGICAL_FORMATION", 70, 75], ["Clostridium", "PROBLEM", 23, 34], ["a wound", "PROBLEM", 68, 75], ["Clostridium", "OBSERVATION", 23, 34], ["wound", "OBSERVATION", 70, 75]]], ["These anaerobic bacteria cause tetanus, botulism, and gas gangrene.", [["tetanus", "DISEASE", 31, 38], ["botulism", "DISEASE", 40, 48], ["gas gangrene", "DISEASE", 54, 66], ["These anaerobic bacteria", "PROBLEM", 0, 24], ["tetanus", "PROBLEM", 31, 38], ["botulism", "PROBLEM", 40, 48], ["gas gangrene", "PROBLEM", 54, 66], ["anaerobic bacteria", "OBSERVATION", 6, 24], ["botulism", "OBSERVATION", 40, 48], ["gas gangrene", "OBSERVATION", 54, 66]]], ["Anthrax spores can survive for as long as 100 years in soil.", [["spores", "ANATOMY", 8, 14], ["Anthrax", "DISEASE", 0, 7]]], ["Heavy rain, excavation, and tilling may bring them to the surface and cause an outbreak of anthrax among livestock.", [["surface", "ANATOMY", 58, 65], ["anthrax", "DISEASE", 91, 98], ["surface", "CELLULAR_COMPONENT", 58, 65], ["excavation", "TREATMENT", 12, 22], ["rain", "OBSERVATION_MODIFIER", 6, 10], ["excavation", "OBSERVATION", 12, 22], ["outbreak", "OBSERVATION_MODIFIER", 79, 87]]], ["In medieval Europe, specific pasturelands were avoided for domesticated animal grazing because of the risk of anthrax.Nonliving reservoirs ::: Reservoirs ::: EpidemiologyFood, including milk, when not handled properly, can be the reservoir for a wide variety of pathogenic organisms.", [["milk", "ANATOMY", 186, 190], ["anthrax", "DISEASE", 110, 117], ["milk", "ORGANISM_SUBSTANCE", 186, 190], ["anthrax", "PROBLEM", 110, 117], ["pathogenic organisms", "PROBLEM", 262, 282]]], ["Food may be contaminated by feces, or the animal itself may be infected, such as in the case of chickens with Campylobacter or Salmonella.", [["feces", "ANATOMY", 28, 33], ["Campylobacter or Salmonella", "DISEASE", 110, 137], ["feces", "ORGANISM_SUBSTANCE", 28, 33], ["chickens", "ORGANISM", 96, 104], ["chickens", "SPECIES", 96, 104], ["chickens", "SPECIES", 96, 104], ["infected", "PROBLEM", 63, 71], ["chickens", "PROBLEM", 96, 104], ["Campylobacter", "PROBLEM", 110, 123], ["Salmonella", "PROBLEM", 127, 137], ["may be", "UNCERTAINTY", 5, 11], ["contaminated", "OBSERVATION", 12, 24], ["feces", "OBSERVATION", 28, 33], ["may be", "UNCERTAINTY", 56, 62], ["infected", "OBSERVATION", 63, 71], ["Campylobacter", "OBSERVATION", 110, 123], ["Salmonella", "OBSERVATION", 127, 137]]], ["Food can also be contaminated with the ubiquitous spores of Botulinum, which can cause a form of paralysis called botulism.", [["paralysis", "DISEASE", 97, 106], ["botulism", "DISEASE", 114, 122], ["paralysis", "PROBLEM", 97, 106], ["botulism", "PROBLEM", 114, 122], ["paralysis", "OBSERVATION", 97, 106], ["botulism", "OBSERVATION", 114, 122]]], ["Pasteurization and food sterilization are important public health safeguards against these infections.", [["infections", "DISEASE", 91, 101], ["Pasteurization", "TREATMENT", 0, 14], ["food sterilization", "TREATMENT", 19, 37], ["these infections", "PROBLEM", 85, 101], ["food sterilization", "OBSERVATION", 19, 37], ["infections", "OBSERVATION", 91, 101]]], ["Seafood can be contaminated from bacteria in the water.", [["Seafood", "TREATMENT", 0, 7], ["bacteria", "PROBLEM", 33, 41], ["bacteria", "OBSERVATION", 33, 41]]], ["Soft cheeses are common reservoirs for Listeria monocytogenes.", [["Soft cheeses", "ANATOMY", 0, 12], ["Listeria monocytogenes", "ORGANISM", 39, 61], ["Listeria monocytogenes", "SPECIES", 39, 61], ["Listeria monocytogenes", "SPECIES", 39, 61], ["Listeria monocytogenes", "PROBLEM", 39, 61], ["cheeses", "OBSERVATION", 5, 12], ["Listeria monocytogenes", "OBSERVATION", 39, 61]]], ["Sometimes, unexpected foods become reservoirs for bacterial infection, as in the case of alfalfa and other raw seed sprouts, which since the 1970s were known to be reservoirs for both Salmonella and Escherichia coli.", [["seed sprouts", "ANATOMY", 111, 123], ["bacterial infection", "DISEASE", 50, 69], ["alfalfa", "ORGANISM_SUBDIVISION", 89, 96], ["seed sprouts", "MULTI-TISSUE_STRUCTURE", 111, 123], ["Escherichia coli", "ORGANISM", 199, 215], ["Escherichia coli", "SPECIES", 199, 215], ["alfalfa", "SPECIES", 89, 96], ["Salmonella", "SPECIES", 184, 194], ["Escherichia coli", "SPECIES", 199, 215], ["bacterial infection", "PROBLEM", 50, 69], ["alfalfa", "PROBLEM", 89, 96], ["Escherichia coli", "PROBLEM", 199, 215], ["infection", "OBSERVATION", 60, 69], ["Escherichia coli", "OBSERVATION", 199, 215]]], ["It is thought that the presoaking and germination of the seeds in nutrient solutions is conducive to the growth and multiplication of these pathogenic bacteria.", [["the presoaking and germination of the seeds", "PROBLEM", 19, 62], ["nutrient solutions", "TREATMENT", 66, 84], ["the growth", "PROBLEM", 101, 111], ["these pathogenic bacteria", "PROBLEM", 134, 159]]], ["The seeds themselves can become contaminated at any point in their production and distribution.", [["seeds", "ANATOMY", 4, 9], ["contaminated", "OBSERVATION", 32, 44], ["distribution", "OBSERVATION_MODIFIER", 82, 94]]], ["Transmission via these uncooked foodstuffs has been documented to cause the majority of foodborne bacterial outbreaks in some locations.Nonliving reservoirs ::: Reservoirs ::: EpidemiologyWater generally becomes a reservoir for infection when it is contaminated by soil microbes, or animal or human feces.", [["feces", "ANATOMY", 299, 304], ["infection", "DISEASE", 228, 237], ["human", "ORGANISM", 293, 298], ["feces", "ORGANISM_SUBDIVISION", 299, 304], ["human", "SPECIES", 293, 298], ["human", "SPECIES", 293, 298], ["foodborne bacterial outbreaks", "PROBLEM", 88, 117], ["a reservoir", "TREATMENT", 212, 223], ["infection", "PROBLEM", 228, 237], ["foodborne", "OBSERVATION_MODIFIER", 88, 97], ["bacterial", "OBSERVATION_MODIFIER", 98, 107], ["outbreaks", "OBSERVATION", 108, 117], ["infection", "OBSERVATION", 228, 237]]], ["There is also concern about the potential for terrorists to use water as a reservoir for bioterrorism pathogens.Nonliving reservoirs ::: Reservoirs ::: EpidemiologyMany inanimate objects are considered fomites, as they are capable of indirectly transmitting infection from one person to another by acting as an intermediate point in the cycle of transmission.", [["infection", "DISEASE", 258, 267], ["person", "SPECIES", 277, 283], ["a reservoir", "TREATMENT", 73, 84], ["bioterrorism pathogens", "PROBLEM", 89, 111], ["indirectly transmitting infection", "PROBLEM", 234, 267], ["objects", "OBSERVATION", 179, 186], ["infection", "OBSERVATION", 258, 267]]], ["Fomites commonly found in households that allow transmission of infection between family members include doorknobs, toilet seats, and utensils.", [["infection", "DISEASE", 64, 73], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73]]], ["At daycare centers and pediatrician's offices, infection is transmitted via toys handled by children with contaminated hands.", [["infection", "DISEASE", 47, 56], ["children", "ORGANISM", 92, 100], ["hands", "ORGANISM_SUBDIVISION", 119, 124], ["children", "SPECIES", 92, 100], ["infection", "PROBLEM", 47, 56], ["infection", "OBSERVATION", 47, 56]]], ["In hospitals, there are countless fomites capable of spreading infection.", [["infection", "DISEASE", 63, 72], ["spreading infection", "PROBLEM", 53, 72], ["spreading", "OBSERVATION_MODIFIER", 53, 62], ["infection", "OBSERVATION", 63, 72]]], ["Many respiratory infections are not spread through aerosols, but rather through respiratory secretions (saliva, sputum, etc.) being deposited on surfaces and hands, with secondary transmission via hand-to-mouth contact to the next host (Table 1).Contact ::: Modes of Transmission ::: EpidemiologyTransmission via contact includes direct skin-to-skin or mucous membrane-to-mucous membrane contact or fecal\u2013oral transmission of intestinal bacteria.", [["respiratory", "ANATOMY", 5, 16], ["respiratory secretions", "ANATOMY", 80, 102], ["sputum", "ANATOMY", 112, 118], ["hand", "ANATOMY", 197, 201], ["skin", "ANATOMY", 337, 341], ["skin", "ANATOMY", 345, 349], ["mucous membrane", "ANATOMY", 353, 368], ["mucous membrane", "ANATOMY", 372, 387], ["fecal\u2013oral", "ANATOMY", 399, 409], ["intestinal", "ANATOMY", 426, 436], ["respiratory infections", "DISEASE", 5, 27], ["saliva", "ORGANISM_SUBSTANCE", 104, 110], ["skin", "ORGAN", 337, 341], ["skin", "ORGAN", 345, 349], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 353, 368], ["mucous membrane", "CELLULAR_COMPONENT", 372, 387], ["intestinal", "ORGAN", 426, 436], ["Many respiratory infections", "PROBLEM", 0, 27], ["respiratory secretions (saliva, sputum", "PROBLEM", 80, 118], ["direct skin", "TEST", 330, 341], ["mucous membrane", "PROBLEM", 353, 368], ["intestinal bacteria", "PROBLEM", 426, 445], ["respiratory", "ANATOMY", 5, 16], ["infections", "OBSERVATION", 17, 27], ["hands", "ANATOMY", 158, 163], ["mouth", "ANATOMY", 205, 210], ["skin", "ANATOMY", 337, 341], ["skin", "ANATOMY", 345, 349], ["mucous", "ANATOMY", 353, 359], ["mucous", "ANATOMY", 372, 378], ["intestinal", "ANATOMY", 426, 436], ["bacteria", "OBSERVATION", 437, 445]]], ["Transfusion of contaminated blood products also transmits several bacterial infections, such as syphilis.Airborne ::: Modes of Transmission ::: EpidemiologySome bacteria are carried on air currents in droplet nuclei.", [["blood", "ANATOMY", 28, 33], ["droplet nuclei", "ANATOMY", 201, 215], ["bacterial infections", "DISEASE", 66, 86], ["syphilis", "DISEASE", 96, 104], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["droplet nuclei", "CELLULAR_COMPONENT", 201, 215], ["contaminated blood products", "TREATMENT", 15, 42], ["several bacterial infections", "PROBLEM", 58, 86], ["syphilis", "PROBLEM", 96, 104], ["Some bacteria", "PROBLEM", 156, 169], ["air currents", "TEST", 185, 197], ["bacterial", "OBSERVATION_MODIFIER", 66, 75], ["infections", "OBSERVATION", 76, 86], ["bacteria", "OBSERVATION", 161, 169], ["air currents", "OBSERVATION", 185, 197], ["droplet nuclei", "OBSERVATION", 201, 215]]], ["Q fever, tuberculosis, and Legionella travel great distances from their origin.", [["fever", "DISEASE", 2, 7], ["tuberculosis", "DISEASE", 9, 21], ["fever", "PROBLEM", 2, 7], ["tuberculosis", "PROBLEM", 9, 21], ["Legionella", "PROBLEM", 27, 37], ["fever", "OBSERVATION", 2, 7], ["tuberculosis", "OBSERVATION", 9, 21], ["Legionella", "OBSERVATION", 27, 37], ["origin", "ANATOMY_MODIFIER", 72, 78]]], ["Animals with Q fever have been known to transmit infection to other animals as far as 10 miles away.Droplet ::: Modes of Transmission ::: EpidemiologyWhen an infection is spread via droplets greater than 5 \u03bcm in diameter, this type of spread is not considered airborne given that the droplet is unlikely to travel through the air for more than 1 m.", [["Q fever", "DISEASE", 13, 20], ["infection", "DISEASE", 49, 58], ["infection", "DISEASE", 158, 167], ["Animals", "ORGANISM", 0, 7], ["Q fever", "PROBLEM", 13, 20], ["an infection", "PROBLEM", 155, 167], ["infection", "OBSERVATION", 49, 58], ["infection", "OBSERVATION", 158, 167], ["not considered", "UNCERTAINTY", 245, 259]]], ["They are generally more susceptible than airborne droplet nuclei to filtering in the nose via nasal hairs or to removal by nasal or facial masks.Vectors ::: Modes of Transmission ::: EpidemiologyTypically, the arthropod (mosquito, tick, louse) takes a blood meal from an infected host (which can be human or animal) and transfers pathogens to an uninfected individual.", [["droplet nuclei", "ANATOMY", 50, 64], ["nose", "ANATOMY", 85, 89], ["nasal hairs", "ANATOMY", 94, 105], ["nasal", "ANATOMY", 123, 128], ["facial", "ANATOMY", 132, 138], ["blood", "ANATOMY", 252, 257], ["nose", "ORGAN", 85, 89], ["nasal hairs", "MULTI-TISSUE_STRUCTURE", 94, 105], ["nasal", "ORGANISM_SUBDIVISION", 123, 128], ["louse", "ORGANISM_SUBDIVISION", 237, 242], ["blood", "ORGANISM_SUBSTANCE", 252, 257], ["human", "ORGANISM", 299, 304], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 299, 304], ["nasal hairs", "PROBLEM", 94, 105], ["removal", "TREATMENT", 112, 119], ["a blood meal", "TREATMENT", 250, 262], ["an infected host", "PROBLEM", 268, 284], ["nose", "ANATOMY", 85, 89], ["nasal hairs", "ANATOMY", 94, 105], ["nasal", "ANATOMY", 123, 128], ["facial", "ANATOMY", 132, 138], ["infected host", "OBSERVATION_MODIFIER", 271, 284]]], ["Bacteria such as Shigella can adhere to the foot pad of house flies and be transmitted in this manner.Vehicular (including food, water, and fomite transmission) ::: Modes of Transmission ::: EpidemiologyBacterial infection due to food and water generally develops when bacteria enter the intestine via the mouth.", [["foot pad", "ANATOMY", 44, 52], ["intestine", "ANATOMY", 288, 297], ["mouth", "ANATOMY", 306, 311], ["Bacterial infection", "DISEASE", 203, 222], ["intestine", "ORGAN", 288, 297], ["mouth", "ORGANISM_SUBDIVISION", 306, 311], ["Bacteria", "PROBLEM", 0, 8], ["Shigella", "PROBLEM", 17, 25], ["Bacterial infection", "PROBLEM", 203, 222], ["bacteria", "PROBLEM", 269, 277], ["foot", "ANATOMY", 44, 48], ["infection", "OBSERVATION", 213, 222], ["intestine", "ANATOMY", 288, 297], ["mouth", "ANATOMY", 306, 311]]], ["Those organisms that survive the low pH of the stomach and are not swept away by the mucus of the small intestine adhere to the cell surfaces.", [["stomach", "ANATOMY", 47, 54], ["mucus", "ANATOMY", 85, 90], ["small intestine", "ANATOMY", 98, 113], ["cell surfaces", "ANATOMY", 128, 141], ["stomach", "ORGAN", 47, 54], ["mucus", "ORGANISM_SUBSTANCE", 85, 90], ["small intestine", "ORGAN", 98, 113], ["cell surfaces", "CELLULAR_COMPONENT", 128, 141], ["Those organisms", "PROBLEM", 0, 15], ["low pH", "OBSERVATION_MODIFIER", 33, 39], ["stomach", "ANATOMY", 47, 54], ["mucus", "OBSERVATION", 85, 90], ["small intestine", "ANATOMY", 98, 113], ["cell surfaces", "OBSERVATION", 128, 141]]], ["There they may invade the host cells or release toxins, causing diarrhea.Vehicular (including food, water, and fomite transmission) ::: Modes of Transmission ::: EpidemiologyInfection acquired from fomites is usually the result of the organism attaching to the host's skin (generally on their hand) when they come in contact with a contaminated object, and then being deposited onto a mucus membrane when the host touches his or her face, or in some cases his or her genitals, with the contaminated body part (Table 2).Zoonoses ::: Prevention of Bacterial InfectionAnimals transmit disease in various ways.", [["cells", "ANATOMY", 31, 36], ["skin", "ANATOMY", 268, 272], ["hand", "ANATOMY", 293, 297], ["mucus membrane", "ANATOMY", 385, 399], ["genitals", "ANATOMY", 467, 475], ["body", "ANATOMY", 499, 503], ["diarrhea", "DISEASE", 64, 72], ["Bacterial Infection", "DISEASE", 546, 565], ["host cells", "CELL", 26, 36], ["skin", "ORGAN", 268, 272], ["hand", "ORGANISM_SUBDIVISION", 293, 297], ["mucus membrane", "CELLULAR_COMPONENT", 385, 399], ["genitals", "ORGANISM_SUBDIVISION", 467, 475], ["body", "ORGANISM_SUBDIVISION", 499, 503], ["host cells", "CELL_TYPE", 26, 36], ["diarrhea", "PROBLEM", 64, 72], ["Infection", "PROBLEM", 174, 183], ["fomites", "PROBLEM", 198, 205], ["the organism", "PROBLEM", 231, 243], ["Bacterial Infection", "PROBLEM", 546, 565], ["transmit disease", "PROBLEM", 573, 589], ["host cells", "OBSERVATION", 26, 36], ["skin", "ANATOMY", 268, 272], ["Bacterial", "OBSERVATION_MODIFIER", 546, 555], ["Infection", "OBSERVATION", 556, 565]]], ["Some exposures, such as anthrax from animal hides, may be occupational, others, such as Campylobacter or Yersinia, result from contamination of food or water by animal feces.", [["anthrax", "DISEASE", 24, 31], ["Campylobacter or Yersinia", "DISEASE", 88, 113], ["feces", "ORGANISM_SUBDIVISION", 168, 173], ["Campylobacter", "PROBLEM", 88, 101], ["Yersinia", "PROBLEM", 105, 113], ["Yersinia", "OBSERVATION", 105, 113]]], ["Measures to prevent infection include the use of personal protective equipment when handling animals, animal vaccinations (such as for anthrax or brucellosis), use of pesticides to prevent transmission from animal to human by insect bite, isolation or destruction of diseased animals, and proper disposal of animal waste and carcasses.", [["infection", "DISEASE", 20, 29], ["anthrax", "DISEASE", 135, 142], ["brucellosis", "DISEASE", 146, 157], ["insect bite", "DISEASE", 226, 237], ["human", "ORGANISM", 217, 222], ["carcasses", "ORGANISM_SUBDIVISION", 325, 334], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 217, 222], ["infection", "PROBLEM", 20, 29], ["personal protective equipment", "TREATMENT", 49, 78], ["animal vaccinations", "TREATMENT", 102, 121], ["anthrax", "PROBLEM", 135, 142], ["brucellosis", "PROBLEM", 146, 157], ["pesticides", "TREATMENT", 167, 177], ["destruction of diseased animals", "PROBLEM", 252, 283], ["infection", "OBSERVATION", 20, 29], ["diseased", "OBSERVATION", 267, 275]]], ["For control of plague, rat populations can be suppressed by the use of poisons as well as improved sanitation.", [["rat", "ORGANISM", 23, 26], ["rat", "SPECIES", 23, 26], ["rat", "SPECIES", 23, 26], ["plague", "PROBLEM", 15, 21], ["plague", "OBSERVATION", 15, 21]]], ["Infections acquired from insect vectors can be minimized by the use of window screens, insect repellent, and protective clothing.", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10], ["insect vectors", "TREATMENT", 25, 39], ["window screens", "TEST", 71, 85], ["protective clothing", "TREATMENT", 109, 128]]], ["Checking the body (including pets) for ticks at the end of each day can prevent transmission of tickborne bacterial infections, as most require a sufficient period of time after attachment to transmit infection.Water Treatment ::: Prevention of Bacterial InfectionImproperly treated water can lead to outbreaks of typhoid, Escherichia coli, or Shigella as well as viral and parasitic diseases.", [["body", "ANATOMY", 13, 17], ["bacterial infections", "DISEASE", 106, 126], ["infection", "DISEASE", 201, 210], ["typhoid", "DISEASE", 314, 321], ["Escherichia coli", "DISEASE", 323, 339], ["viral and parasitic diseases", "DISEASE", 364, 392], ["body", "ORGANISM_SUBDIVISION", 13, 17], ["Escherichia coli", "ORGANISM", 323, 339], ["Escherichia coli", "SPECIES", 323, 339], ["Escherichia coli", "SPECIES", 323, 339], ["ticks", "PROBLEM", 39, 44], ["tickborne bacterial infections", "PROBLEM", 96, 126], ["transmit infection", "PROBLEM", 192, 210], ["Bacterial InfectionImproperly", "PROBLEM", 245, 274], ["typhoid", "PROBLEM", 314, 321], ["Escherichia coli", "PROBLEM", 323, 339], ["Shigella", "PROBLEM", 344, 352], ["viral and parasitic diseases", "PROBLEM", 364, 392], ["body", "ANATOMY", 13, 17], ["bacterial", "OBSERVATION_MODIFIER", 106, 115], ["infections", "OBSERVATION", 116, 126], ["infection", "OBSERVATION", 201, 210], ["Bacterial InfectionImproperly", "OBSERVATION", 245, 274], ["typhoid", "OBSERVATION", 314, 321], ["Escherichia coli", "OBSERVATION", 323, 339], ["viral", "OBSERVATION_MODIFIER", 364, 369], ["parasitic diseases", "OBSERVATION", 374, 392]]], ["Improvement of the water supply in developed areas has been instrumental in decreasing the burden of infection in communities.", [["infection", "DISEASE", 101, 110], ["the water supply", "TREATMENT", 15, 31], ["infection", "PROBLEM", 101, 110], ["water supply", "OBSERVATION", 19, 31], ["areas", "OBSERVATION_MODIFIER", 45, 50], ["instrumental", "OBSERVATION_MODIFIER", 60, 72], ["decreasing", "OBSERVATION_MODIFIER", 76, 86], ["burden", "OBSERVATION_MODIFIER", 91, 97], ["infection", "OBSERVATION", 101, 110]]], ["The process of modern water treatment involves filtration, settling, and coagulation to remove particles that may carry bacteria; aeration; and chlorination or treatment with another reactive halogen.", [["halogen", "CHEMICAL", 192, 199], ["modern water treatment", "TREATMENT", 15, 37], ["filtration", "TREATMENT", 47, 57], ["coagulation", "TREATMENT", 73, 84], ["bacteria", "PROBLEM", 120, 128], ["chlorination", "TREATMENT", 144, 156], ["treatment", "TREATMENT", 160, 169], ["another reactive halogen", "TREATMENT", 175, 199]]], ["Novel disinfection methods increasingly being used include ultrafiltration and the use of ozone or ultraviolet (UV) light.", [["ozone", "CHEMICAL", 90, 95], ["ozone", "CHEMICAL", 90, 95], ["ozone", "SIMPLE_CHEMICAL", 90, 95], ["Novel disinfection methods", "TREATMENT", 0, 26], ["ultrafiltration", "TREATMENT", 59, 74], ["ozone", "TREATMENT", 90, 95], ["ultraviolet (UV)", "TREATMENT", 99, 115], ["disinfection", "OBSERVATION", 6, 18]]], ["Water can be tested for the presence of fecal bacteria with relatively simple and inexpensive kits.", [["fecal bacteria", "PROBLEM", 40, 54], ["fecal", "ANATOMY", 40, 45], ["bacteria", "OBSERVATION", 46, 54]]], ["The number of coliforms (bacteria typically found in feces) present in a given quantity of treated water is taken as a measure of fecal contamination.", [["feces", "ANATOMY", 53, 58], ["fecal", "ANATOMY", 130, 135], ["coliforms", "CHEMICAL", 14, 23], ["feces", "ORGANISM_SUBDIVISION", 53, 58], ["fecal", "ORGANISM_SUBSTANCE", 130, 135], ["coliforms (bacteria", "PROBLEM", 14, 33], ["fecal contamination", "PROBLEM", 130, 149], ["coliforms", "OBSERVATION", 14, 23], ["fecal contamination", "OBSERVATION", 130, 149]]], ["When traveling in developing countries or while camping, treating water with chlorine tablets or iodine solution or boiling the water for 5 min decreases the likelihood of acquiring bacterial intestinal infection.Air ::: Prevention of Bacterial InfectionControlling the spread of airborne bacteria is extremely difficult.", [["intestinal", "ANATOMY", 192, 202], ["chlorine", "CHEMICAL", 77, 85], ["iodine", "CHEMICAL", 97, 103], ["intestinal infection", "DISEASE", 192, 212], ["chlorine", "CHEMICAL", 77, 85], ["iodine", "CHEMICAL", 97, 103], ["chlorine tablets", "SIMPLE_CHEMICAL", 77, 93], ["iodine", "SIMPLE_CHEMICAL", 97, 103], ["intestinal", "ORGAN", 192, 202], ["chlorine tablets", "TREATMENT", 77, 93], ["iodine solution", "TREATMENT", 97, 112], ["acquiring bacterial intestinal infection", "PROBLEM", 172, 212], ["Bacterial Infection", "PROBLEM", 235, 254], ["airborne bacteria", "PROBLEM", 280, 297], ["bacterial", "OBSERVATION_MODIFIER", 182, 191], ["intestinal", "ANATOMY", 192, 202], ["infection", "OBSERVATION", 203, 212], ["Bacterial", "OBSERVATION_MODIFIER", 235, 244], ["Infection", "OBSERVATION", 245, 254], ["spread", "OBSERVATION_MODIFIER", 270, 276], ["airborne bacteria", "OBSERVATION", 280, 297]]], ["Sterilizing the air is impossible.", [["air", "OBSERVATION", 16, 19]]], ["In hospitals, laminar-flow units are used so that air contaminated by patients with airborne bacterial infections such as tuberculosis does not flow to other parts of the building.", [["bacterial infections", "DISEASE", 93, 113], ["tuberculosis", "DISEASE", 122, 134], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["laminar-flow units", "TREATMENT", 14, 32], ["air", "PROBLEM", 50, 53], ["airborne bacterial infections", "PROBLEM", 84, 113], ["tuberculosis", "PROBLEM", 122, 134], ["laminar", "OBSERVATION_MODIFIER", 14, 21], ["flow units", "OBSERVATION", 22, 32], ["tuberculosis", "OBSERVATION", 122, 134]]], ["Susceptible individuals should minimize or eliminate their time in rooms where infectious agents may be present (e.g., tuberculosis, measles, or varicella).Milk and Food ::: Prevention of Bacterial InfectionMilk and food must be handled properly and protected from bacterial contamination at every stage of preparation including at their source, during transport and storage, and during preparation for consumption.", [["tuberculosis", "DISEASE", 119, 131], ["measles", "DISEASE", 133, 140], ["varicella", "DISEASE", 145, 154], ["individuals", "ORGANISM", 12, 23], ["Milk", "ORGANISM_SUBSTANCE", 156, 160], ["Susceptible individuals", "PROBLEM", 0, 23], ["infectious agents", "TREATMENT", 79, 96], ["tuberculosis", "PROBLEM", 119, 131], ["measles", "PROBLEM", 133, 140], ["varicella", "PROBLEM", 145, 154], ["Bacterial InfectionMilk", "PROBLEM", 188, 211], ["bacterial contamination", "PROBLEM", 265, 288], ["infectious", "OBSERVATION", 79, 89], ["tuberculosis", "OBSERVATION", 119, 131], ["Bacterial InfectionMilk", "OBSERVATION", 188, 211]]], ["Milk is pasteurized, a process that consists of heating the milk for a specified period of time.", [["milk", "ANATOMY", 60, 64], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["milk", "ORGANISM_SUBSTANCE", 60, 64], ["heating the milk", "TREATMENT", 48, 64]]], ["The allowable bacterial counts before and after pasteurization are standardized.", [["The allowable bacterial counts", "TEST", 0, 30], ["bacterial counts", "OBSERVATION", 14, 30]]], ["In order to maintain these low bacterial counts, pasteurized milk must remain at 5\u201310 \u00b0C during transport and storage.", [["milk", "ANATOMY", 61, 65], ["milk", "ORGANISM_SUBSTANCE", 61, 65], ["these low bacterial counts", "PROBLEM", 21, 47], ["low bacterial", "OBSERVATION_MODIFIER", 27, 40]]], ["Listeria, an organism which has a predilection to infect pregnant women, is tolerant of these cold temperatures, and can continue to grow, particularly in soft cheeses, which provide an excellent growth medium.", [["Listeria", "CHEMICAL", 0, 8], ["women", "ORGANISM", 66, 71], ["women", "SPECIES", 66, 71], ["Listeria", "PROBLEM", 0, 8], ["an organism", "PROBLEM", 10, 21], ["these cold temperatures", "PROBLEM", 88, 111], ["organism", "OBSERVATION", 13, 21]]], ["Pregnant women are therefore cautioned against eating soft cheeses, even those that have been pasteurized.", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14]]], ["An important public health approach for foodstuffs, with wide industry and regulatory adoption, is the identification of critical places or points where contamination is most likely, known by the acronym HACCP (Hazard And Critical Control Point analysis).", [["Critical Control Point analysis", "TEST", 222, 253], ["most likely", "UNCERTAINTY", 170, 181]]], ["In many countries all food manufacturers must have an HACCP plan in place to assist with their focus on eliminating foodborne infections.Milk and Food ::: Prevention of Bacterial InfectionIn developing and tropical countries, soil may be enriched with human feces.", [["feces", "ANATOMY", 258, 263], ["foodborne infections", "DISEASE", 116, 136], ["Milk", "ORGANISM_SUBSTANCE", 137, 141], ["human", "ORGANISM", 252, 257], ["feces", "ORGANISM_SUBDIVISION", 258, 263], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["foodborne infections", "PROBLEM", 116, 136], ["Bacterial InfectionIn", "PROBLEM", 169, 190], ["infections", "OBSERVATION", 126, 136], ["Bacterial InfectionIn", "OBSERVATION", 169, 190], ["tropical", "OBSERVATION_MODIFIER", 206, 214]]], ["Produce is therefore at risk for contamination with pathogenic bacteria.", [["contamination", "PROBLEM", 33, 46], ["pathogenic bacteria", "PROBLEM", 52, 71]]], ["Any food may be contaminated by the hands of workers who handle it during harvesting or processing for distribution.", [["harvesting", "TREATMENT", 74, 84]]], ["Cooking immediately prior to eating reduces the risk by killing the bacteria; however, some bacteria such as Staphylococcus, Bacillus, and Clostridium produce toxins that are not inactivated by heat.Human Reservoirs ::: Prevention of Bacterial InfectionImmunization is one of the great technological advances of the modern era.", [["Bacterial InfectionImmunization", "DISEASE", 234, 265], ["Staphylococcus, Bacillus", "ORGANISM", 109, 133], ["Human", "ORGANISM", 199, 204], ["Staphylococcus", "SPECIES", 109, 123], ["Human", "SPECIES", 199, 204], ["Human", "SPECIES", 199, 204], ["the bacteria", "PROBLEM", 64, 76], ["some bacteria", "PROBLEM", 87, 100], ["Staphylococcus", "PROBLEM", 109, 123], ["Bacillus", "PROBLEM", 125, 133], ["Clostridium produce toxins", "PROBLEM", 139, 165], ["Bacterial InfectionImmunization", "PROBLEM", 234, 265], ["Staphylococcus", "OBSERVATION", 109, 123], ["Bacterial InfectionImmunization", "OBSERVATION", 234, 265]]], ["Immunization can be passive, by transfer of antibody against a specific disease, or active, by administering a small dose of the organism and allowing the body to produce its own antibody.", [["body", "ANATOMY", 155, 159], ["body", "ORGANISM_SUBDIVISION", 155, 159], ["antibody", "PROTEIN", 44, 52], ["Immunization", "TREATMENT", 0, 12], ["antibody", "TREATMENT", 44, 52], ["a specific disease", "PROBLEM", 61, 79], ["a small dose of the organism", "TREATMENT", 109, 137], ["active", "OBSERVATION_MODIFIER", 84, 90]]], ["Live bacterial vaccines include Bacillus Calmette-Guerin (BCG) for tuberculosis, oral typhoid vaccine, and a tularemia vaccine.", [["oral", "ANATOMY", 81, 85], ["Bacillus Calmette-Guerin", "CHEMICAL", 32, 56], ["tuberculosis", "DISEASE", 67, 79], ["typhoid", "DISEASE", 86, 93], ["tularemia", "DISEASE", 109, 118], ["Bacillus Calmette-Guerin", "ORGANISM", 32, 56], ["BCG", "ORGANISM", 58, 61], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["Bacillus Calmette", "SPECIES", 32, 49], ["Bacillus Calmette-Guerin", "SPECIES", 32, 56], ["Live bacterial vaccines", "TREATMENT", 0, 23], ["Bacillus Calmette", "TREATMENT", 32, 49], ["Guerin (BCG", "TREATMENT", 50, 61], ["tuberculosis", "PROBLEM", 67, 79], ["oral typhoid vaccine", "TREATMENT", 81, 101], ["a tularemia vaccine", "TREATMENT", 107, 126]]], ["Other bacterial vaccines are antigenic derivatives of the organism, such as the vaccines for meningococcus, streptococcus, diphtheria, pertussis, and anthrax.", [["meningococcus, streptococcus, diphtheria, pertussis", "DISEASE", 93, 144], ["anthrax", "DISEASE", 150, 157], ["meningococcus, streptococcus", "ORGANISM", 93, 121], ["diphtheria, pertussis", "ORGANISM", 123, 144], ["diphtheria, pertussis", "SPECIES", 123, 144], ["Other bacterial vaccines", "TREATMENT", 0, 24], ["antigenic derivatives", "TREATMENT", 29, 50], ["the organism", "PROBLEM", 54, 66], ["the vaccines", "TREATMENT", 76, 88], ["meningococcus", "PROBLEM", 93, 106], ["streptococcus", "PROBLEM", 108, 121], ["diphtheria", "PROBLEM", 123, 133], ["pertussis", "PROBLEM", 135, 144], ["anthrax", "PROBLEM", 150, 157], ["bacterial vaccines", "OBSERVATION", 6, 24]]], ["It would be impossible to develop a vaccine for every known species of bacteria capable of causing disease, and therefore the other measures of prevention of infection will always be of critical importance.Human Reservoirs ::: Prevention of Bacterial InfectionThe spread of disease from person to person can be prevented by quarantine, the use of isolation measures, and antibiotic prophylaxis.", [["infection", "DISEASE", 158, 167], ["Bacterial Infection", "DISEASE", 241, 260], ["Human", "ORGANISM", 206, 211], ["Human", "SPECIES", 206, 211], ["person", "SPECIES", 287, 293], ["person", "SPECIES", 297, 303], ["Human", "SPECIES", 206, 211], ["a vaccine", "TREATMENT", 34, 43], ["bacteria", "PROBLEM", 71, 79], ["disease", "PROBLEM", 99, 106], ["infection", "PROBLEM", 158, 167], ["Bacterial Infection", "PROBLEM", 241, 260], ["disease", "PROBLEM", 274, 281], ["isolation measures", "TREATMENT", 347, 365], ["antibiotic prophylaxis", "TREATMENT", 371, 393], ["infection", "OBSERVATION", 158, 167], ["Bacterial", "OBSERVATION_MODIFIER", 241, 250], ["Infection", "OBSERVATION", 251, 260], ["spread", "OBSERVATION_MODIFIER", 264, 270]]], ["In the fourteenth century, suspected plague victims were required to stay on ships or in their homes for 40 days until it was clear that they would not exhibit signs of the disease.", [["the disease", "PROBLEM", 169, 180], ["plague", "OBSERVATION_MODIFIER", 37, 43], ["disease", "OBSERVATION", 173, 180]]], ["In the twenty-first century, large numbers of people were quarantined in Toronto and Hong Kong due to severe acute respiratory syndrome (SARS), a virus.", [["acute respiratory syndrome", "DISEASE", 109, 135], ["SARS", "DISEASE", 137, 141], ["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["severe acute respiratory syndrome", "PROBLEM", 102, 135], ["SARS", "PROBLEM", 137, 141], ["a virus", "PROBLEM", 144, 151], ["large", "OBSERVATION_MODIFIER", 29, 34], ["numbers", "OBSERVATION_MODIFIER", 35, 42], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["respiratory syndrome", "OBSERVATION", 115, 135]]], ["Today, the only bacterial infections for which the WHO still uses quarantine measures are plague and cholera.", [["infections", "DISEASE", 26, 36], ["cholera", "DISEASE", 101, 108], ["bacterial infections", "PROBLEM", 16, 36], ["quarantine measures", "TREATMENT", 66, 85], ["plague", "PROBLEM", 90, 96], ["cholera", "PROBLEM", 101, 108], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["infections", "OBSERVATION", 26, 36]]], ["In hospitals, standard precautions are used on all patients regardless of whether they have known infection, and special isolation precautions are instituted for patients with specific infections such as highly resistant, or easily transmitted, bacteria.", [["infection", "DISEASE", 98, 107], ["infections", "DISEASE", 185, 195], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 162, 170], ["standard precautions", "TREATMENT", 14, 34], ["known infection", "PROBLEM", 92, 107], ["special isolation precautions", "TREATMENT", 113, 142], ["specific infections", "PROBLEM", 176, 195], ["easily transmitted, bacteria", "PROBLEM", 225, 253], ["infection", "OBSERVATION", 98, 107]]], ["Standard precautions include the practice of performing hand hygiene (washing hands or applying waterless hand sanitizer) after touching a patient, using gloves for contact with body fluids, secretions, excretions, and contaminated items, and using a cover gown, mask, and eye protection when body fluid splashes are likely.", [["hand", "ANATOMY", 56, 60], ["hand", "ANATOMY", 106, 110], ["body", "ANATOMY", 178, 182], ["secretions", "ANATOMY", 191, 201], ["eye", "ANATOMY", 273, 276], ["body fluid", "ANATOMY", 293, 303], ["hand", "ORGANISM_SUBDIVISION", 56, 60], ["hand", "ORGANISM_SUBDIVISION", 106, 110], ["patient", "ORGANISM", 139, 146], ["body", "ORGANISM_SUBDIVISION", 178, 182], ["eye", "ORGANISM_SUBDIVISION", 273, 276], ["body", "ORGANISM_SUBDIVISION", 293, 297], ["patient", "SPECIES", 139, 146], ["Standard precautions", "TREATMENT", 0, 20], ["hand hygiene", "TREATMENT", 56, 68], ["washing hands", "TREATMENT", 70, 83], ["waterless hand sanitizer", "TREATMENT", 96, 120], ["gloves", "TREATMENT", 154, 160], ["contact with body fluids", "TREATMENT", 165, 189], ["a cover gown", "TREATMENT", 249, 261], ["mask", "TREATMENT", 263, 267], ["eye protection", "TREATMENT", 273, 287], ["body fluid splashes", "PROBLEM", 293, 312], ["eye", "ANATOMY", 273, 276], ["fluid splashes", "OBSERVATION", 298, 312]]], ["Patients infected with airborne bacteria such as tuberculosis are placed in special laminar air flow rooms.", [["tuberculosis", "DISEASE", 49, 61], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["airborne bacteria", "PROBLEM", 23, 40], ["tuberculosis", "PROBLEM", 49, 61], ["airborne bacteria", "OBSERVATION", 23, 40], ["tuberculosis", "OBSERVATION", 49, 61], ["laminar", "ANATOMY_MODIFIER", 84, 91], ["air flow", "OBSERVATION", 92, 100]]], ["Patients with antibiotic-resistant nosocomial bacterial infection or colonization such as methicillin-resistant Staphylococcus and vancomycin-resistant Enterococcus are cohorted in rooms with others like themselves and gloves are routinely used in their care.", [["nosocomial bacterial infection", "DISEASE", 35, 65], ["methicillin", "CHEMICAL", 90, 101], ["vancomycin", "CHEMICAL", 131, 141], ["Enterococcus", "CHEMICAL", 152, 164], ["methicillin", "CHEMICAL", 90, 101], ["vancomycin", "CHEMICAL", 131, 141], ["Patients", "ORGANISM", 0, 8], ["methicillin", "SIMPLE_CHEMICAL", 90, 101], ["vancomycin", "SIMPLE_CHEMICAL", 131, 141], ["Patients", "SPECIES", 0, 8], ["antibiotic", "TREATMENT", 14, 24], ["resistant nosocomial bacterial infection", "PROBLEM", 25, 65], ["colonization", "PROBLEM", 69, 81], ["methicillin-resistant Staphylococcus", "TREATMENT", 90, 126], ["vancomycin", "TREATMENT", 131, 141], ["resistant Enterococcus", "PROBLEM", 142, 164], ["gloves", "TREATMENT", 219, 225], ["resistant", "OBSERVATION_MODIFIER", 25, 34], ["nosocomial", "OBSERVATION_MODIFIER", 35, 45], ["bacterial", "OBSERVATION_MODIFIER", 46, 55], ["infection", "OBSERVATION", 56, 65], ["resistant", "OBSERVATION_MODIFIER", 142, 151], ["Enterococcus", "OBSERVATION", 152, 164]]], ["Patients who have diarrhea caused by the spore-forming bacteria Clostridium difficile are placed in private rooms when possible, and cover gowns and gloves are used to prevent spread of spores throughout the hospital.", [["diarrhea", "DISEASE", 18, 26], ["Clostridium difficile", "DISEASE", 64, 85], ["Patients", "ORGANISM", 0, 8], ["Clostridium difficile", "ORGANISM", 64, 85], ["Patients", "SPECIES", 0, 8], ["Clostridium difficile", "SPECIES", 64, 85], ["Clostridium difficile", "SPECIES", 64, 85], ["diarrhea", "PROBLEM", 18, 26], ["the spore-forming bacteria Clostridium difficile", "PROBLEM", 37, 85], ["gowns", "TREATMENT", 139, 144], ["gloves", "TREATMENT", 149, 155], ["bacteria", "OBSERVATION_MODIFIER", 55, 63], ["Clostridium difficile", "OBSERVATION", 64, 85]]], ["Special cleaning agents are used in these rooms to kill the spores.Human Reservoirs ::: Prevention of Bacterial InfectionAntibiotic prophylaxis is used in certain settings to prevent bacterial infection.", [["spores", "ANATOMY", 60, 66], ["bacterial infection", "DISEASE", 183, 202], ["Human", "ORGANISM", 67, 72], ["Human", "SPECIES", 67, 72], ["Human", "SPECIES", 67, 72], ["Special cleaning agents", "TREATMENT", 0, 23], ["Bacterial InfectionAntibiotic prophylaxis", "TREATMENT", 102, 143], ["bacterial infection", "PROBLEM", 183, 202], ["Bacterial", "OBSERVATION_MODIFIER", 102, 111], ["InfectionAntibiotic prophylaxis", "OBSERVATION", 112, 143], ["bacterial", "OBSERVATION_MODIFIER", 183, 192], ["infection", "OBSERVATION", 193, 202]]], ["As a mass prevention technique, it is not very effective, since infection with resistant organisms would be expected to develop in response to antibiotic use.", [["infection", "DISEASE", 64, 73], ["a mass prevention technique", "TREATMENT", 3, 30], ["infection", "PROBLEM", 64, 73], ["resistant organisms", "PROBLEM", 79, 98], ["antibiotic use", "TREATMENT", 143, 157], ["mass", "OBSERVATION", 5, 9], ["infection", "OBSERVATION", 64, 73]]], ["It is, however, very useful in preventing infection in close contacts of patients with meningococcal meningitis and pertussis, in preventing development of sexually transmitted disease in those exposed, and in preventing serious disease in known carriers of diphtheria and tuberculosis.", [["infection", "DISEASE", 42, 51], ["meningococcal meningitis", "DISEASE", 87, 111], ["pertussis", "DISEASE", 116, 125], ["sexually transmitted disease", "DISEASE", 156, 184], ["diphtheria", "DISEASE", 258, 268], ["tuberculosis", "DISEASE", 273, 285], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["infection", "PROBLEM", 42, 51], ["meningococcal meningitis", "PROBLEM", 87, 111], ["pertussis", "PROBLEM", 116, 125], ["sexually transmitted disease", "PROBLEM", 156, 184], ["serious disease", "PROBLEM", 221, 236], ["diphtheria", "PROBLEM", 258, 268], ["tuberculosis", "PROBLEM", 273, 285], ["infection", "OBSERVATION", 42, 51], ["meningitis", "OBSERVATION", 101, 111], ["serious", "OBSERVATION_MODIFIER", 221, 228], ["disease", "OBSERVATION", 229, 236], ["diphtheria", "OBSERVATION", 258, 268], ["tuberculosis", "OBSERVATION", 273, 285]]], ["Antibiotic prophylaxis has been shown to be useful for patients undergoing certain surgical procedures to prevent postoperative infection, and for patients with severe immunosuppression due to bone marrow or solid organ transplantation.Human Reservoirs ::: Prevention of Bacterial InfectionLifestyle changes can have a major impact on the spread of infection.", [["bone marrow", "ANATOMY", 193, 204], ["solid organ", "ANATOMY", 208, 219], ["postoperative infection", "DISEASE", 114, 137], ["infection", "DISEASE", 349, 358], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 147, 155], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 193, 204], ["organ", "ORGAN", 214, 219], ["Human", "ORGANISM", 236, 241], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 147, 155], ["Human", "SPECIES", 236, 241], ["Human", "SPECIES", 236, 241], ["Antibiotic prophylaxis", "TREATMENT", 0, 22], ["certain surgical procedures", "TREATMENT", 75, 102], ["postoperative infection", "PROBLEM", 114, 137], ["severe immunosuppression", "TREATMENT", 161, 185], ["bone marrow", "PROBLEM", 193, 204], ["solid organ transplantation", "TREATMENT", 208, 235], ["Bacterial InfectionLifestyle changes", "PROBLEM", 271, 307], ["infection", "PROBLEM", 349, 358], ["postoperative", "OBSERVATION_MODIFIER", 114, 127], ["infection", "OBSERVATION", 128, 137], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["immunosuppression", "OBSERVATION", 168, 185], ["bone", "ANATOMY", 193, 197], ["solid organ transplantation", "OBSERVATION", 208, 235], ["Bacterial InfectionLifestyle", "OBSERVATION", 271, 299], ["infection", "OBSERVATION", 349, 358]]], ["Safer sex practices decrease the spread of sexually transmitted infection.", [["sexually transmitted infection", "DISEASE", 43, 73], ["Safer sex practices", "TREATMENT", 0, 19], ["sexually transmitted infection", "PROBLEM", 43, 73], ["spread", "OBSERVATION_MODIFIER", 33, 39], ["infection", "OBSERVATION", 64, 73]]], ["Simple personal hygiene measures can also have a dramatic effect on the incidence of infection.", [["infection", "DISEASE", 85, 94], ["Simple personal hygiene measures", "TREATMENT", 0, 32], ["infection", "PROBLEM", 85, 94], ["infection", "OBSERVATION", 85, 94]]], ["In Karachi, Pakistan, diarrhea and acute respiratory infection, often caused by bacteria, are leading causes of death.", [["respiratory", "ANATOMY", 41, 52], ["diarrhea", "DISEASE", 22, 30], ["acute respiratory infection", "DISEASE", 35, 62], ["death", "DISEASE", 112, 117], ["diarrhea", "PROBLEM", 22, 30], ["acute respiratory infection", "PROBLEM", 35, 62], ["bacteria", "PROBLEM", 80, 88], ["death", "PROBLEM", 112, 117], ["diarrhea", "OBSERVATION", 22, 30], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory", "ANATOMY", 41, 52], ["infection", "OBSERVATION", 53, 62], ["bacteria", "OBSERVATION", 80, 88]]], ["Between 2002 and 2003, U.S. and Pakistani health officials conducted a study (Luby et al., 2005) in which households in squatter settlements were randomly assigned to be part of a hygiene campaign (involving education and the distribution of soap) or to be simply observed.", [["a study", "TEST", 69, 76]]], ["Washing hands with soap reduced the incidence of diarrhea and pneumonia by half, and the incidence of impetigo, a superficial bacterial skin infection, by one-third.", [["skin", "ANATOMY", 136, 140], ["diarrhea", "DISEASE", 49, 57], ["pneumonia", "DISEASE", 62, 71], ["impetigo", "DISEASE", 102, 110], ["skin infection", "DISEASE", 136, 150], ["hands", "ORGANISM_SUBDIVISION", 8, 13], ["impetigo", "PATHOLOGICAL_FORMATION", 102, 110], ["skin", "ORGAN", 136, 140], ["soap", "TREATMENT", 19, 23], ["diarrhea", "PROBLEM", 49, 57], ["pneumonia", "PROBLEM", 62, 71], ["impetigo", "PROBLEM", 102, 110], ["a superficial bacterial skin infection", "PROBLEM", 112, 150], ["diarrhea", "OBSERVATION", 49, 57], ["pneumonia", "OBSERVATION", 62, 71], ["impetigo", "OBSERVATION", 102, 110], ["superficial", "OBSERVATION_MODIFIER", 114, 125], ["bacterial", "OBSERVATION_MODIFIER", 126, 135], ["skin", "ANATOMY", 136, 140], ["infection", "OBSERVATION", 141, 150]]], ["In the developed world, numerous studies have shown an association between poor hand hygiene and the spread of multidrug-resistant organisms within hospitals, and countless studies have shown that compliance with hand hygiene requirements remains low in health-care settings.", [["hand", "ANATOMY", 80, 84], ["hand", "ANATOMY", 213, 217], ["hand", "ORGANISM_SUBDIVISION", 80, 84], ["hand", "ORGANISM_SUBDIVISION", 213, 217], ["numerous studies", "TEST", 24, 40], ["poor hand hygiene", "PROBLEM", 75, 92], ["multidrug-resistant organisms", "PROBLEM", 111, 140], ["countless studies", "TEST", 163, 180], ["hand hygiene requirements", "TREATMENT", 213, 238]]], ["Body lice, which carry louse-borne typhus, are associated with poor general hygiene.", [["typhus", "DISEASE", 35, 41], ["typhus", "ORGANISM", 35, 41], ["Body lice", "PROBLEM", 0, 9], ["typhus", "PROBLEM", 35, 41]]], ["Improved personal hygiene and delousing procedures (heat and chemical treatment) are used to control infestation.Stains and Microscopy ::: Diagnostic TestsStains are applied to specimens that have been fixed to a microscope slide.", [["specimens", "ANATOMY", 177, 186], ["delousing procedures", "TREATMENT", 30, 50], ["heat", "TREATMENT", 52, 56], ["chemical treatment)", "TREATMENT", 61, 80], ["infestation", "PROBLEM", 101, 112], ["Microscopy", "TEST", 124, 134], ["Diagnostic TestsStains", "TEST", 139, 161], ["specimens", "TEST", 177, 186], ["a microscope slide", "TEST", 211, 229]]], ["Typically, the first test performed to diagnose a possible bacterial infection is the Gram stain.", [["bacterial infection", "DISEASE", 59, 78], ["the first test", "TEST", 11, 25], ["bacterial infection", "PROBLEM", 59, 78], ["the Gram stain", "TEST", 82, 96], ["possible", "UNCERTAINTY", 50, 58], ["bacterial", "OBSERVATION_MODIFIER", 59, 68], ["infection", "OBSERVATION", 69, 78]]], ["The cell wall is made of sugars and amino acids, and in Gram-positive bacteria this wall is thick, lies external to the cell membrane, and contains other macromolecules, whereas in Gram-negative bacteria the wall is thin and is overlaid by an outer membrane.", [["cell wall", "ANATOMY", 4, 13], ["wall", "ANATOMY", 84, 88], ["cell membrane", "ANATOMY", 120, 133], ["wall", "ANATOMY", 208, 212], ["outer membrane", "ANATOMY", 243, 257], ["amino acids", "CHEMICAL", 36, 47], ["sugars", "CHEMICAL", 25, 31], ["amino acids", "CHEMICAL", 36, 47], ["cell wall", "TISSUE", 4, 13], ["sugars", "SIMPLE_CHEMICAL", 25, 31], ["amino acids", "AMINO_ACID", 36, 47], ["cell membrane", "CELLULAR_COMPONENT", 120, 133], ["Gram-negative bacteria", "GENE_OR_GENE_PRODUCT", 181, 203], ["wall", "TISSUE", 208, 212], ["outer membrane", "CELLULAR_COMPONENT", 243, 257], ["sugars", "TEST", 25, 31], ["amino acids", "TEST", 36, 47], ["Gram", "TEST", 56, 60], ["thick", "PROBLEM", 92, 97], ["other macromolecules", "PROBLEM", 148, 168], ["Gram", "TEST", 181, 185], ["cell wall", "OBSERVATION", 4, 13], ["positive bacteria", "OBSERVATION_MODIFIER", 61, 78], ["wall", "ANATOMY_MODIFIER", 84, 88], ["thick", "OBSERVATION", 92, 97], ["cell membrane", "OBSERVATION", 120, 133], ["macromolecules", "OBSERVATION_MODIFIER", 154, 168], ["negative bacteria", "OBSERVATION", 186, 203], ["wall", "ANATOMY_MODIFIER", 208, 212], ["thin", "OBSERVATION_MODIFIER", 216, 220], ["outer membrane", "OBSERVATION", 243, 257]]], ["When subjected to the Gram staining procedure, Gram-positive organisms, such as the staphylococci, retain the purple stain, whereas Gram-negative organisms do not.", [["Gram", "GENE_OR_GENE_PRODUCT", 47, 51], ["Gram", "GENE_OR_GENE_PRODUCT", 132, 136], ["the Gram staining procedure", "TEST", 18, 45], ["Gram-positive organisms", "PROBLEM", 47, 70], ["the staphylococci", "PROBLEM", 80, 97], ["the purple stain", "TEST", 106, 122], ["Gram", "TEST", 132, 136]]], ["A second stain is then added to allow visualization of the Gram-negative organisms, such as E. coli, which appear pink or red under the microscope.", [["Gram", "GENE_OR_GENE_PRODUCT", 59, 63], ["E. coli", "ORGANISM", 92, 99], ["E. coli", "SPECIES", 92, 99], ["E. coli", "SPECIES", 92, 99], ["A second stain", "TEST", 0, 14], ["the Gram", "TEST", 55, 63], ["E. coli", "PROBLEM", 92, 99], ["the microscope", "TEST", 132, 146], ["negative organisms", "OBSERVATION", 64, 82], ["E. coli", "OBSERVATION", 92, 99], ["pink", "OBSERVATION_MODIFIER", 114, 118]]], ["Identifying the causative agent under the microscope as either Gram-positive or Gram-negative (see the section titled \u2018Structure and classification of bacteria,\u2019 above) allows the clinician to more accurately predict the antibiotic that is likely to be effective.", [["Gram-", "GENE_OR_GENE_PRODUCT", 63, 68], ["the microscope", "TEST", 38, 52], ["Gram-positive", "PROBLEM", 63, 76], ["bacteria", "PROBLEM", 151, 159], ["the antibiotic", "TREATMENT", 217, 231], ["likely to be", "UNCERTAINTY", 240, 252]]], ["The morphology of the bacteria under the microscope (short vs. long, plump vs. thin, branching vs. straight) provides another clue to the identity of the organism.", [["the bacteria", "PROBLEM", 18, 30], ["the microscope", "TEST", 37, 51], ["short vs. long, plump vs. thin, branching vs. straight)", "PROBLEM", 53, 108], ["bacteria", "OBSERVATION", 22, 30]]], ["Some organisms such as the Mycobacteria which include tuberculosis, do not readily take up Gram stain and require special stains to be visualized.", [["tuberculosis", "DISEASE", 54, 66], ["Some organisms", "PROBLEM", 0, 14], ["the Mycobacteria", "PROBLEM", 23, 39], ["tuberculosis", "PROBLEM", 54, 66], ["Gram stain", "TEST", 91, 101], ["special stains", "TEST", 114, 128], ["Mycobacteria", "OBSERVATION", 27, 39], ["tuberculosis", "OBSERVATION", 54, 66]]], ["Other stains that are less commonly used contain specific immunofluorescent-labeled antisera and provide a diagnosis of such organisms as group A hemolytic streptococcus, plague, and syphilis.", [["hemolytic streptococcus", "DISEASE", 146, 169], ["plague", "DISEASE", 171, 177], ["syphilis", "DISEASE", 183, 191], ["Other stains", "TEST", 0, 12], ["specific immunofluorescent", "TEST", 49, 75], ["such organisms", "PROBLEM", 120, 134], ["group A hemolytic streptococcus", "PROBLEM", 138, 169], ["plague", "PROBLEM", 171, 177], ["syphilis", "PROBLEM", 183, 191]]], ["While a species-level diagnosis is not possible with this method, it does help to rapidly categorize the type of infection and to guide initial treatment.Dark Field and Fluorescent Microscopy ::: Diagnostic TestsDark field microscopy is a technique that involves adapting the microscope so that the organisms are viewed against a dark instead of light background, with the light source illuminating the bacterium from the side rather than from behind the organisms.", [["infection", "DISEASE", 113, 122], ["a species-level diagnosis", "TEST", 6, 31], ["infection", "PROBLEM", 113, 122], ["initial treatment", "TREATMENT", 136, 153], ["Fluorescent Microscopy", "TEST", 169, 191], ["Diagnostic Tests", "TEST", 196, 212], ["Dark field microscopy", "TEST", 212, 233], ["a technique", "TEST", 237, 248], ["the microscope", "TEST", 272, 286], ["the organisms", "TEST", 295, 308], ["a dark instead of light background", "PROBLEM", 328, 362], ["the bacterium", "PROBLEM", 399, 412], ["not possible", "UNCERTAINTY", 35, 47], ["infection", "OBSERVATION", 113, 122]]], ["The spirochetes, thin bacteria that include the agents of syphilis and yaws, are visualized this way.", [["syphilis", "DISEASE", 58, 66], ["yaws", "DISEASE", 71, 75], ["The spirochetes, thin bacteria", "PROBLEM", 0, 30], ["syphilis", "PROBLEM", 58, 66]]], ["Fluorescent microscopy, with or without special dyes, is a technique that utilizes a UV light source and can be used to visualize Mycobacteria such as tuberculosis.Antigen Detection ::: Diagnostic TestsCommercial kits are used to identify a variety of organisms from body fluid specimens.", [["body fluid specimens", "ANATOMY", 267, 287], ["tuberculosis", "DISEASE", 151, 163], ["body fluid specimens", "ORGANISM_SUBSTANCE", 267, 287], ["Fluorescent microscopy", "TEST", 0, 22], ["special dyes", "TREATMENT", 40, 52], ["a technique", "TREATMENT", 57, 68], ["a UV light source", "TREATMENT", 83, 100], ["Mycobacteria", "PROBLEM", 130, 142], ["tuberculosis", "PROBLEM", 151, 163], ["Diagnostic TestsCommercial kits", "TEST", 186, 217], ["body fluid specimens", "TEST", 267, 287], ["Mycobacteria", "OBSERVATION", 130, 142], ["tuberculosis", "OBSERVATION", 151, 163]]], ["Legionnaire's disease is diagnosed from a urine sample, meningococcal or pneumococcal meningitis from cerebrospinal fluid, and Streptococcus pyogenes from a throat swab.", [["urine sample", "ANATOMY", 42, 54], ["cerebrospinal fluid", "ANATOMY", 102, 121], ["throat swab", "ANATOMY", 157, 168], ["Legionnaire's disease", "DISEASE", 0, 21], ["meningitis", "DISEASE", 86, 96], ["urine", "ORGANISM_SUBSTANCE", 42, 47], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 102, 121], ["Streptococcus pyogenes", "ORGANISM", 127, 149], ["Streptococcus pyogenes", "SPECIES", 127, 149], ["pneumococcal", "SPECIES", 73, 85], ["Streptococcus pyogenes", "SPECIES", 127, 149], ["Legionnaire's disease", "PROBLEM", 0, 21], ["a urine sample", "TEST", 40, 54], ["meningococcal", "PROBLEM", 56, 69], ["pneumococcal meningitis", "PROBLEM", 73, 96], ["cerebrospinal fluid", "PROBLEM", 102, 121], ["Streptococcus pyogenes", "PROBLEM", 127, 149], ["a throat swab", "TEST", 155, 168], ["disease", "OBSERVATION", 14, 21], ["pneumococcal", "OBSERVATION_MODIFIER", 73, 85], ["meningitis", "OBSERVATION", 86, 96], ["cerebrospinal fluid", "OBSERVATION", 102, 121], ["Streptococcus pyogenes", "OBSERVATION", 127, 149]]], ["Recently, a commercial kit for the detection of Helicobacter pylori antigen in feces was developed, which has greater sensitivity and specificity than does the detection of antibody to this organism.", [["feces", "ANATOMY", 79, 84], ["Helicobacter pylori", "ORGANISM", 48, 67], ["feces", "ORGANISM_SUBSTANCE", 79, 84], ["Helicobacter pylori antigen", "PROTEIN", 48, 75], ["Helicobacter pylori", "SPECIES", 48, 67], ["Helicobacter pylori", "SPECIES", 48, 67], ["Helicobacter pylori antigen in feces", "PROBLEM", 48, 84], ["antibody to this organism", "PROBLEM", 173, 198], ["Helicobacter pylori", "OBSERVATION", 48, 67]]], ["The advantage of this approach is its rapidity.Nucleic Acid Probes and Polymerase Chain Reaction ::: Diagnostic TestsProbes are molecules that identify the presence of certain known genes in a specimen without the necessity for culture.", [["specimen", "ANATOMY", 193, 201], ["this approach", "TREATMENT", 17, 30], ["Nucleic Acid Probes", "TREATMENT", 47, 66], ["culture", "TEST", 228, 235], ["genes", "OBSERVATION", 182, 187]]], ["Probes for the toxins of E. coli or cholera can be applied directly to feces.", [["feces", "ANATOMY", 71, 76], ["Probes", "GENE_OR_GENE_PRODUCT", 0, 6], ["E. coli", "ORGANISM", 25, 32], ["cholera", "ORGANISM", 36, 43], ["feces", "ORGANISM_SUBSTANCE", 71, 76], ["E. coli", "SPECIES", 25, 32], ["E. coli", "SPECIES", 25, 32], ["E. coli", "PROBLEM", 25, 32], ["cholera", "PROBLEM", 36, 43], ["E. coli", "OBSERVATION", 25, 32]]], ["Probes for gonorrhea and chlamydia are applied to genital secretions or urine.", [["genital secretions", "ANATOMY", 50, 68], ["urine", "ANATOMY", 72, 77], ["gonorrhea", "DISEASE", 11, 20], ["chlamydia", "DISEASE", 25, 34], ["Probes", "ORGANISM_SUBSTANCE", 0, 6], ["genital", "ORGANISM", 50, 57], ["secretions", "ORGANISM_SUBSTANCE", 58, 68], ["urine", "ORGANISM_SUBSTANCE", 72, 77], ["Probes", "TREATMENT", 0, 6], ["gonorrhea", "PROBLEM", 11, 20], ["chlamydia", "PROBLEM", 25, 34], ["genital secretions or urine", "PROBLEM", 50, 77], ["chlamydia", "OBSERVATION", 25, 34]]], ["The polymerase chain reaction (PCR) is used to amplify a small amount of DNA from a few bacteria to produce millions of copies in a few hours.", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["The polymerase chain reaction", "PROBLEM", 0, 29], ["PCR", "TEST", 31, 34], ["a small amount of DNA", "PROBLEM", 55, 76], ["a few bacteria", "PROBLEM", 82, 96], ["chain", "OBSERVATION_MODIFIER", 15, 20], ["small", "OBSERVATION_MODIFIER", 57, 62], ["amount", "OBSERVATION_MODIFIER", 63, 69]]], ["Bacteria for which this technique has been useful include Helicobacter pylori, the agent responsible for gastric ulcer disease, and Mycoplasma pneumoniae, which causes walking pneumonia.Culture ::: Diagnostic TestsA basic microbiology laboratory is generally able to culture bacteria from blood, sputum, and urine, but with the right materials any body fluid or tissue can be processed for culture.", [["gastric ulcer", "ANATOMY", 105, 118], ["blood", "ANATOMY", 289, 294], ["sputum", "ANATOMY", 296, 302], ["urine", "ANATOMY", 308, 313], ["body fluid", "ANATOMY", 348, 358], ["tissue", "ANATOMY", 362, 368], ["Helicobacter pylori", "DISEASE", 58, 77], ["gastric ulcer disease", "DISEASE", 105, 126], ["Mycoplasma pneumoniae", "DISEASE", 132, 153], ["pneumonia", "DISEASE", 176, 185], ["Helicobacter pylori", "ORGANISM", 58, 77], ["gastric ulcer", "PATHOLOGICAL_FORMATION", 105, 118], ["Mycoplasma pneumoniae", "ORGANISM", 132, 153], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["sputum", "ORGANISM_SUBSTANCE", 296, 302], ["urine", "ORGANISM_SUBSTANCE", 308, 313], ["body fluid", "ORGANISM_SUBSTANCE", 348, 358], ["tissue", "TISSUE", 362, 368], ["Helicobacter pylori", "SPECIES", 58, 77], ["Mycoplasma pneumoniae", "SPECIES", 132, 153], ["Helicobacter pylori", "SPECIES", 58, 77], ["Mycoplasma pneumoniae", "SPECIES", 132, 153], ["Bacteria", "PROBLEM", 0, 8], ["this technique", "TREATMENT", 19, 33], ["Helicobacter pylori", "PROBLEM", 58, 77], ["the agent", "TREATMENT", 79, 88], ["gastric ulcer disease", "PROBLEM", 105, 126], ["Mycoplasma pneumoniae", "PROBLEM", 132, 153], ["walking pneumonia", "PROBLEM", 168, 185], ["Culture", "TEST", 186, 193], ["Diagnostic Tests", "TEST", 198, 214], ["culture bacteria", "TEST", 267, 283], ["blood, sputum, and urine", "TEST", 289, 313], ["culture", "TEST", 390, 397], ["Helicobacter pylori", "OBSERVATION", 58, 77], ["gastric", "ANATOMY", 105, 112], ["ulcer", "OBSERVATION", 113, 118], ["Mycoplasma pneumoniae", "OBSERVATION", 132, 153], ["walking", "OBSERVATION_MODIFIER", 168, 175], ["pneumonia", "OBSERVATION", 176, 185], ["right", "ANATOMY_MODIFIER", 328, 333], ["body", "ANATOMY", 348, 352], ["fluid", "OBSERVATION", 353, 358]]], ["Specimens suspected of being infected with bacteria are plated on solid nutrient-rich media or inoculated into broth.", [["Specimens", "TEST", 0, 9], ["bacteria", "PROBLEM", 43, 51], ["infected", "OBSERVATION", 29, 37], ["bacteria", "OBSERVATION_MODIFIER", 43, 51]]], ["On solid media, bacteria grow and produce colonies composed of thousands of cells.", [["colonies", "ANATOMY", 42, 50], ["cells", "ANATOMY", 76, 81], ["cells", "CELL", 76, 81], ["solid media", "TREATMENT", 3, 14], ["bacteria", "PROBLEM", 16, 24], ["colonies", "PROBLEM", 42, 50], ["thousands of cells", "PROBLEM", 63, 81], ["cells", "OBSERVATION", 76, 81]]], ["Colonies of different species have characteristic appearances and smells that help in their identification.", [["different species", "PROBLEM", 12, 29], ["different species", "OBSERVATION", 12, 29]]], ["In broth, growth is detected by the presence of turbidity and then the broth is subcultured onto solid media for identification.", [["the broth", "TREATMENT", 67, 76], ["growth", "OBSERVATION_MODIFIER", 10, 16]]], ["Some parasitic bacteria, such as Chlamydia and rickettsia, cannot be grown on artificial media and require the presence of host cells (cell culture) for growth.", [["cells", "ANATOMY", 128, 133], ["cell", "ANATOMY", 135, 139], ["Chlamydia and rickettsia", "DISEASE", 33, 57], ["host cells", "CELL", 123, 133], ["cell culture", "CELL", 135, 147], ["host cells", "CELL_TYPE", 123, 133], ["Some parasitic bacteria", "PROBLEM", 0, 23], ["Chlamydia", "PROBLEM", 33, 42], ["rickettsia", "PROBLEM", 47, 57], ["artificial media", "TREATMENT", 78, 94], ["host cells", "PROBLEM", 123, 133], ["cell culture", "TEST", 135, 147], ["parasitic", "OBSERVATION_MODIFIER", 5, 14], ["bacteria", "OBSERVATION", 15, 23], ["rickettsia", "OBSERVATION", 47, 57], ["host cells", "OBSERVATION", 123, 133]]], ["Others, such as Mycobacterium leprae (the agent of leprosy) and Treponema pallidum (the agent of syphilis) cannot be grown at all except in live animals.", [["Mycobacterium leprae", "DISEASE", 16, 36], ["leprosy", "DISEASE", 51, 58], ["Treponema pallidum", "DISEASE", 64, 82], ["syphilis", "DISEASE", 97, 105], ["Mycobacterium leprae", "ORGANISM", 16, 36], ["Treponema pallidum", "ORGANISM", 64, 82], ["Mycobacterium leprae", "SPECIES", 16, 36], ["Treponema pallidum", "SPECIES", 64, 82], ["Mycobacterium leprae", "SPECIES", 16, 36], ["Treponema pallidum", "SPECIES", 64, 82], ["Mycobacterium leprae", "PROBLEM", 16, 36], ["leprosy)", "TREATMENT", 51, 59], ["Treponema pallidum", "PROBLEM", 64, 82], ["syphilis", "PROBLEM", 97, 105]]], ["Once a bacterial colony is present on solid medium, it can be identified by classifying it based on its ability to grow under aerobic or anaerobic conditions, by observing its appearance on Gram stain, by testing its ability to produce enzymes and metabolize sugars as detected by simple tests, and by its ability to utilize various substrates for growth.", [["colony", "ANATOMY", 17, 23], ["sugars", "CHEMICAL", 259, 265], ["sugars", "SIMPLE_CHEMICAL", 259, 265], ["enzymes", "PROTEIN", 236, 243], ["a bacterial colony", "PROBLEM", 5, 23], ["Gram stain", "TEST", 190, 200], ["enzymes", "TEST", 236, 243], ["metabolize sugars", "TEST", 248, 265], ["simple tests", "TEST", 281, 293], ["bacterial colony", "OBSERVATION", 7, 23], ["solid medium", "OBSERVATION_MODIFIER", 38, 50]]], ["After the organism is identified, its susceptibility to various antibiotics must be determined in order to guide therapy.", [["various antibiotics", "TREATMENT", 56, 75], ["therapy", "TREATMENT", 113, 120]]], ["The organism is incubated with the various test antibiotics in order to determine whether it will grow in their presence.Serology ::: Diagnostic TestsTesting for antigen\u2013antibody interactions can be a useful way to determine the presence of a bacterial infection, particularly in the case of organisms that are difficult to grow in the laboratory.", [["bacterial infection", "DISEASE", 243, 262], ["the various test antibiotics", "TREATMENT", 31, 59], ["Serology", "TEST", 121, 129], ["Diagnostic TestsTesting", "TEST", 134, 157], ["antigen\u2013antibody interactions", "PROBLEM", 162, 191], ["a bacterial infection", "PROBLEM", 241, 262], ["organisms", "PROBLEM", 292, 301], ["bacterial", "OBSERVATION_MODIFIER", 243, 252], ["infection", "OBSERVATION", 253, 262]]], ["Serological testing is limited in most cases by the need for several weeks to pass in order for the body to develop an immune response to the infection.", [["body", "ANATOMY", 100, 104], ["infection", "DISEASE", 142, 151], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["Serological testing", "TEST", 0, 19], ["the infection", "PROBLEM", 138, 151], ["infection", "OBSERVATION", 142, 151]]], ["Serology is particularly useful for bacterial infections such as syphilis and brucellosis, which are not easy to grow in culture.", [["bacterial infections", "DISEASE", 36, 56], ["syphilis", "DISEASE", 65, 73], ["brucellosis", "DISEASE", 78, 89], ["Serology", "TEST", 0, 8], ["bacterial infections", "PROBLEM", 36, 56], ["syphilis", "PROBLEM", 65, 73], ["brucellosis", "PROBLEM", 78, 89], ["culture", "TEST", 121, 128], ["infections", "OBSERVATION", 46, 56], ["brucellosis", "OBSERVATION", 78, 89]]], ["Indeed, sometimes the only way to judge the efficacy of treatment for an infection is to follow serological results.", [["infection", "DISEASE", 73, 82], ["treatment", "TREATMENT", 56, 65], ["an infection", "PROBLEM", 70, 82], ["infection", "OBSERVATION", 73, 82]]], ["For example, with syphilis one may expect a fourfold decrease in the strength of the serological response after successful treatment.TreatmentAn ideal antimicrobial agent acts at a target site that is present in the infecting organism but not the host cells.", [["cells", "ANATOMY", 252, 257], ["syphilis", "DISEASE", 18, 26], ["host cells", "CELL", 247, 257], ["host cells", "CELL_TYPE", 247, 257], ["syphilis", "PROBLEM", 18, 26], ["successful treatment", "TREATMENT", 112, 132], ["TreatmentAn ideal antimicrobial agent", "TREATMENT", 133, 170], ["a target site", "PROBLEM", 179, 192], ["the infecting organism", "PROBLEM", 212, 234], ["fourfold", "OBSERVATION_MODIFIER", 44, 52], ["decrease", "OBSERVATION_MODIFIER", 53, 61], ["infecting organism", "OBSERVATION", 216, 234], ["host cells", "OBSERVATION", 247, 257]]], ["Four major sites in the bacterial cell can be targeted by antibiotics because they are sufficiently different from human cells.", [["cell", "ANATOMY", 34, 38], ["cells", "ANATOMY", 121, 126], ["bacterial cell", "CELL", 24, 38], ["human", "ORGANISM", 115, 120], ["cells", "CELL", 121, 126], ["human cells", "CELL_TYPE", 115, 126], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["the bacterial cell", "PROBLEM", 20, 38], ["antibiotics", "TREATMENT", 58, 69], ["bacterial cell", "OBSERVATION", 24, 38], ["human cells", "OBSERVATION", 115, 126]]], ["These are the cell wall, the cell membrane, the nucleic acid synthetic pathway, and the ribosome.", [["cell wall", "ANATOMY", 14, 23], ["cell membrane", "ANATOMY", 29, 42], ["ribosome", "ANATOMY", 88, 96], ["nucleic acid", "CHEMICAL", 48, 60], ["cell wall", "CELLULAR_COMPONENT", 14, 23], ["cell membrane", "CELLULAR_COMPONENT", 29, 42], ["ribosome", "CELLULAR_COMPONENT", 88, 96], ["cell", "OBSERVATION", 14, 18], ["wall", "ANATOMY_MODIFIER", 19, 23], ["cell membrane", "OBSERVATION", 29, 42], ["ribosome", "OBSERVATION_MODIFIER", 88, 96]]], ["Antibacterial agents, or antibiotics, are typically products of other microorganisms, elaborated by them in order to compete for space and resources.", [["Antibacterial agents", "TREATMENT", 0, 20], ["antibiotics", "TREATMENT", 25, 36], ["other microorganisms", "PROBLEM", 64, 84]]], ["There are three ways to classify an antibacterial agent:1.Based on whether it is bactericidal (kills bacteria) or bacteristatic (inhibits growth of bacteria);2.By its chemical structure;3.By its target site.", [["target site", "DNA", 195, 206], ["an antibacterial agent", "TREATMENT", 33, 55], ["bactericidal (kills bacteria", "PROBLEM", 81, 109], ["bacteristatic (inhibits growth of bacteria", "PROBLEM", 114, 156], ["bactericidal", "OBSERVATION_MODIFIER", 81, 93], ["chemical structure", "OBSERVATION", 167, 185]]]], "PMC7194607": [["The long-term impact is that online video lectures are likely to continue after the pandemic.Didactic Teaching ProgramsGrand rounds are conducted via online platforms because of restricted movements, that is, complete or partial lockdowns.", [["the pandemic", "PROBLEM", 80, 92], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["restricted movements", "OBSERVATION", 178, 198]]], ["This approach also is easily adopted and increases the availability of invited national or international speakers (no need for travel), with reduced costs.", [["reduced costs", "PROBLEM", 141, 154]]], ["The long-term impact is that online grand rounds are likely to continue, but only as a component of the curriculum, because physical interaction and networking remain important.Didactic Teaching ProgramsInternational conferences (e.g., the Association for Research in Vision and Ophthalmology, World Ophthalmology Congress) also have moved online.", [["long-term impact", "OBSERVATION_MODIFIER", 4, 20]]], ["The long-term impact is that online large conferences may not continue, because conferences play key roles for interaction and networking.", [["long-term impact", "OBSERVATION_MODIFIER", 4, 20]]], ["However, a virtual option likely will be a regular feature of all major international conferences.Patient CareOutpatient volume has decreased (some >75%) and is restricted to urgent care.", [["Patient", "SPECIES", 98, 105], ["Patient CareOutpatient volume", "TEST", 98, 127], ["urgent care", "TREATMENT", 175, 186], ["decreased", "OBSERVATION_MODIFIER", 132, 141]]], ["Personal protective equipment is required in clinics to prevent possible infection of patients and staff.", [["infection", "DISEASE", 73, 82], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["Personal protective equipment", "TREATMENT", 0, 29], ["infection", "PROBLEM", 73, 82], ["possible", "UNCERTAINTY", 64, 72], ["infection", "OBSERVATION", 73, 82]]], ["A consequence of the decreased volume is that many patients are losing sight irreversibly.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["the decreased volume", "PROBLEM", 17, 37], ["decreased", "OBSERVATION_MODIFIER", 21, 30], ["volume", "OBSERVATION_MODIFIER", 31, 37]]], ["Before COVID-19, many AMCs previously had developed virtual clinics and telemedicine programs.2,3 Now patient acceptance has increased, including coding and billing for telemedicine services by insurers, which may hasten the adoption of such telemedicine programs.4 For patients with mobile phones or computers, some AMCs can conduct face-to-face interviews.", [["AMCs", "PATHOLOGICAL_FORMATION", 22, 26], ["patient", "ORGANISM", 102, 109], ["patients", "ORGANISM", 270, 278], ["patient", "SPECIES", 102, 109], ["patients", "SPECIES", 270, 278], ["COVID", "TEST", 7, 12], ["telemedicine programs", "TREATMENT", 72, 93], ["such telemedicine programs", "TREATMENT", 237, 263], ["increased", "OBSERVATION_MODIFIER", 125, 134]]], ["Others have adopted new technologies for visual acuity and visual field tests via telemedicine.", [["visual acuity", "TEST", 41, 54], ["visual field tests", "TEST", 59, 77]]], ["Home monitoring equipment such as OCT may be possible for patients who can afford it.5 To reassure patients who fear contagion at the AMC and to re-establish follow-up, some AMCs are scheduling appointments in safe environments outside the hospital.", [["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 99, 107], ["Home monitoring equipment", "TREATMENT", 0, 25]]], ["The long-term impact is that digital and telehealth initiatives are likely to be sustained, because virtual clinics and telemedicine will be established clinical practice for screening and monitoring of stable patients.6 This approach may address some important problems in patient management, such as the failure of patients to receive the degree of clinical care in practice environments (e.g., rigorous follow-up for management of age-related macular degeneration) that they are required to receive in registration clinical trials.Patient CareSurgical volume has decreased (some >75%) during the pandemic and also is restricted to urgent or emergent conditions.", [["macular", "ANATOMY", 446, 453], ["macular degeneration", "DISEASE", 446, 466], ["patients", "ORGANISM", 210, 218], ["patient", "ORGANISM", 274, 281], ["patients", "ORGANISM", 317, 325], ["macular", "TISSUE", 446, 453], ["patients", "SPECIES", 210, 218], ["patient", "SPECIES", 274, 281], ["patients", "SPECIES", 317, 325], ["Patient", "SPECIES", 534, 541], ["screening", "TEST", 175, 184], ["monitoring", "TEST", 189, 199], ["patient management", "TREATMENT", 274, 292], ["management", "TREATMENT", 420, 430], ["macular degeneration", "PROBLEM", 446, 466], ["Patient CareSurgical volume", "TEST", 534, 561], ["emergent conditions", "TREATMENT", 644, 663], ["long-term impact", "OBSERVATION_MODIFIER", 4, 20], ["stable", "OBSERVATION_MODIFIER", 203, 209], ["macular degeneration", "OBSERVATION", 446, 466], ["volume", "OBSERVATION_MODIFIER", 555, 561], ["decreased", "OBSERVATION_MODIFIER", 566, 575]]], ["However, because many AMCs are level 1 trauma units, complex cases (e.g., orbital cellulitis with abscess, intraocular foreign bodies) continue to receive surgery.", [["abscess", "ANATOMY", 98, 105], ["intraocular foreign bodies", "ANATOMY", 107, 133], ["trauma", "DISEASE", 39, 45], ["cellulitis", "DISEASE", 82, 92], ["abscess", "DISEASE", 98, 105], ["AMCs", "CANCER", 22, 26], ["complex cases (e.g., orbital cellulitis", "PROBLEM", 53, 92], ["abscess", "PROBLEM", 98, 105], ["intraocular foreign bodies", "TREATMENT", 107, 133], ["surgery", "TREATMENT", 155, 162], ["orbital", "ANATOMY", 74, 81], ["cellulitis", "OBSERVATION", 82, 92], ["abscess", "OBSERVATION", 98, 105], ["intraocular", "OBSERVATION", 107, 118], ["foreign bodies", "OBSERVATION", 119, 133]]], ["In many AMCs, ambulatory surgery centers are closed, and ophthalmology cases are performed in the main operating rooms.", [["AMCs", "ANATOMY", 8, 12], ["AMCs", "CANCER", 8, 12], ["ambulatory surgery", "TREATMENT", 14, 32]]], ["The need for appropriate equipment for eye surgery in the main operating rooms thus has been demonstrated.", [["eye", "ANATOMY", 39, 42], ["eye", "ORGAN", 39, 42], ["appropriate equipment", "TREATMENT", 13, 34], ["eye surgery", "TREATMENT", 39, 50]]], ["Academic medical centers also have increased the rigor of protocols to ensure health and safety of operating room personnel during anesthesia induction, particularly for general anesthesia cases (with aerosol generation), before, during, and after surgery.", [["anesthesia induction", "TREATMENT", 131, 151], ["general anesthesia cases", "TREATMENT", 170, 194], ["aerosol generation", "TREATMENT", 201, 219], ["surgery", "TREATMENT", 248, 255], ["increased", "OBSERVATION_MODIFIER", 35, 44]]], ["The long-term impact is that routine elective surgeries will be increased after the pandemic.", [["routine elective surgeries", "TREATMENT", 29, 55], ["the pandemic", "PROBLEM", 80, 92], ["long-term impact", "OBSERVATION_MODIFIER", 4, 20]]], ["Heightened safety standards are likely to persist indefinitely.Clinical Teaching ProgramsBecause of changes in outpatient practice, residents will become experts in telemedicine and remote monitoring.", [["remote monitoring", "TEST", 182, 199]]], ["This will accelerate incorporation of artificial intelligence into clinical practice.7 The pandemic also has had significant impact on surgical training for residents (e.g., 4\u20136 months of reduced surgical volume).", [["surgical training", "TREATMENT", 135, 152], ["reduced surgical volume", "TREATMENT", 188, 211], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["impact", "OBSERVATION_MODIFIER", 125, 131]]], ["Given the travel restrictions, no alternative surgical sites exist for residents.", [["alternative surgical sites", "TREATMENT", 34, 60]]], ["Training may need to rely more heavily on virtual reality surgical simulators.8 During this pandemic, medical students likely will not have exposure to ophthalmology.", [["surgical simulators", "TREATMENT", 58, 77]]], ["The long-term impact on clinical standards resulting from a reduction in clinical and surgical exposure on this cohort of graduating ophthalmology trainees is unclear.", [["a reduction in clinical and surgical exposure", "PROBLEM", 58, 103], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["reduction", "OBSERVATION_MODIFIER", 60, 69]]], ["Academic medical centers will need to modify residency curriculum to include data science, informatics, virtual reality training, and telemedicine.Clinical ResearchOnly essential clinical research has been permitted in most AMCs (e.g., clinical trials for sight-threatening conditions).", [["sight-threatening conditions", "PROBLEM", 256, 284]]], ["A decrease in patient follow-up and treatment because of fear of acquiring COVID-19 in the clinic may impact clinical trial outcomes.", [["COVID-19", "CHEMICAL", 75, 83], ["COVID-19", "CHEMICAL", 75, 83], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["treatment", "TREATMENT", 36, 45], ["COVID", "TEST", 75, 80], ["decrease", "OBSERVATION_MODIFIER", 2, 10]]], ["Telemedicine has been used to contact patients, but remote diagnostics (e.g., vision, OCT), although useful for routine clinical care, may not be suitable for clinical trials.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["routine clinical care", "TREATMENT", 112, 133]]], ["Some AMCs are establishing mobile vans for clinical trial patients for assessment and treatment.", [["AMCs", "ANATOMY", 5, 9], ["AMCs", "CANCER", 5, 9], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["assessment", "TEST", 71, 81], ["treatment", "TREATMENT", 86, 95]]], ["The long-term impact is that clinical research protocols likely will need to adapt to account for future pandemics, including novel data acquisition, telemedicine, online questionnaires, and remote monitoring.", [["clinical research protocols", "TREATMENT", 29, 56], ["novel data acquisition", "TEST", 126, 148], ["remote monitoring", "TEST", 191, 208], ["long-term impact", "OBSERVATION_MODIFIER", 4, 20]]], ["Regulatory agencies may modify their requirements regarding data capture.Basic ResearchSimilarly, only essential basic laboratory research activities are permitted in most AMCs.", [["AMCs", "ANATOMY", 172, 176], ["AMCs", "CANCER", 172, 176], ["essential", "OBSERVATION_MODIFIER", 103, 112], ["basic", "OBSERVATION_MODIFIER", 113, 118]]], ["Automated support systems (e.g., power, temperature control) need to operate reliably, but a need exists to maintain core activities (e.g., cell culture, animal care).", [["cell", "ANATOMY", 140, 144], ["cell", "CELL", 140, 144], ["power, temperature control", "TREATMENT", 33, 59], ["cell culture", "TEST", 140, 152]]], ["The long-term impact is that some changes to basic research protocols are likely.Academic Management and Working from HomeAll nonessential nonclinical personnel have started to work from home.", [["basic research protocols", "TREATMENT", 45, 69], ["Academic Management", "TREATMENT", 81, 100], ["long-term impact", "OBSERVATION_MODIFIER", 4, 20]]], ["Most academic work can be carried out remotely, including conducting meetings, telephone management, scheduling, grant administration, and budget preparation.", [["telephone management", "TREATMENT", 79, 99], ["budget preparation", "TREATMENT", 139, 157]]], ["The long-term impact is that acceptance of working from home will increase.", [["long-term impact", "OBSERVATION_MODIFIER", 4, 20]]], ["Many staff members have children and elderly family members at home, and society value and impetus to maintain work from home programs may increase in the future.Academic Management and Working from HomeOver the century, AMCs have evolved and adapted to changes to meet their triple mission of clinical care, teaching, and research.", [["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["home programs", "TREATMENT", 121, 134], ["Academic Management", "TREATMENT", 162, 181], ["clinical care", "TREATMENT", 294, 307]]], ["Many changes in practices during this pandemic will be accelerated and sustained and will become part of the new normal after the COVID-19 pandemic.", [["the COVID", "TEST", 126, 135], ["pandemic", "PROBLEM", 139, 147]]]], "ab73a88afa7e9f811a93ebba70fda1ff0dbd2168": [["The global impact of COVID-19 in researchThe Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the virus of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 1 .The global impact of COVID-19 in researchCOVID-19 has reached a pandemic level.", [["COVID-19", "CHEMICAL", 21, 29], ["Coronavirus Disease", "DISEASE", 45, 64], ["COVID-19", "CHEMICAL", 71, 79], ["infectious disease", "DISEASE", 87, 105], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 136, 174], ["COVID-19", "CHEMICAL", 214, 222], ["researchCOVID-19", "CHEMICAL", 226, 242], ["Coronavirus Disease-2019", "ORGANISM", 45, 69], ["COVID-19", "ORGANISM", 71, 79], ["Coronavirus Disease-2019 (COVID-19", "SPECIES", 45, 79], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", "SPECIES", 129, 189], ["COVID", "TEST", 21, 26], ["The Coronavirus Disease", "PROBLEM", 41, 64], ["COVID", "TEST", 71, 76], ["an infectious disease", "PROBLEM", 84, 105], ["the virus", "PROBLEM", 116, 125], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 129, 174], ["SARS-CoV", "TEST", 178, 186], ["COVID", "TEST", 214, 219], ["researchCOVID", "TEST", 226, 239], ["global", "OBSERVATION_MODIFIER", 4, 10], ["impact", "OBSERVATION_MODIFIER", 11, 17], ["Coronavirus Disease", "OBSERVATION", 45, 64], ["infectious", "OBSERVATION", 87, 97], ["Severe", "OBSERVATION_MODIFIER", 129, 135], ["Acute", "OBSERVATION_MODIFIER", 136, 141], ["Respiratory Syndrome", "OBSERVATION", 142, 162], ["global", "OBSERVATION_MODIFIER", 197, 203], ["impact", "OBSERVATION_MODIFIER", 204, 210]]], ["Soon after, Harvard University announced its closure until May.", [["its closure", "TREATMENT", 41, 52], ["closure", "OBSERVATION", 45, 52]]], ["However, this regulation has yet to flatten the infection curve of COVID-19.", [["infection", "DISEASE", 48, 57], ["the infection curve", "PROBLEM", 44, 63], ["COVID", "TEST", 67, 72], ["infection", "OBSERVATION", 48, 57]]], ["As of 17 July 2020, there have been 13,547,206 confirmed cases with 584,,058 deaths globally 3 .", [["deaths", "DISEASE", 77, 83]]], ["With the timely activation of the public health system, Taiwan is one of the countries with an early response to COVID-19 3 .", [["COVID-19", "CHEMICAL", 113, 121], ["COVID", "TEST", 113, 118]]], ["Currently, Taiwan received a 'rotten egg' from the pandemic with 452 cases diagnosed with COVID-19 and 7 cases of death, which fortunately is a relatively lower mortality rate compared to other countries.The global impact of COVID-19 in researchGiven the experience of SARS in 2003 and Dengue fever in 2015, the Taiwanese government was able to rapidly take action on this emerging infectious disease 3 .", [["death", "DISEASE", 114, 119], ["SARS", "DISEASE", 269, 273], ["Dengue fever", "DISEASE", 286, 298], ["infectious disease", "DISEASE", 382, 400], ["COVID", "TEST", 90, 95], ["death", "PROBLEM", 114, 119], ["COVID", "TEST", 225, 230], ["SARS", "PROBLEM", 269, 273], ["Dengue fever", "PROBLEM", 286, 298], ["global", "OBSERVATION_MODIFIER", 208, 214], ["impact", "OBSERVATION_MODIFIER", 215, 221]]], ["This well-established insurance system with high coverage not only relieves the economic burden of health care but is an efficient patient tracking system for travel and exposure history.", [["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138]]], ["Instead of instituting a local, citywide, or national lockdown, most people in Taiwan maintain their daily activities, including biomedical research.The active response of research institutes in Taiwan facing COVID-19There are several pivotal decisions and measures that contained COVID-19 and simultaneously permitted the function of research and educational institutes.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["active", "OBSERVATION_MODIFIER", 153, 159], ["response", "OBSERVATION_MODIFIER", 160, 168]]], ["In this global public health crisis, Taiwan tries the best to refrain from a lockdown.", [["global", "OBSERVATION_MODIFIER", 8, 14]]], ["With the above strategies (Figure 1) , as of April 28, 2020 there are \"zero\" newly documented cases of COVID-19 over the past 3 consecutive days and most of the research and education institutes function as usual 3 .", [["COVID", "TEST", 103, 108]]]], "0ee0228e079bef93905721f1d5809f6f08cc7a62": [["IntroductionSince the emergence of COVID-19 in January 2020 there has been considerable interest in the use of ultraviolet (UV) light to disinfect blood plasma [1] [2] [3] , equipment [4] [5] [6] [7] and air [8] , in the hope that this might reduce transmission of the disease.", [["blood", "ANATOMY", 147, 152], ["COVID-19", "CHEMICAL", 35, 43], ["[4] [5] [6]", "CHEMICAL", 184, 195], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["plasma", "ORGANISM_SUBSTANCE", 153, 159], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 160, 171], ["equipment [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 174, 199], ["ultraviolet (UV", "TREATMENT", 111, 126], ["blood plasma", "TEST", 147, 159], ["the disease", "PROBLEM", 265, 276], ["disease", "OBSERVATION", 269, 276]]], ["In particular, upper-room ultraviolet germicidal irradiation (UVGI), a technology that disinfects room air, has been muted as a potential intervention that might prove effective against COVID-19 [8] [9] [10] .", [["ultraviolet germicidal", "CHEMICAL", 26, 48], ["COVID-19 [8] [9", "CHEMICAL", 186, 201], ["COVID-19 [8] [9] [10]", "CHEMICAL", 186, 207], ["COVID-19 [8] [9] [10]", "SIMPLE_CHEMICAL", 186, 207], ["ultraviolet germicidal irradiation", "TREATMENT", 26, 60], ["a potential intervention", "TREATMENT", 126, 150], ["COVID", "TEST", 186, 191], ["germicidal irradiation", "OBSERVATION", 38, 60]]], ["Upperroom UVGI utilizes UV-C light at wavelengths close to 254 nm to create an irradiation field above the heads of room occupants ( Figure 1 ) that disinfects aerosolised bacteria and viruses suspended in the air [11] [12] [13] .", [["UV-C", "CHEMICAL", 24, 28], ["an irradiation field", "TREATMENT", 76, 96], ["aerosolised bacteria", "PROBLEM", 160, 180], ["viruses", "PROBLEM", 185, 192]]], ["Because UV-C light is harmful to humans, such systems utilize baffles that obscure the UV lamps from eyesight so that room occupants are safe.", [["UV-C", "CHEMICAL", 8, 12], ["humans", "ORGANISM", 33, 39], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39], ["the UV lamps", "TREATMENT", 83, 95]]], ["As such, upper-room UVGI is a well-established technology [14, 15] that has proven effective as a public health intervention to prevent the spread of airborne diseases such as measles [16] and tuberculosis (TB) [17, 18] in buildings.IntroductionGiven that COVID-19 can be transmitted by the inhalation of aerosolised respiratory droplets containing the SARS-CoV-2 virus [8, 19, 20] , and that several studies have recovered viral RNA from hospital air samples [21] [22] [23] [24] , there is reason to believe that upper-room UVGI might be effective at 'killing' (inactivating) SARS-CoV-2 virions in the air, thus reducing the transmission of COVID-19 in buildings and other enclosed spaces.", [["airborne diseases", "DISEASE", 150, 167], ["measles", "DISEASE", 176, 183], ["tuberculosis", "DISEASE", 193, 205], ["TB", "DISEASE", 207, 209], ["COVID-19", "CHEMICAL", 256, 264], ["UVGI", "CHEMICAL", 525, 529], ["SARS", "DISEASE", 577, 581], ["COVID-19", "CHEMICAL", 642, 650], ["SARS-CoV-2 virus", "ORGANISM", 353, 369], ["UVGI", "SIMPLE_CHEMICAL", 525, 529], ["air", "ORGAN", 603, 606], ["viral RNA", "RNA", 424, 433], ["CoV-2 virus", "SPECIES", 358, 369], ["SARS-CoV-2 virus", "SPECIES", 353, 369], ["a public health intervention", "TREATMENT", 96, 124], ["airborne diseases", "PROBLEM", 150, 167], ["measles", "PROBLEM", 176, 183], ["tuberculosis", "PROBLEM", 193, 205], ["aerosolised respiratory droplets", "TREATMENT", 305, 337], ["the SARS", "TEST", 349, 357], ["CoV", "TEST", 358, 361], ["several studies", "TEST", 393, 408], ["hospital air samples", "TEST", 439, 459], ["SARS", "PROBLEM", 577, 581], ["CoV", "TEST", 582, 585], ["COVID", "TEST", 642, 647], ["airborne diseases", "OBSERVATION", 150, 167], ["respiratory droplets", "OBSERVATION", 317, 337], ["air", "ANATOMY", 603, 606]]], ["However, this presupposes that the technology is capable of delivering irradiation doses high enough to inactivate SARS-CoV-2 virions in respiratory droplets suspended in the air, something thatIntroductionhas not yet been proven.", [["respiratory droplets", "ANATOMY", 137, 157], ["SARS", "DISEASE", 115, 119], ["irradiation doses", "TREATMENT", 71, 88], ["SARS", "PROBLEM", 115, 119], ["CoV", "TEST", 120, 123], ["respiratory droplets", "TREATMENT", 137, 157], ["respiratory droplets", "OBSERVATION", 137, 157], ["air", "ANATOMY", 175, 178]]], ["Given this and the urgent need to develop interventions to break the chain of infection associated with COVID-19, we designed the short feasibility study reported here with the aim of evaluating whether or not upper-room UVGI might be an effective intervention against COVID-19.TheoryAt any point in time the amount of viral inactivation (disinfection) achieved for a given UV radiant flux (irradiance) can be described using the following first order decay equation [25] :Theory(1)TheoryWhere: N 0 and N t are the number of viable viral particles (virions) at time zero and t seconds respectively; Z is the UV susceptibility constant for the virus (m 2 /J); E is the radiant (irradiation) flux (W/m 2 ); and t is time in seconds.TheoryThe UV irradiation dose received by the virus is simply:TheoryWhere: H is the observed UV irradiation dose (J/m 2 ).TheoryBy combining equations 1 and 2, and rearranging we can obtain a value for Z:TheoryWhere: f is the survival fraction.TheoryBecause the relationship between the UV dose and the natural logarithm of the survival fraction is broadly linear for most viral species, it means that the behaviour of any given virus exposed to UV-C light can be succinctly described by the value of Z, irrespective of the actual UV dose applied.", [["infection", "DISEASE", 78, 87], ["UVGI", "CHEMICAL", 221, 225], ["UV", "CHEMICAL", 740, 742], ["UV", "CHEMICAL", 1017, 1019], ["UV-C", "CHEMICAL", 1176, 1180], ["COVID-19", "CHEMICAL", 104, 112], ["interventions", "TREATMENT", 42, 55], ["infection", "PROBLEM", 78, 87], ["the short feasibility study", "TEST", 126, 153], ["COVID", "TEST", 269, 274], ["viral inactivation (disinfection", "TREATMENT", 319, 351], ["UV radiant flux", "TREATMENT", 374, 389], ["the UV susceptibility", "PROBLEM", 604, 625], ["the virus", "PROBLEM", 639, 648], ["The UV irradiation dose", "TREATMENT", 736, 759], ["UV irradiation dose (J/m", "TREATMENT", 823, 847], ["the survival fraction", "PROBLEM", 952, 973], ["the UV dose", "TREATMENT", 1013, 1024], ["the survival fraction", "TREATMENT", 1054, 1075], ["most viral species", "PROBLEM", 1098, 1116], ["virus", "PROBLEM", 1159, 1164], ["the actual UV dose", "TREATMENT", 1250, 1268], ["infection", "OBSERVATION", 78, 87], ["viral inactivation", "OBSERVATION", 319, 337], ["viral particles", "OBSERVATION", 532, 547]]], ["As such, for any given viral species, if the value of Z is known, then it should be possible to predict with reasonable accuracy how the virus will behave when exposed to a given UV-C dose in any context.", [["UV-C", "CHEMICAL", 179, 183], ["UV-C", "SIMPLE_CHEMICAL", 179, 183], ["viral species", "PROBLEM", 23, 36], ["the virus", "PROBLEM", 133, 142], ["UV-C dose", "TREATMENT", 179, 188]]], ["Microbes that exhibit larger Z values are more susceptible to UV damage, whereas those with small Z values are more difficult to inactivate.TheoryUV inactivation plots for most viral species tend to be straight lines, although some might exhibit a curve [26] .", [["larger Z values", "PROBLEM", 22, 37], ["UV damage", "PROBLEM", 62, 71], ["small Z values", "PROBLEM", 92, 106], ["TheoryUV inactivation plots", "PROBLEM", 140, 167], ["most viral species", "PROBLEM", 172, 190], ["straight lines", "TREATMENT", 202, 216], ["larger", "OBSERVATION_MODIFIER", 22, 28], ["Z values", "OBSERVATION_MODIFIER", 29, 37], ["UV damage", "OBSERVATION", 62, 71], ["small", "OBSERVATION_MODIFIER", 92, 97], ["Z values", "OBSERVATION_MODIFIER", 98, 106], ["straight lines", "OBSERVATION_MODIFIER", 202, 216]]], ["Notwithstanding this, the model described in equation 1 is still a good approximation for most viral species [25] up until the point where the 'target' becomes saturated with UV photons.", [["most viral species", "PROBLEM", 90, 108], ["UV photons", "TREATMENT", 175, 185]]], ["At this point, because all the virions have already been inactivated, increasing the UV dose further has no effect and so the linear relationship All rights reserved.", [["UV", "CHEMICAL", 85, 87], ["all the virions", "TREATMENT", 23, 38], ["the UV dose", "TREATMENT", 81, 92]]], ["No reuse allowed without permission.Theory(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.TheoryThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.", [["The copyright holder", "TREATMENT", 183, 203], ["med", "ANATOMY", 121, 124]]], ["12.20129254 doi: medRxiv preprint between UV dose and the log reduction become decoupled, with the result that the Z value no long applies.TheoryInstead of quantifying UV inactivation in terms of survival fraction, many researchers, particularly those working in biology, describe the reduction in the microbial count in terms of log reduction, which can be converted to survival fraction as follows:TheoryWhere: A is the log 10 reduction in the number of viable virions.TheorySpecifically, with regard to upper-room UVGI, once the Z value has been obtained for the target microbe, it is then possible to determine the irradiation flux required to disinfect it, using the methodology described in Beggs and Sleigh [11] .", [["virions", "ANATOMY", 463, 470], ["UV", "CHEMICAL", 42, 44], ["medRxiv", "TREATMENT", 17, 24], ["UV dose", "TREATMENT", 42, 49], ["the log reduction", "TREATMENT", 54, 71], ["the Z value", "TEST", 111, 122], ["quantifying UV inactivation", "TREATMENT", 156, 183], ["survival fraction", "PROBLEM", 196, 213], ["the microbial count", "TEST", 298, 317], ["log reduction", "TREATMENT", 330, 343], ["the Z value", "TEST", 528, 539], ["the irradiation flux", "PROBLEM", 615, 635], ["UV inactivation", "OBSERVATION", 168, 183], ["reduction", "OBSERVATION_MODIFIER", 285, 294], ["microbial count", "OBSERVATION", 302, 317], ["viable", "OBSERVATION_MODIFIER", 456, 462], ["virions", "OBSERVATION", 463, 470]]], ["If this is the case, then the average particle residence time, t res , (in seconds) in the room space will be:TheoryWhere: n is the room ventilation rate in air changes per hour (AC/h).TheoryFrom equation 5 it can be approximated that the average particle residence time in the upper-room UV field, t uv , (in seconds) will be:TheoryWhere: h r is the floor-to-ceiling height (m), and h uv is the depth of the upper-room UV zone (m).TheoryAll rights reserved.", [["the room ventilation rate", "TREATMENT", 128, 153]]], ["No reuse allowed without permission.Theory(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.TheoryThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.", [["The copyright holder", "TREATMENT", 183, 203], ["med", "ANATOMY", 121, 124]]], ["12.20129254 doi: medRxiv preprint Because Z values are often determined experimentally using microbes suspended in liquids or on surfaces, it may be necessary to adjust the Z value for use with upper-room UVGI systems [12, 27] , as follows:TheoryWhere: Z ur is the effective upper-room Z value (m 2 /J), and c ur is a correction coefficient.TheorySo if we assume that the air in a room is well mixed, by combining equations 2, 3 and 6 it is possible to compute the average irradiation flux, E r , that is required to achieve a desired survival fraction, f r :Theory\u00d7 ln ( f r ) .(8)Alternatively, the disinfection achieved by an upper-room UVGI system can be thought of as being equivalent to additional air changes in the room space.", [["medRxiv", "TREATMENT", 17, 24], ["Z values", "TEST", 42, 50], ["microbes suspended in liquids", "TREATMENT", 93, 122], ["the disinfection", "TREATMENT", 597, 613], ["additional air changes in the room space", "PROBLEM", 693, 733], ["air", "OBSERVATION", 372, 375], ["ln", "ANATOMY", 567, 569], ["air", "OBSERVATION", 704, 707]]], ["In this scenario, the UV rate constant, k uv , which can be thought of as the equivalent air change rate per second, can be determined using [12] :(8)So in a ventilated room in which contamination ceases at time zero, we can utilize both the UV rate constant, k uv , and a rate constant, k v , for the ventilation (i.e. n \u00f7 3600), to produce a decay model for the room space:(8)Where; C 0 and C t are the concentrations of viable viral particles in the room space (virions/m 3 ) at time zero and t seconds respectively; k v is the ventilation rate constant; k d is the particulate deposition rate constant (e.g. 0.0014 s -1 [19] ); and t is time in seconds.(8)All rights reserved.", [["C 0", "SIMPLE_CHEMICAL", 385, 388], ["the UV rate", "TEST", 18, 29], ["k uv", "TREATMENT", 260, 264], ["the ventilation", "TREATMENT", 298, 313], ["k v", "TEST", 520, 523], ["the ventilation rate", "TEST", 527, 547], ["k d", "TEST", 558, 561], ["viral particles", "OBSERVATION", 430, 445]]], ["No reuse allowed without permission.(8)(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(8)The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprintAnalysis of published dataA search of the relevant scientific literature was undertaken to identify published data relating to the UV irradiation of the three closely related coronaviruses: SARS-CoV-2, the causative agent of COVID-19; SARS-CoV-1, the causative agent of severe acute respiratory syndrome (SARS); and MERS-CoV, the causative agent of middle east respiratory syndrome (MERS).Analysis of published dataBecause the experimental methods used in the various UV studies varied greatly, as did the level of detail reported, it was necessary to adopt a standardized approach so that valid comparisons could be made.", [["acute respiratory syndrome", "DISEASE", 595, 621], ["SARS", "DISEASE", 623, 627], ["middle east respiratory syndrome", "DISEASE", 667, 699], ["MERS", "DISEASE", 701, 705], ["coronaviruses", "ORGANISM", 493, 506], ["SARS-CoV-2", "ORGANISM", 508, 518], ["COVID-19", "ORGANISM", 543, 551], ["SARS-CoV-1", "ORGANISM", 553, 563], ["MERS-CoV", "ORGANISM", 634, 642], ["CoV-1", "SPECIES", 558, 563], ["SARS-CoV-2", "SPECIES", 508, 518], ["COVID-19", "SPECIES", 543, 551], ["SARS-CoV-1", "SPECIES", 553, 563], ["MERS-CoV", "SPECIES", 634, 642], ["The copyright holder", "TREATMENT", 177, 197], ["medRxiv", "TREATMENT", 302, 309], ["the UV irradiation", "TREATMENT", 445, 463], ["CoV", "TEST", 513, 516], ["COVID", "TEST", 543, 548], ["SARS", "TEST", 553, 557], ["severe acute respiratory syndrome", "PROBLEM", 588, 621], ["SARS)", "PROBLEM", 623, 628], ["MERS-CoV", "PROBLEM", 634, 642], ["middle east respiratory syndrome", "PROBLEM", 667, 699], ["the various UV studies", "TEST", 774, 796], ["a standardized approach", "TREATMENT", 876, 899], ["valid comparisons", "TEST", 908, 925], ["med", "ANATOMY", 118, 121], ["severe", "OBSERVATION_MODIFIER", 588, 594], ["acute", "OBSERVATION_MODIFIER", 595, 600], ["respiratory syndrome", "OBSERVATION", 601, 621], ["middle", "ANATOMY_MODIFIER", 667, 673], ["respiratory syndrome", "OBSERVATION", 679, 699]]], ["It was therefore decided that, rather than estimating the Z value for a nominal log one reduction (i.e. D 90 ) as others have done [28] , we would instead use the log reduction values and UV doses reported in the various studies to calculate the respective Z values using equation 3.", [["a nominal log one reduction", "TREATMENT", 70, 97], ["the log reduction values", "TREATMENT", 159, 183], ["UV doses", "TREATMENT", 188, 196], ["the various studies", "TEST", 209, 228]]], ["In so doing, we were able to utilize the results from studies that would otherwise be excluded because the log reductions achieved were far in excess of one.Analysis of published dataWhere researchers performed experiments using a range of UV doses, we calculated the Z value for two UV doses, one near the start of the inactivation process and the other just before the saturation point.Analysis of published dataIn order to compare the Z values for the coronaviruses with those for influenza, we utilized experimental results produced by Heimbuch & Harnish [4] who irradiated coupons of respirator material inoculated with SARS-CoV-1 and MERS-CoV, as well as four strains of influenza A, allowing direct comparisons to be made between the viral species.Estimating an effective upper-room Z value for aerosolised SARS-CoV-2In order to evaluate how SARS-CoV-2 might behave in the presence of UV-C when aerosolised, we reviewed the available literature on the subject [25, [28] [29] [30] [31] with the aim of estimating a value for the coefficient, c ur , in equation 7, which we then used to estimate the effective upper-room Z value, Z ur .", [["influenza", "DISEASE", 484, 493], ["influenza A", "DISEASE", 677, 688], ["SARS", "DISEASE", 814, 818], ["SARS", "DISEASE", 849, 853], ["coronaviruses", "ORGANISM", 455, 468], ["SARS-CoV-1", "ORGANISM", 625, 635], ["MERS-CoV", "ORGANISM", 640, 648], ["influenza A", "ORGANISM", 677, 688], ["[28] [29] [30] [31]", "SIMPLE_CHEMICAL", 972, 991], ["SARS-CoV-1", "SPECIES", 625, 635], ["MERS-CoV", "SPECIES", 640, 648], ["influenza A", "SPECIES", 677, 688], ["studies", "TEST", 54, 61], ["the log reductions", "TREATMENT", 103, 121], ["a range of UV doses", "TREATMENT", 229, 248], ["two UV doses", "TREATMENT", 280, 292], ["the inactivation process", "TREATMENT", 316, 340], ["the Z values", "TEST", 434, 446], ["the coronaviruses", "PROBLEM", 451, 468], ["influenza", "PROBLEM", 484, 493], ["respirator material", "TREATMENT", 589, 608], ["SARS", "PROBLEM", 625, 629], ["CoV", "TEST", 630, 633], ["MERS", "PROBLEM", 640, 644], ["influenza A", "PROBLEM", 677, 688], ["the viral species", "PROBLEM", 737, 754], ["aerosolised SARS", "PROBLEM", 802, 818], ["SARS", "PROBLEM", 849, 853], ["viral species", "OBSERVATION", 741, 754]]], ["In order to reflect the uncertainty associated with this, we compared effective Z values for aerosolised coronaviruses reported in the literature with values obtained for SARS-CoV-1 in liquids to obtain the range of possible values for c ur .", [["coronaviruses", "ORGANISM", 105, 118], ["SARS-CoV-1", "SPECIES", 171, 181], ["effective Z values", "TEST", 70, 88], ["aerosolised coronaviruses", "PROBLEM", 93, 118], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179]]], ["No reuse allowed without permission.Estimating an effective upper-room Z value for aerosolised SARS-CoV-2(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Estimating an effective upper-room Z value for aerosolised SARS-CoV-2The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprintComputation of required upper-room UV irradiation fluxHaving estimated the value of Z ur for SARS-CoV-2 from the literature, we then used equations 6 and 8 to estimate the average upper-room irradiation flux that would be required to achieve a 50 -90% reduction in aerosolised SARS-CoV-2 virions (through the action of the UV-C alone) in a 4.2 \u00d7 4.2 \u00d7 2.5 m high room space for a range of ventilation rates.Computation of required upper-room UV irradiation fluxThese dimensions were chosen because they are typical for an upper-room UVGI installation in which the lamp height is 2.1 m above the floor [15] .", [["SARS", "DISEASE", 95, 99], ["SARS", "DISEASE", 727, 731], ["UV-C", "CHEMICAL", 773, 777], ["aerosolised SARS", "PROBLEM", 83, 99], ["aerosolised SARS-CoV", "PROBLEM", 287, 307], ["The copyright holder", "TREATMENT", 309, 329], ["upper-room UV irradiation", "TREATMENT", 474, 499], ["SARS", "PROBLEM", 543, 547], ["CoV", "TEST", 548, 551], ["aerosolised SARS", "PROBLEM", 715, 731], ["CoV-2 virions", "TREATMENT", 732, 745], ["the UV", "TREATMENT", 769, 775], ["upper-room UV irradiation flux", "TREATMENT", 881, 911], ["the lamp height", "TEST", 1010, 1025], ["med", "ANATOMY", 184, 187]]], ["In the model we assumed that the air was completely mixed, which meant that according to equation 6, aerosol particles would spend on average 16% of their room residency time in the UV zone.Computation of required upper-room UV irradiation fluxIn addition to computing the required UV flux, we also wanted to know how a standard upperroom UV fitting might perform when challenged by SARS-CoV-2.", [["SARS-CoV", "SPECIES", 383, 391], ["the air", "PROBLEM", 29, 36], ["aerosol particles", "TREATMENT", 101, 118], ["upper-room UV irradiation fluxIn", "TREATMENT", 214, 246], ["UV flux", "TREATMENT", 282, 289], ["a standard upperroom UV fitting", "TREATMENT", 318, 349], ["air", "OBSERVATION", 33, 36], ["UV", "ANATOMY", 182, 184], ["zone", "ANATOMY_MODIFIER", 185, 189]]], ["In accordance with the guidelines stated by First [15] , we assumed that the room contained a single 30 W (input) UV fitting capable of delivering an average upper-room flux of 50 \u03bc W/cm 2 , and modelled its performance in terms of equivalent ventilation rate using equation 9.Analysis of the published literatureThe results of the literature search are summarized in Table 1 , which shows the UV-C doses applied and log reductions achieved in six studies investigating SARS-CoV-1 and two studies investigating MERS-CoV.", [["SARS", "DISEASE", 470, 474], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 470, 480], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 511, 519], ["SARS-CoV", "SPECIES", 470, 478], ["MERS-CoV", "SPECIES", 511, 519], ["a single 30 W (input) UV fitting", "TREATMENT", 92, 124], ["the literature search", "TEST", 328, 349], ["the UV-C doses", "TREATMENT", 390, 404], ["log reductions", "TREATMENT", 417, 431], ["six studies", "TEST", 444, 455], ["SARS", "TEST", 470, 474], ["CoV", "TEST", 475, 478], ["two studies", "TEST", 485, 496]]], ["Although no studies were found that specifically looked at the inactivation of SARS-CoV-2 using UV-C light, three studies were found that used a combination of UV-A and UV-B light (270-360 nm), together with the photosensitiser, riboflavin, to disinfect SARS-CoV-2 [1, 2] and MERS-CoV [32] in blood products ( Table 2) .Analysis of the published literatureAlthough these studies did not utilize UV-C light, it was nevertheless decided to report the results of these studies here so that direct comparisons could be made between SARS-CoV-2 and MERS-CoV.", [["blood", "ANATOMY", 293, 298], ["SARS", "DISEASE", 79, 83], ["UV-A", "CHEMICAL", 160, 164], ["UV-B", "CHEMICAL", 169, 173], ["riboflavin", "CHEMICAL", 229, 239], ["SARS", "DISEASE", 254, 258], ["riboflavin", "CHEMICAL", 229, 239], ["riboflavin", "SIMPLE_CHEMICAL", 229, 239], ["MERS-CoV [32]", "SIMPLE_CHEMICAL", 276, 289], ["blood", "ORGANISM_SUBSTANCE", 293, 298], ["SARS-CoV-2", "ORGANISM", 528, 538], ["MERS-CoV", "ORGANISM", 543, 551], ["SARS-CoV", "SPECIES", 254, 262], ["MERS-CoV", "SPECIES", 276, 284], ["SARS-CoV", "SPECIES", 528, 536], ["MERS-CoV", "SPECIES", 543, 551], ["studies", "TEST", 12, 19], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["UV", "TREATMENT", 96, 98], ["three studies", "TEST", 108, 121], ["UV", "TREATMENT", 160, 162], ["A and UV", "TREATMENT", 163, 171], ["the photosensitiser", "TREATMENT", 208, 227], ["riboflavin", "TREATMENT", 229, 239], ["SARS", "TEST", 254, 258], ["CoV", "TEST", 259, 262], ["MERS", "TEST", 276, 280], ["CoV", "TEST", 281, 284], ["blood products", "TREATMENT", 293, 307], ["these studies", "TEST", 365, 378], ["these studies", "TEST", 460, 473], ["direct comparisons", "TEST", 487, 505], ["SARS", "TEST", 528, 532], ["CoV", "TEST", 533, 536]]], ["The MERS-CoV irradiation study by Bedell et al. [33] is included for completeness, even though the authors did not report the UV dose received by the virus, making it impossible to compute a Z value for this study.Analysis of the published literatureThe computed Z values for the respective experiments are shown in Tables 3 (UV-C) and 4 (UV-A/B plus riboflavin).", [["riboflavin", "CHEMICAL", 351, 361], ["riboflavin", "CHEMICAL", 351, 361], ["riboflavin", "SIMPLE_CHEMICAL", 351, 361], ["CoV irradiation study", "TEST", 9, 30], ["the UV dose", "TREATMENT", 122, 133], ["this study", "TEST", 203, 213], ["The computed Z values", "TEST", 250, 271], ["the respective experiments", "TEST", 276, 302], ["UV-A/B plus riboflavin", "TREATMENT", 339, 361]]], ["From these it can be seen that the Z values for the MERS-CoV virus All rights reserved.", [["MERS-CoV virus", "SPECIES", 52, 66], ["the Z values", "TEST", 31, 43], ["the MERS", "PROBLEM", 48, 56], ["CoV virus All rights", "TREATMENT", 57, 77]]], ["No reuse allowed without permission.Analysis of the published literature(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Analysis of the published literatureThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint were similar in magnitude to those for both SARS-CoV-1 (UV-C) and SARS-CoV-2 (UV-A/B).Analysis of the published literatureWith UV-C irradiation the mean Z value for SARS-CoV-1 was 0.00489 (SD = 0.00611) m 2 /J, whereas that for MERS-CoV was 0.00104 m 2 /J. Likewise, for UV-A/B plus riboflavin the corresponding Z values were 0.00020 (SD = 0.00009) m 2 /J and 0.00016 m 2 /J for SARS-CoV-2 and MERS-CoV respectively.Analysis of the published literatureThe calculated Z values for influenza UV-C irradiation experiments undertaken by Heimbuch & Harnish [4] are presented in Table 5 .", [["SARS", "DISEASE", 429, 433], ["UV-C", "CHEMICAL", 512, 516], ["SARS", "DISEASE", 550, 554], ["riboflavin", "CHEMICAL", 668, 678], ["UV-C", "CHEMICAL", 875, 879], ["riboflavin", "CHEMICAL", 668, 678], ["UV-C", "SIMPLE_CHEMICAL", 441, 445], ["SARS-CoV-2", "ORGANISM", 451, 461], ["UV-A/B", "CELL", 463, 469], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 613, 621], ["riboflavin", "SIMPLE_CHEMICAL", 668, 678], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 779, 787], ["SARS-CoV-1", "SPECIES", 429, 439], ["SARS-CoV", "SPECIES", 451, 459], ["SARS-CoV-1", "SPECIES", 550, 560], ["MERS-CoV", "SPECIES", 613, 621], ["SARS-CoV", "SPECIES", 764, 772], ["MERS-CoV", "SPECIES", 779, 787], ["The copyright holder", "TREATMENT", 243, 263], ["medRxiv preprint", "TREATMENT", 368, 384], ["both SARS", "TEST", 424, 433], ["CoV", "TEST", 434, 437], ["SARS", "PROBLEM", 451, 455], ["CoV", "TEST", 456, 459], ["Analysis", "TEST", 471, 479], ["the published literatureWith UV", "TREATMENT", 483, 514], ["C irradiation", "TREATMENT", 515, 528], ["the mean Z value", "TEST", 529, 545], ["SARS", "TEST", 550, 554], ["CoV", "TEST", 555, 558], ["UV", "TEST", 656, 658], ["riboflavin", "TREATMENT", 668, 678], ["the corresponding Z values", "TEST", 679, 705], ["SARS", "TEST", 764, 768], ["CoV", "TEST", 769, 772], ["MERS", "TEST", 779, 783], ["The calculated Z values", "TEST", 837, 860], ["influenza UV", "TREATMENT", 865, 877], ["C irradiation experiments", "TREATMENT", 878, 903], ["med", "ANATOMY", 151, 154]]], ["These experiments, which were carried out using inoculated coupons of respirator material, revealed that in this context the Z values for the various influenza A strains were of the same order of magnitude as those for SARS-CoV-1 and MERS-CoV.Effective upper-room Z values for aerosolised SARS-CoV-2A review of the literature revealed that relatively few experimental studies have been performed involving the UV irradiation of aerosolised viruses, with only one undertaken on a coronavirus [29] .", [["influenza A strains", "ORGANISM", 150, 169], ["SARS-CoV-1", "ORGANISM", 219, 229], ["MERS-CoV", "ORGANISM", 234, 242], ["SARS-CoV-1", "SPECIES", 219, 229], ["MERS-CoV", "SPECIES", 234, 242], ["the Z values", "TEST", 121, 133], ["the various influenza A strains", "PROBLEM", 138, 169], ["SARS", "TEST", 219, 223], ["CoV", "TEST", 224, 227], ["MERS", "PROBLEM", 234, 238], ["Effective upper-room Z values", "TEST", 243, 272], ["aerosolised SARS", "PROBLEM", 277, 293], ["the UV irradiation", "TREATMENT", 406, 424], ["aerosolised viruses", "PROBLEM", 428, 447], ["a coronavirus", "PROBLEM", 477, 490]]], ["A summary of the findings of several key studies are presented in Table 6 , which reveals that most viral species appear to be relatively easy to disinfect when suspended in droplets in the air.", [["several key studies", "TEST", 29, 48], ["most viral species", "PROBLEM", 95, 113], ["viral species", "OBSERVATION", 100, 113], ["air", "ANATOMY", 190, 193]]], ["In particular, aerosolised viruses appear to be more vulnerable to UV damage than when they are suspended in a liquid or on a substrate.", [["aerosolised viruses", "PROBLEM", 15, 34], ["UV damage", "PROBLEM", 67, 76], ["a substrate", "TREATMENT", 124, 135], ["viruses", "OBSERVATION", 27, 34], ["damage", "OBSERVATION", 70, 76]]], ["For example, for the 24 irradiation experiments involving adenoviruses suspended in liquid, reported by Kowalski [28] , the average Z value was 0.00586 m 2 /J, which is an order of magnitude less than the values of 0.0546 and 0.0390 m 2 /J for aerosolised adenoviruses, attributed to Jensen [31] and Walker and Ko [29] respectively.", [["adenoviruses", "ORGANISM", 58, 70], ["adenoviruses", "ORGANISM", 256, 268], ["the 24 irradiation experiments", "TREATMENT", 17, 47], ["adenoviruses", "PROBLEM", 58, 70], ["the average Z value", "TEST", 120, 139], ["aerosolised adenoviruses", "PROBLEM", 244, 268], ["Walker", "TREATMENT", 300, 306]]], ["Regarding coronaviruses, Walker and Ko [29] also performed experiments on aerosolised murine (mouse) hepatitis virus (MHV) coronavirus in a single pass test rig.", [["murine (mouse) hepatitis virus (MHV) coronavirus", "DISEASE", 86, 134], ["coronaviruses", "ORGANISM", 10, 23], ["murine (", "ORGANISM", 86, 94], ["mouse) hepatitis virus (MHV) coronavirus", "ORGANISM", 94, 134], ["murine", "SPECIES", 86, 92], ["mouse", "SPECIES", 94, 99], ["hepatitis virus", "SPECIES", 101, 116], ["MHV) coronavirus", "SPECIES", 118, 134], ["mouse", "SPECIES", 94, 99], ["hepatitis virus", "SPECIES", 101, 116], ["MHV", "SPECIES", 118, 121], ["coronaviruses", "PROBLEM", 10, 23], ["hepatitis virus (MHV) coronavirus", "PROBLEM", 101, 134]]], ["This revealed a Z value of 0.377 \u00b1 0.119 m 2 /J for this virus, which is several orders of magnitude greater than the values obtained above for SARS-CoV-1 and MERS-CoV in liquids and on surfaces (Table 3 ).", [["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 144, 154], ["MERS-CoV", "SIMPLE_CHEMICAL", 159, 167], ["SARS-CoV", "SPECIES", 144, 152], ["MERS-CoV", "SPECIES", 159, 167], ["a Z value", "TEST", 14, 23], ["this virus", "PROBLEM", 52, 62], ["magnitude", "TEST", 91, 100], ["SARS", "TEST", 144, 148], ["CoV", "TEST", 149, 152], ["MERS", "PROBLEM", 159, 163], ["CoV in liquids", "TREATMENT", 164, 178]]], ["Although we are comparing different species of coronavirus here, evidence from Bedell et al. [33] , who irradiated MHV coronavirus and MERS-CoV in Petri dishes, suggests that it is nonetheless valid.", [["MHV coronavirus", "DISEASE", 115, 130], ["coronavirus", "ORGANISM", 47, 58], ["MHV coronavirus", "ORGANISM", 115, 130], ["MERS-CoV", "ORGANISM", 135, 143], ["MHV coronavirus", "SPECIES", 115, 130], ["MHV coronavirus", "SPECIES", 115, 130], ["MERS-CoV", "SPECIES", 135, 143], ["coronavirus", "PROBLEM", 47, 58], ["irradiated MHV coronavirus", "PROBLEM", 104, 130], ["CoV in Petri dishes", "TREATMENT", 140, 159], ["MHV coronavirus", "OBSERVATION", 115, 130], ["Petri dishes", "OBSERVATION", 147, 159]]], ["They found that 5 minutes exposed to a UV-C light source resulted in a 2.71 log reduction for the MHV coronavirus, whereas the same exposure resulted in a 5.91 log reduction for MERS-CoV.", [["UV-C", "CHEMICAL", 39, 43], ["MHV coronavirus", "ORGANISM", 98, 113], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 178, 186], ["MHV coronavirus", "SPECIES", 98, 113], ["MHV coronavirus", "SPECIES", 98, 113], ["MERS-CoV", "SPECIES", 178, 186], ["a UV", "TEST", 37, 41], ["a 2.71 log reduction", "TREATMENT", 69, 89], ["the MHV coronavirus", "PROBLEM", 94, 113], ["MERS", "PROBLEM", 178, 182], ["MHV coronavirus", "OBSERVATION", 98, 113]]], ["This suggests that MHV coronavirus is actually more resistant to UV damage than MERS-CoV, and as such, supports Walker and Ko's [29] conclusion that All rights reserved.", [["MHV coronavirus", "DISEASE", 19, 34], ["MHV coronavirus", "ORGANISM", 19, 34], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 80, 88], ["MHV coronavirus", "SPECIES", 19, 34], ["MERS-CoV", "SPECIES", 80, 88], ["MHV coronavirus", "PROBLEM", 19, 34], ["UV damage", "PROBLEM", 65, 74], ["MHV coronavirus", "OBSERVATION", 19, 34]]], ["No reuse allowed without permission.Effective upper-room Z values for aerosolised SARS-CoV-2(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Effective upper-room Z values for aerosolised SARS-CoV-2The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint coronaviruses are much easier to inactivate in the air compared with on surfaces and in liquids.Effective upper-room Z values for aerosolised SARS-CoV-2Comparing the computed Z values for UV irradiation experiments on coronaviruses conducted in air (0.37700 m 2 /J [29] ) with equivalents in liquid (0.00134 m 2 /J) [34] ; 0.01833 m 2 /J [26] , it would appear that irradiating the coronavirus in liquid requires a UV dose that is in the region 20 -281 times higher than that required when the virus is suspended in air.Effective upper-room Z values for aerosolised SARS-CoV-2From this we estimated that the value of the adjustment coefficient c ur would be in a range 0.05 -0.0036.Upper-room UVGI simulation resultsBecause the Z value for aerosolised MHV coronavirus appeared to be indicative of how airborne SARS-CoV-2 might behave in a UV-C field, a decision was made to use Walker and Ko's mean Z value of 0.377 m 2 /J to evaluate the expected performance of an upper-room UVGI installation.", [["SARS", "DISEASE", 82, 86], ["SARS", "DISEASE", 567, 571], ["coronavirus", "DISEASE", 807, 818], ["UV", "CHEMICAL", 840, 842], ["SARS", "DISEASE", 991, 995], ["SARS", "DISEASE", 1235, 1239], ["medRxiv preprint coronaviruses", "ORGANISM", 408, 438], ["coronaviruses", "ORGANISM", 643, 656], ["coronavirus", "ORGANISM", 807, 818], ["MHV coronavirus", "ORGANISM", 1177, 1192], ["MHV coronavirus", "SPECIES", 1177, 1192], ["SARS-CoV", "SPECIES", 567, 575], ["SARS-CoV", "SPECIES", 991, 999], ["MHV coronavirus", "SPECIES", 1177, 1192], ["aerosolised SARS", "PROBLEM", 70, 86], ["aerosolised SARS-CoV", "PROBLEM", 261, 281], ["The copyright holder", "TREATMENT", 283, 303], ["medRxiv preprint coronaviruses", "TREATMENT", 408, 438], ["Effective upper-room Z values", "TEST", 521, 550], ["aerosolised SARS", "PROBLEM", 555, 571], ["CoV", "TEST", 572, 575], ["the computed Z values", "TEST", 587, 608], ["UV irradiation experiments", "TREATMENT", 613, 639], ["coronaviruses", "PROBLEM", 643, 656], ["equivalents in liquid", "TREATMENT", 702, 723], ["irradiating the coronavirus in liquid", "PROBLEM", 791, 828], ["a UV dose", "TREATMENT", 838, 847], ["the virus", "PROBLEM", 915, 924], ["aerosolised SARS", "PROBLEM", 979, 995], ["the Z value", "TEST", 1149, 1160], ["aerosolised MHV coronavirus", "PROBLEM", 1165, 1192], ["Walker", "TREATMENT", 1303, 1309], ["med", "ANATOMY", 171, 174], ["air", "OBSERVATION", 476, 479], ["coronavirus", "OBSERVATION", 807, 818], ["virus", "OBSERVATION", 919, 924], ["air", "OBSERVATION", 941, 944]]], ["Notwithstanding this, because of the uncertainty associated with how aerosolised SARS-CoV-2 might behave in reality, we also modelled a worst-case scenario in which Z ur was 0.0377 m 2 /J. Table 7 presents the results of the room analysis using these two values for Z ur , for a range of ventilation rates.", [["SARS", "DISEASE", 81, 85], ["how aerosolised SARS", "PROBLEM", 65, 85], ["the room analysis", "TEST", 221, 238], ["Z ur", "TEST", 266, 270], ["a range of ventilation rates", "TREATMENT", 277, 305]]], ["From this it can be seen that there is a direct inverse relationship between particle residence time in the UV field, t uv , and the required irradiation flux, E r , as predicted by equation 8.", [["irradiation flux", "TREATMENT", 142, 158], ["irradiation flux", "OBSERVATION", 142, 158]]], ["This means that for any given Z value, the value of E r will double as the room ventilation rate doubles.", [["Z value", "TEST", 30, 37], ["the room ventilation rate doubles", "TREATMENT", 71, 104]]], ["The table also reveals that there is a direct inverse relationship between Z ur and E r .", [["E r", "GENE_OR_GENE_PRODUCT", 84, 87]]], ["From the calculated values in this table it can be seen that if Z ur , = 0.377 m 2 /J, then with an average UV flux of just 10 \u03bc W/cm 2 it should be possible to achieve >90% inactivation of SARS-CoV-2, even at a ventilation rate of 8 AC/h.", [["SARS", "DISEASE", 190, 194], ["SARS-CoV", "SPECIES", 190, 198], ["the calculated values", "TEST", 5, 26], ["an average UV flux", "TREATMENT", 97, 115], ["SARS", "TEST", 190, 194], ["CoV", "TEST", 195, 198], ["a ventilation rate", "TEST", 210, 228], ["UV flux", "OBSERVATION", 108, 115]]], ["Given that accepted guidelines [15] recommend for a room 2.5 m high, one 30 W (input) UV lamp per 18.58 m 2 of floor area, which will produce an average flux in the region 50 \u03bc W/cm 2 , this means that even under this worse-case scenario it should still be possible to achieve disinfection rates >90% for all but the highest ventilation rates.Upper-room UVGI simulation resultsAll rights reserved.", [["floor area", "ANATOMY", 111, 121], ["disinfection rates", "TEST", 277, 295], ["average", "OBSERVATION_MODIFIER", 145, 152], ["flux", "OBSERVATION", 153, 157]]], ["No reuse allowed without permission.Upper-room UVGI simulation results(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Upper-room UVGI simulation resultsThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint When we fixed the UV flux at an average of 50 \u03bc W/cm 2 , we found that for Z ur , = 0.377 m 2 /J the upper-room UVGI installation produced an equivalent air change rate of 108.6 AC/h, whereas if Z ur , = 0.0377 m 2 /J this fell to 10.9 AC/h.", [["The copyright holder", "TREATMENT", 239, 259], ["medRxiv", "TREATMENT", 364, 371], ["the UV flux", "PROBLEM", 395, 406], ["Z ur", "TEST", 456, 460], ["med", "ANATOMY", 149, 152], ["equivalent", "OBSERVATION_MODIFIER", 523, 533], ["air change", "OBSERVATION", 534, 544]]], ["These values were constant and unaffected by the actual room ventilation rate.DiscussionAlthough the impact of UV-C on SARS-CoV-2 has not yet been experimentally investigated for aerosols, the results of our analysis suggest that it is highly lightly that the UV-C Z value for this virus will be similar in magnitude to that for SARS-CoV-1 and MERS-CoV.", [["UV-C", "CHEMICAL", 111, 115], ["SARS", "DISEASE", 119, 123], ["SARS", "DISEASE", 329, 333], ["UV-C", "SIMPLE_CHEMICAL", 111, 115], ["SARS-CoV-2", "ORGANISM", 119, 129], ["SARS-CoV-1", "ORGANISM", 329, 339], ["MERS-CoV", "ORGANISM", 344, 352], ["SARS-CoV-1", "SPECIES", 329, 339], ["MERS-CoV", "SPECIES", 344, 352], ["the actual room ventilation rate", "TEST", 45, 77], ["UV", "TREATMENT", 111, 113], ["SARS", "PROBLEM", 119, 123], ["our analysis", "TEST", 204, 216], ["the UV", "TEST", 256, 262], ["C Z value", "PROBLEM", 263, 272], ["this virus", "PROBLEM", 277, 287], ["SARS", "TEST", 329, 333], ["CoV", "TEST", 334, 337], ["constant", "OBSERVATION_MODIFIER", 18, 26]]], ["This is because MERS-CoV behaves very similarly to SARS-CoV-1 when exposed to UV-C light (Table 3 ) and also very similar to SARS-CoV-2 when exposed to UV-A/B and riboflavin ( Table 4 ).", [["SARS", "DISEASE", 51, 55], ["UV-C", "CHEMICAL", 78, 82], ["SARS", "DISEASE", 125, 129], ["UV-A/B", "CHEMICAL", 152, 158], ["riboflavin", "CHEMICAL", 163, 173], ["riboflavin", "CHEMICAL", 163, 173], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["SARS-CoV-1", "ORGANISM", 51, 61], ["B", "CELL", 157, 158], ["riboflavin", "SIMPLE_CHEMICAL", 163, 173], ["MERS-CoV", "SPECIES", 16, 24], ["SARS-CoV-1", "SPECIES", 51, 61], ["SARS-CoV", "SPECIES", 125, 133], ["CoV", "TEST", 56, 59], ["UV", "TREATMENT", 152, 154], ["A/B and riboflavin", "TREATMENT", 155, 173]]], ["As such, there are grounds for believing that the UV-C susceptibility constant, Z, for SARS-CoV-2 will be similar to those of the other two coronaviruses.DiscussionOne problem often encountered when comparing UV irradiation results from disparate researchers is that experimenters often utilize different methodologies to evaluate log reductions in microbial species, with varying doses of UV administered.", [["UV", "CHEMICAL", 390, 392], ["coronaviruses", "ORGANISM", 140, 153], ["SARS-CoV", "SPECIES", 87, 95], ["the UV-C susceptibility constant", "PROBLEM", 46, 78], ["Z", "TEST", 80, 81], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95], ["the other two coronaviruses", "PROBLEM", 126, 153], ["UV irradiation", "TREATMENT", 209, 223], ["different methodologies", "TREATMENT", 295, 318], ["log reductions in microbial species", "PROBLEM", 331, 366], ["UV administered", "TREATMENT", 390, 405], ["coronaviruses", "OBSERVATION", 140, 153], ["microbial species", "OBSERVATION", 349, 366]]], ["In particular, the type of substrate or media used can greatly influence the outcome of the experiment.", [["substrate or media", "TREATMENT", 27, 45]]], ["This is because the substrate or media can absorb the UV photons and shield the virus.", [["the UV photons", "TREATMENT", 50, 64], ["the virus", "PROBLEM", 76, 85], ["UV photons", "OBSERVATION", 54, 64]]], ["For this reason we included the results of Heimbuch and Harnish [4] in Tables 3 and 5 , because they performed the same irradiation experiment on SARS-CoV-1 and MERS-CoV, as well as on four strains of influenza A, thus allowing direct comparisons to be made.", [["influenza", "DISEASE", 201, 210], ["CoV-1", "ORGANISM", 151, 156], ["MERS-CoV", "ORGANISM", 161, 169], ["SARS-CoV-1", "SPECIES", 146, 156], ["MERS-CoV", "SPECIES", 161, 169], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["influenza A", "PROBLEM", 201, 212]]], ["From Tables 3 and 5 it can be seen that the Z values for the influenza strains are of a similar order of magnitude as those for the coronaviruses, implying that in this context SARS-CoV-1 and MERS-CoV were about as difficult to inactivate as influenza A. This is a surprising finding, because others have suggested that the UV dose required to disinfect SARS-CoV-2 might be much higher than that required to disinfect influenza A [5] .", [["influenza", "DISEASE", 61, 70], ["UV", "CHEMICAL", 324, 326], ["SARS", "DISEASE", 354, 358], ["influenza", "DISEASE", 418, 427], ["coronaviruses", "ORGANISM", 132, 145], ["SARS-CoV-1", "ORGANISM", 177, 187], ["MERS-CoV", "ORGANISM", 192, 200], ["SARS-CoV-1", "SPECIES", 177, 187], ["MERS-CoV", "SPECIES", 192, 200], ["A.", "SPECIES", 252, 254], ["the Z values", "TEST", 40, 52], ["the influenza strains", "PROBLEM", 57, 78], ["the coronaviruses", "PROBLEM", 128, 145], ["CoV", "TEST", 182, 185], ["influenza", "PROBLEM", 242, 251], ["the UV dose", "TREATMENT", 320, 331], ["SARS", "PROBLEM", 354, 358], ["CoV", "TEST", 359, 362], ["influenza", "PROBLEM", 418, 427]]], ["Indeed, in a summary collated from hundreds of published studies by Kowalski [28] , the Z values for influenza A in water were reported as being in the range 0.04800 -0.13810 m 2 /J, much higher than the values achieved by Heimbuch and Harnish [4] .", [["water", "SIMPLE_CHEMICAL", 116, 121], ["the Z values", "TEST", 84, 96], ["influenza", "PROBLEM", 101, 110]]], ["As such, this suggests that the substrate or medium in which microbe is irradiated plays an important role in influencing the magnitude of the Z value achieved.", [["the Z value", "TEST", 139, 150], ["medium", "OBSERVATION_MODIFIER", 45, 51]]], ["Indeed, it is well known in other contexts that UV-C light can be attenuated as it All rights reserved.", [["UV-C light", "TREATMENT", 48, 58]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint passes through liquids [35] .", [["medRxiv preprint passes through liquids", "TREATMENT", 316, 355], ["med", "ANATOMY", 125, 128]]], ["When UV light passes through a suspension of particles in water, its intensity is reduced due to both scattering and absorption of the light [36] .DiscussionAbsorption occurs because the light beam interacts with atoms and molecules in the liquid to raise their energy level, with the result that energy is lost from the beam, whereas scattering occurs when particulates in the fluid interfere with the UV light making it more diffuse [35] .DiscussionParticulates can also shield microbes from UV light.", [["fluid", "ANATOMY", 378, 383], ["fluid", "ORGANISM_SUBSTANCE", 378, 383], ["a suspension of particles in water", "TREATMENT", 29, 63], ["the UV light", "TREATMENT", 399, 411], ["reduced", "OBSERVATION_MODIFIER", 82, 89], ["fluid", "OBSERVATION", 378, 383], ["diffuse", "OBSERVATION_MODIFIER", 427, 434]]], ["This means that UV inactivation of microbial suspensions in liquid films >1.2 mm can be greatly inhibited, due to the low penetration depth of UV light through concentrated suspensions [37] .", [["UV inactivation", "TREATMENT", 16, 31], ["microbial suspensions in liquid films", "TEST", 35, 72], ["the low penetration depth", "PROBLEM", 114, 139], ["UV light", "TREATMENT", 143, 151], ["microbial", "OBSERVATION_MODIFIER", 35, 44], ["suspensions", "OBSERVATION_MODIFIER", 45, 56], ["low penetration", "OBSERVATION_MODIFIER", 118, 133]]], ["Consequently, when interpreting the Z values for SARS-CoV-1 and MERS-CoV in Table 3 , it is important to view them as being strictly contextual.DiscussionWith regard to UV irradiation of aerosolised viruses, very few published experimental studies exist, with only one specifically relating to a coronavirus [29] .", [["SARS", "DISEASE", 49, 53], ["coronavirus", "DISEASE", 296, 307], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 49, 59], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 64, 72], ["SARS-CoV", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 64, 72], ["the Z values", "TEST", 32, 44], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["UV irradiation", "TREATMENT", 169, 183], ["aerosolised viruses", "PROBLEM", 187, 206], ["a coronavirus", "PROBLEM", 294, 307]]], ["As a result there is a paucity of good quality data relating to UV-C irradiation of SARS-CoV-1, SARS-CoV-2 and MERS-CoV in the air.", [["UV-C", "CHEMICAL", 64, 68], ["SARS", "DISEASE", 84, 88], ["C", "SIMPLE_CHEMICAL", 67, 68], ["SARS-CoV-1", "ORGANISM", 84, 94], ["SARS-CoV-2", "ORGANISM", 96, 106], ["MERS-CoV", "ORGANISM", 111, 119], ["SARS-CoV-1", "SPECIES", 84, 94], ["SARS-CoV", "SPECIES", 96, 104], ["MERS-CoV", "SPECIES", 111, 119], ["UV-C irradiation", "TREATMENT", 64, 80], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["MERS", "PROBLEM", 111, 115], ["air", "ANATOMY", 127, 130]]], ["Consequently, we had to establish whether or not Walker and Ko's [29] published Z value of 0.377 m 2 /J was valid for SARS-CoV-2 in air.", [["SARS-CoV", "SPECIES", 118, 126], ["Z value", "TEST", 80, 87], ["SARS", "PROBLEM", 118, 122], ["CoV", "TEST", 123, 126], ["air", "ANATOMY", 132, 135]]], ["Comparison with the Z values presented in Table 3 reveals that this value is several orders of magnitude greater than those achieve when coronaviruses are irradiated in liquid or on equipment substrates.", [["coronaviruses", "ORGANISM", 137, 150], ["the Z values", "TEST", 16, 28], ["this value", "TEST", 63, 73], ["coronaviruses", "PROBLEM", 137, 150], ["equipment substrates", "TREATMENT", 182, 202]]], ["Also the finding appears to be broadly in keeping with the behaviour of adenoviruses when irradiated in air and in liquid.", [["adenoviruses", "ORGANISM", 72, 84], ["adenoviruses", "PROBLEM", 72, 84], ["appears to be", "UNCERTAINTY", 17, 30], ["broadly", "OBSERVATION_MODIFIER", 31, 38], ["adenoviruses", "OBSERVATION", 72, 84], ["air", "OBSERVATION_MODIFIER", 104, 107]]], ["Furthermore, because Bedell et al. [33] found MERS-CoV to be more susceptible to UV-C damage than MHV coronavirus, this strongly supports the use of Walker and Ko's [29] Z value for MHV coronavirus as a valid surrogate for SARS-CoV-2 in air.DiscussionHaving said this, because the UV susceptibility of the target microbe is crucial to the performance of any upper-room UVGI installation, Walker and Ko's Z value for coronaviruses should be treated with caution, as it may in time turn out to be incorrect.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 46, 54], ["C", "SIMPLE_CHEMICAL", 84, 85], ["MHV coronavirus", "ORGANISM", 98, 113], ["MHV coronavirus", "ORGANISM", 182, 197], ["coronaviruses", "ORGANISM", 416, 429], ["MHV coronavirus", "SPECIES", 98, 113], ["MHV coronavirus", "SPECIES", 182, 197], ["MERS-CoV", "SPECIES", 46, 54], ["MHV coronavirus", "SPECIES", 98, 113], ["MHV coronavirus", "SPECIES", 182, 197], ["SARS-CoV", "SPECIES", 223, 231], ["CoV", "PROBLEM", 51, 54], ["UV", "TREATMENT", 81, 83], ["C damage", "PROBLEM", 84, 92], ["MHV coronavirus", "PROBLEM", 98, 113], ["Walker", "TREATMENT", 149, 155], ["MHV coronavirus", "PROBLEM", 182, 197], ["a valid surrogate", "TEST", 201, 218], ["SARS", "PROBLEM", 223, 227], ["CoV", "TEST", 228, 231], ["Walker", "TREATMENT", 388, 394], ["coronaviruses", "PROBLEM", 416, 429], ["caution", "TREATMENT", 453, 460], ["air", "ANATOMY", 237, 240]]], ["For this reason, when we assessed the performance of the upper-room UVGI in our hypothetical room, we used both 0.377 and 0.0377 m 2 /J in our simulations.", [["upper-room UVGI", "DNA", 57, 72]]], ["In so doing, we effectively modelled both the expected and worst-case scenarios.DiscussionThe results for the expected and worst-case scenarios in Table 7 , strongly suggest that upper-room UVGI, if applied correctly, should be effective at disinfecting SARS-CoV-2 virions suspended in respiratory droplets in the air.", [["respiratory droplets", "ANATOMY", 286, 306], ["UVGI", "CHEMICAL", 190, 194], ["SARS", "DISEASE", 254, 258], ["CoV-2 virions", "TREATMENT", 259, 272], ["respiratory droplets", "OBSERVATION", 286, 306], ["air", "ANATOMY", 314, 317]]], ["This finding is of course is very much dependent on the surrogate Z ur value being truly representative for SARS-CoV-2.", [["SARS", "DISEASE", 108, 112], ["SARS-CoV", "SPECIES", 108, 116], ["SARS", "PROBLEM", 108, 112], ["CoV", "TEST", 113, 116]]], ["With respect to this, one limitation of our study is that we did not distinguish between the Z values achieved using a single-pass test rig, such as that used by Walker and Ko [29] , and those achieved in real-All rights reserved.", [["our study", "TEST", 40, 49], ["a single-pass test rig", "TREATMENT", 117, 139]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint life by an upper-room UVGI system.", [["medRxiv preprint life", "TREATMENT", 316, 337], ["med", "ANATOMY", 125, 128]]], ["With the latter, because the irradiation process is fragmented, compared with a single-pass system, it is thought that higher UV doses might be required to achieve equivalent levels of inactivation [12, 27] .", [["the irradiation process", "PROBLEM", 25, 48], ["higher UV doses", "TREATMENT", 119, 134], ["fragmented", "OBSERVATION_MODIFIER", 52, 62]]], ["However, while this specifically applies to aerosolised bacteria that can rapidly repair UV damage when the irradiation process becomes fragmented [38] , it is not known to what extent this applies to viruses, which are not metabolically active, although it is known that through photoreactivation viruses can repair UV damage [39].DiscussionOne great advantage of upper-room UVGI is that it can be retrospectively fitted into buildings provided that the floor to ceiling height is large enough to ensure that the UV field does not impinge on room occupants [15] .", [["floor", "ORGANISM_SUBDIVISION", 455, 460], ["aerosolised bacteria", "PROBLEM", 44, 64], ["UV damage", "PROBLEM", 89, 98], ["the irradiation process", "PROBLEM", 104, 127], ["viruses", "PROBLEM", 201, 208], ["photoreactivation viruses", "TREATMENT", 280, 305], ["UV damage", "OBSERVATION", 89, 98], ["fragmented", "OBSERVATION_MODIFIER", 136, 146], ["viruses", "OBSERVATION", 201, 208], ["large", "OBSERVATION", 482, 487]]], ["By installing such as system it is possible to effectively 'turbo-charge' the efficacy of the ventilation system.", [["the ventilation system", "TREATMENT", 90, 112], ["ventilation system", "OBSERVATION", 94, 112]]], ["Indeed, our analysis suggests that it is possible to achieve >100 equivalent AC/h by installing upper-room UVGI.", [["our analysis", "TEST", 8, 20]]], ["Using equation 9, we can calculate the UV rate constant, k uv , which can be thought of as the equivalent air change rate per second.", [["the UV rate", "TEST", 35, 46], ["air change", "OBSERVATION", 106, 116]]], ["Once known, this in turn can be used, together with the ventilation and particulate deposition rate constants, k v , and k d , in equation 10, to compute the concentration of viral partials in the room space at any point in time.ConclusionWe have been able to demonstrate that the UV-C susceptibility constant, Z, for SARS-CoV-2 is likely to be similar to that exhibited by the SARS-CoV-1 and MERS-CoV viruses.ConclusionFurthermore, we have found evidence suggesting that SARS-CoV-2 when suspended in air is reasonably easy to inactivate using UV light at 254 nm.", [["SARS", "DISEASE", 318, 322], ["SARS", "DISEASE", 472, 476], ["CoV-1", "ORGANISM", 383, 388], ["MERS-CoV viruses", "ORGANISM", 393, 409], ["CoV-2", "ORGANISM", 477, 482], ["SARS-CoV", "SPECIES", 318, 326], ["SARS-CoV-1", "SPECIES", 378, 388], ["MERS-CoV viruses", "SPECIES", 393, 409], ["the ventilation", "TREATMENT", 52, 67], ["k v", "TEST", 111, 114], ["the UV", "TEST", 277, 283], ["C susceptibility constant", "PROBLEM", 284, 309], ["Z", "TEST", 311, 312], ["SARS", "PROBLEM", 318, 322], ["CoV", "TEST", 323, 326], ["the SARS", "TEST", 374, 382], ["CoV", "TEST", 383, 386], ["MERS", "PROBLEM", 393, 397], ["CoV viruses", "PROBLEM", 398, 409], ["SARS", "PROBLEM", 472, 476], ["CoV", "TEST", 477, 480], ["UV light", "TREATMENT", 544, 552], ["viral partials", "OBSERVATION", 175, 189], ["CoV viruses", "OBSERVATION", 398, 409], ["evidence suggesting", "UNCERTAINTY", 447, 466], ["SARS", "OBSERVATION", 472, 476]]], ["As such, this suggests that upperroom UVGI may have great potential as an intervention to inhibit the transmission of COVID-19 in buildings, especially in situations where achieving high ventilation rates might otherwise be impractical.", [["UVGI", "CHEMICAL", 38, 42], ["COVID-19", "CHEMICAL", 118, 126], ["an intervention", "TREATMENT", 71, 86], ["COVID", "TEST", 118, 123]]], ["No reuse allowed without permission.Conclusion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 125, 128]]], ["No reuse allowed without permission.Conclusion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint Tables Table 1.", [["The copyright holder", "TREATMENT", 191, 211], ["med", "ANATOMY", 125, 128]]], ["UV-C doses applied and log reductions achieved in various studies relating to the SARS-CoV-1 and MERS-CoV viruses. * Estimated from plots and data presented in source material.", [["UV-C", "CHEMICAL", 0, 4], ["SARS", "DISEASE", 82, 86], ["UV-C", "SIMPLE_CHEMICAL", 0, 4], ["CoV-1", "ORGANISM", 87, 92], ["MERS-CoV viruses", "ORGANISM", 97, 113], ["SARS-CoV-1", "SPECIES", 82, 92], ["MERS-CoV viruses", "SPECIES", 97, 113], ["UV-C doses", "TREATMENT", 0, 10], ["log reductions", "TREATMENT", 23, 37], ["various studies", "TEST", 50, 65], ["the SARS", "TEST", 78, 86], ["CoV", "TEST", 87, 90], ["MERS", "PROBLEM", 97, 101], ["CoV viruses", "PROBLEM", 102, 113], ["CoV viruses", "OBSERVATION", 102, 113]]], ["Legend: nr -not reported in source material.", [["nr", "OBSERVATION", 8, 10]]], ["Legend: nr -not reported in source material.ConclusionAll rights reserved.", [["nr", "OBSERVATION", 8, 10]]], ["No reuse allowed without permission.Conclusion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint this version posted June 14, 2020.Conclusion* Estimated from plots and data presented in source material.", [["The copyright holder", "TREATMENT", 191, 211], ["med", "ANATOMY", 125, 128]]], ["No reuse allowed without permission.Conclusion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint All rights reserved.", [["The copyright holder", "TREATMENT", 191, 211], ["medRxiv", "TREATMENT", 316, 323], ["med", "ANATOMY", 125, 128]]], ["No reuse allowed without permission.Conclusion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint Figure 1 .", [["The copyright holder", "TREATMENT", 191, 211], ["med", "ANATOMY", 125, 128]]], ["An upper-room UVGI installation.", [["An upper-room UVGI installation", "TREATMENT", 0, 31]]], ["No reuse allowed without permission.Figures(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.FiguresThe copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129254 doi: medRxiv preprint", [["medRxiv", "TREATMENT", 310, 317], ["med", "ANATOMY", 122, 125]]]], "1d9926ab4fdc7f5b3cf56c331910c1188619d9b9": [["IntroductionIn December 2019, patients with pneumonia of unknown causes were found in some medical institutions in Wuhan, Hubei province, China.", [["pneumonia", "DISEASE", 44, 53], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["pneumonia", "PROBLEM", 44, 53], ["pneumonia", "OBSERVATION", 44, 53]]], ["1 On January 7, 2020, the virus was isolated from a sample of a positive patient and the entire genome sequence of the virus was obtained.", [["sample", "ANATOMY", 52, 58], ["patient", "ORGANISM", 73, 80], ["entire genome sequence", "DNA", 89, 111], ["patient", "SPECIES", 73, 80], ["the virus", "PROBLEM", 22, 31], ["the virus", "PROBLEM", 115, 124], ["virus", "OBSERVATION", 119, 124]]], ["2 Subsequent studies indicated that the virus belonged to the type b coronavirus family, and its genetic characteristics were obviously different from Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).", [["Acute Respiratory Syndrome", "DISEASE", 158, 184], ["SARS", "DISEASE", 186, 190], ["Middle East Respiratory Syndrome", "DISEASE", 196, 228], ["MERS", "DISEASE", 230, 234], ["type b coronavirus", "ORGANISM", 62, 80], ["type b coronavirus", "SPECIES", 62, 80], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 151, 191], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 196, 235], ["Subsequent studies", "TEST", 2, 20], ["the virus", "PROBLEM", 36, 45], ["Severe Acute Respiratory Syndrome (SARS)", "PROBLEM", 151, 191], ["Middle East Respiratory Syndrome", "PROBLEM", 196, 228], ["Severe", "OBSERVATION_MODIFIER", 151, 157], ["Acute", "OBSERVATION_MODIFIER", 158, 163], ["Respiratory Syndrome", "OBSERVATION", 164, 184], ["Middle", "ANATOMY_MODIFIER", 196, 202], ["Respiratory Syndrome", "OBSERVATION", 208, 228]]], ["3, 4 The World Health Organization (WHO) declared the new coronavirus pneumonia as a public health emergency of international concern on 31 January 2020, and officially named it \"coronavirus disease 2019 (Covid-19)\"on February 11, 2020 .", [["coronavirus pneumonia", "DISEASE", 58, 79], ["coronavirus disease", "DISEASE", 179, 198], ["coronavirus", "ORGANISM", 58, 69], ["the new coronavirus pneumonia", "PROBLEM", 50, 79], ["coronavirus disease", "PROBLEM", 179, 198], ["new", "OBSERVATION_MODIFIER", 54, 57], ["coronavirus", "OBSERVATION_MODIFIER", 58, 69], ["pneumonia", "OBSERVATION", 70, 79]]], ["Covid-19 is mainly transmitted from human-to-human by respiratory droplets and close contact, and may also be transmitted through fecal mouth and aerosol.", [["respiratory droplets", "ANATOMY", 54, 74], ["fecal mouth", "ANATOMY", 130, 141], ["Covid-19", "CHEMICAL", 0, 8], ["Covid-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 36, 41], ["human", "ORGANISM", 45, 50], ["fecal", "ORGANISM_SUBDIVISION", 130, 135], ["mouth", "ORGANISM_SUBDIVISION", 136, 141], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 45, 50], ["Covid", "TEST", 0, 5]]], ["5, 6 The clinical manifestations of Covid-19 are very similar to SARS, and patients may develop acute respiratory distress syndrome (ARDS), which is highly likely to require intensive care and even lead to death.", [["respiratory", "ANATOMY", 102, 113], ["SARS", "DISEASE", 65, 69], ["acute respiratory distress syndrome", "DISEASE", 96, 131], ["ARDS", "DISEASE", 133, 137], ["death", "DISEASE", 206, 211], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Covid", "TEST", 36, 41], ["SARS", "PROBLEM", 65, 69], ["acute respiratory distress syndrome", "PROBLEM", 96, 131], ["ARDS", "PROBLEM", 133, 137], ["intensive care", "TREATMENT", 174, 188], ["death", "PROBLEM", 206, 211], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory distress syndrome", "OBSERVATION", 102, 131], ["highly likely", "UNCERTAINTY", 149, 162]]], ["7 Since January 2020, the Covid-19 has spread rapidly from Wuhan to other parts of China and other countries around the world.", [["Covid-19", "CHEMICAL", 26, 34]]], ["[8] [9] [10] As of March 13, 2020, a total of 132,758 laboratory-confirmed cases (80,991 in China) and 4955 deaths (3180 in China) had been reported worldwide.", [["deaths", "DISEASE", 108, 114]]], ["11 With the increasing number of confirmed and suspected cases globally, the situation of disease prevention and control is extremely critical.IntroductionSince the outbreak of Covid-19, several studies have successively reported the clinical characteristics of patients infected with Covid-19, but almost all the research All rights reserved.", [["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["Covid-19", "SPECIES", 177, 185], ["disease prevention", "TREATMENT", 90, 108], ["Covid", "TEST", 177, 182], ["several studies", "TEST", 187, 202], ["Covid", "TEST", 285, 290], ["infected", "OBSERVATION", 271, 279]]], ["No reuse allowed without permission.Introduction(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.IntroductionThe copyright holder for this preprint this version posted March 23, 2020. . https://doi.org/10.1101/2020.03.19.20038539 doi: medRxiv preprint was conducted in Wuhan or other cities in inland China.", [["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprint", "TREATMENT", 321, 337], ["med", "ANATOMY", 127, 130]]], ["[12] [13] [14] [15] Hainan province is an independent island located at the southern tip of China, unlike the rest of China, Hainan province belongs to tropical monsoon climate.", [["[12] [13] [14] [15] Hainan", "CHEMICAL", 0, 26], ["[12] [13] [14] [15", "SIMPLE_CHEMICAL", 0, 18]]], ["Previous studies have found that climate affects the spread of SARS virus.", [["SARS", "DISEASE", 63, 67], ["SARS virus", "ORGANISM", 63, 73], ["SARS virus", "SPECIES", 63, 73], ["Previous studies", "TEST", 0, 16], ["SARS virus", "PROBLEM", 63, 73], ["SARS virus", "OBSERVATION", 63, 73]]], ["16 Therefore, we describe the clinical characteristics and laboratory findings of patients infected with Covid-19 in Hainan province to explore whether it is different from other regions in China, and to provide an insight into the prevention and treatment of Covid-19 across China, especially to other places with similar climate and environment as Hainan province.Study Design and ParticipantsWe conducted a retrospective study focusing on the clinical characteristics of Commission of the People's Republic of China.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Participants", "SPECIES", 383, 395], ["People", "SPECIES", 492, 498], ["Covid-19", "SPECIES", 260, 268], ["Covid", "TEST", 105, 110], ["Covid", "TEST", 260, 265], ["a retrospective study", "TEST", 408, 429]]], ["18 A confirmed case was defined as a positive result to high-throughput sequencing or real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay for nasal and pharyngeal swab specimens.", [["nasal", "ANATOMY", 163, 168], ["pharyngeal swab specimens", "ANATOMY", 173, 198], ["nasal", "ORGANISM_SUBDIVISION", 163, 168], ["pharyngeal swab specimens", "CANCER", 173, 198], ["transcriptase polymerase", "TEST", 104, 128], ["chain-reaction", "PROBLEM", 129, 143], ["RT-PCR) assay", "TEST", 145, 158], ["nasal and pharyngeal swab specimens", "TEST", 163, 198], ["nasal", "ANATOMY", 163, 168], ["pharyngeal", "ANATOMY", 173, 183]]], ["7 Only the laboratory-confirmed cases were included in the analysis.Study Design and ParticipantsThe study was approved by the institutional ethics board of the Second Affiliated All rights reserved.", [["Participants", "SPECIES", 85, 97], ["the analysis", "TEST", 55, 67], ["The study", "TEST", 97, 106]]], ["No reuse allowed without permission.Study Design and Participants(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Data CollectionAll medical records of patients were extracted by a doctor assigned by local hospital and sent to the data processing center in Haikou.", [["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["Data Collection", "TEST", 200, 215], ["med", "ANATOMY", 144, 147]]], ["A team of experienced respiratory clinicians reviewed and abstracted the data.", [["the data", "TEST", 69, 77]]], ["If the data were with mission or doubt, the coordinators in Haikou contacted the doctor who is responsible for the treatment of the patient for clarification.Data CollectionThe epidemiological characteristics (demographic data, exposure history, and underlying comorbidities), clinical (symptoms and signs), laboratory (ie, complete blood count, blood chemistry, coagulation test, liver and renal function, electrolytes) and radiological findings (chest X-ray or computed tomography), treatment (ie, antiviral therapy, corticosteroid therapy, respiratory support) and outcomes (remained in hospital, discharges, death) data were extracted from electronic medical records. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. injury was defined if the serum levels of cardiac biomarkers (eg, troponin I) were above the 99th percentile upper reference limit or new abnormalities were shown in electrocardiography and echocardiography.", [["blood", "ANATOMY", 333, 338], ["blood", "ANATOMY", 346, 351], ["liver", "ANATOMY", 381, 386], ["renal", "ANATOMY", 391, 396], ["respiratory", "ANATOMY", 543, 554], ["serum", "ANATOMY", 834, 839], ["cardiac", "ANATOMY", 850, 857], ["death", "DISEASE", 612, 617], ["patient", "ORGANISM", 132, 139], ["blood", "ORGANISM_SUBSTANCE", 333, 338], ["blood", "ORGANISM_SUBSTANCE", 346, 351], ["liver", "ORGAN", 381, 386], ["renal", "ORGAN", 391, 396], ["serum", "ORGANISM_SUBSTANCE", 834, 839], ["cardiac", "ORGAN", 850, 857], ["troponin I", "GENE_OR_GENE_PRODUCT", 874, 884], ["troponin I", "PROTEIN", 874, 884], ["patient", "SPECIES", 132, 139], ["Data Collection", "TEST", 158, 173], ["demographic data", "TEST", 210, 226], ["underlying comorbidities", "PROBLEM", 250, 274], ["clinical (symptoms", "PROBLEM", 277, 295], ["complete blood count", "TEST", 324, 344], ["blood chemistry", "TEST", 346, 361], ["coagulation test", "TEST", 363, 379], ["electrolytes", "TEST", 407, 419], ["radiological findings", "TEST", 425, 446], ["chest X-ray", "TEST", 448, 459], ["computed tomography", "TEST", 463, 482], ["treatment", "TREATMENT", 485, 494], ["antiviral therapy", "TREATMENT", 500, 517], ["corticosteroid therapy", "TREATMENT", 519, 541], ["respiratory support", "TREATMENT", 543, 562], ["injury", "PROBLEM", 808, 814], ["the serum levels", "TEST", 830, 846], ["cardiac biomarkers", "TEST", 850, 868], ["troponin I", "TEST", 874, 884], ["new abnormalities", "PROBLEM", 942, 959], ["electrocardiography", "TEST", 974, 993], ["echocardiography", "TEST", 998, 1014], ["liver", "ANATOMY", 381, 386], ["renal", "ANATOMY", 391, 396], ["chest", "ANATOMY", 448, 453], ["med", "ANATOMY", 751, 754], ["cardiac", "ANATOMY", 850, 857]]], ["22 The durations from onset of disease to first hospital visit, admission, severe, discharge or death were recorded.", [["death", "DISEASE", 96, 101], ["disease", "PROBLEM", 31, 38], ["death", "PROBLEM", 96, 101], ["severe", "OBSERVATION_MODIFIER", 75, 81]]], ["The clinical outcomes were monitored up to March 13, 2020, the final date of follow-up.Statistical AnalysisCategorical variables were presented as the counts and percentages in each category, and chi-square tests and Fisher's exact tests were used for comparing as appropriate.Statistical AnalysisContinuous variables were presented as medians and interquartile ranges (IQR) and compared with Wilcoxon rank-sum tests.", [["Statistical AnalysisCategorical variables", "PROBLEM", 87, 128], ["the counts", "TEST", 147, 157], ["chi-square tests", "TEST", 196, 212], ["Fisher's exact tests", "TEST", 217, 237], ["Statistical AnalysisContinuous variables", "PROBLEM", 277, 317], ["Wilcoxon rank", "TEST", 393, 406], ["sum tests", "TEST", 407, 416]]], ["All analyses were performed using SPSS (Statistical Package for the Social Sciences) version 22.0 software (SPSS Inc), and the statistical significance was two-sided P values <0.05.", [["All analyses", "TEST", 0, 12]]], ["Distribution map was plotted using ArcGis version 10.2.2ResultsAs of March 13, 2020, a total of 168 patients (Non-severe: 132; Severe: 36) were infected with Covid-19 in Hainan province.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["Distribution map", "TEST", 0, 16], ["ArcGis version", "TEST", 35, 49], ["Covid", "TEST", 158, 163]]], ["The distribution of patients infected with Covid-19 across Hainan province is presented in Figure 1 .", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["Covid-19", "SPECIES", 43, 51], ["Covid", "TEST", 43, 48], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["infected", "OBSERVATION", 29, 37]]], ["The demographic and clinical characteristics of patients by severity group are presented in Table 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ResultsThe copyright holder for this preprint this version posted March 23, 2020. .Hainan ProvinceThe numerator denotes the number of discharge patients and the denominator denotes the number of laboratory-confirmed casesHainan ProvinceThe most common symptoms at onset of illness were fever (65.5%), dry cough (48.8%) and expectoration (32.1%), while rhinorrhea (3.6%), abdominal pain (4.2%), vomiting (4.2%), dyspnea (4.2%), arthralgia (1.2%), pharyngeal congestion (0.6%), pharyngeal discomfort (4.2%), dry throat (3.0%), shortness of breath (2.4%) and hemoptysis (0.6%) were rare.", [["abdominal", "ANATOMY", 606, 615], ["pharyngeal", "ANATOMY", 681, 691], ["pharyngeal", "ANATOMY", 711, 721], ["illness", "DISEASE", 508, 515], ["fever", "DISEASE", 521, 526], ["dry cough", "DISEASE", 536, 545], ["expectoration", "DISEASE", 558, 571], ["rhinorrhea", "DISEASE", 587, 597], ["abdominal pain", "DISEASE", 606, 620], ["vomiting", "DISEASE", 629, 637], ["dyspnea", "DISEASE", 646, 653], ["arthralgia", "DISEASE", 662, 672], ["pharyngeal congestion", "DISEASE", 681, 702], ["pharyngeal discomfort", "DISEASE", 711, 732], ["dry throat", "DISEASE", 741, 751], ["shortness of breath", "DISEASE", 760, 779], ["hemoptysis", "DISEASE", 791, 801], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 379, 387], ["abdominal", "ORGANISM_SUBDIVISION", 606, 615], ["pharyngeal", "ORGAN", 681, 691], ["pharyngeal", "ORGAN", 711, 721], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 379, 387], ["common symptoms", "PROBLEM", 480, 495], ["illness", "PROBLEM", 508, 515], ["fever", "PROBLEM", 521, 526], ["dry cough", "PROBLEM", 536, 545], ["expectoration", "TEST", 558, 571], ["rhinorrhea", "PROBLEM", 587, 597], ["abdominal pain", "PROBLEM", 606, 620], ["vomiting", "PROBLEM", 629, 637], ["dyspnea", "PROBLEM", 646, 653], ["arthralgia", "PROBLEM", 662, 672], ["pharyngeal congestion", "PROBLEM", 681, 702], ["pharyngeal discomfort", "PROBLEM", 711, 732], ["dry throat", "PROBLEM", 741, 751], ["shortness of breath", "PROBLEM", 760, 779], ["hemoptysis", "PROBLEM", 791, 801], ["med", "ANATOMY", 179, 182], ["abdominal", "ANATOMY", 606, 615], ["arthralgia", "OBSERVATION", 662, 672], ["pharyngeal", "ANATOMY", 681, 691], ["congestion", "OBSERVATION", 692, 702], ["pharyngeal", "ANATOMY", 711, 721], ["discomfort", "OBSERVATION", 722, 732], ["throat", "ANATOMY", 745, 751], ["hemoptysis", "OBSERVATION", 791, 801]]], ["On admission, 24 (14.3%), 12 (7.1%), and 12 (7.1%) patients are with history of hypertension, diabetes, and cardiovascular disease, respectively.Hainan ProvinceCompared with non-severe patients, severe patients were significantly older (median, 61 years vs 49 years; P < 0.05), were more likely to have higher temperature All rights reserved.", [["cardiovascular", "ANATOMY", 108, 122], ["hypertension", "DISEASE", 80, 92], ["diabetes", "DISEASE", 94, 102], ["cardiovascular disease", "DISEASE", 108, 130], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 202, 210], ["hypertension", "PROBLEM", 80, 92], ["diabetes", "PROBLEM", 94, 102], ["cardiovascular disease", "PROBLEM", 108, 130], ["hypertension", "OBSERVATION", 80, 92], ["diabetes", "OBSERVATION", 94, 102], ["cardiovascular disease", "OBSERVATION", 108, 130], ["severe", "OBSERVATION_MODIFIER", 195, 201]]], ["No reuse allowed without permission.Hainan Province(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Hainan ProvinceThe copyright holder for this preprint this version posted March 23, 2020. . https://doi.org/10.1101/2020.03.19.20038539 doi: medRxiv preprint (median, 37.0\u00b0C vs 36.8\u00b0C; P < 0.05) and heart rate (median, 92.0 bpm vs 80.5 bpm; P < 0.05) on admission, and more likely to have underlying comorbidities, including hypertension (30.6% vs 9.8%; P < 0.05), diabetes (19.4% vs 3.8%; P < 0.05) and cardiovascular disease (CVD) (16.7% vs 4.5%; P < 0.05).Radiologic and Laboratory FindingsThe radiologic and laboratory findings on admission are shown in Table 2 .", [["heart", "ANATOMY", 385, 390], ["cardiovascular", "ANATOMY", 590, 604], ["hypertension", "DISEASE", 511, 523], ["diabetes", "DISEASE", 551, 559], ["cardiovascular disease", "DISEASE", 590, 612], ["CVD", "DISEASE", 614, 617], ["heart", "ORGAN", 385, 390], ["cardiovascular", "ANATOMICAL_SYSTEM", 590, 604], ["The copyright holder", "TREATMENT", 201, 221], ["vs", "TEST", 360, 362], ["\u00b0C", "TEST", 367, 369], ["P", "TEST", 371, 372], ["heart rate", "TEST", 385, 395], ["bpm", "TEST", 410, 413], ["bpm", "TEST", 422, 425], ["P", "TEST", 427, 428], ["underlying comorbidities", "PROBLEM", 475, 499], ["hypertension", "PROBLEM", 511, 523], ["vs", "TEST", 531, 533], ["P", "TEST", 540, 541], ["diabetes", "PROBLEM", 551, 559], ["vs", "TEST", 567, 569], ["P", "TEST", 576, 577], ["cardiovascular disease", "PROBLEM", 590, 612], ["CVD", "TEST", 614, 617], ["P", "TEST", 635, 636], ["med", "ANATOMY", 130, 133], ["heart", "ANATOMY", 385, 390], ["comorbidities", "OBSERVATION", 486, 499], ["hypertension", "OBSERVATION", 511, 523], ["cardiovascular", "ANATOMY", 590, 604], ["disease", "OBSERVATION", 605, 612]]], ["Of 133 patients who underwent chest computed tomography (CT), the most common patterns were ground-glass opacity (60.2%) and bilateral patchy shadowing (42.9%).", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["chest computed tomography", "TEST", 30, 55], ["CT", "TEST", 57, 59], ["ground-glass opacity", "PROBLEM", 92, 112], ["bilateral patchy shadowing", "PROBLEM", 125, 151], ["chest", "ANATOMY", 30, 35], ["ground", "OBSERVATION", 92, 98], ["glass opacity", "OBSERVATION", 99, 112], ["bilateral", "ANATOMY_MODIFIER", 125, 134], ["patchy", "OBSERVATION_MODIFIER", 135, 141], ["shadowing", "OBSERVATION_MODIFIER", 142, 151]]], ["Of 51 patients who underwent chest X-ray, the most common patterns were bilateral patchy shadowing (35.3%) and local patchy shadowing (31.4%).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["chest X-ray", "TEST", 29, 40], ["bilateral patchy shadowing", "PROBLEM", 72, 98], ["local patchy shadowing", "PROBLEM", 111, 133], ["chest", "ANATOMY", 29, 34], ["bilateral", "ANATOMY_MODIFIER", 72, 81], ["patchy", "OBSERVATION_MODIFIER", 82, 88], ["shadowing", "OBSERVATION", 89, 98], ["local", "OBSERVATION_MODIFIER", 111, 116], ["patchy", "OBSERVATION_MODIFIER", 117, 123], ["shadowing", "OBSERVATION_MODIFIER", 124, 133]]], ["Typical chest CT findings of infected patients on admission were shown in Figure 2 .Radiologic and Laboratory FindingsAll rights reserved.", [["chest", "ANATOMY", 8, 13], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Typical chest CT", "TEST", 0, 16], ["chest", "ANATOMY", 8, 13], ["infected", "OBSERVATION", 29, 37]]], ["No reuse allowed without permission.Radiologic and Laboratory Findings(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 149, 152]]], ["A Computed tomography images on day 10 after symptom onset B Computed tomography images after treatment on day 23 after symptom onset All rights reserved.", [["A Computed tomography images", "TEST", 0, 28], ["Computed tomography images", "TEST", 61, 87], ["treatment", "TREATMENT", 94, 103]]], ["No reuse allowed without permission.Radiologic and Laboratory Findings(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 149, 152]]], ["A, Chest computed tomographic images obtained on February 10, 2020, show ground glass opacity in both lungs on day 10 after symptom onset.Radiologic and Laboratory FindingsB, Images taken on February 23, 2020, show fibrous cord shadows in both lungs, and the absorption of inflammation.Radiologic and Laboratory FindingsAll rights reserved.", [["lungs", "ANATOMY", 102, 107], ["fibrous cord", "ANATOMY", 215, 227], ["lungs", "ANATOMY", 244, 249], ["inflammation", "DISEASE", 273, 285], ["lungs", "ORGAN", 102, 107], ["fibrous cord", "TISSUE", 215, 227], ["lungs", "ORGAN", 244, 249], ["Chest computed tomographic images", "TEST", 3, 36], ["ground glass opacity in both lungs", "PROBLEM", 73, 107], ["symptom onset", "PROBLEM", 124, 137], ["Images", "TEST", 175, 181], ["fibrous cord shadows in both lungs", "PROBLEM", 215, 249], ["inflammation", "PROBLEM", 273, 285], ["Chest", "ANATOMY", 3, 8], ["ground glass opacity", "OBSERVATION", 73, 93], ["both", "ANATOMY_MODIFIER", 97, 101], ["lungs", "ANATOMY", 102, 107], ["fibrous cord shadows", "OBSERVATION", 215, 235], ["both", "ANATOMY_MODIFIER", 239, 243], ["lungs", "ANATOMY", 244, 249], ["absorption", "OBSERVATION_MODIFIER", 259, 269], ["inflammation", "OBSERVATION", 273, 285]]], ["No reuse allowed without permission.Radiologic and Laboratory Findings(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 149, 152]]], ["Figure 1 .Clinical Outcomes, Complications and TreatmentOf the all 168 patients, 160 have been discharged, 6 have died and 2 remain hospitalized ( Table 3 ).", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["The median time from onset of symptoms to first hospital visit, diagnosis and hospital admission was 1 day (IQR, 0-4), 4.5 days (IQR, 2-7)Clinical Outcomes, Complications and Treatmentand 5 days (IQR, 2-7), respectively (Table 4) .", [["symptoms", "PROBLEM", 30, 38]]], ["For severe patients, the median time from onset of symptoms to severe illness was 11 days (IQR, 7-13).", [["illness", "DISEASE", 70, 77], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["symptoms", "PROBLEM", 51, 59], ["severe illness", "PROBLEM", 63, 77], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["illness", "OBSERVATION", 70, 77]]], ["For discharged patients, the median time from onset of symptoms to discharged was 22 days (IQR, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , and the median time from hospital admission to discharged was 17 days (IQR, 12-21).", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["symptoms", "PROBLEM", 55, 63]]], ["For dead patients, the median time from onset of symptoms to death All rights reserved.", [["death", "DISEASE", 61, 66], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["symptoms", "PROBLEM", 49, 57]]], ["No reuse allowed without permission.Clinical Outcomes, Complications and Treatment(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Clinical Outcomes, Complications and TreatmentThe copyright holder for this preprint this version posted March 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["Treatment", "TREATMENT", 73, 82], ["Treatment", "TREATMENT", 254, 263], ["The copyright holder", "TREATMENT", 263, 283], ["med", "ANATOMY", 161, 164], ["med", "ANATOMY", 417, 420]]], ["The rate of severe illness and death in our study were higher than a study conducted in the multicenter 23 and a study conducted in Wenzhou, Zhejiang province, 12 but lower than studies conducted in Wuhan.", [["illness", "DISEASE", 19, 26], ["death", "DISEASE", 31, 36], ["severe illness", "PROBLEM", 12, 26], ["death", "PROBLEM", 31, 36], ["our study", "TEST", 40, 49], ["a study", "TEST", 67, 74], ["a study", "TEST", 111, 118], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["illness", "OBSERVATION", 19, 26]]], ["7, 14, 15 The reason may be that a large number of elderly people come to Hainan at end of each year for avoiding cold winter.", [["7, 14, 15", "CHEMICAL", 0, 9], ["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["large", "OBSERVATION_MODIFIER", 35, 40]]], ["55 (32.7%) patients over 60 years old in our study, this group may have more comorbidities, and more likely to develop into severe illness once infected with Covid-19.", [["illness", "DISEASE", 131, 138], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["our study", "TEST", 41, 50], ["severe illness", "PROBLEM", 124, 138], ["Covid", "TEST", 158, 163], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["illness", "OBSERVATION", 131, 138]]], ["Consistent with previous findings, 15, 23 we found that the older and patients with comorbidities (hypertension, diabetes and CVD) were more likely to develop severe illness.", [["hypertension", "DISEASE", 99, 111], ["diabetes", "DISEASE", 113, 121], ["CVD", "DISEASE", 126, 129], ["illness", "DISEASE", 166, 173], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["comorbidities", "PROBLEM", 84, 97], ["hypertension", "PROBLEM", 99, 111], ["diabetes", "PROBLEM", 113, 121], ["CVD", "PROBLEM", 126, 129], ["severe illness", "PROBLEM", 159, 173], ["hypertension", "OBSERVATION", 99, 111], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["illness", "OBSERVATION", 166, 173]]], ["All death in patients (5 imported cases and 1 local case) have a kind of comorbidity, 2 of them have two comorbidities.", [["death", "DISEASE", 4, 9], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["comorbidity", "PROBLEM", 73, 84]]], ["The possible reason may be the chronic course of hypertension and diabetes leading consistent damage to the micro-vascular walls, resulting in both inefficacy of immune cell infiltration and drug deliver into lung areas.", [["micro-vascular walls", "ANATOMY", 108, 128], ["immune cell", "ANATOMY", 162, 173], ["lung areas", "ANATOMY", 209, 219], ["hypertension", "DISEASE", 49, 61], ["diabetes", "DISEASE", 66, 74], ["micro-vascular walls", "MULTI-TISSUE_STRUCTURE", 108, 128], ["immune cell", "CELL", 162, 173], ["lung", "ORGAN", 209, 213], ["hypertension", "PROBLEM", 49, 61], ["diabetes", "PROBLEM", 66, 74], ["damage to the micro-vascular walls", "PROBLEM", 94, 128], ["immune cell infiltration", "PROBLEM", 162, 186], ["drug deliver into lung areas", "TREATMENT", 191, 219], ["possible reason may be", "UNCERTAINTY", 4, 26], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["hypertension", "OBSERVATION", 49, 61], ["diabetes", "OBSERVATION", 66, 74], ["micro-vascular walls", "ANATOMY", 108, 128], ["immune cell infiltration", "OBSERVATION", 162, 186], ["lung", "ANATOMY", 209, 213]]], ["24,25 In our study, 8 patients were young patients aged 0 to 17 years, the youngest was 3 months and 19 days, and the oldest was 17 years old.Clinical Outcomes, Complications and TreatmentThe 8 adolescent patients were all relatively mild without significant changes in radiology and laboratory test, moreover, none of them progressed to critical ill case, similar results have also reported in another study conducted in Guangzhou.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 205, 213], ["Treatment", "TREATMENT", 179, 188], ["laboratory test", "TEST", 284, 299], ["another study", "TEST", 395, 408], ["mild", "OBSERVATION", 234, 238]]], ["26 The mechanism responsible for this phenomenon is not clear yet and further research is needed to explore the possible causes.Clinical Outcomes, Complications and TreatmentIn consistence with previous studies, fever, dry cough and expectoration were All rights reserved.", [["fever", "DISEASE", 212, 217], ["dry cough", "DISEASE", 219, 228], ["expectoration", "DISEASE", 233, 246], ["this phenomenon", "PROBLEM", 33, 48], ["Treatment", "TREATMENT", 165, 174], ["previous studies", "TEST", 194, 210], ["fever", "PROBLEM", 212, 217], ["dry cough", "PROBLEM", 219, 228], ["expectoration", "PROBLEM", 233, 246], ["mechanism responsible for", "UNCERTAINTY", 7, 32]]], ["No reuse allowed without permission.Clinical Outcomes, Complications and Treatment(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Clinical Outcomes, Complications and TreatmentThe copyright holder for this preprint this version posted March 23, 2020. . https://doi.org/10.1101/2020.03.19.20038539 doi: medRxiv preprint the most common symptoms in our study, and it's worth noting that not all patients infected with Covid-19 had fever, or fever at initial stage.", [["fever", "DISEASE", 516, 521], ["fever", "DISEASE", 526, 531], ["patients", "ORGANISM", 480, 488], ["patients", "SPECIES", 480, 488], ["Treatment", "TREATMENT", 73, 82], ["Treatment", "TREATMENT", 254, 263], ["The copyright holder", "TREATMENT", 263, 283], ["medRxiv", "TREATMENT", 389, 396], ["the most common symptoms", "PROBLEM", 406, 430], ["our study", "TEST", 434, 443], ["Covid", "TEST", 503, 508], ["fever", "PROBLEM", 516, 521], ["fever", "PROBLEM", 526, 531], ["med", "ANATOMY", 161, 164], ["infected", "OBSERVATION", 489, 497]]], ["23,27 Fever, as an alarm syndrome, is less frequent in Covid-19 than other coronavirus (MERS and SARS), so more attention should be paid to Covid-19 patients without fever for their role as source of infection.", [["Fever", "DISEASE", 6, 11], ["alarm syndrome", "DISEASE", 19, 33], ["SARS", "DISEASE", 97, 101], ["fever", "DISEASE", 166, 171], ["infection", "DISEASE", 200, 209], ["coronavirus", "ORGANISM", 75, 86], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Fever", "PROBLEM", 6, 11], ["an alarm syndrome", "PROBLEM", 16, 33], ["Covid", "TEST", 55, 60], ["SARS", "PROBLEM", 97, 101], ["fever", "PROBLEM", 166, 171], ["infection", "PROBLEM", 200, 209], ["alarm syndrome", "OBSERVATION", 19, 33], ["infection", "OBSERVATION", 200, 209]]], ["Moreover, vomit and high fever (>39.0) is related to severe case on admission and during hospitalization in our analysis.Clinical Outcomes, Complications and TreatmentThe radiological abnormalities are a part of diagnosis, all patients have lesion in radiology, and the radiological progression of Covid-19 in severe patient is gradual.Clinical Outcomes, Complications and TreatmentThe initial radiological lesion are patchy shadows in bilateral or unilateral lower lungs in outer bands, and then progress to 1/3 of both lower lungs, then involve both upper lungs, and eventually develop into \"white lung\".", [["lesion", "ANATOMY", 241, 247], ["lesion", "ANATOMY", 407, 413], ["lower lungs", "ANATOMY", 460, 471], ["lower lungs", "ANATOMY", 521, 532], ["upper lungs", "ANATOMY", 552, 563], ["lung", "ANATOMY", 600, 604], ["fever", "DISEASE", 25, 30], ["patients", "ORGANISM", 227, 235], ["patient", "ORGANISM", 317, 324], ["lungs", "ORGAN", 466, 471], ["lungs", "ORGAN", 527, 532], ["upper", "ORGAN", 552, 557], ["lungs", "ORGAN", 558, 563], ["lung", "ORGAN", 600, 604], ["patients", "SPECIES", 227, 235], ["patient", "SPECIES", 317, 324], ["vomit", "PROBLEM", 10, 15], ["high fever", "PROBLEM", 20, 30], ["our analysis", "TEST", 108, 120], ["Treatment", "TREATMENT", 158, 167], ["The radiological abnormalities", "PROBLEM", 167, 197], ["lesion", "PROBLEM", 241, 247], ["Covid", "TEST", 298, 303], ["Treatment", "TREATMENT", 373, 382], ["The initial radiological lesion", "PROBLEM", 382, 413], ["patchy shadows in bilateral or unilateral lower lungs in outer bands", "PROBLEM", 418, 486], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["lesion", "OBSERVATION", 241, 247], ["gradual", "OBSERVATION_MODIFIER", 328, 335], ["radiological", "OBSERVATION_MODIFIER", 394, 406], ["lesion", "OBSERVATION", 407, 413], ["patchy", "OBSERVATION_MODIFIER", 418, 424], ["shadows", "OBSERVATION", 425, 432], ["bilateral", "ANATOMY_MODIFIER", 436, 445], ["unilateral", "ANATOMY_MODIFIER", 449, 459], ["lower", "ANATOMY_MODIFIER", 460, 465], ["lungs", "ANATOMY", 466, 471], ["outer bands", "OBSERVATION", 475, 486], ["both", "ANATOMY_MODIFIER", 516, 520], ["lower", "ANATOMY_MODIFIER", 521, 526], ["lungs", "ANATOMY", 527, 532], ["both", "ANATOMY_MODIFIER", 547, 551], ["upper", "ANATOMY_MODIFIER", 552, 557], ["lungs", "ANATOMY", 558, 563], ["lung", "ANATOMY", 600, 604]]], ["In considering of Covid-19 pneumonia progression and 4 or 5 days interval from symptoms onset to diagnosis, a lung CT scan or X-ray routinely in every 3 or 4 days were recommended for the evaluating progression and early diagnosis of Covid-19.Clinical Outcomes, Complications and TreatmentIn concert with recent studies in laboratory tests, 7,14,23,28 lymphopenia, thrombocytopenia and neutrocytosis in severely ill ones suggest the acute mix-infections of bacteria, virus, and even fungi, the activation of circulating immune cell could amplify immune response cascade, inducing both immune cell and cytokine storm, therefore increasing chances of developing septic shock and the organs failure.", [["lung", "ANATOMY", 110, 114], ["immune cell", "ANATOMY", 520, 531], ["immune cell", "ANATOMY", 585, 596], ["organs", "ANATOMY", 681, 687], ["pneumonia", "DISEASE", 27, 36], ["lymphopenia", "DISEASE", 352, 363], ["thrombocytopenia", "DISEASE", 365, 381], ["neutrocytosis", "DISEASE", 386, 399], ["septic shock", "DISEASE", 660, 672], ["organs failure", "DISEASE", 681, 695], ["lung", "ORGAN", 110, 114], ["immune cell", "CELL", 520, 531], ["immune cell", "CELL", 585, 596], ["organs", "ORGAN", 681, 687], ["cytokine", "PROTEIN", 601, 609], ["Covid", "TEST", 18, 23], ["pneumonia progression", "PROBLEM", 27, 48], ["symptoms", "PROBLEM", 79, 87], ["a lung CT scan", "TEST", 108, 122], ["Covid", "TEST", 234, 239], ["Treatment", "TREATMENT", 280, 289], ["recent studies", "TEST", 305, 319], ["laboratory tests", "TEST", 323, 339], ["lymphopenia", "PROBLEM", 352, 363], ["thrombocytopenia", "PROBLEM", 365, 381], ["neutrocytosis", "PROBLEM", 386, 399], ["severely ill ones", "PROBLEM", 403, 420], ["the acute mix-infections of bacteria", "PROBLEM", 429, 465], ["virus", "PROBLEM", 467, 472], ["even fungi", "PROBLEM", 478, 488], ["circulating immune cell", "PROBLEM", 508, 531], ["immune response cascade", "PROBLEM", 546, 569], ["cytokine storm", "TREATMENT", 601, 615], ["developing septic shock", "PROBLEM", 649, 672], ["the organs failure", "PROBLEM", 677, 695], ["pneumonia", "OBSERVATION", 27, 36], ["lung", "ANATOMY", 110, 114], ["thrombocytopenia", "OBSERVATION", 365, 381], ["acute", "OBSERVATION_MODIFIER", 433, 438], ["mix-infections", "OBSERVATION", 439, 453], ["bacteria", "OBSERVATION", 457, 465], ["immune cell", "OBSERVATION", 520, 531], ["immune cell", "OBSERVATION", 585, 596], ["cytokine storm", "OBSERVATION", 601, 615], ["septic shock", "OBSERVATION", 660, 672], ["organs", "ANATOMY", 681, 687], ["failure", "OBSERVATION", 688, 695]]], ["Interestingly, the decrease of eosinophils is pronounced in severe patients in our study, and eosinophil counts are even lower in some critically ill patients.", [["eosinophils", "ANATOMY", 31, 42], ["eosinophil", "ANATOMY", 94, 104], ["critically ill", "DISEASE", 135, 149], ["eosinophils", "CELL", 31, 42], ["patients", "ORGANISM", 67, 75], ["eosinophil", "CELL", 94, 104], ["patients", "ORGANISM", 150, 158], ["eosinophils", "CELL_TYPE", 31, 42], ["eosinophil", "CELL_TYPE", 94, 104], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 150, 158], ["the decrease of eosinophils", "PROBLEM", 15, 42], ["our study", "TEST", 79, 88], ["eosinophil counts", "TEST", 94, 111], ["decrease", "OBSERVATION_MODIFIER", 19, 27], ["eosinophils", "OBSERVATION", 31, 42], ["pronounced", "OBSERVATION_MODIFIER", 46, 56], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["eosinophil counts", "OBSERVATION", 94, 111], ["lower", "OBSERVATION_MODIFIER", 121, 126]]], ["Despite the fact that use of glucocorticoids would lead to eosinophilia, we All rights reserved.", [["glucocorticoids", "CHEMICAL", 29, 44], ["eosinophilia", "DISEASE", 59, 71], ["glucocorticoids", "TREATMENT", 29, 44], ["eosinophilia", "PROBLEM", 59, 71], ["eosinophilia", "OBSERVATION", 59, 71]]], ["No reuse allowed without permission.Clinical Outcomes, Complications and Treatment(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Clinical Outcomes, Complications and TreatmentThe copyright holder for this preprint this version posted March 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Clinical Outcomes, Complications and TreatmentThe copyright holder for this preprint this version posted March 23, 2020. . https://doi.org/10.1101/2020.03.19.20038539 doi: medRxiv preprint results without any clinical symptoms after 3 to34 days after discharge.", [["Treatment", "TREATMENT", 73, 82], ["Treatment", "TREATMENT", 254, 263], ["The copyright holder", "TREATMENT", 263, 283], ["Treatment", "TREATMENT", 510, 519], ["The copyright holder", "TREATMENT", 519, 539], ["any clinical symptoms", "PROBLEM", 678, 699], ["med", "ANATOMY", 161, 164], ["med", "ANATOMY", 417, 420]]], ["At present, the cause of the returning positive of RT-PCR still remains unclear, though there were no evidence shows that kind of patients have the infectivity, we still suggest the current standards for hospital discharge should be reevaluated, and the detection and management of discharged patients should be strengthened.Clinical Outcomes, Complications and TreatmentOur study has some limitations.", [["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 293, 301], ["RT-PCR", "TEST", 51, 57], ["the infectivity", "PROBLEM", 144, 159], ["Treatment", "TREATMENT", 362, 371], ["Our study", "TEST", 371, 380], ["no evidence shows", "UNCERTAINTY", 99, 116]]], ["First, though we have included all the patients of Covid-19 in Hainan province, the sample size was still relatively small and the patients were only from Hainan province, it might be that more clinical features related to Covid-19 would not be identified yet.", [["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 131, 139], ["Covid", "TEST", 51, 56], ["the sample size", "TEST", 80, 95], ["Covid", "TEST", 223, 228], ["size", "OBSERVATION_MODIFIER", 91, 95], ["relatively", "OBSERVATION_MODIFIER", 106, 116], ["small", "OBSERVATION_MODIFIER", 117, 122]]], ["Secondly, some cases had incomplete record of the radiologic and laboratory testing, given the different procedures among different hospitals.Clinical Outcomes, Complications and TreatmentIn conclusion, patients infected with Covid-19 have a severe rate of 21.4% and a fatality rate of 3.6% in Hainan province.", [["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["the radiologic", "TEST", 46, 60], ["laboratory testing", "TEST", 65, 83], ["Covid", "TEST", 226, 231], ["a severe rate", "TEST", 240, 253], ["a fatality rate", "TEST", 267, 282], ["severe", "OBSERVATION_MODIFIER", 242, 248]]], ["The elderly people with diabetes, hypertension and CVD are more likely to develop severe cases.", [["diabetes", "DISEASE", 24, 32], ["hypertension", "DISEASE", 34, 46], ["CVD", "DISEASE", 51, 54], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["diabetes", "PROBLEM", 24, 32], ["hypertension", "PROBLEM", 34, 46], ["CVD", "PROBLEM", 51, 54], ["severe cases", "PROBLEM", 82, 94], ["diabetes", "OBSERVATION", 24, 32], ["hypertension", "OBSERVATION", 34, 46], ["more likely", "UNCERTAINTY", 59, 70], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["cases", "OBSERVATION", 89, 94]]], ["Fever is the most common symptom, though it does not occur in all patients before hospital admission.Clinical Outcomes, Complications and TreatmentIn light of the rapid spread of Covid-19 around the world, and no specialized medication to treat Covid-19, early identification and diagnosis is important for the prevention and treatment of Covid-19 to prevent patients from developing into critical illness.Clinical Outcomes, Complications and TreatmentAll rights reserved.", [["Fever", "DISEASE", 0, 5], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 359, 367], ["Covid-19", "SPECIES", 179, 187], ["Fever", "PROBLEM", 0, 5], ["the most common symptom", "PROBLEM", 9, 32], ["Treatment", "TREATMENT", 138, 147], ["Covid", "TEST", 179, 184], ["specialized medication", "TREATMENT", 213, 235], ["Covid", "TEST", 245, 250], ["Covid", "TEST", 339, 344], ["critical illness", "PROBLEM", 389, 405], ["Treatment", "TREATMENT", 443, 452], ["most common", "OBSERVATION_MODIFIER", 13, 24], ["rapid", "OBSERVATION_MODIFIER", 163, 168], ["spread", "OBSERVATION_MODIFIER", 169, 175]]], ["No reuse allowed without permission.Clinical Outcomes, Complications and Treatment(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgementsWe thank all the hospital staff members for their efforts in collecting the information that was used in this study, and Chinese Academy of Medical Sciences for the support.AcknowledgementsAll rights reserved.", [["Treatment", "TREATMENT", 73, 82], ["this study", "TEST", 338, 348], ["the support", "TREATMENT", 394, 405], ["med", "ANATOMY", 161, 164]]], ["No reuse allowed without permission.Acknowledgements(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgementsThe copyright holder for this preprint this version posted March 23, 2020.", [["med", "ANATOMY", 131, 134], ["med", "ANATOMY", 267, 270]]], ["No reuse allowed without permission.Acknowledgements(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgementsThe copyright holder for this preprint this version posted March 23, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgementsThe copyright holder for this preprint this version posted March 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgementsThe copyright holder for this preprint this version posted March 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgementsThe copyright holder for this preprint this version posted March 23, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgementsThe copyright holder for this preprint this version posted March 23, 2020. . https://doi.org/10.1101/2020.03.19.20038539 doi: medRxiv preprint", [["medRxiv", "TREATMENT", 1781, 1788], ["med", "ANATOMY", 131, 134], ["med", "ANATOMY", 359, 362], ["med", "ANATOMY", 495, 498], ["med", "ANATOMY", 721, 724], ["med", "ANATOMY", 947, 950], ["med", "ANATOMY", 1175, 1178], ["med", "ANATOMY", 1311, 1314], ["med", "ANATOMY", 1447, 1450], ["med", "ANATOMY", 1583, 1586]]]], "2af5713a97c69565489dfc0154a24bf1e78b9980": [["IntroductionSignal transduction relies on scaffolding proteins that coordinate the assembly of signaling complexes.", [["scaffolding proteins", "PROTEIN", 42, 62], ["signaling complexes", "PROTEIN", 95, 114], ["scaffolding proteins", "TREATMENT", 42, 62], ["signaling complexes", "PROBLEM", 95, 114], ["signaling complexes", "OBSERVATION", 95, 114]]], ["These molecular scaffolds are composed of modular interaction domains that bring their interacting partners close in space and thereby facilitate the interactions between the proteins [1] .", [["modular interaction domains", "PROTEIN", 42, 69], ["These molecular scaffolds", "TREATMENT", 0, 25], ["modular interaction domains", "PROBLEM", 42, 69], ["scaffolds", "OBSERVATION", 16, 25]]], ["This review is focused on the PDZ domain, which is one of the most widespread proteinprotein interacting modules.", [["PDZ", "GENE_OR_GENE_PRODUCT", 30, 33], ["PDZ domain", "PROTEIN", 30, 40], ["proteinprotein interacting modules", "PROTEIN", 78, 112], ["the PDZ domain", "TEST", 26, 40], ["widespread", "OBSERVATION_MODIFIER", 67, 77], ["proteinprotein", "OBSERVATION", 78, 92], ["interacting modules", "OBSERVATION", 93, 112]]], ["The name is derived from the three proteins in which it was first identified almost 20 years ago, namely postsynaptic density protein-95 (PDZ-95), disks large tumor suppressor (DLG) and zonula occludens-1 (ZO-1) [2] [3] [4] .", [["tumor", "ANATOMY", 159, 164], ["tumor", "DISEASE", 159, 164], ["postsynaptic density protein-95", "GENE_OR_GENE_PRODUCT", 105, 136], ["PDZ-95", "GENE_OR_GENE_PRODUCT", 138, 144], ["tumor", "CANCER", 159, 164], ["zonula occludens-1", "GENE_OR_GENE_PRODUCT", 186, 204], ["ZO-1", "GENE_OR_GENE_PRODUCT", 206, 210], ["2] [3] [4]", "SIMPLE_CHEMICAL", 213, 223], ["postsynaptic density protein-95", "PROTEIN", 105, 136], ["PDZ", "PROTEIN", 138, 141], ["95", "PROTEIN", 142, 144], ["tumor suppressor", "PROTEIN", 159, 175], ["DLG", "PROTEIN", 177, 180], ["postsynaptic density protein", "TEST", 105, 133], ["PDZ", "TEST", 138, 141], ["disks large tumor suppressor", "PROBLEM", 147, 175], ["zonula occludens", "TEST", 186, 202], ["large", "OBSERVATION_MODIFIER", 153, 158], ["tumor", "OBSERVATION", 159, 164]]], ["PDZ domains are commonly involved in processes of cell signaling and polarity, and are predominantly found in multi-cellular organisms, with for example more than 250 human PDZ domains found in over 150 different proteins.", [["cell", "ANATOMY", 50, 54], ["PDZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 50, 54], ["human", "ORGANISM", 167, 172], ["PDZ", "GENE_OR_GENE_PRODUCT", 173, 176], ["PDZ domains", "PROTEIN", 0, 11], ["human PDZ domains", "PROTEIN", 167, 184], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["PDZ domains", "PROBLEM", 0, 11], ["cell signaling", "PROBLEM", 50, 64], ["multi-cellular organisms", "PROBLEM", 110, 134], ["human PDZ domains", "TEST", 167, 184], ["cell signaling", "OBSERVATION", 50, 64], ["polarity", "OBSERVATION_MODIFIER", 69, 77], ["predominantly", "OBSERVATION_MODIFIER", 87, 100], ["multi-cellular organisms", "OBSERVATION", 110, 134]]], ["The low abundance of PDZ domains in unicellular organisms led to the suggestion that PDZ domains co-evolved with multi-cellularity [5] .IntroductionPDZ domains are over-and-above known as protein-protein interacting modules recognizing short peptide stretches at the Cterminus of their target proteins [6, 7] , but their functional repertoire also include recognition of internal peptide motifs [8] [9] [10] [11] , hetero-and/or homo-dimerization [12, 13] and interactions with membrane phospholipids [14] [15] [16] [17] .", [["membrane", "ANATOMY", 478, 486], ["PDZ", "GENE_OR_GENE_PRODUCT", 21, 24], ["PDZ", "GENE_OR_GENE_PRODUCT", 85, 88], ["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 395, 412], ["hetero", "SIMPLE_CHEMICAL", 415, 421], ["homo-dimerization [12, 13]", "SIMPLE_CHEMICAL", 429, 455], ["membrane phospholipids [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 478, 520], ["PDZ domains", "PROTEIN", 21, 32], ["PDZ domains", "PROTEIN", 85, 96], ["IntroductionPDZ domains", "PROTEIN", 136, 159], ["protein-protein interacting modules", "PROTEIN", 188, 223], ["Cterminus of their target proteins", "PROTEIN", 267, 301], ["The low abundance of PDZ domains", "PROBLEM", 0, 32], ["unicellular organisms", "PROBLEM", 36, 57], ["PDZ domains", "PROBLEM", 85, 96], ["IntroductionPDZ domains", "PROBLEM", 136, 159], ["protein interacting modules", "PROBLEM", 196, 223], ["short peptide stretches", "PROBLEM", 236, 259], ["internal peptide motifs", "TEST", 371, 394], ["hetero", "TEST", 415, 421], ["membrane phospholipids", "TEST", 478, 500], ["low abundance", "OBSERVATION_MODIFIER", 4, 17], ["PDZ", "OBSERVATION", 21, 24], ["unicellular organisms", "OBSERVATION", 36, 57]]], ["The ligands are commonly transmembrane receptors or ion channels.", [["transmembrane", "ANATOMY", 25, 38], ["transmembrane receptors", "PROTEIN", 25, 48], ["ion channels", "PROTEIN", 52, 64], ["ion channels", "OBSERVATION", 52, 64]]], ["The interactions tend to be promiscuous, and one PDZ domain can commonly recognize various peptide ligands and the same ligand can be recognized by different PDZ domains [6] .", [["PDZ domain", "PROTEIN", 49, 59], ["PDZ domains", "PROTEIN", 158, 169], ["one PDZ domain", "PROBLEM", 45, 59], ["various peptide ligands", "PROBLEM", 83, 106]]], ["The plasticity of PDZ interactions is further reflected in the ease by which the specificity of the interactions can be changed by mutagenesis of either ligands or PDZ domains [18] [19] [20] [21] , which allowed frequent rewiring of PDZ-ligand interactions during evolution [22] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 18, 21], ["[18] [19] [20] [21]", "SIMPLE_CHEMICAL", 176, 195], ["PDZ", "PROTEIN", 18, 21], ["PDZ domains", "PROTEIN", 164, 175], ["PDZ", "PROTEIN", 233, 236], ["PDZ interactions", "PROBLEM", 18, 34], ["PDZ domains", "PROBLEM", 164, 175]]], ["The function of PDZ domains can be tuned by various means such as changes in physiological buffer conditions [23, 24] , allosteric changes [25] and phosphorylation [26] posing them as dynamic regulators of cell signaling.", [["cell", "ANATOMY", 206, 210], ["PDZ", "GENE_OR_GENE_PRODUCT", 16, 19], ["cell", "CELL", 206, 210], ["PDZ domains", "PROTEIN", 16, 27], ["PDZ domains", "PROBLEM", 16, 27], ["changes in physiological buffer conditions", "PROBLEM", 66, 108], ["phosphorylation", "TREATMENT", 148, 163]]], ["This review is focused on the plasticity of PDZ interactions, starting from the structure of the domain and the versatility of the ligand-binding partners and ending with an overview of the regulatory mechanisms tuning the interactions.Structure of PDZ domains and their integration in scaffolding proteinsPDZ domains consist of 80-90 amino acids and share a common fold of five to six b-strands (b1-b6) and two a-helices as shown by the over 300 PDZ structures currently deposited in the PDB data bank (Fig. 1) .", [["amino acids", "CHEMICAL", 335, 346], ["amino acids", "CHEMICAL", 335, 346], ["PDZ", "GENE_OR_GENE_PRODUCT", 44, 47], ["PDZ", "GENE_OR_GENE_PRODUCT", 249, 252], ["PDZ", "GENE_OR_GENE_PRODUCT", 306, 309], ["amino acids", "AMINO_ACID", 335, 346], ["b1-b6", "GENE_OR_GENE_PRODUCT", 397, 402], ["PDZ", "PROTEIN", 44, 47], ["PDZ domains", "PROTEIN", 249, 260], ["scaffolding proteins", "PROTEIN", 286, 306], ["PDZ domains", "PROTEIN", 306, 317], ["b1", "PROTEIN", 397, 399], ["b6", "PROTEIN", 400, 402], ["a-helices", "PROTEIN", 412, 421], ["PDZ structures", "PROTEIN", 447, 461], ["PDZ domains", "PROBLEM", 249, 260], ["scaffolding proteinsPDZ domains", "TEST", 286, 317], ["amino acids", "TEST", 335, 346], ["PDZ", "OBSERVATION", 249, 252], ["common fold", "ANATOMY", 359, 370], ["PDB", "ANATOMY", 489, 492]]], ["Their average sequence identity is only 30% and although sharing the same core structure, PDZ domains often have variable loop regions and might contain additional secondary structural elements that may affect the structure and function [27] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 90, 93], ["PDZ domains", "PROTEIN", 90, 101], ["variable loop regions", "PROTEIN", 113, 134], ["variable loop regions", "PROBLEM", 113, 134], ["additional secondary structural elements", "PROBLEM", 153, 193], ["PDZ", "OBSERVATION", 90, 93], ["variable", "OBSERVATION_MODIFIER", 113, 121], ["loop", "OBSERVATION", 122, 126], ["secondary structural elements", "OBSERVATION", 164, 193]]], ["Indeed, even the archetypical structure of PSD-95 PDZ3 holds an additional C-terminal a-helix that influences the dynamics of the protein [28] [29] [30] .", [["C", "CHEMICAL", 75, 76], ["PSD-95", "GENE_OR_GENE_PRODUCT", 43, 49], ["PSD", "PROTEIN", 43, 46], ["PDZ3", "PROTEIN", 50, 54], ["C-terminal a-helix", "PROTEIN", 75, 93], ["PSD", "TEST", 43, 46], ["an additional C-terminal a-helix", "TREATMENT", 61, 93], ["the protein", "TEST", 126, 137]]], ["The PDZ structure is robust and tolerates extensive mutagenesis [31] as well as topological changes such as circular permutations (Fig. 1 ) [32] [33] [34] [35] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 4, 7], ["PDZ structure", "PROTEIN", 4, 17], ["The PDZ structure", "PROBLEM", 0, 17], ["extensive mutagenesis", "TREATMENT", 42, 63], ["circular permutations", "TEST", 108, 129], ["robust", "OBSERVATION_MODIFIER", 21, 27]]], ["The canonical metazoan PDZ domains have a b1-b2-b3-a1-b4-b5-a2-b6 secondary structure arrangements and make part of scaffolding proteins [6] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 23, 26], ["canonical metazoan PDZ domains", "PROTEIN", 4, 34], ["b1-b2-b3-a1-b4", "PROTEIN", 42, 56], ["-b5", "PROTEIN", 56, 59], ["a2", "PROTEIN", 60, 62], ["b6", "PROTEIN", 63, 65], ["scaffolding proteins", "PROTEIN", 116, 136], ["The canonical metazoan PDZ domains", "PROBLEM", 0, 34], ["a b1-b2-", "TEST", 40, 48], ["metazoan PDZ", "OBSERVATION", 14, 26]]], ["PDZ domains in bacteria, plant and yeast generally make part of proteases and are circularly permuted as compared to the canonical PDZ domains, typically having a symmetric b2-b3-a1-b4-b5-a2-b6-b1 secondary structure arrangement.", [["PDZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["PDZ", "GENE_OR_GENE_PRODUCT", 131, 134], ["PDZ domains", "PROTEIN", 0, 11], ["proteases", "PROTEIN", 64, 73], ["canonical PDZ domains", "PROTEIN", 121, 142], ["b2-b3-a1-b4-b5-a2-b6", "PROTEIN", 173, 193], ["-b1", "PROTEIN", 193, 196], ["yeast", "SPECIES", 35, 40], ["yeast", "SPECIES", 35, 40], ["PDZ domains in bacteria", "PROBLEM", 0, 23], ["proteases", "PROBLEM", 64, 73], ["bacteria", "OBSERVATION", 15, 23], ["symmetric", "OBSERVATION_MODIFIER", 163, 172], ["secondary structure", "OBSERVATION", 197, 216]]], ["In these organisms, PDZ domains are less common, yeast has for example only one PDZ protein holding four PDZ domains [5] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 20, 23], ["PDZ", "GENE_OR_GENE_PRODUCT", 80, 83], ["PDZ domains", "PROTEIN", 20, 31], ["PDZ protein", "PROTEIN", 80, 91], ["PDZ domains", "PROTEIN", 105, 116], ["yeast", "SPECIES", 49, 54], ["yeast", "SPECIES", 49, 54], ["PDZ domains", "PROBLEM", 20, 31], ["less common", "OBSERVATION_MODIFIER", 36, 47]]], ["The structure of the PDZ domains of bacterial RseP revealed an alternative connectivity of the secondary structure elements (b3-a1-b4-b5-a2-b6-b1-b2) [36] , which is shared with the PDZ tandem of human GRASP55 [37] .", [["RseP", "GENE_OR_GENE_PRODUCT", 46, 50], ["b5-a2-b6-b1-b2", "GENE_OR_GENE_PRODUCT", 134, 148], ["human", "ORGANISM", 196, 201], ["PDZ domains", "PROTEIN", 21, 32], ["bacterial RseP", "PROTEIN", 36, 50], ["secondary structure elements", "DNA", 95, 123], ["b3-a1", "PROTEIN", 125, 130], ["b4", "PROTEIN", 131, 133], ["b5", "DNA", 134, 136], ["b2", "DNA", 146, 148], ["PDZ", "PROTEIN", 182, 185], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 196, 201], ["bacterial RseP", "TEST", 36, 50], ["b3-a1", "TEST", 125, 130], ["b4", "TEST", 131, 133], ["bacterial RseP", "OBSERVATION", 36, 50], ["alternative connectivity", "OBSERVATION", 63, 87], ["secondary structure", "OBSERVATION", 95, 114]]], ["In all cases, PDZ domains have their N-and C-termini close in space, which facilitates their integration in pre-existing protein scaffolds.Structure of PDZ domains and their integration in scaffolding proteinsPDZ domains are found in a wide range of proteins, from those that almost exclusively consist of a single PDZ domain such as Tax1-binding protein 3 (TIP-1), to proteins that contain several PDZ domains such as multiple PDZ domain protein, and scaffolds combining PDZ domains with other modular domains such as phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 2 protein that contains a RhoGef domain, a pleckstrin homology (PH) domain, two DEP domains and a PDZ tandem (i.e. two PDZ domains connected by a short linker).", [["phosphatidylinositol 3,4,5-triphosphate", "CHEMICAL", 519, 558], ["N", "CHEMICAL", 37, 38], ["C", "CHEMICAL", 43, 44], ["phosphatidylinositol 3,4,5-triphosphate", "CHEMICAL", 519, 558], ["PDZ", "GENE_OR_GENE_PRODUCT", 14, 17], ["PDZ", "GENE_OR_GENE_PRODUCT", 152, 155], ["PDZ", "GENE_OR_GENE_PRODUCT", 209, 212], ["Tax1-binding protein 3", "GENE_OR_GENE_PRODUCT", 334, 356], ["TIP-1", "GENE_OR_GENE_PRODUCT", 358, 363], ["phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 2", "GENE_OR_GENE_PRODUCT", 519, 584], ["pleckstrin", "GENE_OR_GENE_PRODUCT", 626, 636], ["PDZ domains", "PROTEIN", 14, 25], ["N-and C-termini", "PROTEIN", 37, 52], ["PDZ domains", "PROTEIN", 152, 163], ["scaffolding proteins", "PROTEIN", 189, 209], ["PDZ domains", "PROTEIN", 209, 220], ["PDZ domain", "PROTEIN", 315, 325], ["Tax1", "PROTEIN", 334, 338], ["binding protein 3", "PROTEIN", 339, 356], ["TIP-1", "PROTEIN", 358, 363], ["PDZ domains", "PROTEIN", 399, 410], ["PDZ domain protein", "PROTEIN", 428, 446], ["PDZ domains", "PROTEIN", 472, 483], ["modular domains", "PROTEIN", 495, 510], ["phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 2 protein", "PROTEIN", 519, 592], ["RhoGef domain", "PROTEIN", 609, 622], ["pleckstrin homology (PH) domain", "PROTEIN", 626, 657], ["DEP domains", "PROTEIN", 663, 674], ["PDZ tandem", "PROTEIN", 681, 691], ["PDZ domains", "PROTEIN", 702, 713], ["short linker", "PROTEIN", 729, 741], ["PDZ domains", "PROBLEM", 14, 25], ["pre-existing protein scaffolds", "TREATMENT", 108, 138], ["PDZ domains", "PROBLEM", 152, 163], ["scaffolding proteinsPDZ domains", "PROBLEM", 189, 220], ["a single PDZ domain", "PROBLEM", 306, 325], ["Tax1-binding protein", "TEST", 334, 354], ["TIP", "TEST", 358, 361], ["several PDZ domains", "PROBLEM", 391, 410], ["multiple PDZ domain protein", "PROBLEM", 419, 446], ["scaffolds combining PDZ domains", "PROBLEM", 452, 483], ["other modular domains", "PROBLEM", 489, 510], ["phosphatidylinositol", "TEST", 519, 539], ["triphosphate-dependent Rac exchanger 2 protein", "TREATMENT", 546, 592], ["a RhoGef domain", "TREATMENT", 607, 622], ["a pleckstrin homology", "TEST", 624, 645], ["two DEP domains", "TREATMENT", 659, 674], ["a PDZ tandem", "TREATMENT", 679, 691], ["two PDZ domains", "TREATMENT", 698, 713], ["a short linker)", "TREATMENT", 727, 742], ["protein scaffolds", "OBSERVATION", 121, 138], ["PDZ", "OBSERVATION", 152, 155], ["proteinsPDZ", "OBSERVATION", 201, 212], ["wide", "OBSERVATION_MODIFIER", 236, 240], ["several PDZ", "OBSERVATION", 391, 402]]], ["In some cases, two tightly connected PDZ domains form a functional unit, or supramodule, with distinct functional properties from the isolated PDZ domains [38] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 37, 40], ["PDZ domains", "PROTEIN", 37, 48], ["supramodule", "PROTEIN", 76, 87], ["PDZ domains", "PROTEIN", 143, 154], ["two tightly connected PDZ domains", "PROBLEM", 15, 48], ["supramodule", "PROBLEM", 76, 87], ["the isolated PDZ domains", "PROBLEM", 130, 154], ["functional unit", "OBSERVATION_MODIFIER", 56, 71]]], ["For example, PDZ4 in the PDZ4-5 tandem of glutamate receptorinteracting protein 1 (GRIP1) does not bind to peptides but serve as structural support for the PDZ5 [39] .", [["PDZ4", "CHEMICAL", 13, 17], ["glutamate", "CHEMICAL", 42, 51], ["glutamate", "CHEMICAL", 42, 51], ["PDZ4", "GENE_OR_GENE_PRODUCT", 13, 17], ["PDZ4-5", "GENE_OR_GENE_PRODUCT", 25, 31], ["glutamate receptorinteracting protein 1", "GENE_OR_GENE_PRODUCT", 42, 81], ["GRIP1", "GENE_OR_GENE_PRODUCT", 83, 88], ["PDZ4", "PROTEIN", 13, 17], ["PDZ4", "PROTEIN", 25, 29], ["glutamate receptorinteracting protein 1", "PROTEIN", 42, 81], ["GRIP1", "PROTEIN", 83, 88], ["PDZ4", "TEST", 13, 17], ["the PDZ4", "TEST", 21, 29], ["glutamate receptorinteracting protein", "TREATMENT", 42, 79]]], ["PDZ domains may also form supramodular units with other domains.", [["PDZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["PDZ domains", "PROTEIN", 0, 11], ["PDZ domains", "PROBLEM", 0, 11], ["supramodular units", "TREATMENT", 26, 44]]], ["For example, a recent study by Pan and co-workers revealed a supramodular organization of the PDZ3-SRC homology (SH3)-guanylate kinase (GUK) domains of ZO-1, where the PDZ3-SH3 interface forms a hydrophobic pocket that make additional contacts with the connexin43 peptide [40] .", [["guanylate", "CHEMICAL", 118, 127], ["PDZ3", "GENE_OR_GENE_PRODUCT", 94, 98], ["SH3)-guanylate kinase", "GENE_OR_GENE_PRODUCT", 113, 134], ["GUK", "GENE_OR_GENE_PRODUCT", 136, 139], ["ZO-1", "GENE_OR_GENE_PRODUCT", 152, 156], ["PDZ3", "GENE_OR_GENE_PRODUCT", 168, 172], ["SH3", "GENE_OR_GENE_PRODUCT", 173, 176], ["connexin43", "GENE_OR_GENE_PRODUCT", 253, 263], ["PDZ3", "PROTEIN", 94, 98], ["SRC homology (SH3)-guanylate kinase (GUK) domains", "PROTEIN", 99, 148], ["ZO-1", "PROTEIN", 152, 156], ["PDZ3", "PROTEIN", 168, 172], ["SH3", "PROTEIN", 173, 176], ["a recent study", "TEST", 13, 27], ["guanylate kinase", "TEST", 118, 134], ["a hydrophobic pocket", "PROBLEM", 193, 213], ["the connexin43 peptide", "TREATMENT", 249, 271]]], ["In line with these data, protein engineering experiments have highlighted the ease by which PDZ peptide binding affinity and specificity can be greatly enhanced by the addition of a binding inert domain and optimization of the interface residues [33] .C-terminal peptide recognitionThe by far most common PDZ interaction is the recognition of Cterminal ligands with hydrophobic residues at their C-termini [41] .", [["C", "CHEMICAL", 252, 253], ["PDZ", "GENE_OR_GENE_PRODUCT", 92, 95], ["PDZ", "GENE_OR_GENE_PRODUCT", 305, 308], ["PDZ", "PROTEIN", 92, 95], ["binding inert domain", "PROTEIN", 182, 202], ["PDZ", "PROTEIN", 305, 308], ["Cterminal ligands", "PROTEIN", 343, 360], ["these data", "TEST", 13, 23], ["protein engineering experiments", "PROBLEM", 25, 56], ["PDZ peptide binding affinity", "PROBLEM", 92, 120], ["a binding inert domain", "TREATMENT", 180, 202], ["the interface residues", "PROBLEM", 223, 245], ["terminal peptide recognition", "PROBLEM", 254, 282], ["Cterminal ligands", "PROBLEM", 343, 360], ["hydrophobic residues", "PROBLEM", 366, 386]]], ["The carboxylate terminus of the peptide ligand is bound by a conserved carboxylate binding loop (R/K-XXX-G-U-G-U, where X is any amino acid and U a hydrophobic residue) and the peptide is added as an additional b-strand to the grove between b2 and a2, with the last four amino acids in the PDZ-binding motif being most important for recognition ( Fig. 2) [21, 42, 43] .", [["carboxylate", "CHEMICAL", 4, 15], ["amino acid", "CHEMICAL", 129, 139], ["amino acids", "CHEMICAL", 271, 282], ["carboxylate", "CHEMICAL", 4, 15], ["carboxylate", "CHEMICAL", 71, 82], ["amino acid", "CHEMICAL", 129, 139], ["amino acids", "CHEMICAL", 271, 282], ["G-U", "GENE_OR_GENE_PRODUCT", 109, 112], ["amino acid", "AMINO_ACID", 129, 139], ["b2", "GENE_OR_GENE_PRODUCT", 241, 243], ["a2", "GENE_OR_GENE_PRODUCT", 248, 250], ["amino acids", "AMINO_ACID", 271, 282], ["carboxylate terminus", "PROTEIN", 4, 24], ["conserved carboxylate binding loop", "PROTEIN", 61, 95], ["R/K-XXX", "PROTEIN", 97, 104], ["X", "PROTEIN", 120, 121], ["b2", "PROTEIN", 241, 243], ["a2", "PROTEIN", 248, 250], ["PDZ-binding motif", "PROTEIN", 290, 307], ["The carboxylate terminus of the peptide ligand", "TREATMENT", 0, 46], ["a conserved carboxylate binding loop", "TREATMENT", 59, 95], ["any amino acid", "TREATMENT", 125, 139], ["U a hydrophobic residue", "TREATMENT", 144, 167], ["the peptide", "TREATMENT", 173, 184], ["four amino acids", "TREATMENT", 266, 282], ["the PDZ-binding motif", "TREATMENT", 286, 307], ["carboxylate binding loop", "OBSERVATION", 71, 95]]], ["The last amino acid of a PDZ-binding motif is denoted ''0'', the penultimate residue ''\u00c01'' and so on.", [["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 9, 19], ["amino acid", "AMINO_ACID", 9, 19], ["PDZ", "GENE_OR_GENE_PRODUCT", 25, 28], ["PDZ-binding motif", "PROTEIN", 25, 42]]], ["Deviations from the canonical C-terminal peptide binding have been reported for example from structural studies on syntenin-1 PDZ1 [44] and tamalin PDZ [45] , for which the peptides were found to be bound perpendicular to the main b-sheet and only interacting with the PDZ domains through the last two amino acids.C-terminal peptide recognitionPDZ domains were early on divided into specificity classes based on the last amino acids of the C-terminal target peptide, with the typical class I motif being X[T/S]XU-COO-, the class II motif being XUXU-COO-, and the minor class III motif being X[D/ E]XU-COO- [41, 46] .", [["amino acids", "CHEMICAL", 302, 313], ["amino acids", "CHEMICAL", 421, 432], ["C", "CHEMICAL", 30, 31], ["amino acids", "CHEMICAL", 302, 313], ["C", "CHEMICAL", 314, 315], ["amino acids", "CHEMICAL", 421, 432], ["C", "CHEMICAL", 440, 441], ["COO", "CHEMICAL", 513, 516], ["COO", "CHEMICAL", 549, 552], ["X[D/ E]XU-COO", "CHEMICAL", 591, 604], ["syntenin-1", "GENE_OR_GENE_PRODUCT", 115, 125], ["tamalin PDZ [45]", "SIMPLE_CHEMICAL", 140, 156], ["amino acids", "AMINO_ACID", 302, 313], ["amino acids", "AMINO_ACID", 421, 432], ["XUXU-COO", "SIMPLE_CHEMICAL", 544, 552], ["X[D/ E]XU-COO- [41, 46]", "SIMPLE_CHEMICAL", 591, 614], ["main b-sheet", "PROTEIN", 226, 238], ["PDZ domains", "PROTEIN", 269, 280], ["C-terminal peptide recognitionPDZ domains", "PROTEIN", 314, 355], ["class I motif", "PROTEIN", 484, 497], ["COO", "PROTEIN", 513, 516], ["class II motif", "PROTEIN", 523, 537], ["XUXU", "PROTEIN", 544, 548], ["COO", "PROTEIN", 549, 552], ["minor class III motif", "PROTEIN", 563, 584], ["Deviations from the canonical C-terminal peptide binding", "PROBLEM", 0, 56], ["structural studies", "TEST", 93, 111], ["syntenin", "TEST", 115, 123], ["tamalin PDZ", "TREATMENT", 140, 151], ["the PDZ domains", "TREATMENT", 265, 280], ["the last two amino acids", "TREATMENT", 289, 313], ["C-terminal peptide recognitionPDZ domains", "TREATMENT", 314, 355], ["the last amino acids", "TREATMENT", 412, 432], ["the C-terminal target peptide", "TREATMENT", 436, 465], ["T/S", "TEST", 506, 509], ["XUXU", "TEST", 544, 548]]], ["Although this classification system is an oversimplification, it is useful to note that the class I binding PDZ domains have a characteristic His in a-helix 2 that hydrogen bonds with a Ser/Thr at position \u00c02.", [["His", "CHEMICAL", 142, 145], ["hydrogen", "CHEMICAL", 164, 172], ["Ser", "CHEMICAL", 186, 189], ["Thr", "CHEMICAL", 190, 193], ["Ser", "AMINO_ACID", 186, 189], ["Thr at position \u00c02", "AMINO_ACID", 190, 208], ["class I binding PDZ domains", "PROTEIN", 92, 119], ["a-helix 2", "PROTEIN", 149, 158], ["position \u00c02", "PROTEIN", 197, 208], ["the class I binding PDZ domains", "PROBLEM", 88, 119], ["hydrogen bonds", "PROBLEM", 164, 178], ["a Ser/Thr at position \u00c02", "TREATMENT", 184, 208], ["hydrogen bonds", "OBSERVATION", 164, 178]]], ["A more fine-tuned ligand binding specificity was hinted early on when computer-aided design of PSD-95 PDZ3 showed that every position in the target peptide contribute to the binding specificity [19] .", [["PSD-95 PDZ3", "CHEMICAL", 95, 106], ["PSD-95 PDZ3", "SIMPLE_CHEMICAL", 95, 106], ["PSD-95 PDZ3", "PROTEIN", 95, 106], ["PSD", "TEST", 95, 98], ["the binding specificity", "TEST", 170, 193]]], ["Furthermore, it was found that some PDZ domains recognize residues up to position \u00c07; the additional recognition typically being conferred by an extended b2-b3 loop region [47] [48] [49] [50] or an extended a2 [51] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 36, 39], ["PDZ domains", "PROTEIN", 36, 47], ["position \u00c07", "PROTEIN", 73, 84], ["b2", "PROTEIN", 154, 156], ["some PDZ domains recognize residues", "PROBLEM", 31, 66]]], ["In line with these observations, two large-scale studies that addressed PDZ-peptide binding specificities on family-wide scales showed that peptide binding specificity is derived from interactions throughout the binding pocket and that PDZ domains in general are not promiscuous but can be divided in up to 16 different classes based on their ligand binding profile [20, 21] .C-terminal peptide recognitionExperimental and computational data suggest that the binding reaction involves the rate-limiting formation of a weak encounter complex between the C-terminus of a disordered peptide and the PDZ domain, followed by formation of native side chain contacts and rearrangement into the final complex [52] [53] [54] .", [["C", "CHEMICAL", 376, 377], ["C", "CHEMICAL", 553, 554], ["PDZ", "GENE_OR_GENE_PRODUCT", 72, 75], ["PDZ", "GENE_OR_GENE_PRODUCT", 236, 239], ["[52] [53] [54]", "SIMPLE_CHEMICAL", 701, 715], ["PDZ", "PROTEIN", 72, 75], ["PDZ domains", "PROTEIN", 236, 247], ["C-terminus", "PROTEIN", 553, 563], ["PDZ domain", "PROTEIN", 596, 606], ["two large-scale studies", "TEST", 33, 56], ["wide scales", "TEST", 116, 127], ["peptide binding specificity", "PROBLEM", 140, 167], ["the binding pocket", "PROBLEM", 208, 226], ["PDZ domains", "PROBLEM", 236, 247], ["their ligand binding profile", "TEST", 337, 365], ["C-terminal peptide recognition", "PROBLEM", 376, 406], ["computational data", "TEST", 423, 441], ["the binding reaction", "PROBLEM", 455, 475], ["a weak encounter complex", "PROBLEM", 516, 540], ["a disordered peptide", "PROBLEM", 567, 587], ["the PDZ domain", "PROBLEM", 592, 606]]], ["The k on and k off rates are fast and the PDZ-peptide affinities are typically in the low-to-mid micro molar range with changes in affinities correlating with changes in k off [53] .", [["PDZ", "PROTEIN", 42, 45], ["The k", "TEST", 0, 5], ["the PDZ", "TEST", 38, 45], ["peptide affinities", "PROBLEM", 46, 64], ["changes in affinities", "PROBLEM", 120, 141], ["low", "OBSERVATION_MODIFIER", 86, 89], ["mid", "ANATOMY_MODIFIER", 93, 96], ["micro molar", "ANATOMY_MODIFIER", 97, 108]]], ["PDZ domains exhibit a range of dynamic and entropic behaviors, distinct between PDZ domains but also between the same PDZ domain bound to different ligands, suggesting that the dynamics of the domains contribute to the binding specificity [55] [56] [57] [58] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["PDZ", "GENE_OR_GENE_PRODUCT", 80, 83], ["PDZ domains", "PROTEIN", 0, 11], ["PDZ domains", "PROTEIN", 80, 91], ["PDZ domain", "PROTEIN", 118, 128], ["PDZ domains", "PROBLEM", 0, 11], ["entropic behaviors", "PROBLEM", 43, 61], ["distinct between PDZ domains", "PROBLEM", 63, 91], ["the binding specificity", "TEST", 215, 238], ["entropic behaviors", "OBSERVATION", 43, 61], ["different ligands", "OBSERVATION", 138, 155]]], ["For example, differences in dynamics were suggested for PDZ domains recognizing class I and class II peptides, such that dynamics of the b1-b2 and the b2-b3 loops are more critical in class I type binding and the dynamic of the b2-b3 loop and a2 is more critical in type II interactions [56] .", [["b1-b2", "GENE_OR_GENE_PRODUCT", 137, 142], ["b2-b3", "GENE_OR_GENE_PRODUCT", 151, 156], ["class I type", "GENE_OR_GENE_PRODUCT", 184, 196], ["b2-b3", "GENE_OR_GENE_PRODUCT", 228, 233], ["a2", "GENE_OR_GENE_PRODUCT", 243, 245], ["PDZ domains", "PROTEIN", 56, 67], ["b1", "DNA", 137, 139], ["b2", "DNA", 140, 142], ["b2-b3 loops", "DNA", 151, 162], ["b2", "PROTEIN", 228, 230], ["b3", "PROTEIN", 231, 233], ["a2", "PROTEIN", 243, 245], ["b3 loops", "ANATOMY", 154, 162], ["more critical", "OBSERVATION_MODIFIER", 249, 262]]], ["Double mutant cycle analysis of PSD-95 PDZ3 and tyrosine-protein phosphatase non-receptor type 13 (PTP-BL) PDZ2 suggested that Fig. 1 .", [["tyrosine", "CHEMICAL", 48, 56], ["tyrosine", "CHEMICAL", 48, 56], ["PSD-95 PDZ3", "GENE_OR_GENE_PRODUCT", 32, 43], ["tyrosine-protein phosphatase non-receptor type 13", "GENE_OR_GENE_PRODUCT", 48, 97], ["PTP-BL) PDZ2", "GENE_OR_GENE_PRODUCT", 99, 111], ["PSD", "PROTEIN", 32, 35], ["PDZ3", "PROTEIN", 39, 43], ["tyrosine-protein phosphatase non-receptor type 13 (PTP-BL) PDZ2", "PROTEIN", 48, 111], ["Double mutant cycle analysis", "TEST", 0, 28], ["PSD", "TEST", 32, 35], ["PDZ3", "TEST", 39, 43], ["tyrosine-protein phosphatase non-receptor type", "TEST", 48, 94], ["PTP", "TEST", 99, 102]]], ["Cartoon representations of canonical and PDZ-like domains with the N-and C-terminal strands highlighted in blue and red, respectively.", [["N", "CHEMICAL", 67, 68], ["C", "CHEMICAL", 73, 74], ["PDZ", "GENE_OR_GENE_PRODUCT", 41, 44], ["canonical and PDZ-like domains", "PROTEIN", 27, 57], ["N-and C-terminal strands", "DNA", 67, 91], ["canonical and PDZ", "TREATMENT", 27, 44], ["the N", "TREATMENT", 63, 68], ["C-terminal strands", "TREATMENT", 73, 91]]], ["PTP-BL PDZ2 (PDB code 1GM1, left) with indicated secondary elements (b1-b2-b3-a1-b4-b5-a2-b6) represents a canonical metazoan PDZ domain.", [["PTP-BL PDZ2", "GENE_OR_GENE_PRODUCT", 0, 11], ["PDB code 1GM1", "GENE_OR_GENE_PRODUCT", 13, 26], ["PTP", "PROTEIN", 0, 3], ["BL PDZ2", "PROTEIN", 4, 11], ["1GM1", "PROTEIN", 22, 26], ["b1-b2-b3-a1", "DNA", 69, 80], ["b4", "DNA", 81, 83], ["-a2", "PROTEIN", 86, 89], ["b6", "DNA", 90, 92], ["canonical metazoan PDZ domain", "PROTEIN", 107, 136], ["PTP", "TEST", 0, 3], ["BL PDZ2", "TEST", 4, 11], ["PDB code 1GM1", "TEST", 13, 26], ["secondary elements", "PROBLEM", 49, 67], ["b1-", "TEST", 69, 72], ["b3-a1", "TEST", 75, 80], ["b4", "TEST", 81, 83], ["a canonical metazoan PDZ domain", "PROBLEM", 105, 136], ["left", "ANATOMY_MODIFIER", 28, 32], ["secondary elements", "OBSERVATION", 49, 67], ["metazoan PDZ", "OBSERVATION", 117, 129]]], ["The PDZ domain of the D1 C-terminalprocessing protease (middle, PDB code 1FC7) and GRASP55 PDZ1 (right, PDB code 3RLE) illustrate two differentially circularly permuted PDZ structures. mutagenic alterations of the dynamic pathways affected the binding and that the whole PDZ domain and not only the binding site may be used to fine tune specificity [59] .", [["D1 C-terminalprocessing protease", "GENE_OR_GENE_PRODUCT", 22, 54], ["GRASP55 PDZ1", "GENE_OR_GENE_PRODUCT", 83, 95], ["PDZ", "GENE_OR_GENE_PRODUCT", 169, 172], ["PDZ domain", "PROTEIN", 4, 14], ["D1 C", "PROTEIN", 22, 26], ["terminalprocessing protease", "PROTEIN", 27, 54], ["middle, PDB code", "PROTEIN", 56, 72], ["1FC7", "PROTEIN", 73, 77], ["GRASP55 PDZ1", "PROTEIN", 83, 95], ["right, PDB code 3RLE", "PROTEIN", 97, 117], ["PDZ structures", "PROTEIN", 169, 183], ["PDZ domain", "PROTEIN", 271, 281], ["binding site", "PROTEIN", 299, 311], ["terminalprocessing protease", "TREATMENT", 27, 54], ["GRASP55 PDZ1 (right, PDB code 3RLE)", "TREATMENT", 83, 118], ["two differentially circularly permuted PDZ structures", "PROBLEM", 130, 183], ["mutagenic alterations", "PROBLEM", 185, 206], ["the whole PDZ domain", "PROBLEM", 261, 281], ["right", "ANATOMY_MODIFIER", 97, 102], ["PDZ structures", "OBSERVATION", 169, 183]]], ["However, some PDZ domains such as syntenin-1 PDZ2 and shank1 PDZ are promiscuous and may interact with ligands of different classes, which is possible owing to a structural flexibility of the binding sites [60, 61] .Interactions with internal peptide ligandsAlthough C-terminal peptide recognition is the hallmark of PDZ domains, some PDZ domains interact also with internal peptide motifs (Fig. 2) [8] [9] [10] [11] [62] [63] [64] [65] .", [["C", "CHEMICAL", 267, 268], ["PDZ", "GENE_OR_GENE_PRODUCT", 14, 17], ["syntenin-1", "GENE_OR_GENE_PRODUCT", 34, 44], ["PDZ2", "GENE_OR_GENE_PRODUCT", 45, 49], ["shank1 PDZ", "GENE_OR_GENE_PRODUCT", 54, 64], ["PDZ", "GENE_OR_GENE_PRODUCT", 317, 320], ["Fig. 2) [8] [9] [10] [11] [62] [63] [64] [65]", "SIMPLE_CHEMICAL", 391, 436], ["PDZ domains", "PROTEIN", 14, 25], ["syntenin", "PROTEIN", 34, 42], ["PDZ2", "PROTEIN", 45, 49], ["shank1", "PROTEIN", 54, 60], ["PDZ", "PROTEIN", 61, 64], ["binding sites", "PROTEIN", 192, 205], ["PDZ domains", "PROTEIN", 317, 328], ["PDZ domains", "PROTEIN", 335, 346], ["some PDZ domains", "PROBLEM", 9, 25], ["syntenin", "TEST", 34, 42], ["shank1 PDZ", "PROBLEM", 54, 64], ["internal peptide ligands", "TREATMENT", 234, 258], ["C-terminal peptide recognition", "PROBLEM", 267, 297], ["PDZ domains", "PROBLEM", 317, 328], ["some PDZ domains interact", "PROBLEM", 330, 355], ["internal peptide motifs", "TEST", 366, 389]]], ["Indeed, a recent high-throughput yeast two-hybrid screen found that more than half of the identified PDZ interactions did not require a free C-terminal consensus sequence, which suggests that binding to internal peptide motifs may be more common than previously appreciated [66] .", [["C", "CHEMICAL", 141, 142], ["PDZ", "GENE_OR_GENE_PRODUCT", 101, 104], ["PDZ", "PROTEIN", 101, 104], ["C-terminal consensus sequence", "DNA", 141, 170], ["yeast", "SPECIES", 33, 38], ["a recent high-throughput yeast", "PROBLEM", 8, 38], ["hybrid screen", "TEST", 43, 56], ["a free C-terminal consensus sequence", "TEST", 134, 170], ["internal peptide motifs", "TEST", 203, 226]]], ["Although this is an interesting finding that might suggest that a significant percentage of PDZ domains recognize internal peptide motifs, it is unfortunately not clear from the study to what extent the observed interactions are peptide mediated, and to what extent these interactions may engage other parts of the PDZ domains.", [["PDZ", "GENE_OR_GENE_PRODUCT", 92, 95], ["PDZ", "GENE_OR_GENE_PRODUCT", 315, 318], ["PDZ domains", "PROTEIN", 92, 103], ["PDZ domains", "PROTEIN", 315, 326], ["a significant percentage of PDZ domains", "PROBLEM", 64, 103], ["internal peptide motifs", "TEST", 114, 137], ["the study", "TEST", 174, 183], ["significant", "OBSERVATION_MODIFIER", 66, 77]]], ["For binding internal peptide stretches, it is paramount that the PDZpeptide couple overcomes the problems caused by steric clashes between amino acids extending beyond the 0 position and the carboxylate binding groove.", [["amino acids", "CHEMICAL", 139, 150], ["amino acids", "CHEMICAL", 139, 150], ["carboxylate", "CHEMICAL", 191, 202], ["PDZpeptide", "SIMPLE_CHEMICAL", 65, 75], ["amino acids", "AMINO_ACID", 139, 150], ["carboxylate binding groove", "PROTEIN", 191, 217], ["binding internal peptide stretches", "PROBLEM", 4, 38], ["the problems", "PROBLEM", 93, 105], ["steric clashes between amino acids", "PROBLEM", 116, 150], ["the carboxylate binding groove", "TREATMENT", 187, 217], ["steric clashes", "OBSERVATION", 116, 130], ["carboxylate", "OBSERVATION", 191, 202], ["binding groove", "OBSERVATION", 203, 217]]], ["The structures of a-1-syntrophin (SNTA1) PDZ in complex with the ca.", [["a-1-syntrophin", "CHEMICAL", 18, 32], ["SNTA1", "CHEMICAL", 34, 39], ["a-1-syntrophin", "CHEMICAL", 18, 32], ["SNTA1", "CHEMICAL", 34, 39], ["a-1-syntrophin", "SIMPLE_CHEMICAL", 18, 32], ["SNTA1) PDZ", "GENE_OR_GENE_PRODUCT", 34, 44], ["a-1-syntrophin (SNTA1) PDZ", "PROTEIN", 18, 44], ["a-1-syntrophin (SNTA1) PDZ", "TREATMENT", 18, 44], ["ca", "OBSERVATION", 65, 67]]], ["30 amino acid residue extension of the nitric oxide synthas (nNOS) PDZ domain, revealed that steric clashes can be avoided by the peptide adopting a b-strand structure replacing the normally required carboxyl terminus ( Fig. 2A ) [8] .", [["amino acid", "CHEMICAL", 3, 13], ["nitric oxide", "CHEMICAL", 39, 51], ["amino acid", "CHEMICAL", 3, 13], ["nitric oxide synthas", "CHEMICAL", 39, 59], ["carboxyl", "CHEMICAL", 200, 208], ["amino acid", "AMINO_ACID", 3, 13], ["nitric oxide synthas", "SIMPLE_CHEMICAL", 39, 59], ["nitric oxide synthas (nNOS) PDZ domain", "PROTEIN", 39, 77], ["b-strand structure", "PROTEIN", 149, 167], ["carboxyl terminus", "PROTEIN", 200, 217], ["Fig. 2A", "PROTEIN", 220, 227], ["amino acid residue", "TREATMENT", 3, 21], ["the nitric oxide synthas", "TREATMENT", 35, 59], ["PDZ domain", "TEST", 67, 77], ["steric clashes", "PROBLEM", 93, 107], ["a b-strand structure", "TREATMENT", 147, 167], ["carboxyl terminus", "TREATMENT", 200, 217], ["steric clashes", "OBSERVATION", 93, 107]]], ["A recent study on the kinetics of the binding reaction suggested [17] .", [["[17]", "SIMPLE_CHEMICAL", 65, 69], ["A recent study", "TEST", 0, 14], ["the binding reaction", "TEST", 34, 54]]], ["PICK1 PDZ (middle, PDB code 2PKU) interacts with lipid membranes through a conserved Cys-Pro-Cys motif (yellow spheres) and a positive charge cluster (Arg76, Lys79 and Lys81 in blue spheres).", [["lipid membranes", "ANATOMY", 49, 64], ["Cys", "CHEMICAL", 85, 88], ["Pro", "CHEMICAL", 89, 92], ["Cys", "CHEMICAL", 93, 96], ["Arg76", "CHEMICAL", 151, 156], ["Lys79", "CHEMICAL", 158, 163], ["Lys81", "CHEMICAL", 168, 173], ["PICK1", "GENE_OR_GENE_PRODUCT", 0, 5], ["middle, PDB code 2PKU", "GENE_OR_GENE_PRODUCT", 11, 32], ["lipid membranes", "CELLULAR_COMPONENT", 49, 64], ["PICK1 PDZ", "PROTEIN", 0, 9], ["middle, PDB code 2PKU", "PROTEIN", 11, 32], ["Cys-Pro-Cys motif", "PROTEIN", 85, 102], ["positive charge cluster", "PROTEIN", 126, 149], ["Arg76", "PROTEIN", 151, 156], ["Lys81", "PROTEIN", 168, 173], ["PICK1 PDZ (middle, PDB code 2PKU)", "TREATMENT", 0, 33], ["lipid membranes", "TREATMENT", 49, 64], ["a conserved Cys", "TEST", 73, 88], ["Cys motif (yellow spheres", "PROBLEM", 93, 118], ["a positive charge cluster", "PROBLEM", 124, 149], ["middle", "ANATOMY_MODIFIER", 11, 17]]], ["A bound peptide is indicated in red.", [["A bound peptide", "PROBLEM", 0, 15], ["red", "OBSERVATION", 32, 35]]], ["Mutaganic analysis of ZO-1 PDZ2 (right) indicated a set of basic residues to be of importance for the interactions with PIPs containing liposomes (Arg201, Lys246, Arg251 and Lys253 shown as blue spheres) [86] .A Peptide bindingthat native contacts form cooperatively after an initial ratelimiting docking step, and that the b-hairpin thus folds upon binding [67] .", [["Arg201", "CHEMICAL", 147, 153], ["Lys246", "CHEMICAL", 155, 161], ["Arg", "CHEMICAL", 163, 166], ["Lys253", "CHEMICAL", 174, 180], ["ZO-1 PDZ2", "GENE_OR_GENE_PRODUCT", 22, 31], ["PIPs", "SIMPLE_CHEMICAL", 120, 124], ["liposomes", "SIMPLE_CHEMICAL", 136, 145], ["Arg201", "SIMPLE_CHEMICAL", 147, 153], ["Arg251", "AMINO_ACID", 163, 169], ["b-hairpin", "GENE_OR_GENE_PRODUCT", 324, 333], ["ZO", "PROTEIN", 22, 24], ["PDZ2", "PROTEIN", 27, 31], ["PIPs", "PROTEIN", 120, 124], ["b-hairpin", "PROTEIN", 324, 333], ["Mutaganic analysis", "TEST", 0, 18], ["ZO", "TEST", 22, 24], ["basic residues", "PROBLEM", 59, 73], ["PIPs containing liposomes", "TREATMENT", 120, 145], ["right", "ANATOMY_MODIFIER", 33, 38]]], ["However, the interaction between PDZ domains and internal peptide ligands may also be accomplished by already conformationally constrained cyclic peptides [68] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 33, 36], ["PDZ domains", "PROTEIN", 33, 44], ["the interaction between PDZ domains", "PROBLEM", 9, 44], ["internal peptide ligands", "TREATMENT", 49, 73]]], ["In addition, internal peptide ligands may be accommodated by structural changes of PDZ domains as shown for the Par6 PDZ domain in complex with an internal region of the InaD-like protein (PALS1).", [["PDZ", "GENE_OR_GENE_PRODUCT", 83, 86], ["Par6", "GENE_OR_GENE_PRODUCT", 112, 116], ["InaD-like protein", "GENE_OR_GENE_PRODUCT", 170, 187], ["PALS1", "GENE_OR_GENE_PRODUCT", 189, 194], ["PDZ domains", "PROTEIN", 83, 94], ["Par6 PDZ domain", "PROTEIN", 112, 127], ["InaD-like protein", "PROTEIN", 170, 187], ["PALS1", "PROTEIN", 189, 194], ["internal peptide ligands", "PROBLEM", 13, 37], ["structural changes of PDZ domains", "PROBLEM", 61, 94], ["the Par6 PDZ domain", "PROBLEM", 108, 127], ["internal", "ANATOMY_MODIFIER", 13, 21], ["peptide ligands", "OBSERVATION", 22, 37], ["may be", "UNCERTAINTY", 38, 44], ["internal", "ANATOMY_MODIFIER", 147, 155]]], ["In this case, there is a conformational change of the carboxylate binding loop upon peptide binding ( Fig. 2A) and a conserved lysine in the carboxylate binding loop forms a salt bridge with the aspartic acids side chain in position +1 [69] .", [["carboxylate", "CHEMICAL", 54, 65], ["lysine", "CHEMICAL", 127, 133], ["carboxylate", "CHEMICAL", 141, 152], ["aspartic acids", "CHEMICAL", 195, 209], ["carboxylate", "CHEMICAL", 54, 65], ["lysine", "CHEMICAL", 127, 133], ["carboxylate", "CHEMICAL", 141, 152], ["aspartic acids", "CHEMICAL", 195, 209], ["lysine", "AMINO_ACID", 127, 133], ["aspartic acids", "AMINO_ACID", 195, 209], ["carboxylate binding loop", "PROTEIN", 54, 78], ["carboxylate binding loop", "PROTEIN", 141, 165], ["aspartic acids side chain", "PROTEIN", 195, 220], ["a conformational change of the carboxylate binding loop", "PROBLEM", 23, 78], ["a conserved lysine in the carboxylate binding loop", "TREATMENT", 115, 165], ["a salt bridge", "TREATMENT", 172, 185], ["the aspartic acids side chain", "TREATMENT", 191, 220], ["carboxylate binding", "OBSERVATION", 54, 73], ["lysine", "OBSERVATION", 127, 133], ["salt bridge", "OBSERVATION", 174, 185]]], ["Similarly, phage display of Disheveled-2 (Dvl2) PDZ2 with an internal peptide library revealed that Dvl2 PDZ2 recognizes a continuous stretch of 7-8 amino acids with a conserved aspartate residue mimicking the carboxylate of the Cterminal ligand.", [["PDZ2", "CHEMICAL", 105, 109], ["amino acids", "CHEMICAL", 149, 160], ["aspartate", "CHEMICAL", 178, 187], ["amino acids", "CHEMICAL", 149, 160], ["aspartate", "CHEMICAL", 178, 187], ["carboxylate", "CHEMICAL", 210, 221], ["Disheveled-2", "GENE_OR_GENE_PRODUCT", 28, 40], ["Dvl2) PDZ2", "GENE_OR_GENE_PRODUCT", 42, 52], ["Dvl2 PDZ2", "GENE_OR_GENE_PRODUCT", 100, 109], ["amino acids", "AMINO_ACID", 149, 160], ["aspartate", "AMINO_ACID", 178, 187], ["Disheveled-2 (Dvl2) PDZ2", "PROTEIN", 28, 52], ["Dvl2", "PROTEIN", 100, 104], ["PDZ2", "PROTEIN", 105, 109], ["Cterminal ligand", "PROTEIN", 229, 245], ["Disheveled", "TEST", 28, 38], ["an internal peptide library", "TEST", 58, 85], ["a continuous stretch", "TEST", 121, 141], ["a conserved aspartate residue", "PROBLEM", 166, 195], ["internal", "ANATOMY_MODIFIER", 61, 69], ["aspartate residue", "OBSERVATION", 178, 195]]], ["The structural analysis of Dvl2 PDZ2 in complex with different peptide ligands clarified that the protein can interact with both C-terminal and internal peptide ligands owing to a structural flexibility of its binding site [11, 70] .", [["C", "CHEMICAL", 129, 130], ["Dvl2 PDZ2", "GENE_OR_GENE_PRODUCT", 27, 36], ["Dvl2 PDZ2", "PROTEIN", 27, 36], ["C-terminal", "PROTEIN", 129, 139], ["The structural analysis", "TEST", 0, 23], ["Dvl2 PDZ2", "TREATMENT", 27, 36], ["different peptide ligands", "TREATMENT", 53, 78], ["internal peptide ligands", "TREATMENT", 144, 168]]], ["The recognition of internal peptide ligands allows multiple PDZ domains to interact with the same target protein facilitating the assembly of multi protein signaling complexes.", [["PDZ domains", "PROTEIN", 60, 71], ["multi protein signaling complexes", "PROTEIN", 142, 175], ["internal peptide ligands", "TREATMENT", 19, 43], ["multiple PDZ domains", "TREATMENT", 51, 71], ["multi protein signaling complexes", "PROBLEM", 142, 175], ["internal", "ANATOMY_MODIFIER", 19, 27], ["multi protein", "OBSERVATION", 142, 155], ["signaling complexes", "OBSERVATION", 156, 175]]], ["It also opens for the bidentate recognition of a target protein by two PDZ domains that are physically linked or dimerized.", [["PDZ domains", "PROTEIN", 71, 82], ["two PDZ domains", "TREATMENT", 67, 82]]], ["For example, INAD PZ3 recognizes an internal peptide stretch of transient receptor potential protein (TRP) and INAD PDZ5 interacts with the TRP C-terminus, a bidentate interaction that provides INAD with a high affinity for TRP (ca.", [["PZ3", "CHEMICAL", 18, 21], ["TRP", "CHEMICAL", 224, 227], ["C", "CHEMICAL", 144, 145], ["transient receptor potential protein", "GENE_OR_GENE_PRODUCT", 64, 100], ["TRP", "GENE_OR_GENE_PRODUCT", 102, 105], ["INAD PDZ5", "GENE_OR_GENE_PRODUCT", 111, 120], ["INAD", "SIMPLE_CHEMICAL", 194, 198], ["TRP", "GENE_OR_GENE_PRODUCT", 224, 227], ["INAD PZ3", "PROTEIN", 13, 21], ["transient receptor potential protein", "PROTEIN", 64, 100], ["TRP", "PROTEIN", 102, 105], ["INAD", "PROTEIN", 111, 115], ["PDZ5", "PROTEIN", 116, 120], ["TRP C-terminus", "PROTEIN", 140, 154], ["INAD", "PROTEIN", 194, 198], ["transient receptor potential protein (TRP)", "PROBLEM", 64, 106], ["INAD PDZ5", "PROBLEM", 111, 120], ["TRP (ca", "PROBLEM", 224, 231], ["internal peptide stretch", "OBSERVATION", 36, 60]]], ["Another example is given by PSD-95 that interacts with both an internal region and the C-terminus of shaker-type K+ channels [72] .", [["K", "CHEMICAL", 113, 114], ["C", "CHEMICAL", 87, 88], ["K+", "CHEMICAL", 113, 115], ["PSD-95", "GENE_OR_GENE_PRODUCT", 28, 34], ["K+", "SIMPLE_CHEMICAL", 113, 115], ["PSD", "PROTEIN", 28, 31], ["C-terminus", "PROTEIN", 87, 97], ["shaker-type K+ channels", "PROTEIN", 101, 124], ["internal", "ANATOMY_MODIFIER", 63, 71]]], ["An added value of the bidentate binding may be the possibility to independently regulate the interaction with the distinct PDZ domains.PDZ-PDZ interactionsIt was early on discovered that some PDZ domains engage in PDZ-PDZ interactions [8, 12, 13] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 123, 126], ["PDZ", "GENE_OR_GENE_PRODUCT", 135, 138], ["PDZ", "GENE_OR_GENE_PRODUCT", 139, 142], ["PDZ", "GENE_OR_GENE_PRODUCT", 192, 195], ["PDZ", "GENE_OR_GENE_PRODUCT", 214, 217], ["PDZ", "GENE_OR_GENE_PRODUCT", 218, 221], ["PDZ domains", "PROTEIN", 123, 134], ["PDZ", "PROTEIN", 135, 138], ["PDZ", "PROTEIN", 139, 142], ["PDZ domains", "PROTEIN", 192, 203], ["PDZ", "PROTEIN", 214, 217], ["PDZ", "PROTEIN", 218, 221], ["the bidentate binding", "PROBLEM", 18, 39], ["the distinct PDZ domains", "PROBLEM", 110, 134], ["some PDZ domains", "PROBLEM", 187, 203]]], ["For example, INAD PDZ3 and PDZ4 can form either homo-or hetero oligomers, and the PDZ tandems of NHERF1 and NHERF2 can hetero-or homodimerize without affecting peptide binding [12, 13] .", [["PDZ4", "CHEMICAL", 27, 31], ["INAD PDZ3", "GENE_OR_GENE_PRODUCT", 13, 22], ["PDZ4", "GENE_OR_GENE_PRODUCT", 27, 31], ["PDZ", "GENE_OR_GENE_PRODUCT", 82, 85], ["NHERF1", "GENE_OR_GENE_PRODUCT", 97, 103], ["NHERF2", "GENE_OR_GENE_PRODUCT", 108, 114], ["INAD", "PROTEIN", 13, 17], ["PDZ3", "PROTEIN", 18, 22], ["PDZ4", "PROTEIN", 27, 31], ["PDZ", "PROTEIN", 82, 85], ["NHERF1", "PROTEIN", 97, 103], ["NHERF2", "PROTEIN", 108, 114], ["INAD PDZ3", "TREATMENT", 13, 22], ["PDZ4", "TREATMENT", 27, 31], ["hetero oligomers", "PROBLEM", 56, 72], ["NHERF1 and NHERF2", "TREATMENT", 97, 114]]], ["However, the extent of PDZ-PDZ dimerizations was not fully appreciated until a recent study by Chang and co-workers revealed that as much as 30% of PDZ domains engage in PDZ-PDZ interactions with low micromolar affinities [73] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 23, 26], ["PDZ", "GENE_OR_GENE_PRODUCT", 27, 30], ["PDZ", "GENE_OR_GENE_PRODUCT", 148, 151], ["PDZ", "GENE_OR_GENE_PRODUCT", 170, 173], ["PDZ", "PROTEIN", 23, 26], ["PDZ", "PROTEIN", 27, 30], ["PDZ domains", "PROTEIN", 148, 159], ["PDZ", "PROTEIN", 170, 173], ["PDZ", "PROTEIN", 174, 177], ["PDZ-PDZ dimerizations", "PROBLEM", 23, 44], ["a recent study", "TEST", 77, 91], ["PDZ interactions", "PROBLEM", 174, 190], ["low micromolar affinities", "PROBLEM", 196, 221], ["PDZ", "OBSERVATION", 23, 26], ["PDZ", "OBSERVATION", 27, 30]]], ["PDZ-PDZ interactions appear more selective than PDZ-peptide interactions and therefore contribute to defining the precise composition of the protein complexes.", [["PDZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["PDZ", "GENE_OR_GENE_PRODUCT", 4, 7], ["PDZ", "PROTEIN", 0, 3], ["PDZ", "PROTEIN", 4, 7], ["PDZ", "PROTEIN", 48, 51], ["protein complexes", "PROTEIN", 141, 158], ["PDZ interactions", "PROBLEM", 4, 20], ["more selective", "OBSERVATION_MODIFIER", 28, 42]]], ["The prevalence of specific high affinity PDZ-PDZ interactions may suggest that these domains evolved to form multiprotein complexes by the simultaneous interaction with more than one ligand [73] .PDZ-PDZ interactionsStructural studies have shown that PDZ-PDZ dimerization can be accomplished by different means (Fig. 2B) .", [["PDZ", "GENE_OR_GENE_PRODUCT", 41, 44], ["PDZ", "GENE_OR_GENE_PRODUCT", 45, 48], ["PDZ-PDZ", "GENE_OR_GENE_PRODUCT", 251, 258], ["PDZ", "PROTEIN", 41, 44], ["PDZ", "PROTEIN", 45, 48], ["multiprotein complexes", "PROTEIN", 109, 131], ["PDZ", "PROTEIN", 200, 203], ["PDZ", "PROTEIN", 251, 254], ["PDZ", "PROTEIN", 255, 258], ["PDZ interactions", "PROBLEM", 45, 61], ["these domains", "PROBLEM", 79, 92], ["Structural studies", "TEST", 216, 234], ["PDZ-PDZ dimerization", "TREATMENT", 251, 271]]], ["For example, shank1 PDZ and GRIP1 PDZ6 form back-to-back homo-dimers that are stabilized by interactions engaging their unusually long b2-b3 loops and N-terminal b1-strands, and leave the peptide binding pockets of the constituting domains readily available for engaging in peptide interactions [74, 75] .", [["N", "CHEMICAL", 151, 152], ["shank1 PDZ", "GENE_OR_GENE_PRODUCT", 13, 23], ["GRIP1 PDZ6", "GENE_OR_GENE_PRODUCT", 28, 38], ["shank1 PDZ", "PROTEIN", 13, 23], ["GRIP1", "PROTEIN", 28, 33], ["PDZ6", "PROTEIN", 34, 38], ["b2", "PROTEIN", 135, 137], ["b3 loops", "PROTEIN", 138, 146], ["N-terminal b1-strands", "PROTEIN", 151, 172], ["shank1 PDZ", "TREATMENT", 13, 23], ["GRIP1 PDZ6", "TREATMENT", 28, 38], ["the peptide binding pockets", "PROBLEM", 184, 211]]], ["The second PDZ domain of ZO-1 forms a peculiar domain swapped dimeric structure, where the constituting PDZ domains retain their overall fold but have exchanged their b1-and b2-strands; the peptide binding sites are in this case located on opposite sides of the dimeric molecule (Fig. 2B) [76, 77] .", [["ZO-1", "GENE_OR_GENE_PRODUCT", 25, 29], ["PDZ domain", "PROTEIN", 11, 21], ["ZO-1", "PROTEIN", 25, 29], ["peculiar domain swapped dimeric structure", "PROTEIN", 38, 79], ["PDZ domains", "PROTEIN", 104, 115], ["b1", "PROTEIN", 167, 169], ["b2", "PROTEIN", 174, 176], ["peptide binding sites", "PROTEIN", 190, 211], ["dimeric molecule", "PROTEIN", 262, 278], ["a peculiar domain swapped dimeric structure", "PROBLEM", 36, 79], ["the constituting PDZ domains", "PROBLEM", 87, 115], ["the peptide binding sites", "PROBLEM", 186, 211], ["dimeric structure", "OBSERVATION", 62, 79], ["overall fold", "OBSERVATION", 129, 141]]], ["PDZ-PDZ interactions thus commonly leave the peptide binding sites available and may serve to increase the binding avidity of the interactions.", [["PDZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["PDZ", "GENE_OR_GENE_PRODUCT", 4, 7], ["PDZ", "PROTEIN", 0, 3], ["PDZ", "PROTEIN", 4, 7], ["PDZ interactions", "PROBLEM", 4, 20], ["the peptide binding sites", "TREATMENT", 41, 66]]], ["Exceptions to this notion are the SNTA1-nNOS PDZ and PSD-95 PDZ2-nNOS PDZ dimerizations, where the binding of the C-terminal extension of nNOS blocks the binding site of SNTA1 and PSD-95 PDZ2, respectively [8, 78] .PDZ-phospholipid interactionsAs PDZ domains are over-and-above known as protein-protein interacting modules, it was surprising when the first reports came on PDZ domains as phosphoinositide (PIPs) binders now ten years ago [14] .", [["phosphoinositide", "CHEMICAL", 388, 404], ["C", "CHEMICAL", 114, 115], ["SNTA1", "GENE_OR_GENE_PRODUCT", 34, 39], ["NOS", "GENE_OR_GENE_PRODUCT", 41, 44], ["PSD-95", "GENE_OR_GENE_PRODUCT", 53, 59], ["nNOS", "GENE_OR_GENE_PRODUCT", 65, 69], ["nNOS", "GENE_OR_GENE_PRODUCT", 138, 142], ["SNTA1", "GENE_OR_GENE_PRODUCT", 170, 175], ["PSD-95", "GENE_OR_GENE_PRODUCT", 180, 186], ["PDZ2", "GENE_OR_GENE_PRODUCT", 187, 191], ["PDZ", "GENE_OR_GENE_PRODUCT", 215, 218], ["phospholipid", "SIMPLE_CHEMICAL", 219, 231], ["PDZ", "GENE_OR_GENE_PRODUCT", 247, 250], ["phosphoinositide", "SIMPLE_CHEMICAL", 388, 404], ["PIPs", "SIMPLE_CHEMICAL", 406, 410], ["SNTA1", "PROTEIN", 34, 39], ["NOS PDZ", "PROTEIN", 41, 48], ["PSD", "PROTEIN", 53, 56], ["PDZ2", "PROTEIN", 60, 64], ["nNOS", "PROTEIN", 65, 69], ["nNOS", "PROTEIN", 138, 142], ["SNTA1", "PROTEIN", 170, 175], ["PSD", "PROTEIN", 180, 183], ["PDZ", "PROTEIN", 215, 218], ["PDZ domains", "PROTEIN", 247, 258], ["protein-protein interacting modules", "PROTEIN", 287, 322], ["PDZ domains", "PROTEIN", 373, 384], ["phosphoinositide (PIPs) binders", "PROTEIN", 388, 419], ["the SNTA1", "TEST", 30, 39], ["PSD", "TEST", 53, 56], ["PDZ2", "TREATMENT", 60, 64], ["nNOS PDZ dimerizations", "TREATMENT", 65, 87], ["SNTA1", "TEST", 170, 175], ["PSD", "TEST", 180, 183], ["PDZ-phospholipid interactions", "TREATMENT", 215, 244], ["PDZ domains", "TEST", 247, 258], ["protein-protein interacting modules", "PROBLEM", 287, 322], ["PDZ domains", "TREATMENT", 373, 384], ["phosphoinositide (PIPs) binders", "TREATMENT", 388, 419], ["nNOS blocks", "OBSERVATION", 138, 149], ["phospholipid interactions", "OBSERVATION", 219, 244]]], ["PIPs are phosphorylated forms of phosphatidylinositol.", [["phosphatidylinositol", "CHEMICAL", 33, 53], ["phosphatidylinositol", "CHEMICAL", 33, 53], ["PIPs", "SIMPLE_CHEMICAL", 0, 4], ["phosphatidylinositol", "SIMPLE_CHEMICAL", 33, 53], ["PIPs", "PROTEIN", 0, 4], ["PIPs", "TEST", 0, 4], ["phosphatidylinositol", "TREATMENT", 33, 53]]], ["Only a minor percentage of phosphatidylinositol is phosphorylated on one to three of the hydroxyl groups of the inositol headgroup and the seven biologically relevant PIPs species have a defined cellular localization that is regulated by a system of kinases and phosphatases [79, 80] .", [["cellular", "ANATOMY", 195, 203], ["phosphatidylinositol", "CHEMICAL", 27, 47], ["hydroxyl", "CHEMICAL", 89, 97], ["inositol", "CHEMICAL", 112, 120], ["phosphatidylinositol", "CHEMICAL", 27, 47], ["hydroxyl", "CHEMICAL", 89, 97], ["inositol", "CHEMICAL", 112, 120], ["phosphatidylinositol", "SIMPLE_CHEMICAL", 27, 47], ["inositol headgroup", "SIMPLE_CHEMICAL", 112, 130], ["PIPs species", "SIMPLE_CHEMICAL", 167, 179], ["cellular", "CELL", 195, 203], ["PIPs species", "PROTEIN", 167, 179], ["kinases", "PROTEIN", 250, 257], ["phosphatases", "PROTEIN", 262, 274], ["the inositol headgroup", "TREATMENT", 108, 130], ["the seven biologically relevant PIPs species", "PROBLEM", 135, 179], ["phosphatases", "TEST", 262, 274], ["minor", "OBSERVATION_MODIFIER", 7, 12], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["phosphatidylinositol", "OBSERVATION", 27, 47], ["inositol headgroup", "OBSERVATION", 112, 130], ["PIPs species", "OBSERVATION", 167, 179], ["cellular localization", "OBSERVATION", 195, 216]]], ["PIPs are important regulators of cell polarization and signaling.", [["cell", "ANATOMY", 33, 37], ["PIPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 33, 37], ["PIPs", "PROTEIN", 0, 4], ["cell polarization", "OBSERVATION", 33, 50]]], ["They can serve as precursors for second messengers, or function as membrane-bound signaling molecules regulating the localization of signaling complexes.", [["membrane", "ANATOMY", 67, 75], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["membrane-bound signaling molecules", "PROTEIN", 67, 101], ["signaling complexes", "PROTEIN", 133, 152], ["signaling complexes", "PROBLEM", 133, 152]]], ["The PDZ tandems of syntenin-1 and syntenin-2 represent the paradigm examples of PDZ domains interacting with membrane and nuclear PIPs, respectively [14, 16] .", [["membrane", "ANATOMY", 109, 117], ["nuclear PIPs", "ANATOMY", 122, 134], ["PDZ", "GENE_OR_GENE_PRODUCT", 4, 7], ["syntenin-1", "GENE_OR_GENE_PRODUCT", 19, 29], ["syntenin-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["PDZ", "GENE_OR_GENE_PRODUCT", 80, 83], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["nuclear", "CELLULAR_COMPONENT", 122, 129], ["PDZ", "PROTEIN", 4, 7], ["syntenin-1 and syntenin-2", "PROTEIN", 19, 44], ["PDZ domains", "PROTEIN", 80, 91], ["membrane and nuclear PIPs", "PROTEIN", 109, 134], ["The PDZ tandems of syntenin", "TREATMENT", 0, 27], ["syntenin", "TREATMENT", 34, 42], ["PDZ domains", "PROBLEM", 80, 91], ["nuclear PIPs", "TEST", 122, 134], ["PIPs", "OBSERVATION_MODIFIER", 130, 134]]], ["The in vivo importance of the syntenin-1-phosphatidylinositol 4.5-bisphosphate (PIP2) interaction was demonstrated for the recycling of syndecans, cell spreading and directional movements in zebrafish [81, 82] .", [["cell", "ANATOMY", 147, 151], ["syntenin-1-phosphatidylinositol 4.5-bisphosphate", "CHEMICAL", 30, 78], ["PIP2", "CHEMICAL", 80, 84], ["syntenin-1-phosphatidylinositol 4.5-bisphosphate", "CHEMICAL", 30, 78], ["syntenin-1", "GENE_OR_GENE_PRODUCT", 30, 40], ["phosphatidylinositol 4.5-bisphosphate", "GENE_OR_GENE_PRODUCT", 41, 78], ["PIP2", "SIMPLE_CHEMICAL", 80, 84], ["syndecans", "GENE_OR_GENE_PRODUCT", 136, 145], ["cell", "CELL", 147, 151], ["zebrafish", "ORGANISM", 191, 200], ["PIP2", "PROTEIN", 80, 84], ["the syntenin", "TEST", 26, 38], ["phosphatidylinositol", "TREATMENT", 41, 61], ["bisphosphate (PIP2) interaction", "TREATMENT", 66, 97], ["cell spreading", "PROBLEM", 147, 161]]], ["The syntenin-2-PIP2 interaction was suggested to be of importance for targeting the protein to membrane and nuclear pools of PIP2 [16] .", [["membrane", "ANATOMY", 95, 103], ["nuclear", "ANATOMY", 108, 115], ["syntenin-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["PIP2", "GENE_OR_GENE_PRODUCT", 15, 19], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["nuclear", "CELLULAR_COMPONENT", 108, 115], ["PIP2 [16]", "GENE_OR_GENE_PRODUCT", 125, 134], ["PIP2", "PROTEIN", 15, 19], ["The syntenin", "TREATMENT", 0, 12], ["PIP2", "TEST", 125, 129]]], ["Estimates now have it that 20-40% of PDZ domains interacts with phospholipids [15, 17, 83] and in the cases investigated, PDZ-PIPs interactions appear relevant for the function of the PDZ proteins.", [["PDZ", "GENE_OR_GENE_PRODUCT", 37, 40], ["phospholipids", "SIMPLE_CHEMICAL", 64, 77], ["PDZ", "GENE_OR_GENE_PRODUCT", 122, 125], ["PIPs", "GENE_OR_GENE_PRODUCT", 126, 130], ["PDZ", "GENE_OR_GENE_PRODUCT", 184, 187], ["PDZ domains", "PROTEIN", 37, 48], ["PDZ", "PROTEIN", 122, 125], ["PIPs", "PROTEIN", 126, 130], ["PDZ proteins", "PROTEIN", 184, 196], ["phospholipids", "TEST", 64, 77], ["PIPs interactions", "PROBLEM", 126, 143], ["the PDZ proteins", "PROBLEM", 180, 196]]], ["For example, lipid membrane interactions are crucial for the clustering of AMPA receptors by PICK1 [84] .", [["lipid membrane", "ANATOMY", 13, 27], ["AMPA", "CHEMICAL", 75, 79], ["AMPA", "CHEMICAL", 75, 79], ["lipid membrane", "CELLULAR_COMPONENT", 13, 27], ["AMPA receptors", "GENE_OR_GENE_PRODUCT", 75, 89], ["PICK1", "GENE_OR_GENE_PRODUCT", 93, 98], ["AMPA receptors", "PROTEIN", 75, 89], ["PICK1", "PROTEIN", 93, 98], ["lipid membrane interactions", "PROBLEM", 13, 40], ["lipid membrane", "OBSERVATION", 13, 27]]], ["In other cases, a PIPs binding PDZ domain is linked to another PDZ domain that recruits a phosphatase or kinase and thus target the enzyme to its substrate, as exemplified by Par3 where the second PDZ domain interacts with PIPs and the third PDZ domain interact with the PIP3 phosphatase PTEN [51] .PDZ-phospholipid interactionsPIPs-PDZ interactions are commonly in the low-to-mid micro molar range and often occur in tandem with other lipid binding modules, such as the PDZ domain of PICK1 being linked to a BAR domain [84] and the lipid binding PDZ domain of SNTA1 being connected to a PH domain [85] .", [["Par3", "GENE_OR_GENE_PRODUCT", 175, 179], ["PIPs", "GENE_OR_GENE_PRODUCT", 223, 227], ["PIP3", "GENE_OR_GENE_PRODUCT", 271, 275], ["PTEN", "GENE_OR_GENE_PRODUCT", 288, 292], ["PDZ", "GENE_OR_GENE_PRODUCT", 299, 302], ["PICK1", "GENE_OR_GENE_PRODUCT", 485, 490], ["BAR", "GENE_OR_GENE_PRODUCT", 509, 512], ["SNTA1", "GENE_OR_GENE_PRODUCT", 561, 566], ["PIPs binding PDZ domain", "PROTEIN", 18, 41], ["PDZ domain", "PROTEIN", 63, 73], ["phosphatase", "PROTEIN", 90, 101], ["kinase", "PROTEIN", 105, 111], ["Par3", "PROTEIN", 175, 179], ["PDZ domain", "PROTEIN", 197, 207], ["PIPs", "PROTEIN", 223, 227], ["third PDZ domain", "PROTEIN", 236, 252], ["PIP3 phosphatase", "PROTEIN", 271, 287], ["PTEN", "PROTEIN", 288, 292], ["PDZ", "PROTEIN", 299, 302], ["phospholipid interactionsPIPs", "PROTEIN", 303, 332], ["PDZ", "PROTEIN", 333, 336], ["lipid binding modules", "PROTEIN", 436, 457], ["PDZ domain", "PROTEIN", 471, 481], ["PICK1", "PROTEIN", 485, 490], ["BAR domain", "PROTEIN", 509, 519], ["lipid binding PDZ domain", "PROTEIN", 533, 557], ["SNTA1", "PROTEIN", 561, 566], ["PH domain", "PROTEIN", 588, 597], ["a PIPs binding PDZ domain", "PROBLEM", 16, 41], ["another PDZ domain", "PROBLEM", 55, 73], ["a phosphatase", "TEST", 88, 101], ["kinase", "TEST", 105, 111], ["the enzyme", "TEST", 128, 138], ["PIPs", "TREATMENT", 223, 227], ["the third PDZ domain", "TREATMENT", 232, 252], ["the PIP3 phosphatase PTEN", "TEST", 267, 292], ["PDZ", "TEST", 299, 302], ["phospholipid interactionsPIPs", "PROBLEM", 303, 332], ["PDZ interactions", "PROBLEM", 333, 349], ["other lipid binding modules", "TREATMENT", 430, 457], ["the PDZ domain of PICK1", "TREATMENT", 467, 490], ["the lipid binding PDZ domain of SNTA1", "TREATMENT", 529, 566], ["a PH domain", "TEST", 586, 597], ["mid", "ANATOMY_MODIFIER", 377, 380]]], ["Alternatively, PIPs interacting PDZ domains exist as dimers such as ZO-1 PDZ2 [86] and its Drosophila homologue polychaetoid (Pyd) PDZ2 [87] , or form multimers exemplified by of the PDZ domains of bacterial DegP [88] .", [["PIPs", "GENE_OR_GENE_PRODUCT", 15, 19], ["PDZ", "GENE_OR_GENE_PRODUCT", 32, 35], ["ZO-1", "GENE_OR_GENE_PRODUCT", 68, 72], ["polychaetoid", "GENE_OR_GENE_PRODUCT", 112, 124], ["PIPs", "PROTEIN", 15, 19], ["PDZ domains", "PROTEIN", 32, 43], ["ZO", "PROTEIN", 68, 70], ["PDZ2", "PROTEIN", 73, 77], ["Drosophila homologue polychaetoid", "PROTEIN", 91, 124], ["Pyd", "PROTEIN", 126, 129], ["PDZ2", "PROTEIN", 131, 135], ["PDZ domains", "PROTEIN", 183, 194], ["Drosophila", "SPECIES", 91, 101], ["PIPs interacting PDZ domains exist", "PROBLEM", 15, 49], ["ZO", "TEST", 68, 70], ["bacterial DegP", "PROBLEM", 198, 212], ["bacterial DegP", "OBSERVATION", 198, 212]]], ["Combinations of more than one lipid binding module provide proteins with avidity for the lipid membrane making the interactions biologically relevant, although the affinity of each domain may be rather low.", [["lipid membrane", "ANATOMY", 89, 103], ["lipid membrane", "CELLULAR_COMPONENT", 89, 103], ["the lipid membrane", "TREATMENT", 85, 103]]], ["As reviewed by Gallardo and co-authors, PDZ domains employ different means to target PIPs containing lipid membranes such as electrostatic interactions, membrane insertion and basic clusters interacting with the lipid headgroup (Fig. 2C) [15] .", [["lipid membranes", "ANATOMY", 101, 116], ["membrane", "ANATOMY", 153, 161], ["PIPs", "SIMPLE_CHEMICAL", 85, 89], ["lipid membranes", "CELLULAR_COMPONENT", 101, 116], ["membrane", "CELLULAR_COMPONENT", 153, 161], ["PDZ domains", "PROTEIN", 40, 51], ["PIPs", "PROTEIN", 85, 89], ["target PIPs containing lipid membranes", "TREATMENT", 78, 116], ["electrostatic interactions", "PROBLEM", 125, 151], ["membrane insertion", "TREATMENT", 153, 171], ["the lipid headgroup", "TREATMENT", 208, 227], ["lipid membranes", "OBSERVATION", 101, 116], ["electrostatic interactions", "OBSERVATION", 125, 151], ["membrane insertion", "OBSERVATION", 153, 171]]], ["The PDZ domains appear in general to lack well-defined PIPs binding pockets providing stereospecific interactions with distinct PIPs species, which is present in more classic PIPs binding modules such as the PH of PLC-d1 [89] and the PX domain of p40(phox) [90] , and PDZ domains thus tend to have low stereospecificity [16, 17, 87] .PDZ-phospholipid interactionsPDZ-PIPs interactions have been mapped to different structural regions in distinct cases and competition as well as synergy between PIPs and peptide binding have been reported, both of which may be involved in regulating the PDZ function [14, 17, 87] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 4, 7], ["PIPs", "GENE_OR_GENE_PRODUCT", 128, 132], ["PIPs", "GENE_OR_GENE_PRODUCT", 175, 179], ["PLC-d1 [89]", "GENE_OR_GENE_PRODUCT", 214, 225], ["p40(phox) [90]", "GENE_OR_GENE_PRODUCT", 247, 261], ["PDZ", "GENE_OR_GENE_PRODUCT", 268, 271], ["PDZ", "GENE_OR_GENE_PRODUCT", 334, 337], ["phospholipid", "SIMPLE_CHEMICAL", 338, 350], ["PIPs", "GENE_OR_GENE_PRODUCT", 495, 499], ["PDZ", "GENE_OR_GENE_PRODUCT", 588, 591], ["PDZ domains", "PROTEIN", 4, 15], ["PIPs binding pockets", "PROTEIN", 55, 75], ["PIPs species", "PROTEIN", 128, 140], ["PIPs binding modules", "PROTEIN", 175, 195], ["PH", "PROTEIN", 208, 210], ["PLC", "PROTEIN", 214, 217], ["PX domain", "PROTEIN", 234, 243], ["p40(phox) [90]", "PROTEIN", 247, 261], ["PDZ domains", "PROTEIN", 268, 279], ["PDZ", "PROTEIN", 334, 337], ["PIPs", "PROTEIN", 367, 371], ["PIPs", "PROTEIN", 495, 499], ["PDZ", "PROTEIN", 588, 591], ["The PDZ domains", "PROBLEM", 0, 15], ["PIPs binding pockets", "PROBLEM", 55, 75], ["distinct PIPs species", "PROBLEM", 119, 140], ["the PH", "TEST", 204, 210], ["PLC", "TEST", 214, 217], ["the PX domain", "TEST", 230, 243], ["phox", "TEST", 251, 255], ["PDZ domains", "TEST", 268, 279], ["low stereospecificity", "PROBLEM", 298, 319], ["PDZ", "TEST", 334, 337], ["phospholipid interactionsPDZ", "TREATMENT", 338, 366], ["PIPs interactions", "PROBLEM", 367, 384], ["synergy between PIPs and peptide binding", "PROBLEM", 479, 519], ["PIPs species", "OBSERVATION", 128, 140], ["phospholipid interactionsPDZ", "OBSERVATION", 338, 366]]], ["For example, NMR analysis of the PTP-BAS PDZ2b-PIP2/PIP3 interaction suggested it to take place in the groove between a2 and b2 and to be competitive with peptide binding [91] .", [["PTP", "GENE_OR_GENE_PRODUCT", 33, 36], ["PIP2", "GENE_OR_GENE_PRODUCT", 47, 51], ["PIP3", "GENE_OR_GENE_PRODUCT", 52, 56], ["b2", "GENE_OR_GENE_PRODUCT", 125, 127], ["PTP", "PROTEIN", 33, 36], ["PDZ2b", "PROTEIN", 41, 46], ["PIP2", "PROTEIN", 47, 51], ["PIP3", "PROTEIN", 52, 56], ["a2", "PROTEIN", 118, 120], ["b2", "PROTEIN", 125, 127], ["NMR analysis", "TEST", 13, 25], ["the PTP", "TEST", 29, 36], ["BAS PDZ2b", "TEST", 37, 46], ["PIP2/PIP3 interaction", "TREATMENT", 47, 68], ["groove", "ANATOMY_MODIFIER", 103, 109]]], ["Par3 PDZ2 membrane targeting involves the insertion of a cluster of hydrophobic residues into the membrane and non-specific electrostatic interactions between a defined positive charge cluster and the negatively charged lipid membrane (Fig. 2) [17] .", [["membrane", "ANATOMY", 10, 18], ["membrane", "ANATOMY", 98, 106], ["lipid membrane", "ANATOMY", 220, 234], ["Par3", "GENE_OR_GENE_PRODUCT", 0, 4], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["lipid membrane", "CELLULAR_COMPONENT", 220, 234], ["PDZ2", "PROTEIN", 5, 9], ["positive charge cluster", "PROTEIN", 169, 192], ["Par3 PDZ2 membrane", "TREATMENT", 0, 18], ["hydrophobic residues into the membrane", "PROBLEM", 68, 106], ["non-specific electrostatic interactions", "PROBLEM", 111, 150], ["a defined positive charge cluster", "PROBLEM", 159, 192], ["non-specific", "OBSERVATION_MODIFIER", 111, 123], ["electrostatic interactions", "OBSERVATION", 124, 150]]], ["NMR titration of Par3 PDZ2 with PI3P indicated the strongest chemical shift changes to be located to a polar pocket between the b1-b2 and b5-b6 loops, and the lipid headgroup was modeled into this pocket making contacts with Arg532, Lys535 and Glu469 [17] .", [["PI3P", "CHEMICAL", 32, 36], ["Arg532", "CHEMICAL", 225, 231], ["Lys535", "CHEMICAL", 233, 239], ["Glu469", "CHEMICAL", 244, 250], ["Par3 PDZ2", "GENE_OR_GENE_PRODUCT", 17, 26], ["PI3P", "GENE_OR_GENE_PRODUCT", 32, 36], ["b1-b2", "GENE_OR_GENE_PRODUCT", 128, 133], ["b5-b6", "GENE_OR_GENE_PRODUCT", 138, 143], ["lipid headgroup", "SIMPLE_CHEMICAL", 159, 174], ["Arg532", "GENE_OR_GENE_PRODUCT", 225, 231], ["Par3 PDZ2", "PROTEIN", 17, 26], ["PI3P", "PROTEIN", 32, 36], ["b1-b2 and b5-b6 loops", "DNA", 128, 149], ["Par3 PDZ2", "TREATMENT", 17, 26], ["PI3P", "TREATMENT", 32, 36], ["the lipid headgroup", "TREATMENT", 155, 174], ["polar", "ANATOMY_MODIFIER", 103, 108], ["b1", "ANATOMY", 128, 130], ["b2", "ANATOMY", 131, 133], ["b5", "ANATOMY", 138, 140], ["b6 loops", "ANATOMY", 141, 149]]], ["The PIPs binding site of Par3 PDZ2 partially overlaps with the peptide binding region and the authors consistently reported on competition between peptide and lipid binding.", [["PIPs", "GENE_OR_GENE_PRODUCT", 4, 8], ["Par3", "GENE_OR_GENE_PRODUCT", 25, 29], ["lipid", "SIMPLE_CHEMICAL", 159, 164], ["PIPs binding site", "DNA", 4, 21], ["Par3 PDZ2", "PROTEIN", 25, 34], ["Par3 PDZ2", "TREATMENT", 25, 34], ["the peptide binding region", "TREATMENT", 59, 85], ["lipid binding", "PROBLEM", 159, 172], ["PIPs binding", "OBSERVATION", 4, 16]]], ["In line with these data, biochemical analysis of ZO-1 PDZ2 suggested competition between peptide and lipid binding [14, 86] .", [["ZO-1 PDZ2", "GENE_OR_GENE_PRODUCT", 49, 58], ["lipid", "SIMPLE_CHEMICAL", 101, 106], ["ZO-1 PDZ2", "PROTEIN", 49, 58], ["these data", "TEST", 13, 23], ["biochemical analysis", "TEST", 25, 45], ["ZO", "TEST", 49, 51], ["lipid binding", "TEST", 101, 114]]], ["The PDZ domain of PICK1 displays a distinct mode of lipid membrane binding as outlined by biochemical and mutational analysis [84] .", [["lipid membrane", "ANATOMY", 52, 66], ["PICK1", "GENE_OR_GENE_PRODUCT", 18, 23], ["lipid membrane", "CELLULAR_COMPONENT", 52, 66], ["PDZ domain", "PROTEIN", 4, 14], ["PICK1", "PROTEIN", 18, 23], ["The PDZ domain of PICK1", "TEST", 0, 23], ["lipid membrane binding", "PROBLEM", 52, 74], ["mutational analysis", "TEST", 106, 125], ["lipid membrane binding", "OBSERVATION", 52, 74]]], ["The PICK1 PDZ interaction with lipid membranes requires a conserved Cys-Pro-Cys motif in the b2-b3 loop and a juxtaposed positive charge cluster in the b5-a2 loop [84] .", [["lipid membranes", "ANATOMY", 31, 46], ["Cys", "CHEMICAL", 68, 71], ["Pro", "CHEMICAL", 72, 75], ["Cys", "CHEMICAL", 76, 79], ["PICK1", "GENE_OR_GENE_PRODUCT", 4, 9], ["lipid membranes", "CELLULAR_COMPONENT", 31, 46], ["b5-a2", "GENE_OR_GENE_PRODUCT", 152, 157], ["PICK1", "PROTEIN", 4, 9], ["PDZ", "PROTEIN", 10, 13], ["Cys-Pro-Cys motif", "PROTEIN", 68, 85], ["b2", "PROTEIN", 93, 95], ["b3 loop", "PROTEIN", 96, 103], ["juxtaposed positive charge cluster", "PROTEIN", 110, 144], ["b5", "PROTEIN", 152, 154], ["The PICK1 PDZ interaction", "TREATMENT", 0, 25], ["lipid membranes", "TREATMENT", 31, 46], ["a conserved Cys", "TREATMENT", 56, 71], ["a juxtaposed positive charge cluster", "PROBLEM", 108, 144], ["PICK1 PDZ", "OBSERVATION", 4, 13], ["lipid membranes", "OBSERVATION", 31, 46], ["b3 loop", "ANATOMY", 96, 103], ["positive", "OBSERVATION_MODIFIER", 121, 129], ["charge cluster", "OBSERVATION", 130, 144]]], ["The basic cluster provides non-specific electrostatic interactions with the lipid membrane and the Cys-Pro-Cys motif was suggested to insert into the lipid membrane, although the molecular mechanism is not clear.", [["lipid membrane", "ANATOMY", 76, 90], ["lipid membrane", "ANATOMY", 150, 164], ["Cys-Pro-Cys", "CHEMICAL", 99, 110], ["Cys", "CHEMICAL", 99, 102], ["Pro", "CHEMICAL", 103, 106], ["Cys", "CHEMICAL", 107, 110], ["lipid membrane", "CELLULAR_COMPONENT", 76, 90], ["lipid membrane", "CELLULAR_COMPONENT", 150, 164], ["Cys-Pro-Cys motif", "PROTEIN", 99, 116], ["non-specific electrostatic interactions", "PROBLEM", 27, 66], ["the lipid membrane", "TREATMENT", 72, 90], ["the Cys", "TEST", 95, 102], ["non-specific", "OBSERVATION_MODIFIER", 27, 39], ["electrostatic interactions", "OBSERVATION", 40, 66], ["lipid membrane", "ANATOMY", 150, 164], ["not", "UNCERTAINTY", 202, 205], ["clear", "OBSERVATION", 206, 211]]], ["There is no overlap between the peptide binding site and the lipid binding region of PICK1 PDZ, and peptide binding does not appear to compete with lipid membrane binding.PDZ-phospholipid interactionsThe first example of synergistic binding between peptide and PIPs ligands was given by a recent study on the Pyd PDZ2 [87] , where it was found that preloading Pyd PDZ2 with a LKLPPERLI-COO-peptide conferred a sixfold increase in affinity for PIP2.", [["lipid membrane", "ANATOMY", 148, 162], ["Pyd", "CHEMICAL", 360, 363], ["LKLPPERLI-COO-peptide", "CHEMICAL", 376, 397], ["PICK1", "GENE_OR_GENE_PRODUCT", 85, 90], ["lipid membrane", "CELLULAR_COMPONENT", 148, 162], ["PDZ", "GENE_OR_GENE_PRODUCT", 171, 174], ["phospholipid", "SIMPLE_CHEMICAL", 175, 187], ["PIPs", "SIMPLE_CHEMICAL", 261, 265], ["Pyd PDZ2", "SIMPLE_CHEMICAL", 360, 368], ["PIP2", "SIMPLE_CHEMICAL", 443, 447], ["lipid binding region", "PROTEIN", 61, 81], ["PICK1", "PROTEIN", 85, 90], ["PDZ", "PROTEIN", 91, 94], ["PDZ", "PROTEIN", 171, 174], ["Pyd PDZ2", "PROTEIN", 360, 368], ["PIP2", "PROTEIN", 443, 447], ["overlap between the peptide binding site", "PROBLEM", 12, 52], ["PICK1 PDZ", "PROBLEM", 85, 94], ["peptide binding", "PROBLEM", 100, 115], ["lipid membrane binding", "PROBLEM", 148, 170], ["PDZ-phospholipid interactions", "TREATMENT", 171, 200], ["synergistic binding between peptide and PIPs ligands", "PROBLEM", 221, 273], ["a recent study", "TEST", 287, 301], ["a LKLPPERLI", "TREATMENT", 374, 385], ["PIP2", "PROBLEM", 443, 447], ["no", "UNCERTAINTY", 9, 11], ["peptide binding", "OBSERVATION", 32, 47], ["lipid binding", "OBSERVATION", 61, 74], ["PICK1 PDZ", "OBSERVATION", 85, 94], ["lipid membrane binding", "OBSERVATION", 148, 170], ["phospholipid interactions", "OBSERVATION", 175, 200]]], ["The results suggest that peptide binding may tune the affinity for the lipid binding partner and that the protein will be efficiently targeted to the membrane when both peptide and PIPs are available.", [["membrane", "ANATOMY", 150, 158], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["PIPs", "SIMPLE_CHEMICAL", 181, 185], ["peptide binding", "PROBLEM", 25, 40], ["the protein", "PROBLEM", 102, 113]]], ["Mutagenic analysis of Pyd PDZ2 revealed that electrostatic interactions along one face of the a2 are crucial for lipid membrane binding [87] .", [["lipid membrane", "ANATOMY", 113, 127], ["Pyd", "CHEMICAL", 22, 25], ["Pyd PDZ2", "GENE_OR_GENE_PRODUCT", 22, 30], ["a2", "GENE_OR_GENE_PRODUCT", 94, 96], ["lipid membrane", "CELLULAR_COMPONENT", 113, 127], ["Pyd PDZ2", "PROTEIN", 22, 30], ["a2", "PROTEIN", 94, 96], ["Mutagenic analysis", "TEST", 0, 18], ["Pyd PDZ2", "TEST", 22, 30], ["electrostatic interactions", "PROBLEM", 45, 71], ["lipid membrane binding", "PROBLEM", 113, 135], ["electrostatic interactions", "OBSERVATION", 45, 71], ["a2", "ANATOMY", 94, 96]]], ["The study on Pyd PDZ2 further highlighted that PDZ-PIPs interactions may be reinforced by additional interactions with other negatively charged phospholipids, such as phosphatidylserine.PDZ-phospholipid interactionsRecently, a study by Chen and co-workers suggested that up to 40% of PDZ domains may interact with lipid membranes and that these domains function as dual-specificity modules regulating proteins interactions at the membrane [83] .", [["lipid membranes", "ANATOMY", 314, 329], ["membrane", "ANATOMY", 430, 438], ["phosphatidylserine", "CHEMICAL", 167, 185], ["phosphatidylserine", "CHEMICAL", 167, 185], ["Pyd PDZ2", "SIMPLE_CHEMICAL", 13, 21], ["PDZ", "GENE_OR_GENE_PRODUCT", 47, 50], ["PIPs", "GENE_OR_GENE_PRODUCT", 51, 55], ["phospholipids", "SIMPLE_CHEMICAL", 144, 157], ["phosphatidylserine", "SIMPLE_CHEMICAL", 167, 185], ["PDZ", "GENE_OR_GENE_PRODUCT", 186, 189], ["phospholipid", "SIMPLE_CHEMICAL", 190, 202], ["PDZ", "GENE_OR_GENE_PRODUCT", 284, 287], ["lipid membranes", "CELLULAR_COMPONENT", 314, 329], ["membrane", "CELLULAR_COMPONENT", 430, 438], ["Pyd PDZ2", "PROTEIN", 13, 21], ["PDZ", "PROTEIN", 47, 50], ["PDZ", "PROTEIN", 186, 189], ["PDZ domains", "PROTEIN", 284, 295], ["The study", "TEST", 0, 9], ["Pyd PDZ2", "TREATMENT", 13, 21], ["PDZ-PIPs interactions", "TREATMENT", 47, 68], ["other negatively charged phospholipids", "TREATMENT", 119, 157], ["phosphatidylserine", "TREATMENT", 167, 185], ["PDZ-phospholipid interactions", "TREATMENT", 186, 215], ["a study", "TEST", 225, 232], ["PDZ domains", "PROBLEM", 284, 295], ["lipid membranes", "TREATMENT", 314, 329], ["these domains function", "TEST", 339, 361], ["phospholipid interactions", "OBSERVATION", 190, 215]]], ["The study further suggested a classification of lipid-binding PDZ domains based on the localization of their basic clusters, with class A lipid-binding PDZ domains having topologically distinct peptide and lipid binding sites and acting as coincidence detectors of lipid and peptide signaling.", [["lipid", "SIMPLE_CHEMICAL", 48, 53], ["lipid", "SIMPLE_CHEMICAL", 265, 270], ["lipid-binding PDZ domains", "PROTEIN", 48, 73], ["class A lipid-binding PDZ domains", "PROTEIN", 130, 163], ["The study", "TEST", 0, 9], ["lipid-binding PDZ domains", "TREATMENT", 48, 73], ["A lipid-binding PDZ domains", "TREATMENT", 136, 163], ["topologically distinct peptide and lipid binding sites", "PROBLEM", 171, 225], ["lipid and peptide signaling", "PROBLEM", 265, 292], ["lipid binding", "OBSERVATION", 206, 219]]], ["Class B PDZ domains have basic clusters in or near the a2 helix that makes part of the peptide binding site.", [["Class B PDZ", "GENE_OR_GENE_PRODUCT", 0, 11], ["Class B PDZ domains", "PROTEIN", 0, 19], ["a2 helix", "PROTEIN", 55, 63], ["peptide binding site", "PROTEIN", 87, 107], ["the peptide binding site", "PROBLEM", 83, 107], ["basic", "OBSERVATION_MODIFIER", 25, 30], ["clusters", "OBSERVATION_MODIFIER", 31, 39], ["a2 helix", "ANATOMY", 55, 63]]], ["The class B domains were further subdivided into class B1 having the basic cluster at the C-terminal end of a2 and potentially acting as coincidence detectors of PIPs and peptide signaling, and class B2 domains having the basic cluster at the N-terminal end of a2 and displaying competitive peptide and PIPs binding.", [["N", "CHEMICAL", 243, 244], ["PIPs", "GENE_OR_GENE_PRODUCT", 162, 166], ["PIPs", "SIMPLE_CHEMICAL", 303, 307], ["class B domains", "PROTEIN", 4, 19], ["class B1", "PROTEIN", 49, 57], ["C-terminal end", "PROTEIN", 90, 104], ["a2", "PROTEIN", 108, 110], ["PIPs", "PROTEIN", 162, 166], ["class B2 domains", "PROTEIN", 194, 210], ["N-terminal end", "PROTEIN", 243, 257], ["a2", "PROTEIN", 261, 263], ["PIPs and peptide signaling", "PROBLEM", 162, 188], ["class B2 domains", "PROBLEM", 194, 210], ["competitive peptide and PIPs binding", "PROBLEM", 279, 315], ["terminal", "ANATOMY_MODIFIER", 245, 253], ["a2", "ANATOMY", 261, 263], ["competitive peptide", "OBSERVATION", 279, 298], ["PIPs binding", "OBSERVATION", 303, 315]]], ["Future studies of the growing list of lipid binding PDZ domains will elucidate the intriguing interplay between peptide and lipid binding and the biological consequences of these interactions.Regulation of PDZ interactionsPDZ domains are functionally versatile modules that can be dynamically be regulated by various means, as reviewed in the following section.Changes of buffer conditionsPDZ interactions can be regulated by changes in physiological buffer conditions [23, 24] .", [["lipid", "SIMPLE_CHEMICAL", 124, 129], ["PDZ", "GENE_OR_GENE_PRODUCT", 206, 209], ["PDZ", "GENE_OR_GENE_PRODUCT", 222, 225], ["PDZ", "GENE_OR_GENE_PRODUCT", 389, 392], ["lipid binding PDZ domains", "PROTEIN", 38, 63], ["PDZ", "PROTEIN", 206, 209], ["PDZ domains", "PROTEIN", 222, 233], ["PDZ", "PROTEIN", 389, 392], ["Future studies", "TEST", 0, 14], ["lipid binding PDZ domains", "PROBLEM", 38, 63], ["lipid binding", "PROBLEM", 124, 137], ["PDZ interactionsPDZ domains", "PROBLEM", 206, 233], ["functionally versatile modules", "PROBLEM", 238, 268], ["buffer conditionsPDZ interactions", "TREATMENT", 372, 405], ["PDZ", "OBSERVATION", 206, 209]]], ["In particular, the salt and pH dependence of the peptide binding of PSD-95 PDZ3 was found to result from the binding of a chloride to a conserved Arg318 in the carboxylate binding loop and protonation of His372 in a2, respectively [23] .", [["PSD-95 PDZ3", "CHEMICAL", 68, 79], ["chloride", "CHEMICAL", 122, 130], ["carboxylate", "CHEMICAL", 160, 171], ["chloride", "CHEMICAL", 122, 130], ["Arg318", "CHEMICAL", 146, 152], ["carboxylate", "CHEMICAL", 160, 171], ["His372", "CHEMICAL", 204, 210], ["salt", "SIMPLE_CHEMICAL", 19, 23], ["PSD-95 PDZ3", "SIMPLE_CHEMICAL", 68, 79], ["chloride", "SIMPLE_CHEMICAL", 122, 130], ["Arg318", "GENE_OR_GENE_PRODUCT", 146, 152], ["His372", "AMINO_ACID", 204, 210], ["PSD", "PROTEIN", 68, 71], ["PDZ3", "PROTEIN", 75, 79], ["carboxylate binding loop", "PROTEIN", 160, 184], ["His372", "PROTEIN", 204, 210], ["a2", "PROTEIN", 214, 216], ["the salt and pH dependence", "PROBLEM", 15, 41], ["PSD", "TEST", 68, 71], ["a chloride", "PROBLEM", 120, 130], ["the carboxylate binding loop", "TREATMENT", 156, 184]]], ["As the His in a2 is the hallmark for class-1 interacting PDZ domains, it is plausible that pH change may have similar effects on other PDZ domains of the same class.Changes of buffer conditionsPDZ function may further br regulated by changes in redox-potential, with INAD PDZ5 being the best-characterized example [71, 92, 93] .", [["His", "CHEMICAL", 7, 10], ["a2", "GENE_OR_GENE_PRODUCT", 14, 16], ["class-1", "GENE_OR_GENE_PRODUCT", 37, 44], ["PDZ", "GENE_OR_GENE_PRODUCT", 57, 60], ["PDZ", "GENE_OR_GENE_PRODUCT", 193, 196], ["INAD PDZ5", "GENE_OR_GENE_PRODUCT", 267, 276], ["a2", "PROTEIN", 14, 16], ["class-1 interacting PDZ domains", "PROTEIN", 37, 68], ["PDZ domains", "PROTEIN", 135, 146], ["PDZ", "PROTEIN", 193, 196], ["pH change", "PROBLEM", 91, 100], ["buffer conditionsPDZ function", "TREATMENT", 176, 205]]], ["The peptide binding of INAD PDZ5 is controlled by a light-dependent redox-regulated transient change from an open reduced form to an oxidized closed conformation.", [["INAD PDZ5", "GENE_OR_GENE_PRODUCT", 23, 32], ["INAD PDZ5", "PROTEIN", 23, 32], ["The peptide binding of INAD PDZ5", "PROBLEM", 0, 32], ["a light-dependent redox", "TREATMENT", 50, 73], ["transient change", "PROBLEM", 84, 100], ["peptide binding", "OBSERVATION", 4, 19], ["transient", "OBSERVATION_MODIFIER", 84, 93], ["change", "OBSERVATION_MODIFIER", 94, 100], ["oxidized", "OBSERVATION_MODIFIER", 133, 141], ["closed", "OBSERVATION", 142, 148]]], ["In the closed conformation, the peptide-binding pocket is distorted through an intra-molecular disulfide bond formed between Cys606 in b3 and Cys645 in a2, which confers a 20-fold decrease in its affinity for a target peptide [71, 92, 93] .", [["Cys606", "CHEMICAL", 125, 131], ["Cys645", "CHEMICAL", 142, 148], ["disulfide", "CHEMICAL", 95, 104], ["Cys", "CHEMICAL", 125, 128], ["Cys", "CHEMICAL", 142, 145], ["Cys606", "AMINO_ACID", 125, 131], ["b3", "AMINO_ACID", 135, 137], ["Cys645", "AMINO_ACID", 142, 148], ["the peptide-binding pocket", "PROBLEM", 28, 54], ["Cys", "TEST", 125, 128], ["Cys", "TEST", 142, 145], ["a 20-fold decrease in its affinity", "PROBLEM", 170, 204], ["a target peptide", "TEST", 209, 225], ["binding pocket", "OBSERVATION", 40, 54], ["intra-molecular", "OBSERVATION", 79, 94], ["disulfide bond", "OBSERVATION", 95, 109], ["20-fold", "OBSERVATION_MODIFIER", 172, 179], ["decrease", "OBSERVATION_MODIFIER", 180, 188]]], ["INAD PDZ5 is locked in the reduced state by its C-terminal extension being tucked into a groove at the rear of PDZ4.", [["PDZ5", "CHEMICAL", 5, 9], ["C", "CHEMICAL", 48, 49], ["PDZ5", "GENE_OR_GENE_PRODUCT", 5, 9], ["PDZ4", "GENE_OR_GENE_PRODUCT", 111, 115], ["INAD PDZ5", "PROTEIN", 0, 9], ["PDZ4", "PROTEIN", 111, 115], ["INAD PDZ5", "TREATMENT", 0, 9], ["its C-terminal extension", "PROBLEM", 44, 68], ["locked", "OBSERVATION_MODIFIER", 13, 19], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["terminal", "OBSERVATION_MODIFIER", 50, 58], ["extension", "OBSERVATION_MODIFIER", 59, 68], ["groove", "OBSERVATION_MODIFIER", 89, 95], ["rear", "OBSERVATION_MODIFIER", 103, 107]]], ["At lower pH, a His547 in the C-terminal extension is protonated, which uncouples the PDZ4-PDZ5 supramodule and results in a dramatic decrease in redox potential.", [["His547", "CHEMICAL", 15, 21], ["His547", "CHEMICAL", 15, 21], ["C", "CHEMICAL", 29, 30], ["His547", "SIMPLE_CHEMICAL", 15, 21], ["PDZ4", "GENE_OR_GENE_PRODUCT", 85, 89], ["PDZ4", "PROTEIN", 85, 89], ["PDZ5 supramodule", "PROTEIN", 90, 106], ["a dramatic decrease in redox potential", "PROBLEM", 122, 160], ["terminal", "ANATOMY_MODIFIER", 31, 39], ["protonated", "OBSERVATION", 53, 63], ["dramatic", "OBSERVATION_MODIFIER", 124, 132], ["decrease", "OBSERVATION_MODIFIER", 133, 141], ["redox potential", "OBSERVATION", 145, 160]]], ["INAD assembles a signaling complex essential for signaling in Drosophila photoreceptor cells, and acts as a dynamic regulator of cell signaling through the cycles of conformational changes INAD.Changes of buffer conditionsPICK1 PDZ was suggested to be redox-regulated by the formation of a reversible intermolecular disulfide bond engaging Cys44 in the b2-b3 loop under mildly oxidative conditions [94] .", [["photoreceptor cells", "ANATOMY", 73, 92], ["cell", "ANATOMY", 129, 133], ["Cys44", "CHEMICAL", 340, 345], ["disulfide", "CHEMICAL", 316, 325], ["Cys44", "CHEMICAL", 340, 345], ["INAD", "GENE_OR_GENE_PRODUCT", 0, 4], ["Drosophila photoreceptor cells", "CELL", 62, 92], ["cell", "CELL", 129, 133], ["PICK1", "GENE_OR_GENE_PRODUCT", 222, 227], ["PDZ", "GENE_OR_GENE_PRODUCT", 228, 231], ["Cys44", "SIMPLE_CHEMICAL", 340, 345], ["b2-b3", "GENE_OR_GENE_PRODUCT", 353, 358], ["INAD", "PROTEIN", 0, 4], ["signaling complex", "PROTEIN", 17, 34], ["Drosophila photoreceptor cells", "CELL_TYPE", 62, 92], ["INAD", "PROTEIN", 189, 193], ["PICK1", "PROTEIN", 222, 227], ["PDZ", "PROTEIN", 228, 231], ["b2", "PROTEIN", 353, 355], ["b3 loop", "PROTEIN", 356, 363], ["Drosophila", "SPECIES", 62, 72], ["Drosophila", "SPECIES", 62, 72], ["signaling in Drosophila photoreceptor cells", "PROBLEM", 49, 92], ["conformational changes INAD", "PROBLEM", 166, 193], ["buffer conditions", "TREATMENT", 205, 222], ["PICK1 PDZ", "TREATMENT", 222, 231], ["a reversible intermolecular disulfide bond engaging", "TREATMENT", 288, 339], ["mildly oxidative conditions", "PROBLEM", 370, 397], ["Drosophila photoreceptor cells", "OBSERVATION", 62, 92], ["cell", "OBSERVATION", 129, 133], ["buffer conditions", "OBSERVATION", 205, 222], ["b2", "ANATOMY", 353, 355], ["b3 loop", "OBSERVATION", 356, 363], ["mildly", "OBSERVATION_MODIFIER", 370, 376], ["oxidative conditions", "OBSERVATION", 377, 397]]], ["The redox-regulated dimer formation abolishes the lipid membrane binding and also affects the peptide binding, and the authors suggested that this might be of importance for the regulation of PICK1 mediated trafficking processes.", [["lipid membrane", "ANATOMY", 50, 64], ["lipid membrane", "CELLULAR_COMPONENT", 50, 64], ["PICK1", "GENE_OR_GENE_PRODUCT", 192, 197], ["PICK1", "PROTEIN", 192, 197], ["the lipid membrane binding", "PROBLEM", 46, 72], ["PICK1 mediated trafficking processes", "TREATMENT", 192, 228], ["regulated dimer formation", "OBSERVATION", 10, 35], ["lipid membrane binding", "OBSERVATION", 50, 72]]], ["However, it is not clear if PICK1 PDZ is actually redox-regulated in a cellular context.Allosteric changesPDZ domains often have dynamic properties that can be used for allosteric regulation.", [["cellular", "ANATOMY", 71, 79], ["PICK1", "GENE_OR_GENE_PRODUCT", 28, 33], ["PDZ", "GENE_OR_GENE_PRODUCT", 34, 37], ["cellular", "CELL", 71, 79], ["PICK1", "PROTEIN", 28, 33], ["PDZ", "PROTEIN", 34, 37], ["Allosteric changesPDZ domains", "PROTEIN", 88, 117], ["PICK1 PDZ", "PROBLEM", 28, 37], ["Allosteric changesPDZ domains", "TREATMENT", 88, 117], ["allosteric regulation", "TREATMENT", 169, 190]]], ["Indeed, PDZ domains have been popular model systems for the study of single-domain allostery as reviewed by Smock and Gierasch [25] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 8, 11], ["PDZ domains", "PROTEIN", 8, 19], ["the study", "TEST", 56, 65]]], ["Early work by Ranganathan and co-workers identified a network of co-evolving residues stretching from the a1, through the peptide binding site to the a2, and the authors suggested this co-evolving set of residues to be involved in allosteric communication [95] .", [["a1", "PROTEIN", 106, 108], ["a2", "PROTEIN", 150, 152], ["co-evolving residues stretching", "PROBLEM", 65, 96]]], ["Several experimental and computational studies have since then suggested similar networks of connected residues [95] [96] [97] [98] .", [["computational studies", "TEST", 25, 46]]], ["A recent study by Reynolds et al. demonstrated the ease by which such networks can be used to evolve allosteric switches [97] .", [["A recent study", "TEST", 0, 14]]], ["In this study, all surface exposed residues in PSD-95 PDZ3 were probed by saturation mutagenesis.", [["surface", "ANATOMY", 19, 26], ["PSD-95 PDZ3", "SIMPLE_CHEMICAL", 47, 58], ["PSD", "PROTEIN", 47, 50], ["this study", "TEST", 3, 13], ["PSD", "TEST", 47, 50], ["residues", "OBSERVATION_MODIFIER", 35, 43]]], ["Eleven probed surface positions with no obvious spatial relationship to the binding site or to each other affected the peptide binding.", [["surface", "ANATOMY", 14, 21], ["binding site", "DNA", 76, 88], ["the binding site", "PROBLEM", 72, 88], ["surface", "OBSERVATION_MODIFIER", 14, 21], ["no obvious", "UNCERTAINTY", 37, 47]]], ["Ten of the eleven residues make part of networks of connected co-evolving amino acids as suggested by statistical coupling analysis, and the authors proposed that these residues can be used as hot spots for the rapid evolution of allosteric control [97] .Allosteric changesAllosteric regulation of PDZ function has also been suggested for human PTP-BAS/murine PTP-BL PDZ2.", [["amino acids", "CHEMICAL", 74, 85], ["amino acids", "CHEMICAL", 74, 85], ["amino acids", "AMINO_ACID", 74, 85], ["PDZ", "GENE_OR_GENE_PRODUCT", 298, 301], ["human", "ORGANISM", 339, 344], ["PTP-BAS", "GENE_OR_GENE_PRODUCT", 345, 352], ["murine", "ORGANISM", 353, 359], ["PTP-BL PDZ2", "GENE_OR_GENE_PRODUCT", 360, 371], ["PDZ", "PROTEIN", 298, 301], ["human PTP", "PROTEIN", 339, 348], ["BAS", "PROTEIN", 349, 352], ["murine PTP-BL PDZ2", "PROTEIN", 353, 371], ["human", "SPECIES", 339, 344], ["murine", "SPECIES", 353, 359], ["human", "SPECIES", 339, 344], ["the eleven residues", "TREATMENT", 7, 26], ["connected co-evolving amino acids", "TREATMENT", 52, 85], ["statistical coupling analysis", "TEST", 102, 131], ["these residues", "PROBLEM", 163, 177], ["hot spots", "PROBLEM", 193, 202], ["allosteric control", "TREATMENT", 230, 248], ["Allosteric changes", "PROBLEM", 255, 273], ["PDZ function", "TEST", 298, 310], ["human PTP", "TEST", 339, 348], ["BAS/murine PTP", "TEST", 349, 363], ["BL PDZ2", "TREATMENT", 364, 371]]], ["Different studies have indicated the presence of two contiguous interaction pathways in the molecule [57, 59, 95, 99] and the affinity and specificity of the protein was found to be allosterically regulated by the binding of PTP-BL PDZ1 to a surface on PDZ2 opposite to the PDZ2 peptide binding groove [98] .", [["surface", "ANATOMY", 242, 249], ["PTP-BL PDZ1", "GENE_OR_GENE_PRODUCT", 225, 236], ["surface", "CELLULAR_COMPONENT", 242, 249], ["PDZ2", "SIMPLE_CHEMICAL", 253, 257], ["PTP", "PROTEIN", 225, 228], ["BL PDZ1", "PROTEIN", 229, 236], ["PDZ2", "PROTEIN", 253, 257], ["PDZ2", "PROTEIN", 274, 278], ["Different studies", "TEST", 0, 17], ["the affinity", "TEST", 122, 134], ["the protein", "TEST", 154, 165], ["PTP", "TEST", 225, 228], ["BL PDZ1", "TREATMENT", 229, 236], ["PDZ2", "TREATMENT", 253, 257], ["groove", "OBSERVATION_MODIFIER", 295, 301]]], ["The PTP-BL PDZ1-PDZ2 interaction confers a shift of the promiscuous PDZ2 peptide binding specificity towards a more stringent recognition of class 1 peptides [98] .", [["PTP-BL", "GENE_OR_GENE_PRODUCT", 4, 10], ["PDZ2", "GENE_OR_GENE_PRODUCT", 16, 20], ["PDZ2", "GENE_OR_GENE_PRODUCT", 68, 72], ["PTP", "PROTEIN", 4, 7], ["PDZ1", "PROTEIN", 11, 15], ["PDZ2", "PROTEIN", 16, 20], ["PDZ2", "PROTEIN", 68, 72], ["The PTP", "TEST", 0, 7]]], ["Another example of allosteric regulation is given by the PDZ domain of Par6 that was found to be allosterically regulated by the binding of the small GTPase Cdc42 to a CRIB domain adjacent to the PDZ domain [69, 96] .", [["Par6", "GENE_OR_GENE_PRODUCT", 71, 75], ["Cdc42", "GENE_OR_GENE_PRODUCT", 157, 162], ["PDZ domain", "PROTEIN", 57, 67], ["Par6", "PROTEIN", 71, 75], ["small GTPase", "PROTEIN", 144, 156], ["Cdc42", "PROTEIN", 157, 162], ["CRIB domain", "PROTEIN", 168, 179], ["PDZ domain", "PROTEIN", 196, 206], ["allosteric regulation", "TREATMENT", 19, 40], ["the small GTPase Cdc42", "PROBLEM", 140, 162], ["the PDZ domain", "TEST", 192, 206], ["allosteric regulation", "OBSERVATION", 19, 40], ["small", "OBSERVATION_MODIFIER", 144, 149], ["GTPase Cdc42", "OBSERVATION", 150, 162]]], ["The Cdc42-CRIB interaction evokes an allosteric transition of the Par6 PDZ domain from a low-affinity dynamic state to a more rigid high-affinity state, with the changes of the dynamics particularly affecting the b1-b2 loop.", [["Cdc42", "GENE_OR_GENE_PRODUCT", 4, 9], ["CRIB", "GENE_OR_GENE_PRODUCT", 10, 14], ["Par6", "GENE_OR_GENE_PRODUCT", 66, 70], ["b1-b2", "GENE_OR_GENE_PRODUCT", 213, 218], ["Cdc42", "PROTEIN", 4, 9], ["CRIB", "PROTEIN", 10, 14], ["Par6 PDZ domain", "PROTEIN", 66, 81], ["b1", "PROTEIN", 213, 215], ["b2 loop", "PROTEIN", 216, 223], ["The Cdc42", "TEST", 0, 9], ["the Par6 PDZ domain", "PROBLEM", 62, 81], ["a low-affinity dynamic state", "PROBLEM", 87, 115], ["a more rigid high-affinity state", "PROBLEM", 119, 151], ["allosteric transition", "OBSERVATION", 37, 58], ["low-affinity", "OBSERVATION_MODIFIER", 89, 101], ["more rigid", "OBSERVATION_MODIFIER", 121, 131], ["b2 loop", "OBSERVATION", 216, 223]]], ["The details of the allosteric transition were further elucidated in a recent study by Whitney et al., outlining that the conformational switch transposes two adjacent side chains of the conserved carboxylate binding loop [100] .", [["carboxylate", "CHEMICAL", 196, 207], ["carboxylate", "CHEMICAL", 196, 207], ["the allosteric transition", "PROBLEM", 15, 40], ["a recent study", "TEST", 68, 82], ["the conformational switch transposes two adjacent side chains", "TREATMENT", 117, 178], ["the conserved carboxylate binding loop", "TREATMENT", 182, 220]]], ["A curiosity in the context is that the interaction between Par6 PDZ and the internal peptide ligand of PALS1 is decoupled from Cdc42 regulation, which might be explained by this interaction deforming the carboxylate binding loop [101] .Allosteric changesFinally, allosteric regulation is not limited to the canonical PDZ domains.", [["carboxylate", "CHEMICAL", 204, 215], ["carboxylate", "CHEMICAL", 204, 215], ["Par6 PDZ", "GENE_OR_GENE_PRODUCT", 59, 67], ["PALS1", "GENE_OR_GENE_PRODUCT", 103, 108], ["Cdc42", "GENE_OR_GENE_PRODUCT", 127, 132], ["PDZ", "GENE_OR_GENE_PRODUCT", 317, 320], ["Par6 PDZ", "PROTEIN", 59, 67], ["PALS1", "PROTEIN", 103, 108], ["Cdc42", "PROTEIN", 127, 132], ["canonical PDZ domains", "PROTEIN", 307, 328], ["Par6 PDZ", "TREATMENT", 59, 67], ["Cdc42 regulation", "TEST", 127, 143], ["this interaction deforming the carboxylate binding loop", "PROBLEM", 173, 228], ["Allosteric changes", "PROBLEM", 236, 254], ["PDZ", "OBSERVATION", 317, 320]]], ["The binding of specific peptides to PDZ1 of the heatshock factor DegP causes a local rearrangement that is allosterically transmitted to the substrate-binding pocket of the protease domain [102, 103] .", [["DegP", "CHEMICAL", 65, 69], ["PDZ1", "GENE_OR_GENE_PRODUCT", 36, 40], ["DegP", "GENE_OR_GENE_PRODUCT", 65, 69], ["PDZ1", "PROTEIN", 36, 40], ["heatshock factor", "PROTEIN", 48, 64], ["DegP", "PROTEIN", 65, 69], ["substrate-binding pocket", "PROTEIN", 141, 165], ["protease domain", "PROTEIN", 173, 188], ["the heatshock factor DegP", "PROBLEM", 44, 69], ["a local rearrangement", "PROBLEM", 77, 98], ["local rearrangement", "OBSERVATION", 79, 98]]], ["Allosteric regulation thus plays an important role in the dynamic regulation of function of several PDZ proteins.AutoinhibitionDifferent studies have reported on autoinhibition of PDZ proteins with structural evidences being available for X11 a, tamalin and NHERF1 [45, [104] [105] [106] [107] [108] .", [["tamalin", "CHEMICAL", 246, 253], ["tamalin", "CHEMICAL", 246, 253], ["PDZ", "GENE_OR_GENE_PRODUCT", 100, 103], ["PDZ", "GENE_OR_GENE_PRODUCT", 180, 183], ["X11", "SIMPLE_CHEMICAL", 239, 242], ["tamalin", "SIMPLE_CHEMICAL", 246, 253], ["NHERF1", "GENE_OR_GENE_PRODUCT", 258, 264], ["PDZ proteins", "PROTEIN", 100, 112], ["PDZ proteins", "PROTEIN", 180, 192], ["X11", "PROTEIN", 239, 242], ["NHERF1", "PROTEIN", 258, 264], ["Allosteric regulation", "TREATMENT", 0, 21], ["several PDZ proteins", "PROBLEM", 92, 112], ["AutoinhibitionDifferent studies", "TEST", 113, 144], ["PDZ proteins", "PROBLEM", 180, 192], ["NHERF1", "TEST", 258, 264]]], ["In these cases, the C-terminal regions folds back and interact with the PDZ domains.", [["C", "CHEMICAL", 20, 21], ["C-terminal regions", "DNA", 20, 38], ["PDZ domains", "PROTEIN", 72, 83], ["the C-terminal regions folds back", "PROBLEM", 16, 49], ["the PDZ domains", "PROBLEM", 68, 83], ["terminal", "ANATOMY_MODIFIER", 22, 30], ["regions", "ANATOMY_MODIFIER", 31, 38]]], ["The NMR structure of the PDZ tandem of X11a in complex with the C-terminal tail of X11a provided the first structure of an autoinhibitory PDZ interaction.", [["C", "CHEMICAL", 64, 65], ["PDZ", "GENE_OR_GENE_PRODUCT", 25, 28], ["X11a", "GENE_OR_GENE_PRODUCT", 39, 43], ["X11a", "GENE_OR_GENE_PRODUCT", 83, 87], ["PDZ", "GENE_OR_GENE_PRODUCT", 138, 141], ["PDZ", "PROTEIN", 25, 28], ["X11a", "PROTEIN", 39, 43], ["C-terminal tail", "PROTEIN", 64, 79], ["X11a", "PROTEIN", 83, 87], ["PDZ", "PROTEIN", 138, 141], ["an autoinhibitory PDZ interaction", "PROBLEM", 120, 153], ["terminal tail", "ANATOMY", 66, 79], ["autoinhibitory PDZ", "OBSERVATION", 123, 141]]], ["The intramolecular interaction was supported by analytical gel filtration and was suggested to be regulated by phosphorylation [106] .", [["analytical gel filtration", "TREATMENT", 48, 73], ["intramolecular interaction", "OBSERVATION", 4, 30]]], ["The structure of the PDZ domain of tamalin bound to the tamalin C-terminal peptide showed that the peptide can be bound by canonical b-addition or in a non-canonical perpendicular fashion [45] .", [["tamalin", "CHEMICAL", 35, 42], ["tamalin", "CHEMICAL", 35, 42], ["tamalin", "CHEMICAL", 56, 63], ["C", "CHEMICAL", 64, 65], ["tamalin", "GENE_OR_GENE_PRODUCT", 35, 42], ["PDZ domain", "PROTEIN", 21, 31], ["tamalin", "PROTEIN", 35, 42], ["tamalin C", "PROTEIN", 56, 65], ["tamalin bound", "PROBLEM", 35, 48], ["the tamalin C-terminal peptide", "TEST", 52, 82], ["the peptide", "TREATMENT", 95, 106]]], ["The self-interaction is of low affinity (630 lM K D ) andAutoinhibitioncan be competed by C-terminal peptides of metabotropic glutamate receptors that interact with tamalin PDZ with higher affinities (ca.", [["K", "CHEMICAL", 48, 49], ["glutamate", "CHEMICAL", 126, 135], ["C", "CHEMICAL", 90, 91], ["glutamate", "CHEMICAL", 126, 135], ["glutamate receptors", "GENE_OR_GENE_PRODUCT", 126, 145], ["tamalin PDZ", "GENE_OR_GENE_PRODUCT", 165, 176], ["metabotropic glutamate receptors", "PROTEIN", 113, 145], ["tamalin PDZ", "PROTEIN", 165, 176], ["low affinity", "PROBLEM", 27, 39], ["metabotropic glutamate receptors", "TREATMENT", 113, 145], ["tamalin PDZ", "TREATMENT", 165, 176], ["higher affinities (ca", "PROBLEM", 182, 203]]], ["100 lM K D ).", [["lM K D", "CELL_LINE", 4, 10]]], ["Finally, the NMR structures of NHERF1 PDZ2 in complex with the NHERF1 C-terminal ezrin-binding domain revealed that the ligand takes a helical conformation that is accommodated in the PDZ2 binding pocket and stabilizes the native fold [104, 105, 107] .", [["C", "CHEMICAL", 70, 71], ["NHERF1", "GENE_OR_GENE_PRODUCT", 31, 37], ["PDZ2", "GENE_OR_GENE_PRODUCT", 38, 42], ["NHERF1", "GENE_OR_GENE_PRODUCT", 63, 69], ["ezrin", "GENE_OR_GENE_PRODUCT", 81, 86], ["NHERF1", "PROTEIN", 31, 37], ["PDZ2", "PROTEIN", 38, 42], ["NHERF1 C-terminal ezrin-binding domain", "PROTEIN", 63, 101], ["PDZ2 binding pocket", "PROTEIN", 184, 203], ["NHERF1 PDZ2", "PROBLEM", 31, 42], ["the NHERF1 C", "TEST", 59, 71], ["NHERF1 PDZ2", "OBSERVATION", 31, 42]]], ["The self-interaction can be overcome by competition with a cognate peptide ligand binding to the PDZ domain and/or ezrin interacting with the ezrin-binding domain, and can further be regulated by phosphorylation of the C-terminal domain.AutoinhibitionPDZ domains may thus be negatively regulated by intramolecular interactions with their C-terminal tails [45, [104] [105] [106] [107] [108] , but there are also studies suggesting regulatory effects exerted by Nterminal stretches.", [["C", "CHEMICAL", 219, 220], ["C", "CHEMICAL", 338, 339], ["ezrin", "GENE_OR_GENE_PRODUCT", 115, 120], ["ezrin", "GENE_OR_GENE_PRODUCT", 142, 147], ["PDZ domain", "PROTEIN", 97, 107], ["ezrin", "PROTEIN", 115, 120], ["ezrin", "PROTEIN", 142, 147], ["binding domain", "PROTEIN", 148, 162], ["C-terminal domain", "PROTEIN", 219, 236], ["AutoinhibitionPDZ domains", "PROTEIN", 237, 262], ["C-terminal tails", "PROTEIN", 338, 354], ["a cognate peptide ligand binding", "TREATMENT", 57, 89], ["the PDZ domain", "PROBLEM", 93, 107], ["ezrin", "PROBLEM", 115, 120], ["AutoinhibitionPDZ domains", "PROBLEM", 237, 262], ["their C-terminal tails", "TEST", 332, 354], ["regulatory effects", "PROBLEM", 430, 448], ["regulatory effects", "OBSERVATION", 430, 448], ["Nterminal stretches", "OBSERVATION", 460, 479]]], ["For example, the PDZ domains of syntenin-1 appear to be negatively regulated by the N-terminal domain, although the exact molecular details are not known [109, 110] .PhosphoregulationA commonly reported regulatory mechanism of PDZ interactions is phosphorylation of Ser/Thr/Tyr residues in PDZ-binding motives.", [["N", "CHEMICAL", 84, 85], ["Ser", "CHEMICAL", 266, 269], ["Thr", "CHEMICAL", 270, 273], ["Tyr", "CHEMICAL", 274, 277], ["syntenin-1", "GENE_OR_GENE_PRODUCT", 32, 42], ["PDZ", "GENE_OR_GENE_PRODUCT", 227, 230], ["Ser/", "AMINO_ACID", 266, 270], ["Thr/", "AMINO_ACID", 270, 274], ["Tyr residues", "AMINO_ACID", 274, 286], ["PDZ", "GENE_OR_GENE_PRODUCT", 290, 293], ["PDZ domains", "PROTEIN", 17, 28], ["syntenin-1", "PROTEIN", 32, 42], ["N-terminal domain", "PROTEIN", 84, 101], ["PDZ", "PROTEIN", 227, 230], ["PDZ", "PROTEIN", 290, 293], ["the PDZ domains of syntenin", "PROBLEM", 13, 40], ["PhosphoregulationA", "TREATMENT", 166, 184], ["PDZ interactions", "PROBLEM", 227, 243], ["Ser/Thr/Tyr residues", "TREATMENT", 266, 286]]], ["Phosphorylation often occurs at the \u00c02 position of a type 1 binding motif and interferes with PDZ-peptide interactions.", [["PDZ", "GENE_OR_GENE_PRODUCT", 94, 97], ["\u00c02 position", "PROTEIN", 36, 47], ["type 1 binding motif", "PROTEIN", 53, 73], ["PDZ", "PROTEIN", 94, 97], ["Phosphorylation", "TREATMENT", 0, 15], ["a type 1 binding motif", "PROBLEM", 51, 73], ["PDZ-peptide interactions", "TREATMENT", 94, 118]]], ["For example, phosphorylation of Ser411 at the \u00c02 position of the b2-adrenergic receptor by G-protein-coupled-receptor kinase-5 disrupts the interaction with NHERF1 and controls the recycling of the receptor [111] .", [["Ser411", "GENE_OR_GENE_PRODUCT", 32, 38], ["b2-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 65, 87], ["G-protein-coupled-receptor kinase-5", "GENE_OR_GENE_PRODUCT", 91, 126], ["NHERF1", "GENE_OR_GENE_PRODUCT", 157, 163], ["Ser411", "PROTEIN", 32, 38], ["\u00c02 position", "PROTEIN", 46, 57], ["b2-adrenergic receptor", "PROTEIN", 65, 87], ["G-protein-coupled-receptor kinase-5", "PROTEIN", 91, 126], ["NHERF1", "PROTEIN", 157, 163], ["phosphorylation", "TEST", 13, 28], ["NHERF1", "TREATMENT", 157, 163]]], ["Other residues in PDZ-binding motifs may be phosphorylated with similar effects, as shown for syndecan-1 where Tyr \u00c01 phosphorylation confers a loss of interaction with syntenin-1 [112] and connexin-43 for which phosphorylation of Ser \u00c09 or \u00c010 disrupts the interaction with ZO-1 PDZ2 [77, 113, 114] .", [["Tyr", "CHEMICAL", 111, 114], ["Ser", "CHEMICAL", 231, 234], ["PDZ", "GENE_OR_GENE_PRODUCT", 18, 21], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 94, 104], ["Tyr \u00c01", "GENE_OR_GENE_PRODUCT", 111, 117], ["syntenin-1", "GENE_OR_GENE_PRODUCT", 169, 179], ["connexin-43", "GENE_OR_GENE_PRODUCT", 190, 201], ["Ser \u00c09", "AMINO_ACID", 231, 237], ["\u00c010", "AMINO_ACID", 241, 244], ["ZO-1", "GENE_OR_GENE_PRODUCT", 275, 279], ["PDZ", "PROTEIN", 18, 21], ["syndecan-1", "PROTEIN", 94, 104], ["Tyr \u00c01", "PROTEIN", 111, 117], ["syntenin", "PROTEIN", 169, 177], ["connexin-43", "PROTEIN", 190, 201], ["Ser \u00c09 or \u00c010", "PROTEIN", 231, 244], ["ZO", "PROTEIN", 275, 277], ["Other residues in PDZ", "PROBLEM", 0, 21], ["binding motifs", "PROBLEM", 22, 36], ["phosphorylated", "PROBLEM", 44, 58], ["syntenin", "TEST", 169, 177], ["connexin", "TEST", 190, 198]]], ["However, there are also reports on enhanced binding upon phosphorylation of PDZ-binding motifs, or in the proximity of such motifs, and some PDZ domains thus interact with phosphopeptides.", [["PDZ", "GENE_OR_GENE_PRODUCT", 76, 79], ["PDZ", "GENE_OR_GENE_PRODUCT", 141, 144], ["PDZ", "PROTEIN", 76, 79], ["binding motifs", "PROTEIN", 80, 94], ["PDZ domains", "PROTEIN", 141, 152], ["enhanced binding", "PROBLEM", 35, 51], ["phosphorylation of PDZ", "TREATMENT", 57, 79], ["binding motifs", "PROBLEM", 80, 94], ["some PDZ domains", "PROBLEM", 136, 152], ["phosphopeptides", "TREATMENT", 172, 187]]], ["For example, phosphorylation significantly increases the interaction between the PDZ domain of LIM domain-binding protein 3 and C-terminal peptides derived from the calsarcin/myozenin and myotilin family [115] and phosphorylation of ephrinB ligands at Ser \u00c09 triggers binding to GRIP [116] .PhosphoregulationInterestingly, phosphorylation of PDZ binding motifs may have a switch-like function on PDZ function, simultaneously turning ''on'' the interaction with one domain while switching of the interaction with other domains.", [["C", "CHEMICAL", 128, 129], ["Ser", "CHEMICAL", 252, 255], ["LIM domain-binding protein 3", "GENE_OR_GENE_PRODUCT", 95, 123], ["calsarcin", "GENE_OR_GENE_PRODUCT", 165, 174], ["myozenin", "GENE_OR_GENE_PRODUCT", 175, 183], ["myotilin", "GENE_OR_GENE_PRODUCT", 188, 196], ["ephrinB", "GENE_OR_GENE_PRODUCT", 233, 240], ["Ser \u00c09", "AMINO_ACID", 252, 258], ["PDZ", "GENE_OR_GENE_PRODUCT", 342, 345], ["PDZ", "GENE_OR_GENE_PRODUCT", 396, 399], ["PDZ domain", "PROTEIN", 81, 91], ["LIM domain-binding protein 3", "PROTEIN", 95, 123], ["calsarcin", "PROTEIN", 165, 174], ["myozenin", "PROTEIN", 175, 183], ["myotilin family", "PROTEIN", 188, 203], ["ephrinB ligands", "PROTEIN", 233, 248], ["Ser \u00c09", "PROTEIN", 252, 258], ["PDZ binding motifs", "PROTEIN", 342, 360], ["PDZ", "PROTEIN", 396, 399], ["phosphorylation", "PROBLEM", 13, 28], ["LIM domain", "TEST", 95, 105], ["binding protein", "TEST", 106, 121], ["C-terminal peptides", "TREATMENT", 128, 147], ["the calsarcin/myozenin", "TREATMENT", 161, 183], ["myotilin family", "TREATMENT", 188, 203], ["phosphorylation of ephrinB ligands", "TREATMENT", 214, 248], ["Phosphoregulation", "TREATMENT", 291, 308], ["phosphorylation of PDZ binding motifs", "TREATMENT", 323, 360]]], ["In the case of X11 a, such a behavior is manifested in a single protein, as a Tyr \u00c01 phosphorylation of its C-terminus confers a switch from the autoinhibited closed conformation where the C-terminal interacts with the PDZ1 to an open conformation where the C-terminal is recognized by the PDZ2 [106] .", [["Tyr", "CHEMICAL", 78, 81], ["C", "CHEMICAL", 108, 109], ["C", "CHEMICAL", 189, 190], ["C", "CHEMICAL", 258, 259], ["PDZ1", "GENE_OR_GENE_PRODUCT", 219, 223], ["Tyr \u00c01", "PROTEIN", 78, 84], ["C-terminus", "PROTEIN", 108, 118], ["C-terminal", "PROTEIN", 189, 199], ["PDZ1", "PROTEIN", 219, 223], ["C-terminal", "PROTEIN", 258, 268], ["the PDZ1", "TREATMENT", 215, 223]]], ["The prevalence of phosphorylation switches was highlighted in a recent study by Akiva et al. [26] .", [["phosphorylation switches", "TREATMENT", 18, 42], ["a recent study", "TEST", 62, 76], ["phosphorylation switches", "OBSERVATION", 18, 42]]], ["They scanned the available proteomic data of PDZ-interactions in mouse [20] for cases where single phosphomimetic amino acid substitutions (Ser/Thr/Tyr to Asp/Glu) conferred inverse affinities for two PDZ domains.", [["amino acid", "CHEMICAL", 114, 124], ["Glu", "CHEMICAL", 159, 162], ["amino acid", "CHEMICAL", 114, 124], ["Ser", "CHEMICAL", 140, 143], ["Thr", "CHEMICAL", 144, 147], ["Tyr", "CHEMICAL", 148, 151], ["Asp", "CHEMICAL", 155, 158], ["Glu", "CHEMICAL", 159, 162], ["PDZ", "GENE_OR_GENE_PRODUCT", 45, 48], ["mouse", "ORGANISM", 65, 70], ["amino acid", "AMINO_ACID", 114, 124], ["Ser", "AMINO_ACID", 140, 143], ["Thr/Tyr", "AMINO_ACID", 144, 151], ["Asp/", "AMINO_ACID", 155, 159], ["Glu", "AMINO_ACID", 159, 162], ["PDZ", "PROTEIN", 45, 48], ["PDZ domains", "PROTEIN", 201, 212], ["mouse", "SPECIES", 65, 70], ["mouse", "SPECIES", 65, 70], ["single phosphomimetic amino acid substitutions", "TREATMENT", 92, 138], ["Ser/Thr", "TREATMENT", 140, 147], ["Asp/Glu)", "TEST", 155, 163], ["inverse affinities", "PROBLEM", 174, 192], ["two PDZ domains", "PROBLEM", 197, 212]]], ["The study identified 81 potential phosphorylation switches, which suggests this to be a common regulatory mechanism [26] .", [["The study", "TEST", 0, 9], ["potential phosphorylation switches", "TREATMENT", 24, 58], ["phosphorylation switches", "OBSERVATION", 34, 58]]], ["Indeed, it was early on observed that phosphorylation of PDZ binding motifs may have differential effects on PDZ interactions, as exemplified by the report on phosphorylation of the C-terminus of B class ephrins that was shown to confer loss of interaction with syntenin-1 but have little effect on the interaction with PTP-BAS PDZ5 [117] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 57, 60], ["PDZ", "GENE_OR_GENE_PRODUCT", 109, 112], ["B class ephrins", "GENE_OR_GENE_PRODUCT", 196, 211], ["syntenin-1", "GENE_OR_GENE_PRODUCT", 262, 272], ["PTP", "GENE_OR_GENE_PRODUCT", 320, 323], ["PDZ binding motifs", "PROTEIN", 57, 75], ["PDZ", "PROTEIN", 109, 112], ["C-terminus", "PROTEIN", 182, 192], ["B class ephrins", "PROTEIN", 196, 211], ["syntenin-1", "PROTEIN", 262, 272], ["PTP", "PROTEIN", 320, 323], ["phosphorylation of PDZ binding motifs", "PROBLEM", 38, 75], ["syntenin", "TREATMENT", 262, 270], ["PTP", "TEST", 320, 323]]], ["It should further be noted that also other posttranslational modifications can regulate PDZ interactions.", [["PDZ", "GENE_OR_GENE_PRODUCT", 88, 91], ["PDZ", "PROTEIN", 88, 91]]], ["An interesting case is the interaction between PTEN and DLG2 that was reported to be negatively regulated by phosphorylation, but positively regulated by acetylation [118] .PhosphoregulationPDZ function can also be down-regulated by phosphorylation of PDZ domains.", [["PTEN", "GENE_OR_GENE_PRODUCT", 47, 51], ["DLG2", "GENE_OR_GENE_PRODUCT", 56, 60], ["PhosphoregulationPDZ", "GENE_OR_GENE_PRODUCT", 173, 193], ["PDZ", "GENE_OR_GENE_PRODUCT", 252, 255], ["PTEN", "PROTEIN", 47, 51], ["DLG2", "PROTEIN", 56, 60], ["PhosphoregulationPDZ", "PROTEIN", 173, 193], ["PDZ domains", "PROTEIN", 252, 263], ["PTEN and DLG2", "TEST", 47, 60], ["PhosphoregulationPDZ function", "PROBLEM", 173, 202], ["PDZ domains", "PROBLEM", 252, 263]]], ["For example, the peptide binding of DLG1 PDZ1 is diminished by Ca2+/calmodulin-dependent protein kinase II phosphorylation of a Ser232 adjacent to the carboxylate-binding loop [119] , and phosphorylation of Ser77 in a2 of NHERF1 PDZ1 confers a loss of peptide binding [120] .", [["Ca2+", "CHEMICAL", 63, 67], ["calmodulin", "CHEMICAL", 68, 78], ["PDZ1", "CHEMICAL", 229, 233], ["carboxylate", "CHEMICAL", 151, 162], ["DLG1", "GENE_OR_GENE_PRODUCT", 36, 40], ["PDZ1", "GENE_OR_GENE_PRODUCT", 41, 45], ["Ca2+/calmodulin-dependent protein kinase II", "GENE_OR_GENE_PRODUCT", 63, 106], ["Ser232", "GENE_OR_GENE_PRODUCT", 128, 134], ["Ser77", "AMINO_ACID", 207, 212], ["NHERF1", "GENE_OR_GENE_PRODUCT", 222, 228], ["PDZ1", "AMINO_ACID", 229, 233], ["DLG1 PDZ1", "PROTEIN", 36, 45], ["calmodulin", "PROTEIN", 68, 78], ["protein kinase II", "PROTEIN", 89, 106], ["Ser232", "PROTEIN", 128, 134], ["Ser77", "PROTEIN", 207, 212], ["a2", "PROTEIN", 216, 218], ["NHERF1 PDZ1", "PROTEIN", 222, 233], ["the peptide binding of DLG1 PDZ1", "PROBLEM", 13, 45], ["Ca2+", "TEST", 63, 67], ["calmodulin", "TEST", 68, 78], ["dependent protein kinase II phosphorylation", "PROBLEM", 79, 122], ["the carboxylate-binding loop", "TREATMENT", 147, 175], ["phosphorylation", "TEST", 188, 203], ["NHERF1 PDZ1", "TREATMENT", 222, 233], ["a loss of peptide binding", "PROBLEM", 242, 267], ["diminished", "OBSERVATION_MODIFIER", 49, 59]]], ["In addition, the function of PICK1 PDZ has been proposed to be down-regulated by phosphorylation of either Ser77 or Thr82.", [["PICK1", "GENE_OR_GENE_PRODUCT", 29, 34], ["PDZ", "GENE_OR_GENE_PRODUCT", 35, 38], ["Ser77", "GENE_OR_GENE_PRODUCT", 107, 112], ["Thr82", "GENE_OR_GENE_PRODUCT", 116, 121], ["PICK1", "PROTEIN", 29, 34], ["PDZ", "PROTEIN", 35, 38], ["Ser77", "PROTEIN", 107, 112], ["Thr82", "PROTEIN", 116, 121], ["PICK1 PDZ", "PROBLEM", 29, 38]]], ["The phosphomimetic mutation of Thr82 at the N-terminal end of a2 disrupts the interaction between PICK1 PDZ and GluR2 [121] and phosphorylation of Ser77 in the b5-a2 loop affects the clustering of eYFP-PICK1 in COS7 cells, although no effect was observed on peptide binding [122] .", [["COS7 cells", "ANATOMY", 211, 221], ["N", "CHEMICAL", 44, 45], ["Thr82", "GENE_OR_GENE_PRODUCT", 31, 36], ["a2", "GENE_OR_GENE_PRODUCT", 62, 64], ["PICK1", "GENE_OR_GENE_PRODUCT", 98, 103], ["GluR2 [121]", "GENE_OR_GENE_PRODUCT", 112, 123], ["Ser77", "AMINO_ACID", 147, 152], ["b5-a2", "GENE_OR_GENE_PRODUCT", 160, 165], ["eYFP-PICK1", "GENE_OR_GENE_PRODUCT", 197, 207], ["COS7 cells", "CELL", 211, 221], ["Thr82", "PROTEIN", 31, 36], ["N-terminal end", "PROTEIN", 44, 58], ["a2", "PROTEIN", 62, 64], ["PICK1", "PROTEIN", 98, 103], ["PDZ", "PROTEIN", 104, 107], ["GluR2", "PROTEIN", 112, 117], ["Ser77", "PROTEIN", 147, 152], ["b5-a2 loop", "PROTEIN", 160, 170], ["eYFP", "PROTEIN", 197, 201], ["PICK1", "PROTEIN", 202, 207], ["COS7 cells", "CELL_LINE", 211, 221], ["The phosphomimetic mutation", "TEST", 0, 27], ["PICK1 PDZ", "TEST", 98, 107], ["GluR2", "TEST", 112, 117], ["phosphorylation", "TEST", 128, 143], ["eYFP", "TEST", 197, 201], ["PICK1 in COS7 cells", "PROBLEM", 202, 221], ["phosphomimetic mutation", "OBSERVATION", 4, 27], ["COS7 cells", "OBSERVATION", 211, 221], ["no", "UNCERTAINTY", 232, 234]]], ["Interestingly, Thr82 and Ser77 are in vicinity of the positive charge cluster that has been proposed to be of importance for the interaction between PICK1 PDZ and lipid membranes [84] and it is possible that their phosphorylations influence the lipid binding, although no experimental data are available to clarify this point.PhosphoregulationFinally, PDZ function can also be regulated by phosphorylation outside the canonical domain boarders, as previously discussed for the INAD PDZ4-PDZ5 supramodule [71] .", [["lipid membranes", "ANATOMY", 163, 178], ["Thr82", "GENE_OR_GENE_PRODUCT", 15, 20], ["Ser77", "GENE_OR_GENE_PRODUCT", 25, 30], ["PICK1", "GENE_OR_GENE_PRODUCT", 149, 154], ["PDZ", "GENE_OR_GENE_PRODUCT", 155, 158], ["lipid membranes", "CELLULAR_COMPONENT", 163, 178], ["lipid", "SIMPLE_CHEMICAL", 245, 250], ["PDZ", "GENE_OR_GENE_PRODUCT", 352, 355], ["Thr82", "PROTEIN", 15, 20], ["Ser77", "PROTEIN", 25, 30], ["PICK1", "PROTEIN", 149, 154], ["PDZ", "PROTEIN", 155, 158], ["PDZ", "PROTEIN", 352, 355], ["canonical domain boarders", "PROTEIN", 418, 443], ["PDZ4", "PROTEIN", 482, 486], ["PDZ5", "PROTEIN", 487, 491], ["the positive charge cluster", "PROBLEM", 50, 77], ["PICK1 PDZ and lipid membranes", "TREATMENT", 149, 178], ["their phosphorylations", "PROBLEM", 208, 230], ["the lipid binding", "PROBLEM", 241, 258], ["Phosphoregulation", "TREATMENT", 326, 343], ["positive charge", "OBSERVATION", 54, 69]]], ["The phosphorylation of Tyr397 in the C-terminal non-canonical a3 of PDS-95 PDZ3 provides an interesting example of how the dynamics of PDZ domains can be phosphoregulated.", [["Tyr397", "GENE_OR_GENE_PRODUCT", 23, 29], ["PDS-95 PDZ3", "GENE_OR_GENE_PRODUCT", 68, 79], ["PDZ", "GENE_OR_GENE_PRODUCT", 135, 138], ["Tyr397", "PROTEIN", 23, 29], ["C-terminal non-canonical a3 of PDS-95 PDZ3", "PROTEIN", 37, 79], ["PDZ domains", "PROTEIN", 135, 146], ["The phosphorylation", "TEST", 0, 19], ["PDS", "TEST", 68, 71]]], ["The dynamics of PDZ3 of PSD-95 is dampened by the packing of a3 against the PDZ domain, which enhances its peptide binding affinity by a altering the dynamic properties of the domain [29, 30] .", [["PDZ3", "GENE_OR_GENE_PRODUCT", 16, 20], ["PSD-95", "GENE_OR_GENE_PRODUCT", 24, 30], ["a3", "GENE_OR_GENE_PRODUCT", 61, 63], ["PDZ3", "PROTEIN", 16, 20], ["PSD", "PROTEIN", 24, 27], ["a3", "PROTEIN", 61, 63], ["PDZ domain", "PROTEIN", 76, 86], ["PSD", "TEST", 24, 27], ["the PDZ domain", "PROBLEM", 72, 86], ["dampened", "OBSERVATION_MODIFIER", 34, 42]]], ["Phosphorylation of Tyr397 in a3 initiates a rapid equilibrium of docked and undocked conformations, with the undocked conformation having reduced ligand binding affinity [123] .Alternative splicingPDZ interaction are often regulated by alternative splicing of PDZ proteins or their interacting proteins, as extensively reviewed by Sierralta and Mendoza [124] .", [["Tyr397", "AMINO_ACID", 19, 25], ["a3", "GENE_OR_GENE_PRODUCT", 29, 31], ["splicingPDZ", "GENE_OR_GENE_PRODUCT", 189, 200], ["PDZ", "GENE_OR_GENE_PRODUCT", 260, 263], ["Tyr397", "PROTEIN", 19, 25], ["a3", "PROTEIN", 29, 31], ["splicingPDZ", "PROTEIN", 189, 200], ["PDZ proteins", "PROTEIN", 260, 272], ["interacting proteins", "PROTEIN", 282, 302], ["Phosphorylation", "TEST", 0, 15], ["reduced ligand binding affinity", "PROBLEM", 138, 169], ["Alternative splicingPDZ interaction", "PROBLEM", 177, 212], ["PDZ proteins", "PROBLEM", 260, 272], ["their interacting proteins", "PROBLEM", 276, 302]]], ["Typically, PDZ domains or PDZ binding motifs are deleted from different isoform resulting in variable subcellular localizations and functions [124, 125] .", [["subcellular", "ANATOMY", 102, 113], ["PDZ", "GENE_OR_GENE_PRODUCT", 11, 14], ["PDZ", "GENE_OR_GENE_PRODUCT", 26, 29], ["PDZ domains", "PROTEIN", 11, 22], ["PDZ binding motifs", "PROTEIN", 26, 44], ["PDZ binding motifs", "PROBLEM", 26, 44], ["variable", "OBSERVATION_MODIFIER", 93, 101], ["subcellular localizations", "OBSERVATION", 102, 127]]], ["For example, the protein usherin exists in multiple isoforms in murine inner ear of which one is transmembrane and harbors a PDZbinding motif that interacts with the PDZ protein whirlin [126] .", [["inner ear", "ANATOMY", 71, 80], ["transmembrane", "ANATOMY", 97, 110], ["usherin", "GENE_OR_GENE_PRODUCT", 25, 32], ["murine", "ORGANISM", 64, 70], ["inner ear", "ORGAN", 71, 80], ["transmembrane", "CELLULAR_COMPONENT", 97, 110], ["protein usherin", "PROTEIN", 17, 32], ["PDZbinding motif", "PROTEIN", 125, 141], ["PDZ protein", "PROTEIN", 166, 177], ["murine", "SPECIES", 64, 70], ["the protein usherin", "TREATMENT", 13, 32], ["a PDZbinding motif", "TREATMENT", 123, 141], ["inner", "ANATOMY_MODIFIER", 71, 76], ["ear", "ANATOMY", 77, 80]]], ["Whirlin in turn exist as a long isoform containing three PDZ domains of which the first two interact with usherin and a short isoform that only holds one PDZ domain that does not interact with usherin [127, 128] .Alternative splicingAlternative splicing within PDZ domains is considerably less reported.", [["usherin", "CHEMICAL", 193, 200], ["Whirlin", "GENE_OR_GENE_PRODUCT", 0, 7], ["usherin", "GENE_OR_GENE_PRODUCT", 106, 113], ["PDZ", "GENE_OR_GENE_PRODUCT", 261, 264], ["Whirlin", "PROTEIN", 0, 7], ["PDZ domains", "PROTEIN", 57, 68], ["usherin", "PROTEIN", 106, 113], ["PDZ domain", "PROTEIN", 154, 164], ["PDZ domains", "PROTEIN", 261, 272], ["a long isoform containing three PDZ domains", "TREATMENT", 25, 68], ["usherin", "TREATMENT", 106, 113], ["Alternative splicingAlternative splicing within PDZ domains", "PROBLEM", 213, 272], ["considerably", "OBSERVATION_MODIFIER", 276, 288], ["less", "OBSERVATION_MODIFIER", 289, 293]]], ["However, PTP-BAS PDZ2 exist as two functionally distinct isoforms a and b, with the difference between the two isoform being the insertion of five amino acids in the b2-b3 loop.", [["amino acids", "CHEMICAL", 147, 158], ["amino acids", "CHEMICAL", 147, 158], ["PTP-BAS PDZ2", "GENE_OR_GENE_PRODUCT", 9, 21], ["amino acids", "AMINO_ACID", 147, 158], ["b2-b3", "GENE_OR_GENE_PRODUCT", 166, 171], ["PTP", "PROTEIN", 9, 12], ["BAS PDZ2", "PROTEIN", 13, 21], ["b2", "PROTEIN", 166, 168], ["b3 loop", "PROTEIN", 169, 176], ["PTP", "TEST", 9, 12], ["the insertion of five amino acids", "TREATMENT", 125, 158], ["distinct", "OBSERVATION_MODIFIER", 48, 56], ["isoforms", "OBSERVATION_MODIFIER", 57, 65], ["b2", "ANATOMY", 166, 168], ["b3 loop", "OBSERVATION", 169, 176]]], ["The extended loop region folds back onto b2-b3, which leads to a decreased peptide binding affinity.", [["b2-b3", "GENE_OR_GENE_PRODUCT", 41, 46], ["extended loop region", "PROTEIN", 4, 24], ["b2", "PROTEIN", 41, 43], ["b3", "PROTEIN", 44, 46], ["The extended loop region folds", "PROBLEM", 0, 30], ["b2-b3", "TREATMENT", 41, 46], ["a decreased peptide binding affinity", "PROBLEM", 63, 99], ["loop", "OBSERVATION_MODIFIER", 13, 17], ["b3", "ANATOMY", 44, 46], ["decreased peptide", "OBSERVATION", 65, 82], ["binding affinity", "OBSERVATION", 83, 99]]], ["Interestingly, the extended loop region does not interfere with the modest PIPs binding but confers instead a slight increase in PIPs affinity and the alternative splicing may thus tune the preference for the distinct ligands [91] .Competition and viral hijackingThe competition between distinct PDZ proteins can be used for dynamic regulation of cell signaling.", [["cell", "ANATOMY", 347, 351], ["PIPs", "GENE_OR_GENE_PRODUCT", 75, 79], ["PIPs", "GENE_OR_GENE_PRODUCT", 129, 133], ["PDZ", "GENE_OR_GENE_PRODUCT", 296, 299], ["cell", "CELL", 347, 351], ["PIPs", "PROTEIN", 75, 79], ["PIPs", "PROTEIN", 129, 133], ["PDZ proteins", "PROTEIN", 296, 308], ["the extended loop region", "PROBLEM", 15, 39], ["the modest PIPs binding", "PROBLEM", 64, 87], ["a slight increase in PIPs affinity", "PROBLEM", 108, 142], ["the alternative splicing", "TREATMENT", 147, 171], ["distinct PDZ proteins", "TREATMENT", 287, 308], ["cell signaling", "PROBLEM", 347, 361], ["modest", "OBSERVATION_MODIFIER", 68, 74], ["PIPs", "OBSERVATION", 75, 79], ["slight", "OBSERVATION_MODIFIER", 110, 116], ["increase", "OBSERVATION_MODIFIER", 117, 125], ["PIPs affinity", "OBSERVATION", 129, 142], ["viral hijacking", "OBSERVATION", 248, 263], ["cell signaling", "OBSERVATION", 347, 361]]], ["For example, the small protein TIP-1 that is almost entirely composed of a PDZ domain competes with CASK and other PDZ containing scaffolds with type binding I specificity to negatively regulate their function [129] .", [["TIP-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["CASK", "GENE_OR_GENE_PRODUCT", 100, 104], ["PDZ", "GENE_OR_GENE_PRODUCT", 115, 118], ["type binding I", "GENE_OR_GENE_PRODUCT", 145, 159], ["small protein TIP-1", "PROTEIN", 17, 36], ["PDZ domain", "PROTEIN", 75, 85], ["CASK", "PROTEIN", 100, 104], ["PDZ", "PROTEIN", 115, 118], ["the small protein TIP", "TREATMENT", 13, 34], ["a PDZ domain competes", "PROBLEM", 73, 94], ["other PDZ containing scaffolds", "TREATMENT", 109, 139], ["small", "OBSERVATION_MODIFIER", 17, 22], ["protein TIP", "OBSERVATION", 23, 34], ["PDZ", "OBSERVATION", 75, 78]]], ["The competition between TIP-1 and CASK for the potassium channel Kir2.3 leads to uncoupling of Kir2.3 from its basolateral membraneanchoring complex and confers a shift towards endosomal targeting of the channel.", [["basolateral", "ANATOMY", 111, 122], ["endosomal", "ANATOMY", 177, 186], ["potassium", "CHEMICAL", 47, 56], ["potassium", "CHEMICAL", 47, 56], ["TIP-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["CASK", "GENE_OR_GENE_PRODUCT", 34, 38], ["Kir2.3", "GENE_OR_GENE_PRODUCT", 65, 71], ["Kir2.3", "GENE_OR_GENE_PRODUCT", 95, 101], ["endosomal", "CELLULAR_COMPONENT", 177, 186], ["TIP-1", "PROTEIN", 24, 29], ["CASK", "PROTEIN", 34, 38], ["potassium channel Kir2.3", "PROTEIN", 47, 71], ["Kir2.3", "PROTEIN", 95, 101], ["basolateral membraneanchoring complex", "PROTEIN", 111, 148], ["TIP", "TEST", 24, 27], ["the potassium channel Kir2.3", "TREATMENT", 43, 71], ["Kir2.3", "TREATMENT", 95, 101]]], ["Another case involves the expression and the activity of CFTR in colon cancer cells that is positively regulated by interactions with NHERF1 but negatively regulated by interactions with shank2 [130] .", [["colon cancer cells", "ANATOMY", 65, 83], ["colon cancer", "DISEASE", 65, 77], ["CFTR", "GENE_OR_GENE_PRODUCT", 57, 61], ["colon cancer cells", "CELL", 65, 83], ["NHERF1", "GENE_OR_GENE_PRODUCT", 134, 140], ["shank2 [130]", "GENE_OR_GENE_PRODUCT", 187, 199], ["CFTR", "PROTEIN", 57, 61], ["colon cancer cells", "CELL_TYPE", 65, 83], ["NHERF1", "PROTEIN", 134, 140], ["CFTR in colon cancer cells", "PROBLEM", 57, 83], ["colon", "ANATOMY", 65, 70], ["cancer", "OBSERVATION", 71, 77]]], ["Finally, MAGI-3 competes with NHERF2 for binding to LPA receptor type 2 and phospholipase C-b3, with reciprocal effects such that NHERF2 promotes migration and invasion of colon cancer cells, while MAGI-3 inhibits these processes [131] .Competition and viral hijackingAnother form of competition for PDZ interaction is the viral hijacking of PDZ proteins, a topic that was extensively reviewed recently [132, 133] .", [["colon cancer cells", "ANATOMY", 172, 190], ["colon cancer", "DISEASE", 172, 184], ["LPA", "CHEMICAL", 52, 55], ["MAGI-3", "GENE_OR_GENE_PRODUCT", 9, 15], ["NHERF2", "GENE_OR_GENE_PRODUCT", 30, 36], ["LPA receptor type 2", "GENE_OR_GENE_PRODUCT", 52, 71], ["phospholipase C-b3", "GENE_OR_GENE_PRODUCT", 76, 94], ["NHERF2", "GENE_OR_GENE_PRODUCT", 130, 136], ["colon cancer cells", "CELL", 172, 190], ["MAGI-3", "GENE_OR_GENE_PRODUCT", 198, 204], ["PDZ", "GENE_OR_GENE_PRODUCT", 300, 303], ["PDZ", "GENE_OR_GENE_PRODUCT", 342, 345], ["MAGI-3", "PROTEIN", 9, 15], ["NHERF2", "PROTEIN", 30, 36], ["phospholipase C", "PROTEIN", 76, 91], ["b3", "PROTEIN", 92, 94], ["NHERF2", "PROTEIN", 130, 136], ["colon cancer cells", "CELL_TYPE", 172, 190], ["MAGI-3", "PROTEIN", 198, 204], ["PDZ", "PROTEIN", 300, 303], ["PDZ proteins", "PROTEIN", 342, 354], ["NHERF2", "TREATMENT", 30, 36], ["LPA receptor type", "TEST", 52, 69], ["phospholipase C", "TEST", 76, 91], ["reciprocal effects", "PROBLEM", 101, 119], ["NHERF2 promotes migration", "TREATMENT", 130, 155], ["invasion of colon cancer cells", "PROBLEM", 160, 190], ["MAGI", "TEST", 198, 202], ["PDZ interaction", "PROBLEM", 300, 315], ["PDZ proteins", "PROBLEM", 342, 354], ["migration", "OBSERVATION_MODIFIER", 146, 155], ["colon", "ANATOMY", 172, 177], ["cancer cells", "OBSERVATION", 178, 190]]], ["The PDZ-binding motifs in a cell are often sub-optimized to allow for rapid changes of cell signaling and viral proteins can therefore rewire cell signaling by presenting C-terminal motifs of higher affinities.", [["cell", "ANATOMY", 28, 32], ["cell", "ANATOMY", 87, 91], ["cell", "ANATOMY", 142, 146], ["C", "CHEMICAL", 171, 172], ["PDZ", "GENE_OR_GENE_PRODUCT", 4, 7], ["cell", "CELL", 28, 32], ["cell", "CELL", 87, 91], ["cell", "CELL", 142, 146], ["PDZ-binding motifs", "PROTEIN", 4, 22], ["viral proteins", "PROTEIN", 106, 120], ["C-terminal motifs", "PROTEIN", 171, 188], ["The PDZ-binding motifs", "TREATMENT", 0, 22], ["rapid changes of cell signaling", "PROBLEM", 70, 101], ["viral proteins", "PROBLEM", 106, 120], ["higher affinities", "PROBLEM", 192, 209], ["higher affinities", "OBSERVATION", 192, 209]]], ["The first examples of viral hijacking of PDZ protein were given by the three oncoproteins adenovirus type 9 E4-ORF1, human T-lymphotropoic virus type 1 Tac and high-risk human papillomavirus E6 and has since then emerged as a common theme among viruses [132, [134] [135] [136] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 41, 44], ["adenovirus type 9", "ORGANISM", 90, 107], ["E4", "GENE_OR_GENE_PRODUCT", 108, 110], ["human T-lymphotropoic virus type 1", "ORGANISM", 117, 151], ["Tac", "GENE_OR_GENE_PRODUCT", 152, 155], ["human", "ORGANISM", 170, 175], ["papillomavirus", "ORGANISM", 176, 190], ["E6", "ORGANISM", 191, 193], ["PDZ protein", "PROTEIN", 41, 52], ["E4", "PROTEIN", 108, 110], ["ORF1", "DNA", 111, 115], ["Tac", "PROTEIN", 152, 155], ["human", "SPECIES", 117, 122], ["T-lymphotropoic virus", "SPECIES", 123, 144], ["human", "SPECIES", 170, 175], ["papillomavirus", "SPECIES", 176, 190], ["human T-lymphotropoic virus type 1", "SPECIES", 117, 151], ["human papillomavirus E6", "SPECIES", 170, 193], ["viral hijacking of PDZ protein", "PROBLEM", 22, 52], ["human T", "TEST", 117, 124], ["high-risk human papillomavirus E6", "TREATMENT", 160, 193], ["papillomavirus E6", "OBSERVATION", 176, 193]]], ["More recent reports include the hijacking of polarity protein PALS1 by the SARS Coronavirus E protein, which alters tight junction formation and epithelial morphogenesis [137] , and a study by Accardi and coworkers reporting on cooperation between E6 and E7 from human papillomavirus type 16 in the targeting of NHERF1 [138] .Concluding remarksThe PDZ domain is a highly versatile interaction module with the main function of recognizing C-terminal peptide ligands, but with an extended functionality of interacting with alternative ligands such as internal peptide stretches, other PDZ domains and/ or membrane lipids.", [["tight junction", "ANATOMY", 116, 130], ["epithelial", "ANATOMY", 145, 155], ["membrane", "ANATOMY", 603, 611], ["C", "CHEMICAL", 438, 439], ["PALS1", "GENE_OR_GENE_PRODUCT", 62, 67], ["Coronavirus E", "GENE_OR_GENE_PRODUCT", 80, 93], ["tight junction", "CELLULAR_COMPONENT", 116, 130], ["epithelial", "TISSUE", 145, 155], ["E6", "GENE_OR_GENE_PRODUCT", 248, 250], ["E7", "GENE_OR_GENE_PRODUCT", 255, 257], ["human papillomavirus type 16", "ORGANISM", 263, 291], ["NHERF1", "GENE_OR_GENE_PRODUCT", 312, 318], ["PDZ", "GENE_OR_GENE_PRODUCT", 348, 351], ["PDZ", "GENE_OR_GENE_PRODUCT", 583, 586], ["membrane lipids", "CELLULAR_COMPONENT", 603, 618], ["polarity protein", "PROTEIN", 45, 61], ["PALS1", "PROTEIN", 62, 67], ["SARS Coronavirus E protein", "PROTEIN", 75, 101], ["E6", "PROTEIN", 248, 250], ["E7", "PROTEIN", 255, 257], ["NHERF1", "PROTEIN", 312, 318], ["PDZ domain", "PROTEIN", 348, 358], ["PDZ domains", "PROTEIN", 583, 594], ["human", "SPECIES", 263, 268], ["human papillomavirus type 16", "SPECIES", 263, 291], ["polarity protein PALS1", "PROBLEM", 45, 67], ["the SARS Coronavirus E protein", "TEST", 71, 101], ["epithelial morphogenesis", "PROBLEM", 145, 169], ["a study", "TEST", 182, 189], ["The PDZ domain", "PROBLEM", 344, 358], ["recognizing C-terminal peptide ligands", "PROBLEM", 426, 464], ["alternative ligands", "TREATMENT", 521, 540], ["internal peptide stretches", "TREATMENT", 549, 575], ["other PDZ domains", "TREATMENT", 577, 594], ["membrane lipids", "TREATMENT", 603, 618], ["epithelial", "ANATOMY_MODIFIER", 145, 155], ["main", "OBSERVATION_MODIFIER", 409, 413]]], ["The plasticity of PDZ-ligand interactions has made it one of the most common modular domains in multicellular organisms [5, 6] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 18, 21], ["PDZ", "PROTEIN", 18, 21], ["multicellular organisms", "OBSERVATION", 96, 119]]], ["The last two decades have seen an intense research on PDZ domains with numerous experimental and computational studies tackling the fine details of the function of isolated PDZ domains and/or the biology of PDZ proteins.", [["PDZ", "GENE_OR_GENE_PRODUCT", 54, 57], ["PDZ", "GENE_OR_GENE_PRODUCT", 173, 176], ["PDZ", "GENE_OR_GENE_PRODUCT", 207, 210], ["PDZ domains", "PROTEIN", 54, 65], ["PDZ domains", "PROTEIN", 173, 184], ["PDZ proteins", "PROTEIN", 207, 219], ["computational studies", "TEST", 97, 118], ["isolated PDZ domains", "PROBLEM", 164, 184], ["PDZ proteins", "PROBLEM", 207, 219], ["intense", "OBSERVATION_MODIFIER", 34, 41]]], ["It has become clear that at least a subset of PDZ proteins act as dynamic regulators of cell signaling rather than static docking sites.", [["cell", "ANATOMY", 88, 92], ["PDZ", "GENE_OR_GENE_PRODUCT", 46, 49], ["cell", "CELL", 88, 92], ["PDZ proteins", "PROTEIN", 46, 58], ["cell signaling", "PROBLEM", 88, 102], ["clear", "OBSERVATION", 14, 19], ["cell signaling", "OBSERVATION", 88, 102]]], ["In a cellular context, PDZ interactions depend on several factors such as the intrinsic specificity of the domain, the availability of ligands, the cooperative effects with other interaction partners and the dynamic regulation of the PDZ protein and its ligands.", [["cellular", "ANATOMY", 5, 13], ["cellular", "CELL", 5, 13], ["PDZ", "GENE_OR_GENE_PRODUCT", 23, 26], ["PDZ", "GENE_OR_GENE_PRODUCT", 234, 237], ["PDZ", "PROTEIN", 23, 26], ["PDZ protein", "PROTEIN", 234, 245], ["PDZ interactions", "PROBLEM", 23, 39]]], ["For a better understanding of the biology of PDZ proteins it will be crucial to gain a better understanding of the synergy and/or competition between different binding partners and the regulatory mechanisms governing these interactions.", [["PDZ", "GENE_OR_GENE_PRODUCT", 45, 48], ["PDZ proteins", "PROTEIN", 45, 57], ["PDZ proteins", "TREATMENT", 45, 57]]], ["In particular, it will be interesting to follow future studies regarding the interplay between peptide and lipid signaling, the importance of PDZ-PDZ interactions in the organization of multi-protein scaffolds and the biological importance of the suggested phosphorylation switches.", [["lipid", "SIMPLE_CHEMICAL", 107, 112], ["PDZ", "GENE_OR_GENE_PRODUCT", 142, 145], ["PDZ", "GENE_OR_GENE_PRODUCT", 146, 149], ["PDZ", "PROTEIN", 142, 145], ["PDZ", "PROTEIN", 146, 149], ["future studies", "TEST", 48, 62], ["peptide and lipid signaling", "TREATMENT", 95, 122], ["PDZ-PDZ interactions", "TREATMENT", 142, 162], ["multi-protein scaffolds", "TREATMENT", 186, 209], ["phosphorylation switches", "TREATMENT", 257, 281]]], ["In addition, it will be interesting to follow the efforts being made towards the goal of developing highly specific inhibitors of PDZ proteins through the use of bidentate inhibitors targeting PDZ tandems rather than isolated PDZ domains [139] [140] [141] .", [["PDZ", "GENE_OR_GENE_PRODUCT", 130, 133], ["PDZ", "GENE_OR_GENE_PRODUCT", 193, 196], ["PDZ proteins", "PROTEIN", 130, 142], ["PDZ tandems", "PROTEIN", 193, 204], ["PDZ domains", "PROTEIN", 226, 237], ["PDZ proteins", "PROBLEM", 130, 142], ["bidentate inhibitors", "TREATMENT", 162, 182], ["PDZ tandems", "PROBLEM", 193, 204], ["isolated PDZ domains", "PROBLEM", 217, 237]]]], "de9fb10cddd74dbccbb7ddea72b14751075c6953": [["InTRoduCTIonInfectious diseases continue to be a major threat to modern society and coronaviruses (CoVs) are one of the most notable virus families responsible for recent, highly pathogenic viral disease outbreaks.", [["InTRoduCTIonInfectious diseases", "DISEASE", 0, 31], ["viral disease", "DISEASE", 190, 203], ["coronaviruses", "ORGANISM", 84, 97], ["CoVs", "CANCER", 99, 103], ["InTRoduCTIonInfectious diseases", "PROBLEM", 0, 31], ["coronaviruses (CoVs", "PROBLEM", 84, 103], ["highly pathogenic viral disease outbreaks", "PROBLEM", 172, 213], ["pathogenic", "OBSERVATION_MODIFIER", 179, 189], ["viral disease", "OBSERVATION", 190, 203]]], ["Over the last two decades, major outbreaks of deadly CoVs have been reported in humans and livestock, including severe acute respiratory syndrome (SARS) in 2003 [1, 2] , Middle East respiratory syndrome (MERS) in 2012 [3] and most recently, swine acute diarrhoea syndrome (SADS) in 2017 [4] .", [["CoVs", "DISEASE", 53, 57], ["acute respiratory syndrome", "DISEASE", 119, 145], ["SARS", "DISEASE", 147, 151], ["Middle East respiratory syndrome", "DISEASE", 170, 202], ["MERS", "DISEASE", 204, 208], ["swine acute diarrhoea syndrome", "DISEASE", 241, 271], ["SADS", "DISEASE", 273, 277], ["CoVs", "CANCER", 53, 57], ["humans", "ORGANISM", 80, 86], ["humans", "SPECIES", 80, 86], ["swine", "SPECIES", 241, 246], ["humans", "SPECIES", 80, 86], ["severe acute respiratory syndrome", "PROBLEM", 112, 145], ["Middle East respiratory syndrome", "PROBLEM", 170, 202], ["swine acute diarrhoea syndrome", "PROBLEM", 241, 271], ["deadly CoVs", "OBSERVATION", 46, 57], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["respiratory syndrome", "OBSERVATION", 125, 145], ["Middle", "ANATOMY_MODIFIER", 170, 176], ["respiratory syndrome", "OBSERVATION", 182, 202], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["diarrhoea syndrome", "OBSERVATION", 253, 271]]], ["These outbreaks have had a significant impact on the economy, global travel and society, and should serve as a warning for other emergent CoVs.", [["CoVs", "PATHOLOGICAL_FORMATION", 138, 142], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["impact", "OBSERVATION_MODIFIER", 39, 45]]], ["While Asia used to be considered to be the 'hot zone' for such outbreaks, the emergence of MERS highlighted that such events can happen anywhere in the world.InTRoduCTIonCoVs are a family of viruses within the order Nidovirales, and the subfamily Orthocoronavirinae can be divided into four genera, Alphacoronavirus, Betacoronavirus, Deltacoronavirus and Gammacoronavirus, based on antigenic reactivity and/or genome sequences (https:// talk. ictvonline. org/ taxonomy/).", [["MERS", "DISEASE", 91, 95], ["ictvonline", "CHEMICAL", 443, 453], ["InTRoduCTIonCoVs", "GENE_OR_GENE_PRODUCT", 158, 174], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 216, 227], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 247, 265], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 317, 332], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 334, 350], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 355, 371], ["ictvonline", "SIMPLE_CHEMICAL", 443, 453], ["InTRoduCTIonCoVs", "PROTEIN", 158, 174], ["genome sequences", "DNA", 410, 426], ["InTRoduCTIonCoVs", "TREATMENT", 158, 174], ["Nidovirales", "TREATMENT", 216, 227], ["the subfamily Orthocoronavirinae", "TREATMENT", 233, 265], ["Alphacoronavirus", "TREATMENT", 299, 315], ["Betacoronavirus", "TREATMENT", 317, 332], ["Deltacoronavirus", "TREATMENT", 334, 350], ["Gammacoronavirus", "TREATMENT", 355, 371], ["ictvonline", "TREATMENT", 443, 453]]], ["CoVs in general can cause disease in a variety of domestic and wild animals, as well as in humans, whereas alpha-and betacoronaviruses predominantly infect mammals.", [["CoVs", "CHEMICAL", 0, 4], ["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["humans", "ORGANISM", 91, 97], ["alpha", "GENE_OR_GENE_PRODUCT", 107, 112], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 117, 134], ["humans", "SPECIES", 91, 97], ["humans", "SPECIES", 91, 97], ["CoVs", "PROBLEM", 0, 4], ["disease", "PROBLEM", 26, 33], ["variety", "OBSERVATION_MODIFIER", 39, 46], ["infect mammals", "OBSERVATION", 149, 163]]], ["SARS-CoV and MERS-CoV belong to the genus Betacoronavirus, under the subgenera Sarbecovirus and Merbecovirus, respectively [5] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 13, 21], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 42, 57], ["SARS-CoV and MERS-CoV", "DNA", 0, 21], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["MERS", "PROBLEM", 13, 17], ["genus Betacoronavirus", "ANATOMY", 36, 57]]], ["These viruses are genetically distinct [6] .", [["viruses", "OBSERVATION", 6, 13]]], ["SARS-CoV originated in China and spread worldwide, infecting approximately 8000 individuals with a overall mortality rate of 10 % during the 2002-2003 epidemic [7] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8]]], ["Since emerging in 2012 in the Middle East, MERS-CoV has spread to 27 countries and has infected humans with an estimated mortality rate of 35 % [8] .InTRoduCTIonIn addition to SARS-CoV and MERS-CoV, the betacoronavirus human coronavirus OC43 [9] , and the alphacoronaviruses NL63 and 229E-CoV have been reported to cause infections in humans [10, 11] .", [["SARS", "DISEASE", 176, 180], ["infections", "DISEASE", 321, 331], ["MERS-CoV", "ORGANISM", 43, 51], ["humans", "ORGANISM", 96, 102], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 176, 184], ["MERS-CoV", "ORGANISM", 189, 197], ["betacoronavirus", "ORGANISM", 203, 218], ["human coronavirus", "ORGANISM", 219, 236], ["alphacoronaviruses NL63", "ORGANISM", 256, 279], ["229E-CoV", "ORGANISM", 284, 292], ["humans", "ORGANISM", 335, 341], ["humans", "SPECIES", 96, 102], ["human", "SPECIES", 219, 224], ["coronavirus", "SPECIES", 225, 236], ["humans", "SPECIES", 335, 341], ["MERS-CoV", "SPECIES", 43, 51], ["humans", "SPECIES", 96, 102], ["SARS-CoV", "SPECIES", 176, 184], ["MERS-CoV", "SPECIES", 189, 197], ["human coronavirus", "SPECIES", 219, 236], ["229E-CoV", "SPECIES", 284, 292], ["humans", "SPECIES", 335, 341], ["an estimated mortality rate", "TEST", 108, 135], ["SARS", "TEST", 176, 180], ["MERS", "TEST", 189, 193], ["the betacoronavirus human coronavirus OC43", "TEST", 199, 241], ["the alphacoronaviruses", "TEST", 252, 274], ["CoV", "PROBLEM", 289, 292], ["Middle", "ANATOMY_MODIFIER", 30, 36], ["infected", "OBSERVATION", 87, 95], ["infections", "OBSERVATION", 321, 331]]], ["The novel HKU2-related bat coronavirus, SADS-CoV, was identified as the aetiological agent responsible for a large-scale outbreak of fatal disease in China that caused the death of 24 693 piglets [4] .", [["death", "DISEASE", 172, 177], ["HKU2", "GENE_OR_GENE_PRODUCT", 10, 14], ["bat coronavirus", "ORGANISM", 23, 38], ["SADS-CoV", "ORGANISM", 40, 48], ["HKU2", "PROTEIN", 10, 14], ["bat coronavirus", "SPECIES", 23, 38], ["piglets", "SPECIES", 188, 195], ["bat coronavirus", "SPECIES", 23, 38], ["SADS-CoV", "SPECIES", 40, 48], ["The novel HKU2", "TEST", 0, 14], ["bat coronavirus", "PROBLEM", 23, 38], ["SADS-CoV", "PROBLEM", 40, 48], ["fatal disease in China", "PROBLEM", 133, 155], ["the death", "PROBLEM", 168, 177], ["large", "OBSERVATION_MODIFIER", 109, 114], ["fatal disease", "OBSERVATION", 133, 146]]], ["Although SADS-CoV was shown to be incapable of infecting humans in its current form, it remains to be seen whether further adaptation or a related virus can spill over into human populations in the future.InTRoduCTIonBats have been identified as a natural reservoir for a variety of viral diseases, with RNA viruses accounting for the overwhelming majority of emerging pathogens [12] .", [["viral diseases", "DISEASE", 283, 297], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["humans", "ORGANISM", 57, 63], ["human", "ORGANISM", 173, 178], ["InTRoduCTIonBats", "GENE_OR_GENE_PRODUCT", 205, 221], ["SADS", "PROTEIN", 9, 13], ["InTRoduCTIonBats", "PROTEIN", 205, 221], ["humans", "SPECIES", 57, 63], ["human", "SPECIES", 173, 178], ["SADS-CoV", "SPECIES", 9, 17], ["humans", "SPECIES", 57, 63], ["human", "SPECIES", 173, 178], ["SADS", "PROBLEM", 9, 13], ["CoV", "PROBLEM", 14, 17], ["infecting humans", "PROBLEM", 47, 63], ["a related virus", "PROBLEM", 137, 152], ["InTRoduCTIonBats", "TREATMENT", 205, 221], ["a natural reservoir", "TREATMENT", 246, 265], ["viral diseases", "PROBLEM", 283, 297], ["RNA viruses", "PROBLEM", 304, 315], ["emerging pathogens", "PROBLEM", 360, 378], ["infecting", "OBSERVATION", 47, 56], ["viral diseases", "OBSERVATION", 283, 297]]], ["Notably, bats have been recognized to carry exceptionally diverse CoVs from which SARS-CoV, MERS-CoV and SADS-CoV are thought to originate [4, 13] .InTRoduCTIonIn light of these recent events, it is probable that bat-borne CoVs will continue their zoonotic emergence and cause more human SARS-or MERS-like outbreaks.", [["SARS", "DISEASE", 82, 86], ["SARS-or MERS-like outbreaks", "DISEASE", 288, 315], ["CoVs", "CANCER", 66, 70], ["SARS-CoV", "ORGANISM", 82, 90], ["MERS-CoV", "ORGANISM", 92, 100], ["SADS-CoV", "ORGANISM", 105, 113], ["bat-borne CoVs", "ORGANISM", 213, 227], ["human", "ORGANISM", 282, 287], ["SARS-CoV, MERS-CoV and SADS-CoV", "DNA", 82, 113], ["human", "SPECIES", 282, 287], ["SARS-CoV", "SPECIES", 82, 90], ["MERS-CoV", "SPECIES", 92, 100], ["SADS-CoV", "SPECIES", 105, 113], ["human", "SPECIES", 282, 287], ["SADS", "PROBLEM", 105, 109], ["CoV", "PROBLEM", 110, 113], ["bat-borne CoVs", "PROBLEM", 213, 227], ["human SARS", "PROBLEM", 282, 292], ["MERS", "PROBLEM", 296, 300]]], ["One of the ongoing challenges that scientists face with these zoonotic crossover events is ensuring early warning or rapid detection and diagnosis so that effective countermeasures can be implemented.", [["rapid detection", "TEST", 117, 132], ["effective countermeasures", "TREATMENT", 155, 180]]], ["Unfortunately, current detection methodologies and our lack of understanding of cross-species transmission make the prediction of future spillover events nearly impossible.", [["future spillover events", "PROBLEM", 130, 153]]], ["Active surveillance remains our best defence to ameliorate the impact of these events.", [["these events", "PROBLEM", 73, 85]]], ["With limited funding available for these surveillance systems in regions where they are likely to be needed the most, it is currently impossible to achieve sufficient breadth and depth to comprehensively detect all potential spillover events.", [["these surveillance systems", "TEST", 35, 61], ["all potential spillover events", "PROBLEM", 211, 241], ["spillover events", "OBSERVATION", 225, 241]]], ["An investment focused on surveillance of CoVs in bats is considered to be most impactful based on past data and the current trend of emerging infectious diseases worldwide [14] .InTRoduCTIonIn 2013 the National Environment Agency (NEA) and the National Parks Board (NParks) initiated a bat surveillance programme in Singapore.", [["infectious diseases", "DISEASE", 142, 161], ["CoVs", "GENE_OR_GENE_PRODUCT", 41, 45], ["CoVs", "PROBLEM", 41, 45], ["infectious", "OBSERVATION", 142, 152]]], ["Through an island-wide survey, bat species, bat day roosts, population counts and age demographics were determined at each location.", [["bat species", "TEST", 31, 42], ["population counts", "TEST", 60, 77], ["wide", "OBSERVATION_MODIFIER", 18, 22]]], ["Guano samples were collected from three major roost sites and other opportunistic sampling, such as harvesting of dead bat carcasses and oral and rectal swabs from live catches, was performed.", [["Guano samples", "ANATOMY", 0, 13], ["carcasses", "ANATOMY", 123, 132], ["oral", "ANATOMY", 137, 141], ["rectal swabs", "ANATOMY", 146, 158], ["Guano samples", "CANCER", 0, 13], ["roost sites", "MULTI-TISSUE_STRUCTURE", 46, 57], ["bat", "ORGANISM", 119, 122], ["carcasses", "ORGANISM_SUBDIVISION", 123, 132], ["oral", "ORGANISM_SUBDIVISION", 137, 141], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 146, 158], ["Guano samples", "TEST", 0, 13], ["other opportunistic sampling", "TEST", 62, 90], ["harvesting", "TREATMENT", 100, 110], ["dead bat carcasses", "TREATMENT", 114, 132], ["oral and rectal swabs", "TREATMENT", 137, 158], ["rectal", "ANATOMY", 146, 152]]], ["While screening these samples for pathogens of public health concern in Singapore, CoVs were detected in two guano samples and a rectal swab collected from a lesser dog-faced fruit bat.", [["samples", "ANATOMY", 115, 122], ["rectal swab", "ANATOMY", 129, 140], ["CoVs", "GENE_OR_GENE_PRODUCT", 83, 87], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 129, 140], ["dog", "ORGANISM", 165, 168], ["dog", "SPECIES", 165, 168], ["pathogens", "PROBLEM", 34, 43], ["CoVs", "PROBLEM", 83, 87], ["a rectal swab", "TEST", 127, 140], ["rectal", "ANATOMY", 129, 135], ["fruit bat", "OBSERVATION", 175, 184]]], ["The CoV genome is the largest among all known RNA viruses (~30 kb) and whole-genome sequencing is not a simple task, especially from clinical or surveillance samples with limited genetic material [15] .", [["CoV", "ORGANISM", 4, 7], ["CoV genome", "DNA", 4, 14], ["whole-genome sequencing", "TEST", 71, 94], ["surveillance samples", "TEST", 145, 165], ["CoV genome", "OBSERVATION", 4, 14], ["largest", "OBSERVATION_MODIFIER", 22, 29], ["RNA viruses", "OBSERVATION", 46, 57]]], ["To increase the speed and success rate of full-genome sequencing of novel CoVs, we have developed a probe-based enrichment method to specifically capture CoV sequences using a library of 120 nt probes.", [["CoVs", "GENE_OR_GENE_PRODUCT", 74, 78], ["CoV", "ORGANISM", 154, 157], ["CoVs", "DNA", 74, 78], ["CoV sequences", "DNA", 154, 167], ["120 nt probes", "DNA", 187, 200], ["novel CoVs", "PROBLEM", 68, 78], ["a probe-based enrichment method", "TREATMENT", 98, 129], ["CoV sequences", "TEST", 154, 167], ["a library of 120 nt probes", "TREATMENT", 174, 200]]], ["The library contains probes targeting all known CoV sequences [published by the National Center for Biotechnology Information (NCBI) and unpublished].", [["CoV sequences", "DNA", 48, 61]]], ["This new platform was first validated with cultured MERS-CoV and subsequently applied to sequence and characterize the novel CoV detected from bat samples collected in Singapore.Ecological data gathering and guano samplingRoost surveys were performed for the identification of species, determination of the size of roosts and guano collection.", [["samples", "ANATOMY", 147, 154], ["MERS-CoV", "ORGANISM", 52, 60], ["CoV", "ORGANISM", 125, 128], ["bat", "ORGANISM", 143, 146], ["MERS-CoV", "SPECIES", 52, 60], ["the novel CoV", "PROBLEM", 115, 128], ["bat samples", "TEST", 143, 154], ["Ecological data", "TEST", 178, 193], ["guano samplingRoost surveys", "TEST", 208, 235], ["species", "PROBLEM", 277, 284], ["roosts and guano collection", "PROBLEM", 315, 342], ["size", "OBSERVATION_MODIFIER", 307, 311], ["guano collection", "OBSERVATION", 326, 342]]], ["As bats are known to utilize alternative roost sites for different functions, only day roosts were considered for the ground survey to reduce the possibility of double counting [16] .", [["roost sites", "MULTI-TISSUE_STRUCTURE", 41, 52], ["alternative roost sites", "TREATMENT", 29, 52]]], ["Information such as bat species, population counts and age estimates were collected from the day roosts.", [["population counts", "TEST", 33, 50], ["age estimates", "TEST", 55, 68]]], ["Photographs of the roosting bats were taken to assist and complement survey counts.", [["bats", "ORGANISM", 28, 32], ["the roosting bats", "TREATMENT", 15, 32], ["complement survey counts", "TEST", 58, 82]]], ["Individual bats were identified by their eyes, head, nose and wings using a taxonomic key [17] .", [["eyes", "ANATOMY", 41, 45], ["head", "ANATOMY", 47, 51], ["nose", "ANATOMY", 53, 57], ["bats", "ORGANISM", 11, 15], ["eyes", "ORGAN", 41, 45], ["head", "ORGANISM_SUBDIVISION", 47, 51], ["nose", "ORGANISM_SUBDIVISION", 53, 57], ["head", "ANATOMY", 47, 51], ["nose", "ANATOMY", 53, 57]]], ["For estimation of the age of bats, it was assumed that nursing bats were juvenile and all others were adults.Ecological data gathering and guano samplingRepeated surveys were performed at five roost sites [HortPark, Singapore Zoological Garden, Singapore Botanic Garden, Rifle Range Flyover (RRFO) and Lower Peirce Reservoir] and three major roost sites were also identified (East Coast Park, RRFO and Singapore Zoological Garden) for periodic guano sampling.", [["Ecological data", "TEST", 109, 124], ["guano sampling", "TEST", 139, 153], ["Repeated surveys", "TEST", 153, 169], ["Rifle Range Flyover (RRFO)", "TREATMENT", 271, 297], ["Lower Peirce Reservoir", "TREATMENT", 302, 324], ["periodic guano sampling", "TREATMENT", 435, 458]]], ["During sampling, groundsheets were placed under the roosting bats and guano samples were collected from the groundsheets and put into universal transport media.", [["samples", "ANATOMY", 76, 83], ["guano samples", "ORGANISM_SUBSTANCE", 70, 83], ["groundsheets", "TREATMENT", 17, 29], ["guano samples", "TEST", 70, 83], ["universal transport media", "TREATMENT", 134, 159]]], ["In addition, opportunistic rectal swabs were collected from bats that were accidentally caught in mist nets during the NParks bird-ringing programme or provided by the Wildlife Reserve Singapore (WRS).", [["rectal swabs", "ANATOMY", 27, 39], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 27, 39], ["opportunistic rectal swabs", "TEST", 13, 39]]], ["Any bat carcasses found in a nature reserve (SBWR) or donated by pest control companies were sent to the laboratory for testing.", [["Any bat carcasses", "PROBLEM", 0, 17], ["testing", "TEST", 120, 127], ["bat", "ANATOMY", 4, 7], ["carcasses", "OBSERVATION", 8, 17]]], ["Guano samples and rectal swabs were placed in universal transport media and bat carcasses were kept refrigerated before processing in the laboratory.", [["Guano samples", "ANATOMY", 0, 13], ["rectal swabs", "ANATOMY", 18, 30], ["Guano samples", "ORGANISM_SUBSTANCE", 0, 13], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 18, 30], ["bat", "ORGANISM", 76, 79], ["carcasses", "ORGANISM_SUBDIVISION", 80, 89], ["Guano samples", "TEST", 0, 13], ["rectal swabs", "TEST", 18, 30], ["bat carcasses", "TREATMENT", 76, 89], ["rectal", "ANATOMY", 18, 24]]], ["Bat carcasses were swabbed in the oral and rectal cavities before dissection.", [["oral", "ANATOMY", 34, 38], ["rectal cavities", "ANATOMY", 43, 58], ["oral", "ORGANISM_SUBDIVISION", 34, 38], ["rectal cavities", "MULTI-TISSUE_STRUCTURE", 43, 58], ["Bat carcasses", "TREATMENT", 0, 13], ["dissection", "PROBLEM", 66, 76], ["oral", "ANATOMY", 34, 38], ["rectal cavities", "ANATOMY", 43, 58], ["dissection", "OBSERVATION", 66, 76]]], ["Tissues (heart, liver, spleen, lung, kidney, intestine and brain) were then harvested.Ecological data gathering and guano samplingThe geographical distribution of bat roosts in Singapore was plotted in QGIS 3.2.3 (QGIS Development Team, 2018) using the basemap of Singapore downloaded from Onemap (Singapore Land Authority, 2018).", [["Tissues", "ANATOMY", 0, 7], ["heart", "ANATOMY", 9, 14], ["liver", "ANATOMY", 16, 21], ["spleen", "ANATOMY", 23, 29], ["lung", "ANATOMY", 31, 35], ["kidney", "ANATOMY", 37, 43], ["intestine", "ANATOMY", 45, 54], ["brain", "ANATOMY", 59, 64], ["Tissues", "TISSUE", 0, 7], ["heart", "ORGAN", 9, 14], ["liver", "ORGAN", 16, 21], ["spleen", "ORGAN", 23, 29], ["lung", "ORGAN", 31, 35], ["kidney", "ORGAN", 37, 43], ["intestine", "ORGAN", 45, 54], ["brain", "ORGAN", 59, 64], ["Tissues (heart, liver", "TEST", 0, 21], ["Ecological data", "TEST", 86, 101], ["guano sampling", "TEST", 116, 130], ["heart", "ANATOMY", 9, 14], ["liver", "ANATOMY", 16, 21], ["spleen", "ANATOMY", 23, 29], ["lung", "ANATOMY", 31, 35], ["kidney", "ANATOMY", 37, 43], ["intestine", "ANATOMY", 45, 54], ["brain", "ANATOMY", 59, 64], ["harvested", "OBSERVATION", 76, 85], ["geographical", "OBSERVATION_MODIFIER", 134, 146], ["distribution", "OBSERVATION_MODIFIER", 147, 159], ["bat roosts", "OBSERVATION", 163, 173]]], ["Project coordinate system WGS 84 projection (EPSG:4326) was used for plotting.RnA extraction and PCR screening of bat samplesA total of 107 guano samples, 14 rectal swabs and 6 bat carcasses, collected over a period of 3 years, were screened for the presence of CoVs [2] , Japanese encephalitis virus (JEV) [18] , rabies-related lyssavirus [19] , leptospirosis [20] and hantavirus [21] .", [["samples", "ANATOMY", 146, 153], ["rectal swabs", "ANATOMY", 158, 170], ["Japanese encephalitis", "DISEASE", 273, 294], ["JEV", "DISEASE", 302, 305], ["rabies", "DISEASE", 314, 320], ["leptospirosis", "DISEASE", 347, 360], ["hantavirus", "DISEASE", 370, 380], ["RnA", "SIMPLE_CHEMICAL", 78, 81], ["bat", "ORGANISM", 114, 117], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 158, 170], ["CoVs", "GENE_OR_GENE_PRODUCT", 262, 266], ["Japanese encephalitis virus", "ORGANISM", 273, 300], ["JEV", "ORGANISM", 302, 305], ["rabies", "ORGANISM", 314, 320], ["Japanese encephalitis virus", "SPECIES", 273, 300], ["Japanese encephalitis virus", "SPECIES", 273, 300], ["JEV", "SPECIES", 302, 305], ["RnA extraction", "TEST", 78, 92], ["PCR screening", "TEST", 97, 110], ["bat samplesA", "TEST", 114, 126], ["guano samples", "TEST", 140, 153], ["rectal swabs", "TEST", 158, 170], ["CoVs", "PROBLEM", 262, 266], ["Japanese encephalitis virus", "PROBLEM", 273, 300], ["rabies", "PROBLEM", 314, 320], ["lyssavirus", "PROBLEM", 329, 339], ["leptospirosis", "PROBLEM", 347, 360], ["hantavirus", "PROBLEM", 370, 380]]], ["Nucleic acid was extracted from tissue/ guano/swabs using the AllPrep DNA/RNA Mini kit (Qiagen) according to the manufacturer's instructions.", [["tissue", "ANATOMY", 32, 38], ["swabs", "ANATOMY", 46, 51], ["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["tissue", "TISSUE", 32, 38], ["swabs", "ORGANISM_SUBSTANCE", 46, 51], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["AllPrep DNA", "DNA", 62, 73], ["Nucleic acid", "TEST", 0, 12], ["tissue/ guano/swabs", "TREATMENT", 32, 51], ["the AllPrep DNA", "TREATMENT", 58, 73], ["RNA Mini kit (Qiagen)", "TREATMENT", 74, 95], ["acid", "OBSERVATION_MODIFIER", 8, 12]]], ["RNaseOUT (Invitrogen), a ribonuclease inhibitor, was added to each RNA prior to storage at \u221280\u00b0C. RNA was reverse-transcribed using SuperScript Reverse Transcriptase (Invitrogen) according to the manufacturer's instructions.", [["RNaseOUT", "CHEMICAL", 0, 8], ["RNaseOUT", "SIMPLE_CHEMICAL", 0, 8], ["Invitrogen", "SIMPLE_CHEMICAL", 10, 20], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 25, 37], ["RNaseOUT", "PROTEIN", 0, 8], ["RNA", "RNA", 98, 101], ["SuperScript Reverse Transcriptase", "PROTEIN", 132, 165], ["RNaseOUT (Invitrogen)", "TREATMENT", 0, 21], ["a ribonuclease inhibitor", "TREATMENT", 23, 47], ["SuperScript Reverse Transcriptase (Invitrogen)", "TREATMENT", 132, 178]]], ["The cDNA was used as the template for conventional PCR for the detection of coronavirus, hantavirus and leptospirosis with Phusion Flash High-Fidelity PCR Master Mix (Life Technology).", [["hantavirus", "DISEASE", 89, 99], ["leptospirosis", "DISEASE", 104, 117], ["coronavirus", "ORGANISM", 76, 87], ["hantavirus", "ORGANISM", 89, 99], ["cDNA", "DNA", 4, 8], ["The cDNA", "TREATMENT", 0, 8], ["conventional PCR", "TEST", 38, 54], ["the detection", "TEST", 59, 72], ["coronavirus", "PROBLEM", 76, 87], ["hantavirus", "PROBLEM", 89, 99], ["leptospirosis", "PROBLEM", 104, 117], ["Phusion Flash", "TREATMENT", 123, 136], ["coronavirus", "OBSERVATION", 76, 87]]], ["Any PCR products were purified using a PCR purification kit (Qiagen) and sequenced by Sanger sequencing.", [["PCR products", "DNA", 4, 16], ["Any PCR products", "TREATMENT", 0, 16], ["a PCR purification kit", "TREATMENT", 37, 59]]], ["RNA was used as a template for real-time PCR using the QuaniTect SYBR green kit (Qiagen) according to the manufacturer's instructions for the detection of rabies-related lyssavirus and JEV.RnA extraction and PCR screening of bat samplesThe primer sequences for the detection of coronavirus, JEV [18] , rabies-related lyssavirus [19] , leptospirosis [20] and hantavirus [21] are listed in Table S2 (available in the online version of this article).Cells and virusesVero B4 cells (RRID: CVCL_1912) were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10 % foetal bovine serum (FBS) at 37\u00b0C and 5 % CO 2 .", [["samples", "ANATOMY", 229, 236], ["Cells", "ANATOMY", 447, 452], ["Vero B4 cells", "ANATOMY", 464, 477], ["serum", "ANATOMY", 592, 597], ["FBS", "ANATOMY", 599, 602], ["rabies", "DISEASE", 155, 161], ["JEV", "DISEASE", 185, 188], ["RnA", "CHEMICAL", 189, 192], ["leptospirosis", "DISEASE", 335, 348], ["hantavirus", "DISEASE", 358, 368], ["CO", "CHEMICAL", 620, 622], ["rabies", "ORGANISM", 155, 161], ["lyssavirus", "ORGANISM", 170, 180], ["JEV", "ORGANISM", 185, 188], ["RnA", "SIMPLE_CHEMICAL", 189, 192], ["coronavirus", "ORGANISM", 278, 289], ["JEV [18]", "ORGANISM", 291, 299], ["rabies-related lyssavirus", "ORGANISM", 302, 327], ["Cells", "CELL", 447, 452], ["Vero B4 cells", "CELL", 464, 477], ["RRID", "CELL", 479, 483], ["CVCL_1912", "CELL", 485, 494], ["bovine", "ORGANISM", 585, 591], ["serum", "ORGANISM_SUBSTANCE", 592, 597], ["FBS", "ORGANISM_SUBSTANCE", 599, 602], ["RNA", "RNA", 0, 3], ["primer sequences", "DNA", 240, 256], ["virusesVero B4 cells", "CELL_LINE", 457, 477], ["bovine", "SPECIES", 585, 591], ["rabies", "SPECIES", 155, 161], ["JEV", "SPECIES", 185, 188], ["JEV", "SPECIES", 291, 294], ["bovine", "SPECIES", 585, 591], ["a template", "TREATMENT", 16, 26], ["real-time PCR", "TEST", 31, 44], ["the detection", "TEST", 138, 151], ["rabies", "PROBLEM", 155, 161], ["lyssavirus", "PROBLEM", 170, 180], ["JEV", "PROBLEM", 185, 188], ["RnA extraction", "TEST", 189, 203], ["PCR screening", "TEST", 208, 221], ["bat samples", "TEST", 225, 236], ["The primer sequences", "TEST", 236, 256], ["the detection", "TEST", 261, 274], ["coronavirus", "PROBLEM", 278, 289], ["JEV", "TEST", 291, 294], ["rabies", "TEST", 302, 308], ["lyssavirus", "PROBLEM", 317, 327], ["leptospirosis", "PROBLEM", 335, 348], ["hantavirus", "PROBLEM", 358, 368], ["Cells", "TEST", 447, 452], ["CVCL", "TEST", 485, 489], ["foetal bovine serum", "TEST", 578, 597], ["FBS", "TEST", 599, 602], ["B4 cells", "OBSERVATION", 469, 477]]], ["MERS-CoV (accession number: NC_019843) was propagated and amplified in Vero B4 cells in DMEM supplemented with 5 % FBS at 37\u00b0C and 5 % CO 2.", [["Vero B4 cells", "ANATOMY", 71, 84], ["FBS", "ANATOMY", 115, 118], ["CO", "CHEMICAL", 135, 137], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["Vero B4 cells", "CELL", 71, 84], ["FBS", "ORGANISM_SUBSTANCE", 115, 118], ["MERS-CoV", "DNA", 0, 8], ["Vero B4 cells", "CELL_LINE", 71, 84], ["MERS-CoV", "SPECIES", 0, 8], ["Vero B4", "SPECIES", 71, 78], ["Vero B4 cells in DMEM", "TREATMENT", 71, 92], ["5 % FBS", "TREATMENT", 111, 118]]], ["PaKi cells [22] were maintained in DMEM supplemented with 10 % FBS at 37\u00b0C and 5 % CO 2 .", [["PaKi cells", "ANATOMY", 0, 10], ["CO 2", "CHEMICAL", 83, 87], ["PaKi cells", "CELL", 0, 10], ["FBS", "ORGANISM_SUBSTANCE", 63, 66], ["PaKi cells", "CELL_LINE", 0, 10], ["PaKi cells", "TEST", 0, 10], ["FBS", "TEST", 63, 66]]], ["WIV1 (accession number: KF367457.1) was propagated and amplified in Vero cells in DMEM supplemented with 5 % FBS at 37 \u00b0C and 5 % CO 2 .RnA extractionVero B4 cells were infected with MERS-CoV under BSL3 containment and harvested for RNA extraction when cytopathic effect (CPE) was evident.", [["Vero cells", "ANATOMY", 68, 78], ["FBS", "ANATOMY", 109, 112], ["Vero B4 cells", "ANATOMY", 150, 163], ["WIV1", "CHEMICAL", 0, 4], ["CO", "CHEMICAL", 130, 132], ["Vero cells", "CELL", 68, 78], ["FBS", "ORGANISM_SUBSTANCE", 109, 112], ["RnA", "SIMPLE_CHEMICAL", 136, 139], ["Vero B4 cells", "CELL", 150, 163], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 183, 191], ["WIV1", "DNA", 0, 4], ["Vero cells", "CELL_LINE", 68, 78], ["Vero B4 cells", "CELL_LINE", 150, 163], ["WIV1", "SPECIES", 0, 4], ["MERS-CoV", "SPECIES", 183, 191], ["Vero cells in DMEM", "TREATMENT", 68, 86], ["5 % FBS", "TREATMENT", 105, 112], ["RnA extraction", "TREATMENT", 136, 150], ["Vero B4 cells", "PROBLEM", 150, 163], ["CoV under BSL3 containment", "TREATMENT", 188, 214], ["RNA extraction", "TREATMENT", 233, 247], ["cytopathic effect", "PROBLEM", 253, 270], ["CPE", "PROBLEM", 272, 275], ["Vero", "OBSERVATION_MODIFIER", 150, 154], ["B4 cells", "OBSERVATION", 155, 163]]], ["RNA samples were verified as being inactive according to the Duke-NUS ABSL3 protocol prior to removal from the facility.", [["samples", "ANATOMY", 4, 11], ["RNA samples", "TEST", 0, 11], ["removal", "TREATMENT", 94, 101]]], ["RNA was extracted from both MERS-CoV-infected Vero B4 cells and uninfected Vero B4 cells using the Total RNA Kit I (Omega Biotek) according to the manufacturer's instructions.", [["Vero B4 cells", "ANATOMY", 46, 59], ["Vero B4 cells", "ANATOMY", 75, 88], ["MERS-CoV", "ORGANISM", 28, 36], ["Vero B4 cells", "CELL", 46, 59], ["Vero B4 cells", "CELL", 75, 88], ["RNA", "RNA", 0, 3], ["MERS-CoV-infected Vero B4 cells", "CELL_LINE", 28, 59], ["uninfected Vero B4 cells", "CELL_LINE", 64, 88], ["MERS-CoV", "SPECIES", 28, 36], ["Vero B4", "SPECIES", 46, 53], ["Vero B4", "SPECIES", 75, 82], ["RNA", "TEST", 0, 3], ["CoV", "TEST", 33, 36], ["infected Vero B4 cells", "PROBLEM", 37, 59], ["uninfected Vero B4 cells", "TREATMENT", 64, 88], ["the Total RNA Kit I (Omega Biotek)", "TREATMENT", 95, 129], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["Vero B4 cells", "OBSERVATION", 46, 59], ["Vero B4 cells", "OBSERVATION", 75, 88]]], ["RNA was extracted from WIV1-infected Vero cells using the Total RNA Kit I (Omega Biotek) according to the manufacturer's instructions.", [["Vero cells", "ANATOMY", 37, 47], ["Vero cells", "CELL", 37, 47], ["RNA", "RNA", 0, 3], ["WIV1-infected Vero cells", "CELL_LINE", 23, 47], ["WIV1", "TEST", 23, 27], ["infected Vero cells", "PROBLEM", 28, 47], ["the Total RNA Kit I (Omega Biotek)", "TREATMENT", 54, 88], ["infected", "OBSERVATION_MODIFIER", 28, 36], ["Vero cells", "OBSERVATION", 37, 47]]], ["The total amount of RNA was quantified using a Nanodrop (Thermo Scientific).design and assessment of CoV probe libraryFor the solution-based targeted-enrichment methodology, biotinylated DNA probes were designed against 90 coronavirus genomes from the NCBI database and our unpublished studies that are known to infect bats.", [["DNA", "CELLULAR_COMPONENT", 187, 190], ["bats", "ORGANISM", 319, 323], ["CoV probe library", "DNA", 101, 118], ["biotinylated DNA probes", "DNA", 174, 197], ["coronavirus genomes", "DNA", 223, 242], ["a Nanodrop", "TREATMENT", 45, 55], ["assessment", "TEST", 87, 97], ["CoV probe library", "TREATMENT", 101, 118], ["the solution", "TREATMENT", 122, 134], ["biotinylated DNA probes", "TREATMENT", 174, 197], ["90 coronavirus genomes", "PROBLEM", 220, 242], ["the NCBI database", "TEST", 248, 265], ["our unpublished studies", "TEST", 270, 293], ["total", "OBSERVATION_MODIFIER", 4, 9], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["RNA", "OBSERVATION", 20, 23]]], ["The probes were 120 nucleotides (nt) in length and complementary to the viral genome.", [["nucleotides", "CHEMICAL", 20, 31], ["viral genome", "DNA", 72, 84], ["The probes", "TEST", 0, 10], ["nucleotides (nt) in length", "TREATMENT", 20, 46], ["viral genome", "OBSERVATION", 72, 84]]], ["To capture this diversity, we took an iterative approach to the design, where we first designed baits targeting the conserved regions of the genome and then generated baits targeting the variable regions.", [["conserved regions", "DNA", 116, 133], ["an iterative approach", "TREATMENT", 35, 56], ["genome", "ANATOMY", 141, 147], ["variable", "OBSERVATION_MODIFIER", 187, 195]]], ["The full list of 4303 probes designed for CoV can be found in Table S1 .design and assessment of CoV probe libraryTo assess the CoV probe library, next-generation sequencing (NGS) libraries were prepared from 1 \u00b5g of PaKi cellular RNA spiked with serially diluted MERS-CoV RNA.", [["cellular", "ANATOMY", 222, 230], ["CoV", "ORGANISM", 42, 45], ["PaKi cellular", "CELL", 217, 230], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 264, 272], ["4303 probes", "DNA", 17, 28], ["CoV probe library", "DNA", 97, 114], ["CoV probe library", "DNA", 128, 145], ["PaKi cellular RNA", "RNA", 217, 234], ["serially diluted MERS-CoV RNA", "RNA", 247, 276], ["MERS-CoV", "SPECIES", 264, 272], ["CoV", "PROBLEM", 42, 45], ["assessment", "TEST", 83, 93], ["CoV probe library", "TREATMENT", 97, 114], ["the CoV probe library", "TREATMENT", 124, 145], ["next-generation sequencing (NGS) libraries", "TREATMENT", 147, 189], ["PaKi cellular RNA", "TREATMENT", 217, 234]]], ["A volume of 2 \u00b5l of the diluted MERS-CoV RNA was added tonGS sequencing analysisThe prepared libraries were sequenced on a MiSeq machine.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["diluted MERS-CoV RNA", "RNA", 24, 44], ["MiSeq machine", "DNA", 123, 136], ["MERS-CoV", "SPECIES", 32, 40], ["the diluted MERS", "TREATMENT", 20, 36], ["CoV RNA", "TREATMENT", 37, 44], ["GS sequencing analysis", "TEST", 58, 80], ["The prepared libraries", "TREATMENT", 80, 102], ["a MiSeq machine", "TREATMENT", 121, 136]]], ["The resulting reads were then subjected to processing in the VIPR4 pipeline (https:// github. com/ nf-core/ vipr/).", [["nf", "GENE_OR_GENE_PRODUCT", 99, 101], ["vipr", "GENE_OR_GENE_PRODUCT", 108, 112], ["VIPR4 pipeline", "DNA", 61, 75], ["nf", "PROTEIN", 99, 101], ["vipr", "DNA", 108, 112]]], ["Briefly, adapters were trimmed and quality-assessed by Skewer [23] and FASTQC (https://www. bioinformatics. babraham. ac. uk/ projects/ fastqc/), respectively.", [["babraham", "CHEMICAL", 108, 116], ["fastqc", "PROTEIN", 136, 142]]], ["Host reads were then removed by the decont. py script (https:// github. com/ CSB5/ decont/ blob/ master/ decont. py).", [["CSB5", "PROTEIN", 77, 81], ["blob/ master/ decont", "PROBLEM", 91, 111], ["blob", "OBSERVATION", 91, 95]]], ["Coding potential and putative transcriptional regulatory sequences of BtCoV92 module (https:// jgi. doe. gov/ data-and-tools/ bbtools/).", [["BtCoV92", "GENE_OR_GENE_PRODUCT", 70, 77], ["putative transcriptional regulatory sequences", "DNA", 21, 66], ["BtCoV92 module", "DNA", 70, 84], ["doe", "PROBLEM", 100, 103]]], ["The contigs were then polished by incorporating unassembled viral reads through an iterative process until no further viral reads were incorporated (https:// github. com/ nf-core/ vipr/).", [["nf", "GENE_OR_GENE_PRODUCT", 171, 173], ["vipr", "GENE_OR_GENE_PRODUCT", 180, 184], ["github", "DNA", 158, 164], ["nf", "PROTEIN", 171, 173], ["vipr", "DNA", 180, 184], ["an iterative process", "TREATMENT", 80, 100], ["further viral reads", "PROBLEM", 110, 129], ["viral reads", "OBSERVATION", 60, 71]]], ["A final mapping against the assembly was performed with BWA [24] and low-frequency variants were then identified by LoFreq [25] .", [["A final mapping", "TEST", 0, 15], ["BWA", "TEST", 56, 59], ["low-frequency variants", "PROBLEM", 69, 91]]], ["Coverage and variant allele frequency graphs were produced by Bedtools (https:// bedtools. readthedocs. io/ en/ latest/) and ViPR Tools (https:// github. com/ nf-core/ vipr/).Phylogenetic analysisMultiple sequence alignment of the full-genome sequence of BtCoV92 coronavirus and 2211 unique coronavirus sequences present in the NCBI database was carried out using a fast Fourier transformation method in MAFFT v6.940b.", [["readthedocs", "SIMPLE_CHEMICAL", 91, 102], ["ViPR", "GENE_OR_GENE_PRODUCT", 125, 129], ["nf", "GENE_OR_GENE_PRODUCT", 159, 161], ["vipr", "GENE_OR_GENE_PRODUCT", 168, 172], ["BtCoV92 coronavirus", "ORGANISM", 255, 274], ["coronavirus", "ORGANISM", 291, 302], ["ViPR", "PROTEIN", 125, 129], ["github", "DNA", 146, 152], ["nf", "PROTEIN", 159, 161], ["vipr", "DNA", 168, 172], ["full-genome sequence", "DNA", 231, 251], ["BtCoV92 coronavirus and 2211 unique coronavirus sequences", "DNA", 255, 312], ["NCBI database", "DNA", 328, 341], ["coronavirus", "SPECIES", 263, 274], ["BtCoV92 coronavirus", "SPECIES", 255, 274], ["variant allele frequency graphs", "TREATMENT", 13, 44], ["Phylogenetic analysisMultiple sequence alignment", "TEST", 175, 223], ["BtCoV92 coronavirus", "PROBLEM", 255, 274], ["coronavirus sequences", "TEST", 291, 312], ["the NCBI database", "TEST", 324, 341], ["a fast Fourier transformation method", "TREATMENT", 364, 400]]], ["An approximately maximum-likelihood phylogenetic tree was generated using the generalized time-reversible model of nucleotide evolution in FastTree v2.1.7 [26] .", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["approximately", "OBSERVATION_MODIFIER", 3, 16], ["maximum", "OBSERVATION_MODIFIER", 17, 24], ["phylogenetic tree", "OBSERVATION", 36, 53]]], ["FastTree uses SH-like local supports with 1000 resamples to estimate and validate the reliability of each split in the tree.", [["tree", "ANATOMY_MODIFIER", 119, 123]]], ["From the tree, the branch containing the sequence from BtCoV92 coronavirus sequence was selected and a more robust maximumlikelihood phylogenetic tree was created using RAXML [27] with 1000 bootstrap replications.", [["BtCoV92 coronavirus", "ORGANISM", 55, 74], ["BtCoV92 coronavirus sequence", "DNA", 55, 83], ["BtCoV92 coronavirus", "SPECIES", 55, 74], ["the sequence from BtCoV92 coronavirus sequence", "TEST", 37, 83], ["1000 bootstrap replications", "TREATMENT", 185, 212], ["tree", "ANATOMY_MODIFIER", 9, 13], ["branch", "ANATOMY_MODIFIER", 19, 25]]], ["The trees were visualizedActive surveillance of the Singapore bat populationFrom 2013-2016, an island-wide survey was conducted by NParks and NEA to determine the species, demographics and population size of bats at different locations in Singapore.", [["Active", "OBSERVATION_MODIFIER", 25, 31], ["size", "OBSERVATION_MODIFIER", 200, 204]]], ["A total of 27 locations were surveyed and bat roosts were found in 15 of these locations (Fig. 1) .", [["bat roosts", "TEST", 42, 52]]], ["During the collection of bat ecological data (Table 1) , three major bat roosting sites at East Coast Park, RRFO and Singapore Zoological Garden were identified for surveillance and periodic guano sampling.Active surveillance of the Singapore bat populationThirteen out of 15 roost sites only harbour lesser dog-faced bats (Cynopterus brachyotis).", [["dog", "ORGANISM", 308, 311], ["bats", "ORGANISM", 318, 322], ["Cynopterus brachyotis", "ORGANISM", 324, 345], ["dog", "SPECIES", 308, 311], ["Cynopterus brachyotis", "SPECIES", 324, 345], ["Singapore bat", "SPECIES", 233, 246], ["Cynopterus brachyotis", "SPECIES", 324, 345], ["surveillance", "TEST", 165, 177], ["periodic guano sampling", "TEST", 182, 205], ["harbour", "OBSERVATION_MODIFIER", 293, 300], ["lesser", "OBSERVATION_MODIFIER", 301, 307], ["faced bats", "OBSERVATION", 312, 322]]], ["Cave nectar bats (Eonycteris spelaea) were found at RRFO and whiskered bats (Myotis sp.) at HortPark.", [["Cave nectar bats", "ORGANISM", 0, 16], ["Eonycteris spelaea", "ORGANISM", 18, 36], ["Eonycteris spelaea", "SPECIES", 18, 36], ["Myotis sp.", "SPECIES", 77, 87], ["Eonycteris spelaea", "SPECIES", 18, 36], ["nectar bats", "OBSERVATION", 5, 16]]], ["The species and population of bats in the Bukit Timah Caves were undetermined due to insufficient light to allow for counting and visual inspection of the bats without disturbance.", [["bats", "ORGANISM", 30, 34], ["The species", "PROBLEM", 0, 11], ["counting", "TEST", 117, 125], ["visual inspection", "TEST", 130, 147], ["disturbance", "PROBLEM", 168, 179]]], ["Based on a previous survey, the bats were identified as dusky fruit bats (Penthetor lucasi) [28, 29] .", [["bats", "ORGANISM", 32, 36], ["Penthetor lucasi", "SPECIES", 74, 90], ["dusky fruit bats", "SPECIES", 56, 72], ["Penthetor lucasi", "SPECIES", 74, 90], ["a previous survey", "TEST", 9, 26], ["dusky", "OBSERVATION_MODIFIER", 56, 61], ["fruit bats", "OBSERVATION", 62, 72]]], ["An approximately maximum-likelihood phylogenetic tree was generated using the generalized time-reversible model of nucleotide evolution in FastTree v2.1.7.", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["FastTree v2.1.7", "CELL_LINE", 139, 154], ["approximately", "OBSERVATION_MODIFIER", 3, 16], ["maximum", "OBSERVATION_MODIFIER", 17, 24], ["phylogenetic tree", "OBSERVATION", 36, 53], ["generalized", "OBSERVATION_MODIFIER", 78, 89]]], ["FastTree uses SH-like local supports with 1000 resamples to estimate and validate the reliability of each split in the tree.", [["tree", "ANATOMY_MODIFIER", 119, 123]]], ["From the tree, the branch containing the sequence from the Bt92 coronavirus sequence and 58 sequences from NCBI was selected and a more robust maximum-likelihood phylogenetic tree was created using RAXML with 1000 bootstrap replications.", [["Bt92 coronavirus", "ORGANISM", 59, 75], ["Bt92 coronavirus sequence", "DNA", 59, 84], ["coronavirus", "SPECIES", 64, 75], ["Bt92 coronavirus", "SPECIES", 59, 75], ["the Bt92 coronavirus sequence", "TEST", 55, 84], ["NCBI", "TEST", 107, 111], ["RAXML", "TREATMENT", 198, 203], ["1000 bootstrap replications", "TREATMENT", 209, 236], ["tree", "ANATOMY_MODIFIER", 9, 13], ["branch", "ANATOMY_MODIFIER", 19, 25], ["robust", "OBSERVATION_MODIFIER", 136, 142], ["maximum", "OBSERVATION_MODIFIER", 143, 150], ["phylogenetic tree", "OBSERVATION", 162, 179]]], ["The trees were visualized using FigTree v1.4.2.Identification of a CoV-positive sample through active surveillanceA total of 107 guano samples, 14 rectal swabs and 6 bat carcasses were collected and screened for the presence of CoVs, JEV, rabies-related lyssavirus, leptospirosis and hantavirus.", [["sample", "ANATOMY", 80, 86], ["samples", "ANATOMY", 135, 142], ["rectal swabs", "ANATOMY", 147, 159], ["rabies", "DISEASE", 239, 245], ["leptospirosis", "DISEASE", 266, 279], ["hantavirus", "DISEASE", 284, 294], ["CoV", "ORGANISM", 67, 70], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 147, 159], ["CoVs", "GENE_OR_GENE_PRODUCT", 228, 232], ["JEV", "ORGANISM", 234, 237], ["rabies-related lyssavirus", "ORGANISM", 239, 264], ["JEV", "SPECIES", 234, 237], ["a CoV", "TEST", 65, 70], ["guano samples", "TEST", 129, 142], ["rectal swabs", "TEST", 147, 159], ["6 bat carcasses", "TEST", 164, 179], ["CoVs", "PROBLEM", 228, 232], ["JEV", "PROBLEM", 234, 237], ["rabies", "PROBLEM", 239, 245], ["lyssavirus", "PROBLEM", 254, 264], ["leptospirosis", "PROBLEM", 266, 279], ["hantavirus", "PROBLEM", 284, 294]]], ["Three samples collected from lesser dog-faced bats (C. brachyotis) were found to be positive for CoV by PCR targeting a 440 bp region located within the RNAdependent RNA polymerase gene (RdRp) [2] .", [["samples", "ANATOMY", 6, 13], ["dog", "ORGANISM", 36, 39], ["bats", "ORGANISM", 46, 50], ["C. brachyotis", "ORGANISM", 52, 65], ["CoV", "GENE_OR_GENE_PRODUCT", 97, 100], ["440 bp region", "DNA", 120, 133], ["RNAdependent RNA polymerase gene", "DNA", 153, 185], ["RdRp", "DNA", 187, 191], ["dog", "SPECIES", 36, 39], ["C. brachyotis", "SPECIES", 52, 65], ["C. brachyotis", "SPECIES", 52, 65], ["CoV", "SPECIES", 97, 100], ["Three samples", "TEST", 0, 13], ["CoV", "TEST", 97, 100], ["PCR", "TEST", 104, 107], ["a 440 bp region", "TREATMENT", 118, 133], ["lesser", "OBSERVATION_MODIFIER", 29, 35]]], ["This set of primer targets motif A corresponding to MGWDYPKCD and motif C corresponding to MMILSDD within the RdRp gene, which is strictly conserved among known RNA-dependent polymerases [30] [31] [32] [33] .", [["MGWDYPKCD", "GENE_OR_GENE_PRODUCT", 52, 61], ["MMILSDD", "GENE_OR_GENE_PRODUCT", 91, 98], ["MGWDYPKCD", "DNA", 52, 61], ["motif C", "DNA", 66, 73], ["MMILSDD", "DNA", 91, 98], ["RdRp gene", "DNA", 110, 119], ["motif C", "PROBLEM", 66, 73], ["dependent polymerases", "PROBLEM", 165, 186]]], ["CoV sequences (BtCoV22 and BtCoV29) were detected in guano samples collected from the Singapore Zoological Garden and SBWR, respectively.", [["guano samples", "ANATOMY", 53, 66], ["CoV", "GENE_OR_GENE_PRODUCT", 0, 3], ["BtCoV22", "GENE_OR_GENE_PRODUCT", 15, 22], ["BtCoV29", "GENE_OR_GENE_PRODUCT", 27, 34], ["guano samples", "ORGANISM_SUBSTANCE", 53, 66], ["CoV sequences", "DNA", 0, 13], ["BtCoV22", "DNA", 15, 22], ["BtCoV29", "DNA", 27, 34], ["CoV sequences", "TEST", 0, 13], ["BtCoV22", "TEST", 15, 22], ["BtCo", "TEST", 27, 31]]], ["One CoV sequence (BtCoV92) was detected in the rectal swab of a bat carcass collected from SBWR.design of CoV probe library for enrichmentA probe library to cover all known alpha-and betacoronaviruses was designed and constructed from all available non-redundant genome sequences (full length or partial).", [["rectal swab", "ANATOMY", 47, 58], ["CoV", "ORGANISM", 4, 7], ["BtCoV92", "GENE_OR_GENE_PRODUCT", 18, 25], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 47, 58], ["bat", "ORGANISM", 64, 67], ["carcass", "ORGANISM_SUBDIVISION", 68, 75], ["alpha", "GENE_OR_GENE_PRODUCT", 173, 178], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 183, 200], ["CoV sequence", "DNA", 4, 16], ["BtCoV92", "DNA", 18, 25], ["alpha-and betacoronaviruses", "DNA", 173, 200], ["non-redundant genome sequences", "DNA", 249, 279], ["One CoV sequence", "TEST", 0, 16], ["the rectal swab", "TEST", 43, 58], ["CoV probe library", "TREATMENT", 106, 123], ["A probe library", "TREATMENT", 138, 153], ["betacoronaviruses", "PROBLEM", 183, 200], ["rectal", "ANATOMY", 47, 53]]], ["The algorithm BaitMaker [34] was then used to design a custom probe set for coronaviruses (Table S1 ).", [["a custom probe", "TREATMENT", 53, 67], ["coronaviruses", "PROBLEM", 76, 89]]], ["Briefly, BaitMaker utilizes a k-mer-based search pattern strategy to identify regions of conservation and variability within a viral species.", [["BaitMaker", "DNA", 9, 18], ["a k-mer-based search pattern strategy", "TREATMENT", 28, 65], ["a viral species", "PROBLEM", 125, 140], ["viral species", "OBSERVATION", 127, 140]]], ["Non-redundant, non-overlapping probes are then designed to target these regions with a minimum of 85 % identity between the probe and the targeted sequence.", [["targeted sequence", "DNA", 138, 155]]], ["The source code for Bait-Maker software is freely available at: https:// umasangumathi. github. io/ BaitMaker/.Assessment of CoV probe library with MERS-CoVGeneric NGS enables unbiased pathogen discovery, but suffers from issues of low sensitivity and high per-sample cost, mainly due to high background of host genes in most samples.", [["samples", "ANATOMY", 326, 333], ["CoV", "ORGANISM", 125, 128], ["samples", "CANCER", 326, 333], ["BaitMaker", "PROTEIN", 100, 109], ["CoV probe library", "DNA", 125, 142], ["MERS-CoVGeneric NGS", "DNA", 148, 167], ["host genes", "DNA", 307, 317], ["CoV probe library", "TEST", 125, 142], ["CoVGeneric NGS", "TREATMENT", 153, 167], ["low sensitivity", "PROBLEM", 232, 247], ["high per-sample cost", "PROBLEM", 252, 272], ["host genes", "PROBLEM", 307, 317], ["low sensitivity", "OBSERVATION_MODIFIER", 232, 247], ["host genes", "OBSERVATION", 307, 317]]], ["After NGS, removal of host background followed by a de novo assembly strategy is usually used for pathogen discovery when viral RNA is abundant.", [["viral RNA", "RNA", 122, 131], ["NGS", "TEST", 6, 9], ["removal of host background", "TREATMENT", 11, 37], ["a de novo assembly strategy", "TREATMENT", 50, 77], ["viral RNA", "PROBLEM", 122, 131]]], ["However, this approach fails when the amount of viral RNA is low.Assessment of CoV probe library with MERS-CoVTo overcome this issue and to fully realize the power of NGS in pathogen discovery and investigation, several groups (including ours) have now developed an enrichment-based NGS strategy [35] [36] [37] .", [["CoV", "ORGANISM", 79, 82], ["viral RNA", "RNA", 48, 57], ["CoV probe library", "DNA", 79, 96], ["MERS-CoVTo", "DNA", 102, 112], ["viral RNA", "PROBLEM", 48, 57], ["an enrichment", "TEST", 263, 276], ["viral RNA", "OBSERVATION", 48, 57], ["low", "OBSERVATION_MODIFIER", 61, 64]]], ["To improve the signal-to-background noise ratio, NGS libraries are incubated with a set of biotinylated viral capture probes predesigned according to known viral sequences, followed by enrichment with streptavidin-coated beads.", [["streptavidin", "SIMPLE_CHEMICAL", 201, 213], ["NGS libraries", "DNA", 49, 62], ["biotinylated viral capture probes", "DNA", 91, 124], ["viral sequences", "DNA", 156, 171], ["streptavidin", "PROTEIN", 201, 213], ["the signal", "TEST", 11, 21], ["NGS libraries", "PROBLEM", 49, 62], ["biotinylated viral capture probes", "TREATMENT", 91, 124], ["known viral sequences", "PROBLEM", 150, 171], ["streptavidin-coated beads", "TREATMENT", 201, 226]]], ["From the assessment of the CoV probe library, there were at least 100 times the number of reads mapped in the enriched samples as compared to the unenriched samples for each dilution of MERS-CoV RNA ( Table 2 ).", [["samples", "ANATOMY", 119, 126], ["samples", "ANATOMY", 157, 164], ["CoV", "ORGANISM", 27, 30], ["samples", "CANCER", 157, 164], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 186, 194], ["CoV probe library", "DNA", 27, 44], ["MERS-CoV RNA", "RNA", 186, 198], ["MERS-CoV", "SPECIES", 186, 194], ["the assessment", "TEST", 5, 19], ["the CoV probe library", "TEST", 23, 44]]], ["The enrichment strategy was also evaluated on WIV1, an uncharacterized SARS-related coronavirus.", [["SARS", "DISEASE", 71, 75], ["WIV1", "SIMPLE_CHEMICAL", 46, 50], ["coronavirus", "ORGANISM", 84, 95], ["WIV1", "TEST", 46, 50], ["an uncharacterized SARS", "PROBLEM", 52, 75], ["coronavirus", "PROBLEM", 84, 95], ["uncharacterized", "OBSERVATION_MODIFIER", 55, 70], ["SARS", "OBSERVATION", 71, 75]]], ["An increase in the depth of coverage in the enriched sample compared with the unenriched sample was demonstrated (Fig. S1 ).Genome characterization of the novel bat CoVSequences obtained from the three BtCoVs detected in lesser dog-faced bats were analysed and assembled with Geneious (version 9.", [["sample", "ANATOMY", 53, 59], ["sample", "ANATOMY", 89, 95], ["bat", "ORGANISM", 161, 164], ["CoVSequences", "GENE_OR_GENE_PRODUCT", 165, 177], ["BtCoVs", "GENE_OR_GENE_PRODUCT", 202, 208], ["dog", "ORGANISM", 228, 231], ["bats", "ORGANISM", 238, 242], ["BtCoVs", "DNA", 202, 208], ["the unenriched sample", "TEST", 74, 95], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["depth", "OBSERVATION_MODIFIER", 19, 24], ["coverage", "OBSERVATION_MODIFIER", 28, 36]]], ["The 5\u2032-ACGAAC-3\u2032 TRS has also been shown to be the TRS for SARS-CoV [38] .Genome characterization of the novel bat CoVThe genome of BtCoV92 is similar to that of the other CoVs, with a characteristic gene order of 5\u2032-replicase ORF1ab, spike (S), envelope (E), membrane (M) and nucleocapsid (N)-3\u2032.Genome characterization of the novel bat CoVThe BtCoV92 contains four accessory genes interspersed within the structural genes, one ORF encoding none structural protein NS3 between the S and E genes (ORF 3) and three ORFs encoding NS7a, NS7b, NS7c downstream of the N gene (Fig. 2) .", [["membrane", "ANATOMY", 260, 268], ["5\u2032-ACGAAC", "CHEMICAL", 4, 13], ["SARS", "DISEASE", 59, 63], ["CoVThe", "GENE_OR_GENE_PRODUCT", 115, 121], ["BtCoV92", "GENE_OR_GENE_PRODUCT", 132, 139], ["CoVs", "GENE_OR_GENE_PRODUCT", 172, 176], ["5\u2032", "GENE_OR_GENE_PRODUCT", 214, 216], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 227, 233], ["membrane", "CELLULAR_COMPONENT", 260, 268], ["nucleocapsid (N)-3", "GENE_OR_GENE_PRODUCT", 277, 295], ["bat CoVThe", "ORGANISM", 334, 344], ["BtCoV92", "GENE_OR_GENE_PRODUCT", 345, 352], ["E", "GENE_OR_GENE_PRODUCT", 488, 489], ["ORF 3", "GENE_OR_GENE_PRODUCT", 497, 502], ["NS7a", "GENE_OR_GENE_PRODUCT", 528, 532], ["NS7b", "GENE_OR_GENE_PRODUCT", 534, 538], ["NS7c", "GENE_OR_GENE_PRODUCT", 540, 544], ["5\u2032-ACGAAC-3\u2032 TRS", "DNA", 4, 20], ["bat CoVThe genome", "DNA", 111, 128], ["BtCoV92", "DNA", 132, 139], ["CoVs", "DNA", 172, 176], ["5\u2032", "DNA", 214, 216], ["ORF1ab", "PROTEIN", 227, 233], ["spike (S), envelope (E), membrane (M) and nucleocapsid (N)-3\u2032", "PROTEIN", 235, 296], ["CoVThe BtCoV92", "DNA", 338, 352], ["accessory genes", "DNA", 367, 382], ["structural genes", "DNA", 407, 423], ["ORF", "DNA", 429, 432], ["NS3", "PROTEIN", 466, 469], ["S and E genes", "DNA", 482, 495], ["ORF 3", "DNA", 497, 502], ["ORFs", "DNA", 514, 518], ["NS7a", "DNA", 528, 532], ["NS7b", "DNA", 534, 538], ["NS7c", "DNA", 540, 544], ["N gene", "DNA", 563, 569], ["SARS-CoV", "SPECIES", 59, 67], ["Genome characterization", "TEST", 74, 97], ["the other CoVs", "PROBLEM", 162, 176], ["Genome characterization", "TEST", 297, 320], ["the S and E genes", "TREATMENT", 478, 495], ["NS7b", "TREATMENT", 534, 538], ["accessory genes", "OBSERVATION", 367, 382], ["structural genes", "OBSERVATION", 407, 423], ["protein NS3", "OBSERVATION", 458, 469]]], ["NS7c is not typically reported in HKU9, but was only found in the diliman-1525G2 virus found in C. brachyotis in the Philippines [39] .", [["NS7c", "GENE_OR_GENE_PRODUCT", 0, 4], ["HKU9", "GENE_OR_GENE_PRODUCT", 34, 38], ["diliman-1525G2 virus", "ORGANISM", 66, 86], ["C. brachyotis", "ORGANISM", 96, 109], ["NS7c", "PROTEIN", 0, 4], ["HKU9", "CELL_LINE", 34, 38], ["C. brachyotis", "SPECIES", 96, 109], ["diliman-1525G2 virus", "SPECIES", 66, 86], ["C. brachyotis", "SPECIES", 96, 109], ["NS7c", "TREATMENT", 0, 4]]], ["Based on the available partial genome sequence, NS7c was also present in BtCoV22/29, sharing 100 % sequence identity with the NS7c found in BtCoV92.", [["NS7c", "GENE_OR_GENE_PRODUCT", 48, 52], ["BtCoV22/29", "GENE_OR_GENE_PRODUCT", 73, 83], ["partial genome sequence", "DNA", 23, 46], ["NS7c", "DNA", 48, 52], ["BtCoV22/29", "DNA", 73, 83], ["NS7c", "DNA", 126, 130], ["BtCoV92", "DNA", 140, 147], ["the NS7c", "TEST", 122, 130]]], ["BtCoV92 is closely related to the species Rousettus bat coronavirus HKU9 found in Leschenault's rousette and an unidentified species Rousettus sp. found previously in the Guangdong and Yunnan provinces [40] (Fig. 3) .", [["BtCoV92", "CHEMICAL", 0, 7], ["BtCoV92", "GENE_OR_GENE_PRODUCT", 0, 7], ["Rousettus bat coronavirus", "ORGANISM", 42, 67], ["HKU9", "ORGANISM", 68, 72], ["Rousettus sp", "ORGANISM", 133, 145], ["BtCoV92", "PROTEIN", 0, 7], ["Rousettus bat coronavirus", "SPECIES", 42, 67], ["Rousettus bat coronavirus", "SPECIES", 42, 67], ["the species", "TEST", 30, 41], ["bat coronavirus HKU9", "TEST", 52, 72], ["Leschenault's rousette", "PROBLEM", 82, 104], ["species Rousettus", "OBSERVATION", 125, 142]]], ["Bat coronavirus HKU9 and bat coronavirus GCCDC1 are two closely related yet distinct betacoronaviruses.", [["Bat coronavirus", "ORGANISM", 0, 15], ["HKU9", "GENE_OR_GENE_PRODUCT", 16, 20], ["bat coronavirus", "ORGANISM", 25, 40], ["GCCDC1", "GENE_OR_GENE_PRODUCT", 41, 47], ["betacoronaviruses", "CANCER", 85, 102], ["Bat coronavirus", "SPECIES", 0, 15], ["bat coronavirus GCCDC1", "SPECIES", 25, 47], ["Bat coronavirus", "SPECIES", 0, 15], ["bat coronavirus", "SPECIES", 25, 40], ["Bat coronavirus HKU9", "TEST", 0, 20], ["bat coronavirus GCCDC1", "TEST", 25, 47], ["distinct betacoronaviruses", "PROBLEM", 76, 102], ["distinct", "OBSERVATION_MODIFIER", 76, 84], ["betacoronaviruses", "OBSERVATION", 85, 102]]], ["GCCDC1 is genetically less diverse than HKU9 and has a p10 gene from reovirus in its genome [41] .", [["GCCDC1", "GENE_OR_GENE_PRODUCT", 0, 6], ["HKU9", "GENE_OR_GENE_PRODUCT", 40, 44], ["p10", "GENE_OR_GENE_PRODUCT", 55, 58], ["GCCDC1", "PROTEIN", 0, 6], ["HKU9", "DNA", 40, 44], ["p10 gene", "DNA", 55, 63], ["GCCDC1", "TEST", 0, 6], ["genetically", "OBSERVATION_MODIFIER", 10, 21], ["less", "OBSERVATION_MODIFIER", 22, 26], ["diverse", "OBSERVATION_MODIFIER", 27, 34]]], ["HKU9 consists of five lineages and BtCoV92 does not group within any of the five lineages, which makes it a new one [41] .", [["HKU9", "GENE_OR_GENE_PRODUCT", 0, 4], ["HKU9", "PROTEIN", 0, 4], ["BtCoV92", "PROTEIN", 35, 42]]], ["The S and N proteins of BtCoV92 showed 61-72 % and 74-80 % identity to those of the HKU9 species, respectively.", [["BtCoV92", "GENE_OR_GENE_PRODUCT", 24, 31], ["S and N proteins", "PROTEIN", 4, 20], ["BtCoV92", "PROTEIN", 24, 31], ["The S and N proteins", "TEST", 0, 20], ["BtCoV92", "TEST", 24, 31]]], ["We found no recombination between BtCoV92 and HKU9 (NC_009021.1 and HM211101.1) with the Simplot program (data not shown).", [["BtCoV92", "DNA", 34, 41], ["HKU9", "DNA", 46, 50], ["NC_009021.1", "DNA", 52, 63], ["recombination", "PROBLEM", 12, 25], ["BtCoV92", "TEST", 34, 41], ["HKU9", "TEST", 46, 50], ["no", "UNCERTAINTY", 9, 11]]], ["The N protein of BtCoV92 showed 90 % identity with that of the diliman-1525G2 virus and they clustered in the same branch in the N protein phylogenetic analysis ( Fig. 4a and b) .", [["BtCoV92", "GENE_OR_GENE_PRODUCT", 17, 24], ["diliman-1525G2 virus", "ORGANISM", 63, 83], ["N protein", "PROTEIN", 4, 13], ["BtCoV92", "PROTEIN", 17, 24], ["N protein", "PROTEIN", 129, 138], ["diliman-1525G2 virus", "SPECIES", 63, 83], ["The N protein", "TEST", 0, 13], ["BtCoV92", "TEST", 17, 24], ["the diliman", "TEST", 59, 70], ["branch", "ANATOMY_MODIFIER", 115, 121]]], ["Similarly, when using a partial N protein sequence (461 amino acids, 8 missing amino acids from position 351-358 of the N protein), BtCoV22/29 clustered together with BtCoV92 and diliman-1525G2 virus during phylogenetic analysis (Fig. 4b) .", [["amino acids", "CHEMICAL", 56, 67], ["amino acids", "CHEMICAL", 79, 90], ["amino acids", "CHEMICAL", 56, 67], ["amino acids", "CHEMICAL", 79, 90], ["amino acids", "AMINO_ACID", 56, 67], ["amino acids", "AMINO_ACID", 79, 90], ["BtCoV22/29", "GENE_OR_GENE_PRODUCT", 132, 142], ["BtCoV92", "GENE_OR_GENE_PRODUCT", 167, 174], ["diliman-1525G2 virus", "ORGANISM", 179, 199], ["N protein sequence", "PROTEIN", 32, 50], ["N protein", "PROTEIN", 120, 129], ["BtCoV22/29", "PROTEIN", 132, 142], ["BtCoV92", "PROTEIN", 167, 174], ["diliman-1525G2 virus", "SPECIES", 179, 199], ["a partial N protein sequence", "TEST", 22, 50], ["amino acids", "TEST", 56, 67], ["missing amino acids", "TREATMENT", 71, 90], ["the N protein", "TREATMENT", 116, 129], ["BtCoV92", "TEST", 167, 174], ["diliman", "TEST", 179, 186], ["phylogenetic analysis", "TEST", 207, 228]]], ["In a previous study, a betacoronavirus (KX452687) was detected in local E. spelaea [42] and when comparing the N protein partial sequences with those of BtCoV92, BtCoV22/29, these sequences clustered under a different branch from KX452687 in the phylogenetic tree (Fig. 4a ).dISCuSSIonIn 2015 [39] , emerging diseases with epidemic potential were identified by the World Health Organization (WHO) as targets for outbreak preparedness, and SARS-CoV and MERS-CoV were both in the list [43] .", [["betacoronavirus", "CHEMICAL", 23, 38], ["KX452687", "CHEMICAL", 40, 48], ["KX452687", "CHEMICAL", 230, 238], ["SARS", "DISEASE", 439, 443], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 23, 38], ["KX452687", "CANCER", 40, 48], ["E. spelaea", "ORGANISM", 72, 82], ["BtCoV92", "GENE_OR_GENE_PRODUCT", 153, 160], ["BtCoV22/29", "GENE_OR_GENE_PRODUCT", 162, 172], ["SARS-CoV", "ORGANISM", 439, 447], ["MERS-CoV", "ORGANISM", 452, 460], ["N protein partial sequences", "DNA", 111, 138], ["BtCoV92", "DNA", 153, 160], ["BtCoV22/29", "DNA", 162, 172], ["E. spelaea", "SPECIES", 72, 82], ["E. spelaea", "SPECIES", 72, 82], ["SARS-CoV", "SPECIES", 439, 447], ["MERS-CoV", "SPECIES", 452, 460], ["a previous study", "TEST", 3, 19], ["a betacoronavirus", "TEST", 21, 38], ["the N protein partial sequences", "TEST", 107, 138], ["these sequences", "TEST", 174, 189], ["SARS", "PROBLEM", 439, 443], ["branch", "OBSERVATION_MODIFIER", 218, 224], ["phylogenetic tree", "OBSERVATION", 246, 263]]], ["Delayed identification and detection of SARS-CoV during the outbreak from November 2002 to April 2003 resulted in wide spread of disease and increased human fatalities [44] .", [["SARS", "DISEASE", 40, 44], ["fatalities", "DISEASE", 157, 167], ["SARS-CoV", "ORGANISM", 40, 48], ["human", "ORGANISM", 151, 156], ["human", "SPECIES", 151, 156], ["SARS-CoV", "SPECIES", 40, 48], ["human", "SPECIES", 151, 156], ["Delayed identification", "TEST", 0, 22], ["SARS", "PROBLEM", 40, 44], ["CoV", "PROBLEM", 45, 48], ["wide spread of disease", "PROBLEM", 114, 136], ["increased human fatalities", "PROBLEM", 141, 167], ["wide", "OBSERVATION_MODIFIER", 114, 118], ["spread", "OBSERVATION_MODIFIER", 119, 125], ["disease", "OBSERVATION", 129, 136], ["increased", "OBSERVATION_MODIFIER", 141, 150]]], ["Therefore, surveillance remains key for early outbreak alerts and disease interventions.dISCuSSIonIn this study, we reported the characterization of the complete genome sequence of a novel coronavirus in Singapore from lesser dog faced bats (C. brachyotis).", [["coronavirus", "DISEASE", 189, 200], ["coronavirus", "ORGANISM", 189, 200], ["dog", "ORGANISM", 226, 229], ["C. brachyotis", "ORGANISM", 242, 255], ["coronavirus", "SPECIES", 189, 200], ["dog", "SPECIES", 226, 229], ["C. brachyotis", "SPECIES", 242, 255], ["C. brachyotis", "SPECIES", 242, 255], ["surveillance", "TEST", 11, 23], ["this study", "TEST", 101, 111], ["a novel coronavirus", "PROBLEM", 181, 200]]], ["These bats were the most frequently counted bats during the island-wide surveillance and are commonly found in parks, where their food sources (fruit trees) are widely distributed.", [["bats", "ORGANISM", 6, 10], ["fruit trees", "MULTI-TISSUE_STRUCTURE", 144, 155], ["fruit trees", "OBSERVATION", 144, 155], ["widely", "OBSERVATION_MODIFIER", 161, 167], ["distributed", "OBSERVATION_MODIFIER", 168, 179]]], ["They are well adapted to living closely with humans, which inevitably increases the risk of disease transmission and the emergence of zoonoses [45] .", [["zoonoses", "DISEASE", 134, 142], ["humans", "ORGANISM", 45, 51], ["humans", "SPECIES", 45, 51], ["humans", "SPECIES", 45, 51], ["disease transmission", "PROBLEM", 92, 112]]], ["Previously, flaviviruses (Phnom Penh virus, Carey island virus and Jugra virus), Nipah virus and betacoronaviruses have been found in C. brachyotis [39, 46, 47] .", [["Nipah virus", "DISEASE", 81, 92], ["Phnom Penh virus", "ORGANISM", 26, 42], ["Carey island virus", "ORGANISM", 44, 62], ["Jugra virus", "ORGANISM", 67, 78], ["Nipah virus", "ORGANISM", 81, 92], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 97, 114], ["C. brachyotis", "ORGANISM", 134, 147], ["Penh virus", "SPECIES", 32, 42], ["Jugra virus", "SPECIES", 67, 78], ["Nipah virus", "SPECIES", 81, 92], ["C. brachyotis", "SPECIES", 134, 147], ["Phnom Penh virus", "SPECIES", 26, 42], ["Carey island virus", "SPECIES", 44, 62], ["Jugra virus", "SPECIES", 67, 78], ["Nipah virus", "SPECIES", 81, 92], ["C. brachyotis", "SPECIES", 134, 147], ["flaviviruses", "PROBLEM", 12, 24], ["Phnom Penh virus", "PROBLEM", 26, 42], ["Carey island virus", "PROBLEM", 44, 62], ["Jugra virus", "PROBLEM", 67, 78], ["Nipah virus", "PROBLEM", 81, 92], ["betacoronaviruses", "TREATMENT", 97, 114], ["Nipah virus", "OBSERVATION", 81, 92]]], ["Obtaining the full-genome sequences for CoVs from field samples has always been challenging for multiple reasons: (1) the CoV genome (26-32 kb) is the largest non-segmented RNA viral genome known to date [15] ; (2) CoV genomes are genetically highly variable due to the high frequency of recombination among CoVs [48] [48, 49] ; and (3) the absolute amount and relative percentage of viral nucleic acid is generally very low in clinical/field samples.", [["samples", "ANATOMY", 56, 63], ["samples", "ANATOMY", 443, 450], ["nucleic acid", "CHEMICAL", 390, 402], ["CoVs", "GENE_OR_GENE_PRODUCT", 40, 44], ["CoV", "ORGANISM", 122, 125], ["CoV", "ORGANISM", 215, 218], ["full-genome sequences", "DNA", 14, 35], ["CoVs", "DNA", 40, 44], ["CoV genome", "DNA", 122, 132], ["non-segmented RNA viral genome", "DNA", 159, 189], ["CoV genomes", "DNA", 215, 226], ["CoVs from field samples", "TEST", 40, 63], ["the CoV genome", "TEST", 118, 132], ["the largest non-segmented RNA viral genome", "PROBLEM", 147, 189], ["CoV genomes", "PROBLEM", 215, 226], ["the absolute amount", "TEST", 337, 356], ["viral nucleic acid", "TEST", 384, 402], ["viral genome", "OBSERVATION", 177, 189], ["viral nucleic acid", "OBSERVATION", 384, 402]]], ["In the current study, we developed a CoV-targeted probe-based enrichment strategy to improve the efficiency of CoV genome characterization.", [["CoV", "ORGANISM", 111, 114], ["CoV genome", "DNA", 111, 121], ["CoV", "SPECIES", 111, 114], ["the current study", "TEST", 3, 20], ["a CoV-targeted probe", "TREATMENT", 35, 55], ["based enrichment strategy", "TREATMENT", 56, 81], ["CoV genome characterization", "TEST", 111, 138], ["CoV genome", "OBSERVATION", 111, 121]]], ["As a proof of concept, we applied this CoV-enrichment NGS strategy to rapidly characterize the first complete CoV genome sequence in Singapore from a novel CoV detected in C. brachyotis.", [["CoV", "ORGANISM", 110, 113], ["CoV", "ORGANISM", 156, 159], ["C. brachyotis", "ORGANISM", 172, 185], ["CoV genome sequence", "DNA", 110, 129], ["C. brachyotis", "SPECIES", 172, 185], ["C. brachyotis", "SPECIES", 172, 185], ["this CoV-enrichment NGS strategy", "TREATMENT", 34, 66], ["a novel CoV", "PROBLEM", 148, 159], ["C. brachyotis", "PROBLEM", 172, 185], ["C. brachyotis", "OBSERVATION", 172, 185]]], ["Genetically, this newly found CoV belongs to the genus Betacoronavirus and is closely related to the species Rousettus bat coronavirus HKU9 [50] and diliman-1525G2 [39] .dISCuSSIonAs for any probe-based enrichment NGS strategy, our probe library is designed to detect both known CoVs and novel CoVs genetically related to known members of the family.", [["CoV", "ORGANISM", 30, 33], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 55, 70], ["Rousettus bat coronavirus", "ORGANISM", 109, 134], ["CoVs", "GENE_OR_GENE_PRODUCT", 279, 283], ["CoVs", "GENE_OR_GENE_PRODUCT", 294, 298], ["CoVs", "DNA", 279, 283], ["CoVs", "PROTEIN", 294, 298], ["Rousettus bat coronavirus", "SPECIES", 109, 134], ["Rousettus bat coronavirus", "SPECIES", 109, 134], ["the species", "TEST", 97, 108], ["diliman", "TEST", 149, 156], ["any probe-based enrichment NGS strategy", "TREATMENT", 187, 226], ["our probe library", "TEST", 228, 245], ["known CoVs and novel CoVs", "PROBLEM", 273, 298]]]], "23f759af2302db1c2617ec22b05aab5f149e2d59": [["Economic growth is slow.", [["growth", "OBSERVATION_MODIFIER", 9, 15], ["slow", "OBSERVATION_MODIFIER", 19, 23]]], ["There are not enough jobs, and not enough of them are high-level.", [["not", "UNCERTAINTY", 10, 13], ["enough", "OBSERVATION_MODIFIER", 14, 20], ["jobs", "OBSERVATION", 21, 25]]], ["Europe is still characterised by significant poverty and regional inequality.", [["significant", "OBSERVATION_MODIFIER", 33, 44], ["poverty", "OBSERVATION", 45, 52], ["regional inequality", "OBSERVATION", 57, 76]]], ["Europeans' health is affected by serious lifestyle and contagious diseases.", [["contagious diseases", "PROBLEM", 55, 74], ["contagious diseases", "OBSERVATION", 55, 74]]]]}